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SUMMARY 
 
Neurofibromatosis type 1 (NF1) and Neurofibromatosis type 2 (NF2) are distinct 
single gene disorders, which share a predisposition to formation of benign nervous 
system tumours due to loss of tumour suppressor function. Since identification of the 
genes encoding NF1 and NF2 in the early 1990s, significant progress has been made 
in understanding the biological processes and molecular pathways underlying tumour 
formation.  As a result, identifying safe and effective medical approaches to treating 
NF1 and NF2-associated tumours has become a focus of clinical research and patient 
care in recent years.  This thesis presents a comprehensive discussion of the 
complications of NF1 and NF2 and approaches to treatment, with a focus on key 
tumours in each condition. The significant functional impact of these disorders in 
children and young adults is illustrated, demonstrating the need for coordinated care 
from experienced multidisciplinary teams.  
 
Response of the first Australian patients offered novel medications under careful 
prospective monitoring for safety and efficacy, is described.  The approach to 
treatment trials including principles of patient selection, rationale for candidate 
medication choices, and identification of appropriate outcome measures are outlined. 
Treatment response is assessed utilizing multiple criteria including radiologic 
response, functional status and patient reported outcomes. Tumours considered 
include plexiform neurofibromas in NF1, treated with the protein tyrosine kinase 
inhibitor imatinib, with limited benefit.  In NF2, vestibular schwannomas were treated 
using the vascular endothelial growth factor inhibitor bevacizumab, showing definite 
benefit in a proportion of patients.  
 
Refinements in the clinical approach to NF-associated tumours are discussed, 
considering results from this early experience. Optimizing tumour surveillance prior 
to intervention, identifying the most potent yet tolerable agents for use, determining 
when medical therapy should be utilized in concert with surgical and other 
approaches, and establishing ways of stratifying individual risk of disease 
complications and likelihood of treatment benefit, remain important questions for the 
future.  
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CHAPTER 1.  INTRODUCTION 
       
 
The neurofibromatoses are genetic disorders, with an incidence of approximately 
1:3000 in neurofibromatosis type 1 (NF1) (1-3), and a lower incidence of  about 
1:30,000 in neurofibromatosis type 2 (NF2) and schwannomatosis (4-7). NF1 and 
NF2 have been particularly well characterized. However, general knowledge about 
the rarer conditions NF2 and schwannomatosis outside specialist centres is limited, a 
problem magnified in the paediatric population. 
 
NF1, NF2, and schwannomatosis-associated tumour suppressor genes (SMARCB1 and 
LZTR1) cause central and peripheral nervous system tumours to form secondary to 
dysfunction of molecular pathways controlling cell growth, proliferation and survival 
(5, 6, 8). Although the neurofibromatoses are typically associated with histologically 
benign tumours, the potential impact on every aspect of neurologic functioning, 
requires these tumours to be considered “biologically malignant”. Historically, NF-
associated tumours have been difficult to treat, resulting in significant morbidity, and 
risk of early mortality (8). 
 
Key features of NF1 and NF2, and approaches to treatment of the associated tumours, 
are the subject of this thesis and will be introduced here, then discussed in detail in 
subsequent chapters. The hallmark tumours are plexiform neurofibromas (PNF) in 
NF1, and vestibular schwannomas (VS), which are typically bilateral in NF2. 
Schwannomatosis, has important clinical and molecular overlap with NF2, and will be 
briefly described below for completeness, then not further considered here. 
 
Regarding NF1 and NF2, although the literature contains descriptions dating back 
hundreds of years (to 1761 for NF1 and 1822 for NF2; reviewed in (9, 10)), the 
differentiation between these disorders was poorly defined over many years, leading 
to a lack of clarity in the understanding of disease manifestations and natural history 
until the late 1980s.  Establishment of clinical diagnostic criteria distinguishing the 
two disorders in 1988 was an important historical milestone, adding much needed 
clarity (11). Furthermore, in 1990 and 1993, the genes encoding NF1 and NF2 
respectively were found on chromosomes 17 (12, 13) and 22 (14, 15). Identification 
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of their respective proteins, neurofibromin encoded by the NF1 gene (16), and 
schwannomin (also known as merlin) encoded by the NF2 gene (17) followed soon 
after. These advances opened new avenues for establishing disease mechanisms, and 
exploring disease-specific therapies. Since that time the scientific, medical and patient 
communities have worked passionately towards understanding all aspects of the 
biology of NF1 and NF2.  
 
Regarding schwannomatosis, distinct diagnostic criteria have been developed over the 
past 15 years, using both clinical and molecular features (Table 1.1; (7, 18-20)). 
Multiple schwannomas (or less frequently meningiomas) occur, in the absence of 
bilateral vestibular schwannomas, and only rare occurrence of a unilateral vestibular 
schwannoma. Peripheral nerve schwannomas are relatively more common in 
schwannomatosis compared with NF2, whereas other tumours such as ependymomas, 
intradermal skin tumours, skin plaques and ocular manifestations of NF2 are not seen 
in schwannomatosis. Features of schwannomatosis and NF2 have recently been 
compared and contrasted with reference to existing literature describing both 
conditions (18). Chronic pain is often a predominant symptom of schwannomatosis 
(7).   
 
Concomitant mutational inactivation in 2 or more tumour suppressor genes is required 
to cause schwannomatosis.  Most frequently, mutations of SMARCB1 or LZTR1 (both 
located on chromosome 22q, along with the NF2 gene) occur de novo, or may act in 
an autosomal dominant fashion in familial disease.  Germline mutations in these 
genes have recently been identified in 86% of familial and 40% of sporadic 
schwannomatosis patients respectively (18). Furthermore, somatic mutations  of the 
NF2 gene occur in many tumours from schwannomatosis patients. Pathologic and 
molecular analysis of multiple tumours may be required to clarify the diagnosis. 
Clinical and molecular exclusion criteria are also observed, such that 
schwannomatosis would not be diagnosed in the presence of a first degree relative 
with NF2, a germline NF2 mutation, or in a patient having schwannomas only in a 
region previously treated with radiation therapy (Table 1.1;(18)). While there are 
important overlaps between these distinct conditions, optimal surveillance and 
treatment will be disease-specific and dependent on accurate diagnosis. 
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Table 1.1  Diagnostic criteria for schwannomatosis 
 
 
Clinical Diagnosis 
 
≥ 2 non-intradermal schwannomas, one pathologically confirmed and absence of bilateral vestibular 
schwannomas by high resolution MRI* 
 
OR 
 
One pathologically confirmed schwannoma or intracranial meningioma and an affected first-degree 
relative with schwannomatosis 
 
 
 
Combined Molecular and Clinical Diagnosis 
 Molecular  Clinical   
 
≥2 tumours with 22q loss of heterozygosity  + 2 pathologically confirmed  
and 2 different somatic NF2 mutations   schwannomas or meningiomas 
  
OR 
 
Germline SMARCB1 or LZRT1 pathogenic mutations + One pathologically confirmed 
   schwannoma or meningioma 
 
 
 
Exclusion Criteria 
 
Schwannomas occur exclusively in a region of previous radiation therapy    
First-degree relative with NF2 
Germline pathogenic NF2 mutation 
 
*≤3mm slices through internal auditory canals; some mosaic NF2 patients may be included using these criteria at 
a young age; schwannomatosis patients may rarely have unilateral vestibular schannomas or multiple 
meningiomas. 
Modified from (18). 
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EVOLVING CLINICAL KNOWLEDGE AND TREATMENT APPROACHES FOR NF1 AND 
NF2 
Fortunately, the early 21st century has been marked by advances in research and 
clinical practice holding real promise for changing the outcomes of individuals 
affected by NF1 and NF2-associated tumours (8, 21). At the clinical front-line, 
physicians and surgeons have continued to observe and describe patterns of disease 
and natural history. Together with the scientific community, an understanding of 
important factors contributing to tumour development and growth, have been 
established.  Core tumours and their complications have been identified as targets for 
treatment, directing the development and application of specific therapies (22-24). In 
addition, approaches to patient selection and outcome monitoring have been refined to 
optimise critical evaluation of new therapies in clinical trials (25). These efforts have 
been focused on translating the most effective interventions into routine clinic care as 
rapidly as possible. 
 
This thesis provides a commentary on these recent developments from a clinician’s 
perspective, describing experience in tumour surveillance and management at The 
Children’s Hospital at Westmead, together with collaboration from other centres 
around Australia.  
 
The thesis is divided into two sections, considering issues relevant to patients with 
NF1 (Part 1), and NF2 (Part 2).  For each condition, an overview of presentation, 
diagnosis, major complications, treatment challenges and evolving therapeutic 
approaches is provided, with particular reference to paediatric management (Chapter 
2: NF1; Chapter 5: NF2).  A case series is also included in each section.  For NF1, 
the presentation and treatment of tumours in and adjacent to the spinal canal is 
addressed in selected cases, outlining key clinical features to facilitate early diagnosis, 
surveillance for complications, and guidelines for management (Chapter 3).  For NF2, 
a chapter is dedicated to describing the population of children managed at our centre 
over a 22-year period, highlighting differences in the paediatric presentation, and 
severity of disease. The multidisciplinary approach required to address the 
heterogeneity and complexity of associated clinical complications in childhood is 
illustrated (Chapter 6).   
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Subsequent chapters in each section describe a critical approach to treatment of target 
tumours using novel medications. The rationale for selection of each agent as a 
candidate at the time of this study, and principles guiding selection of patients are 
outlined in each chapter.  Specific outcome measures appropriate for each tumour are 
described, and results reported. A multi-dimensional approach attempts to document 
effects on both radiologic features as well as functional outcomes, emphasizing the 
patient’s experience of disease and treatment.  
 
Chapter 4 describes the first Australian NF1 patients treated with a “biologically 
targeted” therapy, imatinib mesylate, for plexiform neurofibromas.  These congenital 
onset tumours are one of the most common causes of significant morbidity in NF1 
(26, 27), and can be extensive and diffusely infiltrative, occurring in any location with 
variable clinical consequences. Childhood is typically a time of active growth, and 
hence a focus for intervention (28).  Developing approaches to the radiologic 
surveillance and measurement of these complex tumours has been critical to 
assessment of treatment response, alongside selection and measurement of appropriate 
clinically relevant patient outcomes. Agents such as anti-angiogenic agents, anti-
fibrinolytics, farnesyltransferase and mammalian target of rapamycin (mTOR) 
inhibitors have been considered as candidate medications in early efforts, with limited 
success (29-32).  The tyrosine kinase inhibitor imatinib mesylate demonstrated 
extremely promising results in pre-clinical and animal studies, and has an acceptable 
safety profile for treatment of a “benign tumour” (33), and hence has become a 
priority for Phase 2 clinical trials.  
 
In NF2, vestibular schwannoma (occurring in 95% of patients) has been the primary 
tumour of interest for medical treatment trials. Similarly, a number of medications 
have been considered as potential candidates, including other tyrosine kinase 
inhibitors erlotinib (34, 35) and lapatinib (36), which act on the epidermal growth 
factor receptor, and have some demonstrated disease activity. Inhibition of 
angiogenesis using bevacizumab, a monoclonal IgG1 antibody that binds to and 
inhibits the action of vascular endothelial growth factor-A (VEGF-A), met with 
particular success in a small group of patients early on (37). These results provided 
the impetus to assess response carefully in additional patients using VEGF inhibitors, 
including the first NF2 patients in Australia for whom medical therapy has been 
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offered, as described here (Chapter 8).  In preparation for treatment of Australian 
patients with NF2, assessment of functional status and quality of life at baseline was 
considered an important complement to established outcomes of hearing function and 
radiologic response (Chapter 7).  Alongside vestibular schwannomas, observations 
have also been made with reference to meningiomas as secondary targets in NF2 
(Chapter 8, Chapter 9).  In addition, the “off-target” effects on multiple tumours are 
presented in a sub-study for a single NF2 patient (Chapter 9), reflecting the extensive 
tumour burden seen in many patients, and the potential for systemic therapy to benefit 
separate tumours concurrently.   
 
Finally, in Chapter 10, I highlight future directions in research and clinical care for 
patients with NF1- and NF2-associated tumours. 
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SECTION 1: 
 
NEUROFIBROMATOSIS TYPE 1   
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CHAPTER 2.  OVERVIEW OF NEUROFIBROMATOSIS TYPE 1: DIAGNOSIS, 
MAJOR COMPLICATIONS AND MANAGEMENT IN CHILDHOOD. 
 
 
Introduction 
Neurofibromatosis type 1 is caused by mutations in the large NF1 gene located on 
chromosome 17q11.2, encoding the protein neurofibromin. Neurofibromin is known 
to act as a tumor suppressor via Ras-GTPase activation, which causes down-
regulation of cellular signalling by the Ras/mitogen-activated protein kinase (MAPK) 
pathway. In individuals with NF1 and nonfunctional neurofibromin, Ras signalling is 
increased, promoting cellular growth, proliferation, and differentiation leading to 
tumor formation and other manifestations of disease, including deficits in 
hippocampal learning(5, 38). Neurofibromin is likely to have additional functions; for 
example, loss of normal GABA-mediated inhibition has recently been shown to 
contribute to corticostriatal dysfunction associated with working memory deficits in 
NF1 (39). 
 
NF1 is a multi-system disorder with diverse clinical manifestations(40). The earliest 
signs of NF1 are cutaneous, including café au lait macules (CALM) and skin fold 
freckling. Cognitive impairment, optic pathway gliomas, plexiform neurofibromas, 
and orthopaedic issues constitute the most common and important clinical problems, 
affecting variable numbers of patients, with a range of severity. Malignant peripheral 
nerve sheath tumours (MPNST) may arise in pre-existing plexiform neurofibromas at 
any age, and portend a poor prognosis(41, 42). MPNST together with gliomas 
contribute significantly to reduced life expectancy for individuals with NF1(43, 44).  
 
The clinical diagnostic features of NF1, along with genetics, disease complications 
and approaches to treatment are reviewed here. 
 
Diagnosis  
Clinical diagnostic criteria for NF1 were established in 1987 and are satisfied when  
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two of the following conditions are met (40):  
• Café au lait macules (six or more larger than 5 mm before puberty or 15 mm after 
puberty) 
• Skin-fold freckling (axillae, groin, neck) 
• Two or more neurofibromas or one or more plexiform neurofibromas  
• Optic pathway glioma 
• Two or more iris Lisch nodules 
• Characteristic skeletal dysplasia (sphenoid wing) 
• Pseudoarthrosis of the long bones 
• Presence of a positive family history of NF1 affecting a first-degree relative. 
 
Young children typically present with multiple café au lait macules in isolation, with 
other signs of NF1 occurring over time (45, 46). Macrocephaly affects about 45% of 
children and progressive head growth may occur over the first 1 or 2 years. A low 
threshold for neuroimaging is appropriate, given an increased incidence of intracranial 
tumors. However, surveillance imaging in the absence of focal neurologic deficit or 
signs of increased intracranial pressure is not recommended. Optic pathway gliomas 
are more common in children less than 8 years of age and can occur during infancy. 
Plexiform neurofibromas are mostly present from birth and become more obvious 
over the first few years of life. Skin-fold freckling is typically seen from about 3 years 
of age, whereas Lisch nodules may appear in middle childhood and cutaneous 
neurofibromas more frequently occur in adolescence and adulthood.  
 
Genetic Testing for NF1 
NF1 is inherited in an autosomal dominant fashion with sporadic mutations occurring 
in about 50% of patients, and a 50% chance of transmission from affected individuals 
during each pregnancy. A mutation is detected in about 95% of individuals who meet 
the NIH NF1 diagnostic criteria(47). If clinical criteria for NF1 are met, genetic 
testing is not considered mandatory in all centres; the 5% false negative rate 
necessitates annual clinical follow-up of all children with suspected NF1 to detect 
potential complications. Furthermore, among the many pathologic mutations 
identified in the NF1 gene, there are few specific genotype-phenotype correlations. 
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Deletion of the entire NF1 gene results in a more severe phenotype (48), associated 
with facial dysmorphism, increased predisposition for MPNST, cardiac abnormalities, 
and overgrowth. A 3-bp in-frame deletion in exon 17 of the NF1 gene is associated 
with a milder phenotype, which does not occur with cutaneous or plexiform 
neurofibromas (49). Missense mutations in codon 1809 also occur with a recognizable 
phenotype including presence of CALM, with or without skin fold freckling and iris 
lisch nodules, and without cutaneous neurofibromas or externally visible plexiform 
neurofibromas. These individuals also more often have Noonan Syndrome features, 
short stature, pulmonary stenosis, and learning difficulties (50). Genetic testing has an 
important role in the context of prenatal testing and pre-implantation genetic 
diagnosis, though its prognostic value is limited by the variable expressivity 
characteristic of most NF1 mutations. Segmental neurofibromatosis and somatic 
mosaicism in both NF1 and NF2 carries a lower recurrence risk (51). 
 
The major differential diagnosis of NF1 is Legius syndrome (also known as 
neurofibromatosis type-1 like syndrome), an autosomal dominant disorder due to 
mutations in the SPRED1 gene, which is also involved in the RasMAPK pathway 
(52). Legius syndrome is characterized by café au lait spots and skinfold freckling, as 
well as an increased frequency of learning difficulties, but importantly, patients do not 
develop neurofibromas, OPGs, Lisch nodules, or bone lesions. Of patients positive for 
a SPRED1 mutation, 48% fulfil NF1 diagnostic criteria based on café au lait spots, 
freckling, and/or a positive family history of a parent with skin manifestations. It is 
estimated that 2% of individuals with a clinical diagnosis of NF1 have Legius 
syndrome; the estimated frequency is 1 in 120,000. At present, genetic screening for 
Legius syndrome is likely to be most useful in families with autosomal dominant café 
au lait spots (with or without freckling) without a mutation in the NF1 gene (52). 
 
Complications 
A recommended surveillance and treatment approach for important complications is 
shown in Table 2.1. The most frequent neurologic complication in childhood is 
cognitive dysfunction (53). There is a “shift to the left” in intellectual functioning: the 
mean IQ for patients with NF1 is in the low 90s, and intellectual impairment (IQ <70) 
occurs in about 6% of patients.  
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Table 2.1a Current surveillance and treatment of the major medical complications associated with NF1 
Complications Surveillance Treatment 
Cognitive impairment 
Autistic Spectrum Disorder 
Developmental screening during preschool years 
Developmental screening during preschool years 
Early intervention by multi-disciplinary team 
Specialist intervention/educational support 
ADHD Screening at intervals during childhood (e.g., at school entry) Stimulant medication 
Learning difficulties Psychologist assessment during early school years (baseline) 
and when specific learning difficulty identified 
Individually tailored educational support; 
candidate for medication in clinical trial 
Speech/language disorder Speech evaluation Speech therapy 
Optic pathway glioma (OPG) Annual ophthalmology evaluation until 8 years of age, every 
2 years ages 8–18; cranial MRI for suspected OPG. 
– 
For known OPG, quarterly ophthalmology evaluation for 1 
year, every 6 months for 1 year, then annually until 8 years 
of age; if older than 8 years, for 3 further years  
Chemotherapy using vincristine and carboplatin 
if clinically indicated for symptomatic or 
progressing tumor 
Plexiform neurofibroma Annual clinical examination to identify and monitor growth; 
MRI every 6–12 months for progressive lesions 
Surgical debulking for progressive, symptomatic 
tumors; candidate for medication in clinical 
trial; analgesia when indicated 
Malignant peripheral nerve 
sheath tumor 
Urgent clinical examination for increasing plexiform 
neurofibroma size, pain, or neurologic dysfunction; MRI, PET, 
biopsy of affected body region  
Wide surgical excision; consider chemotherapy 
and radiotherapy;candidate for medication in 
clinical trial 
Long bone pseudoarthrosis Annual clinical evaluation (infants); x-ray in the event of limb 
deformity 
Referral to experienced orthopaedic surgeon; 
bracing, surgical intervention, and/or 
bisphosphonates  
Scoliosis Annual clinical evaluation throughout childhood; x-ray in the 
event of abnormal spinal curvature 
Referral to experienced orthopaedic surgeon; 
surgical intervention if clinically indicated  
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Table 2.1b   Current surveillance and treatment of the major medical complications associated with neurofibromatosis type 1 
Complications Surveillance Treatment 
Hypertension Annual blood pressure monitoring 
For known hypertension,  
plasma metanephrines (to detect phaeochromocytoma)*, 
renal ultrasound with doppler studies (renal artery stenosis) 
Renal physician referral 
Heart murmur Careful annual examination Echocardiogram; referral to cardiologist 
Anxiety/mood disorder Annual clinical evaluation Referral to psychologist or psychiatrist 
ADHD=attention deficit hyperactivity disorder; *testing not routinely performed in NF clinics for normotensive, asymptomatic patients.
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Academic learning difficulties are common in NF1: about 50% of children with NF1 
perform poorly on tasks of reading, spelling, and mathematics, and specific learning 
disabilities (as defined by IQ–achievement discrepancies) are present in 20% of 
patients. Between 38% and 49% of children with NF1 fulfil the diagnostic criteria for 
attention deficit-hyperactivity disorder (ADHD) (53, 54). Careful screening, 
supportive measures in pre-academic environments, and individually tailored 
educational programs are thus needed.  
 
The neurobiologic basis of cognitive dysfunction and learning disabilities in NF1 is 
not fully understood, although increased total brain volume and corpus callosum 
volume, cerebral asymmetries, and differences in grey and white matter have been 
described in affected individuals. Though T2 hyperintensities are commonly seen in 
childhood, these decrease with increasing age and are of uncertain significance. 
However, the presence of discrete thalamic T2 hyperintensities has been associated 
with severe and generalized cognitive dysfunction (55).  Speech and language 
disorders have been estimated to affect 18% to 58% of school-aged children and 
adolescents with NF1 (53, 56) and 68% of preschoolers (57). Children with NF1 often 
have mild generalized hypotonia in association with less well-developed gross motor 
skills than their unaffected peers, causing minimal functional impairment.  
 
ADHD in the NF1 population is amenable to treatment with stimulant medication (as 
in other children with ADHD), although data on efficacy are limited (54). Studies of 
cognitive functioning in the NF1 mouse model have suggested that attention and 
visual spatial learning deficits (hippocampal-based learning) are due to Ras activation. 
The cholesterol-lowering agent lovastatin, which inhibits GTPases including Ras, 
reverses these deficits in the NF1 mouse model (58).  Unfortunately, a well-designed 
clinical trial of lovastatin in children has now shown no significant effect of treatment 
on attention or visual spatial learning (59).  
 
Optic pathway glioma (OPG) affects 15% to 20% of children with NF1 (60), most 
before 8 years of age, with about half becoming symptomatic (61). Symptoms and 
signs include strabismus, proptosis, visual impairment, optic disk pallor, and 
precocious puberty. 
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Current surveillance recommendations are for an annual general examination to 
monitor growth and pubertal status, and an annual ophthalmologic evaluation up to 
the age of 8 years, followed by an examination every 2 years until 18 years of age 
(60). All children with a suspected diagnosis of OPG should undergo cranial MRI. 
From the time of diagnosis, monitoring to detect progressive disease rests with regular 
skilled pediatric ophthalmology assessment together with repeat MRIs. 
Ophthalmology evaluations are recommended every 3 months for the first year, 
followed by assessments every 6 months for 2 years, and then annual assessments. 
Optimal intervals for MRI surveillance have not yet been established, and different 
centers screen at intervals between 3 and 6 months in the first year. Ocular coherence 
tomography measures retinal nerve fibre layer thickness, which may be helpful as an 
adjunctive measurement for assessing progression in the future (62).  
 
Primary treatment for OPG is with chemotherapy, usually a combination of 
vincristine and carboplatin. There are no definitive evidence-based criteria to guide 
decisions about commencing chemotherapy. A retrospective multicenter study of 10 
major international NF1 centers recently reviewed indications for commencing 
chemotherapy, demonstrating practice variation among institutions, and visual 
deterioration in 28% of treated children (63). Prospective studies using novel agents 
are ongoing.  
 
Other intracranial tumors (typically low-grade gliomas) are less common and tend to 
have a more favorable prognosis than in non-NF1 patients (64).  
 
Cutaneous and subcutaneous neurofibromas can itch and cause localized discomfort. 
The significant cosmetic deformity attendant on multiple lesions typically occurs in 
adulthood; surgical removal is the main intervention, along with laser treatment for 
small cutaneous neurofibromas. 
 
Plexiform neurofibromas are more complex lesions, thought to be congenital (65). A 
recent MRI surveillance study identified plexiform neurofibromas in 57% of 65 
children aged between 1.7 and 17.6 years, similar to estimates in adults. Of the 
children with plexiform neurofibromas, 46% experienced pain or neurologic or motor 
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difficulties, usually associated with larger tumors (66). Symptoms associated with 
tracheal compression may be life threatening.  
 
A recent study of children aged 6-18 years demonstrated pain impacted significantly 
on daily functioning and quality of life despite pharmacologic management (67).  This 
study identified anxiety and depressive symptoms as contributing factors in reduced 
quality of life, indicating the need for non-pharmacologic approaches to treatment in a 
biopsychosocial model of care. 
 
The treatment of complicated plexiform neurofibromas remains a challenge. 
Symptomatic lesions may be amenable to surgical debulking, but complete resection 
may not be possible because of the invasive nature of these tumors, and regrowth is 
common. The goal of surveillance is to identify and treat actively growing 
symptomatic lesions during early childhood to limit disease progression. Three-
dimensional MRI has been shown to be more sensitive than two-dimensional 
measurements for assessing growth, but it is not available in all centers (28). A 
number of novel molecularly targeted agents have been assessed in recent trials or are 
currently being investigated. This includes inhibitors of the c-kit receptor (eg. 
imatinib) (68), mammalian target of rapamycin (mTOR) inhibitors (eg. 
sirolimus/everolimus) (69), and MEK inhibitors (eg. selumetinib) (70). 
 
Patients with NF1, particularly those with a high plexiform neurofibroma tumor 
burden, have a significantly increased risk of malignant peripheral nerve sheath tumor 
(MPNST), with a lifetime risk of 8% to 13% (41); this represents the major threat of 
early mortality. Although sarcomatous change can occur at any age, in the paediatric 
population, MPNST occurs most frequently in adolescence (71). Whole-body MRI 
surveillance during childhood may help to stratify patients into two groups: those 
requiring infrequent ongoing scanning and those at risk of complications from 
existing plexiform neurofibromas, including the risk of transformation to MPNST. 
However, there is currently a paucity of evidence regarding the utility of MR 
surveillance in children with asymptomatic lesions. Prospective studies are needed to 
evaluate the effectiveness of such surveillance.  
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A rapid increase in plexiform neurofibroma growth, increasing pain, and new focal 
neurologic deficits or other regional symptoms and signs should prompt investigation 
with MRI (72) and 18F-2-fluoro-2-deoxy-D-glucose (FDG) positron emission 
tomography PET/CT studies to detect increased glucose metabolism (73, 74). 
MPNST confirmed on biopsy is treated with wide surgical excision and adjuvant 
therapy. Recurrence risk and metastatic potential are high, with median survival of 
approximately 30 months across all ages (42, 71). Low response rates to 
chemotherapy and radiation therapy for MPNST have focused efforts on the 
development of novel medical therapy and carefully coordinated clinical trials to 
improve patient outcomes (75).  
 
NF1 is associated with vasculopathy affecting multiple sites, including abdominal, 
renal, spinal, and intracranial vessels, with various consequences. The best-recognised 
manifestation of NF1 vasculopathy is hypertension secondary to renal artery stenosis. 
Blood pressure should be monitored at least annually, and hypertension should be 
investigated by renal artery ultrasound/Doppler, with surgical or dilation therapy to 
treat stenotic lesions. Most cases of hypertension in NF1 are essential hypertension 
and respond to medical management. Phaeochromocytoma is a very rare complication 
of NF1 but should be screened for in patients with elevated blood pressure. Cerebral 
vasculopathy affects 2% to 5% of children; 30% of these cases present with 
symptoms associated with ischaemia, but the others are diagnosed incidentally. 
Aspirin is recommended for patients with evidence of vasculopathy on neuroimaging 
(76).  
 
Epilepsy occurs at an increased frequency in patients with NF1, affecting 3.8% to 7% 
of children(77), often in association with cerebral tumors and cortical 
malformations(78, 79). In a series of 14 cases, 29% were drug-resistant (80). A recent 
report documented infantile spasms in 0.76% of NF1 patients, compared with 0.02% 
to 0.05% in the general population (81). 
 
Headache is common in NF1, and may go unrecognised. In a recent study of 
headaches in adults, as many as 65% of patients experienced migraines (ages 16-67 
years, mean 36 years) (82). Although most headaches are not associated with 
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intracranial lesions, MRI should be performed in patients with severe or recurrent 
headaches or features suggestive of increased intracranial pressure. 
Orthopaedic complications of NF1 during childhood include scoliosis and long bone 
pseudoarthrosis, which may require operative management (83). Scoliosis occurs in 
about 20% of patients with NF1, but only about 5% require surgical intervention. 
More severe scoliosis tends to present earlier (at 5–10 years of age) and is often 
associated with vertebral dysplasia or bony lesions due to an adjacent plexiform 
neurofibroma. Bony defects of the tibia or other long bones are congenital and usually 
present with bowing or fracture on weight bearing. Fracture can sometimes be 
prevented by protective bracing and bisphosphonate therapy. Bisphosphonate therapy 
has also been shown to promote healing after surgery in mouse models(84). 
Individuals with NF1 are prone to osteopenia which may progress to osteoporosis 
over time(85), for which bisphosphonates may also have a role(86). 
 
Treatment 
Treatment approaches for NF1 are diverse and depend on the specific clinical 
problem. General approaches to therapy are summarized as key points below. 
 
Early intervention including physical therapy, occupational therapy, and speech 
therapy are recommended for children with NF1 and developmental delay. No 
controlled studies have evaluated the benefit of treatment.  
• Surgery usually is not necessary in NF1. It may be considered for selected 
symptomatic cutaneous and subcutaneous neurofibromas and complicated 
plexiform neurofibromas, as well as for large OPGs causing mass effect 
and hydrocephalus with significant visual impairment (87).  
• Complications of surgery for plexiform neurofibromas include excessive 
hemorrhage and neurologic deficit due to nerve damage (40, 45).  
• Early diagnosis and surgical resection with wide margins has been the 
mainstay of treatment for MPNST (88). While chemotherapy to date has 
lacked efficacy (75), molecularly targeted approaches to medical therapy 
continue to be an important focus of ongoing research (21, 89). 
 31  
• Safety and efficacy of surgical correction of scoliosis in NF1 has been 
demonstrated in a case series including 32 children between 11 and 19 
years of age with follow-up for an average of 6.5 years (90). 
• Surgery including encephaloduroarteriomyosynangiosis (known as 
EDAMS or pial synangiosis) may be indicated in the management of 
moyamoya in NF1 (91). 
• Cranial radiotherapy is usually avoided in NF1 because of the increased 
risk of occlusive cerebral vasculopathy (moyamoya) and secondary tumor 
formation (92, 93). 
• Radiotherapy occasionally may be used as a palliative treatment for 
inoperable MPNSTs or as an adjunct to surgical resection or novel medical 
approaches, when the risks of progression or recurrence are thought to 
outweigh the risks of secondary malignancy (21, 71).  
• Data from the first randomized, double blind placebo-controlled trial of 
statin therapy for cognitive dysfunction examined the effectiveness of 
simvastatin in 62 children with NF1. No significant benefit was 
demonstrated overall, but a number of methodologic limitations were cited 
(94). The potential benefit of statins was further evaluated in an 
international multicenter trial using lovastatin, providing Class I evidence 
of no improvement in visual spatial learning or attention in this population 
(59), indicating this treatment should not be used. 
• Vincristine and carboplatin chemotherapy is the current standard of care in 
children with symptomatic progressive OPG in NF1 (21). Outcomes of 
chemotherapy for children with NF1 treated with vincristine/carboplatin 
regimens have included stabilization of vision in 40% and improvement in 
31%; vision deteriorated in 29% of children studied (63). The efficacy of 
new agents (including RAD001) is under investigation, with a view to 
biologically targeted treatment in future (21, 95). 
• Precocious puberty may require treatment with gonadotrophin analogues.  
• There are currently no proven medical therapies to treat plexiform 
neurofibromas as standard of care. Early clinical trials employed 
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differentiating agents, antifibrotic agents, immune suppressants, and 
angiogenesis and farnesyltransferase inhibitors without significant benefit 
(26, 96-98). Some disease activity has been demonstrated with attenuation 
of c-kit signaling using imatinib (68) (see Chapter 4), pegylated interferon 
(99), and inhibition of mitogen-activated protein kinase kinase (MEK 
inhibitor, selumetinib) (70). Hopefully additional data will be available in 
the near future to outline medical approaches for use in routine clinical 
care. 
• Aspirin is recommended for patients with evidence of vasculopathy on 
neuroimaging (76).  
• Pain associated with nerve tumors may be treated with agents such as 
gabapentin, but there are no specific data reporting optimal dose or 
efficacy in NF1 patients.  
• Psychological interventions to support social-emotional functioning are 
indicated alongside pharmacologic pain management (67), and to support 
children with anxiety or mood disorder associated with chronic illness.  
• Seizures are treated with antiepileptic drugs including carbamazepine and 
lamotrigine, with careful consideration of the potential for increased risk of 
side effects on bone health and cognition (40). 
 
Multicenter clinical trials are under way to identify improved treatment options 
for the major complications of NF1 (21, 24).  Results are awaited from a number 
of studies, including assessing the utility of the mTOR inhibitor rapamycin, the 
VEGFR (vascular endothelial growth factor receptor) and the protein tyrosine 
kinase inhibitor imatinib in treating children with plexiform neurofibromas. 
Multiagent regimens include the angiogenesis inhibitor bevacizumab with the 
mTOR inhibitor RAD001 for MPNST, and the epidermal growth factor receptor 
(EFGR) inhibitor erlotinib with mTOR inhibitor rapamycin for low-grade gliomas 
(100, 101). The observation of rapidly progressive moyamoya in a child with 
glioblastoma treated with the angiogenesis inhibitor bevacizumab indicates that 
the NF1 population may be at increased risk of adverse effects from this class of 
medication (102). 
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Conclusion 
A number of key management challenges exist for children with NF1. Effective 
surveillance to identify problems early offers the opportunity to optimize care. An 
individualized approach is needed, particularly for management of the variable 
manifestations of plexiform neurofibromas.  Multimodal therapy will continue to be 
important for children with NF1, given the diverse range of complications arising in 
this condition. However, it is hoped that effective and tolerable medical treatment 
options will increasingly become available with improved outcomes in the near 
future.  
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CHAPTER 3.  COMPLICATIONS OF SPINAL NEUROFIBROMAS IN CHILDREN 
WITH NEUROFIBROMATOSIS TYPE 1: ILLUSTRATIVE CASES AND LITERATURE 
REVIEW. 
 
 
 
 
Introduction 
Neurofibromas and plexiform neurofibromas (PNF) are benign neural tumours 
comprising key diagnostic features of Neurofibromatosis type 1, the most common 
neurocutaneous tumour suppressor syndrome occurring in childhood, with an 
incidence of 1:3,000 (103).  Plexiform neurofibromas can cause significant morbidity 
and have been associated with an increased mortality rate in children with NF1(104).  
 
Neurofibromas occur as discrete bundles of neural and fibrous tissue in cutaneous, 
subcutaneous or deeper tissues, including around spinal nerve roots(26, 40). Whilst 
cutaneous and subcutaneous tumours typically arise during middle childhood 
onwards, plexiform neurofibromas are predominantly congenital lesions(65, 105).  
Plexiform neurofibromas are more complex peripheral nerve sheath tumours, which 
may be diffusely infiltrating with indistinct margins, extending along the length of a 
nerve and involving multiple nerve fascicles (65), located around superficial or deep 
nerves. They may be associated with externally visible increased tissue bulk, 
cutaneous hyperpigmentation or hypertrichosis (65, 106). Although all neurofibromas 
can cause cosmetic disfigurement, cutaneous and subcutaneous tumours otherwise 
cause only minor symptoms including pruritis and discomfort(106). Significant 
symptoms and signs of plexiform neurofibromas occur due to compression or 
displacement of nerves and other adjacent structures, and vary dependent on size and 
location of the tumour. These tumours are richly vascularized, and may stimulate 
underlying bone growth causing bony dysplasia(26).  Although growth rates for 
individual tumours vary over time, most rapid growth occurs during early 
childhood(28, 107).  
 
Whilst clinical studies typically identify about 25% of individuals with externally 
evident PNF(65, 106), internal PNF are demonstrated on MRI in between 40-60% of 
patients(66, 107, 108), leading to symptoms in about half of affected individuals(66).  
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Reports outlining incidence and complications of neurofibromas in the spinal region 
are limited in both adults and children with NF1. Incidence of spinal tumours in 
childhood has been reported at 13.5% in a series of 62 consecutive asymptomatic 
children with NF1 aged 11 months to 18 years (109).  Over time, about 40% of 
individuals with NF1 have spinal tumours(110, 111), with about 2% experiencing 
significant symptoms (106, 111).  
 
Neurofibromas and spinal deformity may cause significant pain, paresis with risk of 
complete paralysis, respiratory compromise or bladder/bowel dysfunction.  Children 
with PNF in this location have been over-represented in early clinical trials between 
1996-2007, reflecting the severity of associated neurologic and orthopaedic 
complications. Spinal cord compression was present in 24% of children, with 
potential cord compression affecting a further 23%, among 59 children treated (96).   
 
It is essential that clinicians are aware of the potential complications attendant on 
tumours in the spinal region in NF1, to ensure appropriate surveillance and treatment 
is instituted to minimize morbidity and risk of early mortality.  A series of illustrative 
cases are presented here outlining the potential complexities of neurofibromas in the 
spinal region, and highlighting important clinical clues to alert the clinician to 
investigate and treat promptly to optimize patient outcome.  Key messages are 
summarized in Panel 3.1. Approaches to management of neurofibromas and 
associated scoliosis in children with NF1 are reviewed and discussed.   
 
This project was approved by the local Human Research Ethics Committee (HREC 
reference LNR/17/SCHN76). 
 
 
Clinical Cases 
The children described here attended the Neurogenetics Clinic at The Children's 
Hospital at Westmead between July 2009 and January 2016 (summarised in Table 
3.1, followed by individual case descriptions). 
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Panel 3.1 Spinal/Paraspinal Neurofibromas: Characteristic Features and Principles 
of Management  
PNF occur on any nerves in 50-60% of patients with NF1 
PNF occur around the spinal region in approximately 13% of NF1 patients 
Spinal neurofibromas are symptomatic in about 2% of individuals with NF1  
Neurofibromas along multiple spinal nerve roots may be associated with plexus and 
peripheral nerve involvement with risk of respiratory insufficiency, muscle wasting and 
weakness, bladder and bowel dysfunction 
 
Risk factors for / symptoms of spinal tumours in NF1 include: 
• Externally visible PNF overlying the spine/neck/limb girdles 
• Large hyperpigmented macules or hypertrichosis overlying the limbs or spine 
• Back Pain 
• Abdominal Pain 
• Scoliosis  
• Hyperreflexia  
• Focal muscle wasting or weakness 
• Gait abnormality 
 
Spinal instability and subluxation are more common in association with PNF. 
Spinal MRI is mandatory in the presence of neurologic symptoms/signs and should be 
considered in the presence of PNF/skin changes overlying the spine/limb girdles or scoliosis. 
Ongoing clinical and neuroimaging surveillance for spinal PN is indicated on a 6-12 monthly 
basis. 
Active surgical treatment should be considered in the presence of significant focal cord 
compression or progressive neurologic deficits.  
Medical treatment may be considered to treat sub-acute progressive lesions with close 
monitoring. 
Chronic pain requires multimodal treatment including pharmacologic and non-
pharmacologic therapy. 
Rapidly increasing pain, progressive focal neurologic signs and tumour growth should 
prompt surgical review and investigation for malignant transformation to MPNST (lifetime 
risk of 8-13% in any individual). 
PNF-plexiform neurofibroma; MPNST-malignant peripheral nerve sheath tumour
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Table 3.1 Characteristics of children with spinal/paraspinal plexiform neurofibromas 
Patient 
 
Age/Sex 
(years; F/M) 
External appearances 
spine / Overlying 
cutaneous changes 
PNF location Scoliosis 
(region)* 
Kyphosis Neurologic 
examination 
Spinal cord 
Involvement 
on MRI 
Indication for  
Spinal MRI 
Operative  
Intervention 
(age, years) 
Morbidity/functional 
Impairments** 
1  11  M Nil Spinal nerve root No No Hyperreflexia 
 
Compression / 
Displacement 
T10 
Abdominal pain Tumour resection 
(10) 
Nil 
2  15  F Nil Paraspinal; 
Large unilateral foot/leg 
T10-L1 No Assymetric brisk 
patellar jerks 
Compression/ 
Displacement 
Complex NF1 
History of resected 
abdominal tumour  
Tumour  
resection 
(11) 
Ant/post fusion for 
kypho-scoliosis 
(14) 
Gait disorder 
(due to leg/foot PNF) 
3  14  F Extensive 
hyperpigmentation over 
the upper arm 
extending to hand; 
Normal spine 
progressing to 
asymmetry of shoulder 
girdles 
 
Shoulder/arm/cervical 
spine 
C4-C6 Yes  
(post-op) 
Hyperreflexia 
Left arm weakness 
Compression Hyperreflexia 
 
Tumour resection  
(10) 
 
Halo traction + 
fusion for 
subsequent 
subluxation 
Mild left arm weakness 
4 8  F Extensive 
hyperpigmentation over 
posterior pelvic girdle 
and upper back 
Midline lower back 
extending R>L buttock; 
Small superficial upper 
back 
 
No No Hyperreflexia 
 
No  Hyperpigmentation 
Midline back 
tissue bulk  
Pain 
- Pain, anxiety 
5 8  M Deep purple bulky 
tumour resembling 
haemangioma 
 
Unilateral face/neck C1-T1 Severe Hyperreflexia 
 
Traction/ 
compression 
Cervical tumour; 
Hyperreflexia 
Tumour debulking  
and fusion 
(8) 
Pre-operative recurrent transient 
episodes of paraparesis; 
Post-op no fixed neurologic 
deficits;  
Pain; 
Home schooling for risk 
minimisation 
 
6 18  F Nil Extensive tumour load: 
Multilevel spinal nerve 
roots; 
Brachial and lumbar plexi; 
Multiple peripheral 
nerves; 
Head/neck 
No No Hyperreflexia  
evolving to 
hyporeflexia, 
wasting, 
weakness, pain, 
sensory deficits, 
bladder and bowel 
dysfunction*** 
Bilateral spinal 
cord 
compression 
C2-C5; 
 
Expansion of 
multiple spinal 
nerve roots 
 
Spinal involvement 
noted incidentally 
on imaging 
head/neck PNF 
Focal tumour 
resection  
(c-spine;17) 
Arrest of progressive deficits post-
op; 
Residual wasting, weakness, pain, 
sensory deficits, bladder and bowel 
dysfunction; respiratory 
insufficiency; 
Anxiety/depression 
7 18  F Overlying cutaneous 
changes 
(paraspinal purplish 
discoloration consistent 
with PNF) 
Posterior 
chest/paraspinal 
  
C/T/L Yes Hyperreflexia 
Dysaesthesia R 
arm 
No but 
extensive 
dural ectasia 
Fusion 
(3 years) 
T3-T10 fusion  
(3) 
Inoperable  
(18) 
Pain/dysaesthesia; Respiratory 
insufficiency; 
Short stature; 
Cosmetic deformity; 
Anxiety/depression 
*C-cervical; T-thoracic; L-lumbar; **No deficits due to operative intervention; ***Multifactorial presumed due to cord compression, radiculopathy and peripheral nerve involvement; PNF-plexiform neurofibroma. 
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Case 1 
This 11-year-old boy had a background of hypothalamic low grade presumed 
astrocytic tumour diagnosed at age 3 years, managed conservatively without visual or 
endocrine impairment. There were no externally visible PNs.  At age eight, persistent 
left lower quadrant abdominal pain occurred.  An abdominal ultrasound was normal.  
On review several months later, there was no localised pain on spinal palpation, full 
range of movement and no abnormalities of the peripheral neurologic examination. 
Some constipation was reported. Due to persistent abdominal pain, an MRI of the 
spine was arranged which demonstrated a lobulated mass at T10 expanding the left 
neural exit foramen and causing severe displacement and cord compression (Figure 
3.1a,b).  Surgical decompression and tumour resection arranged within 10 days 
confirmed PNF on pathology, and was followed by resolution of abdominal pain.  
Four years later, residual tumour increased in size within the canal, without  
significant cord compression, but with extension to involve the paraspinal area  
 
 
 
Figure 3.1 Case 1. MRI of eleven year old child with left abdominal/flank pain due to 
left transforaminal spinal neurofibroma at T10/T11 (coronal STIR, a); at maximal cord 
compression (axial T1 weighted gadolinium enhanced view; spinal cord =long white 
arrow; neurofibroma = short white arrow, b); sagittal T2 weighted image showing 
anterior displacement of the spinal cord (c).  
a
b c
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outside the canal. No new symptoms occurred.  He proceeded to repeat debulking of 
the spinal lesion. Pathology showed atypical findings concerning for malignant 
peripheral nerve sheath tumour, including increased cellularity, extent and severity of 
atypia,   and presence of mitoses. A subsequent operation occurred to ensure complete 
tumour excision, which was uncomplicated.  He remained well five months later. 
 
 
Case 2 
Now aged 15 years, this girl born to non-consanguinous Arabic parents was 
diagnosed with maternally inherited NF1 aged 3 years having café au lait macules 
(CALM) and axillary freckling, with leg length discrepancy and gait assymetry due to 
a large left foot PNF, and several xanthogranulomata over the trunk. She was 
reviewed in our service following arrival from overseas at age 11 years. Interval 
history was reported to include resection of a retroperitoneal abdominal mass 
identified as a PNF, and bowel resection for intussusception within the preceeding 
year. The left leg and foot PNF was associated with a 5cm leg length discrepancy for 
which she required a larger shoe size, and elevated sole for the unaffected side. 
Thoracolumbar scoliosis was noted in Neurogenetics clinic.  Orthopaedic evaluation 
attributed this to pelvic asymmetry rather than true scoliosis. No palpable abdominal 
mass was found and the examination was remarkable for abnormal gait due to leg 
length discrepancy, and hyperreflexia at the knees, right greater than left. An MRI of 
the abdomen and spine was performed given hyperreflexia, and to characterise the 
reported retroperiotoneal and abdominal lesions as a baseline for monitoring over 
time.  Spinal MRI revealed kyphoscoliosis at T11/T12 convex to the right, with 
moderately sized paravertebral PNF involving T10 to L1 nerve roots with intraspinal 
extension at T11, erosion of the right T11 posterior vertebral body with dural ectasia; 
significant displacement and compression of the spinal cord was identified (Figure 3.2 
a-d). No previous films were available for comparison to indicate whether this was a 
static or progressive lesion. The patient was re-examined, with lack of signs of 
myelopathy other than hyperreflexia confirmed.  T10-T12 laminectomy with tumour 
resection was performed, due to concern regarding potential acute vascular 
compromise in the event of tumour growth.  Pathology confirmed PNF.  
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Figure 3.2 Case 2. T2 weighted coronal (a), sagittal (b) and axial (c/d) MRI aged 11 
years showing neurofibroma at T11 with severe cord compression and displacement; 
lobulated PNF in adjacent peritoneal cavity T10-L1 (a); widening of the right neural 
foramen at T11 with scalloping of the posterior vertebral body and dural ectasia 
(c/d); spinal cord indicated by white arrow. 
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Two years later, the patient’s symptoms remained static without back pain.  Gait 
asymmetry persisted with no interval change in examination. Three years later, 
progression of the kyphoscoliosis was identified with minimal change in the tumour.  
A two-stage anterior and posterior spinal fusion (T10-L2) was conducted with 
stabilization of the curve, without complications.  
 
 
Case 3 
This 14-year old girl was followed for several years in clinic. Examination revealed a 
slim child with an extensive area of hyperpigmentation extending from the left elbow 
down the arm to involve the ulnar distribution of the hand with increased tissue bulk 
notable above the elbow, consistent with extensive left arm PNF (Figure 3.3a-b). 
Deep tendon reflexes during serial examinations were brisk with ankle clonus (arms 
greater than legs, right greater than left; mild weakness of the left arm).   At 10 years 
of age, spinal MRI demonstrated extensive PNF underlying the area of 
hyperpigmentation involving the left brachial plexus, peripheral nerves of the left 
arm, paravertebral involvement from C4 to T3 including cervical spinal nerve roots, 
extension into the spinal canal with displacement and compression of the cord from 
C4-C6, together with cord T2 and FLAIR hyperintensity, and associated cervical 
scoliosis (Figure 3.3c-e).  C3-C6 laminectomy with tumour debulking was performed 
9 days later. Postoperative pain was treated with gabapentin with improvement, then 
tapered off over 3 weeks.  The patient was seen in clinic with pain only on palpation 
of the PNF, and stable mild weakness noted in the LUE (4/5).  Repeat plain films 
(Figure 3.3f) and MRI of the spine 6 months later showed anterior subluxation of 
C3/C4 with acute cervical kyphosis and spinal canal stenosis without symptoms or 
signs of cord involvement. The patient was managed with 6 weeks of traction, 
followed by anterior and posterior fusion (C3-C6). Three years later she continues 
well without pain or progressive neurologic deficit.
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Figure 3.3 Case 3 aged 10 years with large CALM over the left shoulder/arm and shoulder asymmetry (L>R; a-b);  
MRI spine coronal STIR image showing L paraspinal PNF with intraspinal and axillary extension (c); axial T2 weighted  
images showing cord compressed anteriorly and to the right (white arrows) with transforaminal tumour extension to 
multilobular PNF left neck (d); sagittal T2 weighted images showing midline neurofibroma at C3-5 causing anterior spinal  
cord displacement and left paraspinal PNF (e); anterior subluxation of C3/C4 6 months after tumour resection (lateral x-ray, f). 
a b c
d fe
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Case 4 
An 8-year-old girl with extensive hyperpigmentation over the upper and lower back 
was noted to have subtle increased tissue bulk underlying the lower back skin changes 
during early childhood (Figure 3.4).  
 
 
 
Figure 3.4 Case 4 (at age 5 years) with diffuse hyperpigmentation over the upper 
back and upper buttocks extending over the anterior hips bilaterally (a-c). Subtle 
increased soft tissue bulk over the midline lower back (c, d white arrows) due to 
plexiform neurofibroma.    
 
 
Lower back pain radiating to the buttocks occurred from 4 years of age, such that 
prolonged sitting caused significant distress, and was treated with 35mg/kg/day 
gabapentin. Deep tendon reflexes were symmetrically brisk, particularly in the legs. 
MRI showed increased bulk of the medulla and cervical spinal cord (not shown), 
along with cutaneous and muscular plexiform neurofibromas over the lumbar region 
without extension to the spinal canal (Figure 3.5). Minor superficial PNF was seen in 
the upper thoracic soft tissues. Chronic pain particularly on compression of the PNF 
contributed to significant concern about falling in the playground, along with 
separation anxiety and need for increased supervision at school.   
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Psychological support was provided for anxiety, along with ongoing analgaesics.  
Persistent increasing pain paralleled gradual expansion of tumour, without 
involvement of the spinal canal. Trametinib was commenced due to significant 
Figure 3.5	Case	4 a.	Axial	STIR	MRI	
showing		plexiform neurofibroma over	
the	lumbosacral	spine	and	buttocks	
without	extension	to	the	spinal	canal.	
b-c.	Coronal	STIR	MRI	showing	buttock	
plexiform neurofibroma extending	into	deeper	muscle	layers	on	 the	left	buttock.	
a
b
c
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functional impairment associated with pain.  After 6 months of therapy, pain and 
anxiety are significantly improved, with daily analgaesic discontinued and normal 
participation in school and community activities, with radiologic monitoring 
underway to track tumour volumes.   
 
Case 5 
Patient 5 is a 12-year old boy, diagnosed with head and neck haemangioma at the time 
of birth.  The expected regression of the haemangioma during the early years of life 
did not occur.  At the age of 4 years he was reviewed by a paediatric neurologist who 
identified café au lait macules with skin fold freckling, and diagnosed NF1. Increased 
tissue bulk was noted in association with the deep purple discoloration of the skin 
affecting the left side of the mandible and neck, extending down over the left 
shoulder.  MRI of the head and neck was arranged which showed imaging findings 
consistent with a highly vascular PNF (Figure 3.6).   
 
 
 
 
 
Figure 3.6 Case 5 at age 4 years showing T2 weighted sagittal MRI of the cervical 
spine showing severe kyphosis with dysplasia affecting the vertebral bodies and 
posterior spinal elements.  PNF anterior to C1-C5 with extension into the spinal 
canal, causing posterior displacement and compression of the cord. 
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Significant kyphoscoliosis was evident on MRI, more obvious than on clinical 
examination due to bulky tumour overlying the spine, with deep extension anterior to 
the vertebral bodies and within the spinal canal causing cord compression and 
displacement. The patient proceeded to have an episode of acute quadriplegia lasting 
minutes following a fall from a bed onto a carpeted floor.  The presumed mechanism 
was due to tension across the spinal cord during neck flexion/extension.  Surgical 
treatment was considered by a multidisciplinary team of neurosurgical and 
orthopaedic specialists experienced in the management of patients with NF1.  The 
family was not keen to proceed due to the risk of significant surgical complications.  
Investigational medical therapy was also considered, and deferred due to concern 
regarding destabilisation of the spine in the event of tumour shrinkage.  The child was 
managed conservatively, with restrictions placed around activity to minimize 
excessive neck movement.  His parents elected home schooling due to concerns about 
the risk of minor trauma in the school environment.  Several subsequent episodes of 
transient paraplegia occurred prompting multidisciplinary reviews at intervals, leading 
to surgical intervention consisting of soft tissue debulking, decompression of the 
foramen magnum and posterior c-spine decompression with fusion from occiput to 
T5.  Six months later persistent neck pain has been managed with gabapentin, and the 
patient has no significant neurologic deficits. 
 
Case 6 
This young woman, with maternally inherited NF1 experienced multiple severe 
complications, including an extensive PNF of the head and neck.  This lesion 
involved the periorbital region, external auricular canal, and intraoral area with 
thickening of the tongue associated with dysarthria and swallowing difficulties. 
Multiple cutaneous neurofibromas became evident during middle childhood.  Deep 
tendon reflexes were symmetrically increased during middle childhood.  
Neurofibromas affecting spinal nerve roots at multiple levels were demonstrated on 
MRI of the head and neck, with extended imaging over time showing high tumour 
burden involving neurofibromas on all spinal nerve roots, brachial and pelvic nerve 
plexi, and major peripheral nerves in all four limbs (Figure 3.7a-b). Several well 
circumscribed tumours were identified within the spinal canal between C1-C4 and 
C6-C7.
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Figure 3.7 Case 6 Extensive PNF tumour load shown on whole body MRI coronal and sagittal STIR images at age 17 years (a,b)  
including enlargement of spinal nerve roots (white arrow, b) at all levels; T2 weighted sagittal cervical spine aged 8 years (c)  
and 18 years (d) showing progressive growth of neurofibroma anterior to C1/2 vertebral bodies and multiple tumours in the  
upper cervical region; cord compression from bilateral spinal nerve root tumours (axial STIR e-f); right facial PNF with tongue 
involvement (c,f). 
 48 
Progressive functional impairments occurred during late adolescence, including 
muscle wasting, weakness, leg pain (treated with gabapentin 50mg/kg/d) and 
multifactorial gait impairment with bilateral foot drop and unrecordable lower 
extremity NCS, reflecting peripheral neuropathy. Surgical treatment included repeated 
debulking of head/neck PN.  However, surgery for spinal/pelvic disease was not 
recommended due to the diffuse extensive PNF involvement. At age 17 years (2012) a 
course of imatinib (Glivec) was prescribed at 300mg bd, increased to 400mg bd. 
Despite therapy, tumour volumes slowly increased, and progressive decline in clinical 
status occurred including requirement for nocturnal CPAP, loss of bladder and bowel 
function and progressive weakness.  Imatinib was ceased after 12 months. The patient 
required a tripod walking aid for support and balance. At age 17 years, rapid decline 
in gait occurred over a few weeks, requiring a wheelchair. Repeat spinal MRI showed 
growth of upper cervical masses at multiple levels (Figure 3.7 c-d), with progressive 
cord compression (Figure 3.7 e-f) and T2 signal hypersensitivity indicating cord 
oedema (not shown). C1-C4 laminectomy and C6-C7 laminoforaminotomy with 
tumour debulking were performed, pathology confirming neurofibromas.  Clinical 
status stabilized with return of aided independent mobilization over short distances 
and power of 4/5. A high suspicion for risk of transformation to malignant peripheral 
nerve sheath tumour continues to be maintained during subsequent clinical follow up 
given the patient’s massive tumour burden.  
 
Case 7 
An 18-year-old girl diagnosed in early childhood had PNF over the left posterior chest 
wall with early onset progressive thoracic kyphoscoliosis (Figure 3.8a). Anterior and 
posterior spinal fusion (T3-T10) with bone allograft was performed at 3 years of age.  
Over subsequent years, progressive curvature occurred above and then below the 
fused spinal region.  By age 11 years, upper thoracic and cervical scoliosis was 
evident on examination with imaging demonstrating progressive severe dural ectasia 
and gradual growth of the thoracic PNF.  Dysaesthesia (tingling and numbness) 
affecting the right arm and shoulder blade became more prominent at 14 years, 
extending to involve the axilla with radiation down the right arm, and increasing pain 
from 16 years.  MRI showed progressive spinal curvature with profound dural ectasia,  	
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osteopenia and minimal change in the soft tissue mass. Investigations were performed 
to assess for MPNST including biopsy of the left chest nodule (Figure 3.8 b, c, white 
arrows), pathology consistent with PNF. Nerve conduction studies showed no major 
sensorimotor changes.  Respiratory insufficiency developed, along with anxiety and 
mood disorder in the context of significant cosmetic deformity with short stature, and 
chronic illness requiring ongoing active management. Pharmacologic treatment with 
gabapentin and SSRIs was instituted along with non-pharmacologic measures.  
Symptoms were attributed to radiculopathy associated with dural ectasia (Figure 3.8 
b, c), with ongoing careful surveillance for MPNST. Consultation between 
experienced neurosurgeons and orthopaedic specialists occurred with international 
colleagues, recommending conservative management given significant operative 
risks. 
 
 
a
c
b
Figure	3.8	Case	7 Coronal	STIR	MRI	at	age	
3	years	showing	left	thoracic	kyphoscol-
iosis with	adjacent	PNF	(white	arrow,	a);	
Coronal	(b)	and	axial	(c)	T2-weighted	MRI	
showing	progression	of	scoliosis	with	signif-
icant expansion	of	the	spinal	canal	and	
dural ectasia	 at	age	18	years;	adjacent	 PNF
then	showing	prominent	nodular	component	
(white	arrows).
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Discussion 
The cases presented illustrate a diversity of symptoms and signs attributable to the 
neurologic and orthopaedic complications of spinal/parapsinal tumours in NF1. 
Comprehensive clinical assessment including general and neurologic examination 
during routine clinical reviews is mandatory, to identify and treat such complications.  
Paediatricians are trained to recognize a range of red flags suggestive of spinal 
pathology that can occur in children with NF1, including back and abdominal pain, 
weakness, bladder or bowel dysfunction and abnormalities in the neurologic 
examination.  Additional NF1-specific clues associated with externally visible 
plexiform neurofibromas over the spine or limb girdles include increased tissue bulk, 
pigmentary changes or hypertrichosis, and scoliosis. The presence of both 
subcutaneous and plexiform neurofibromas in the same patient should raise suspicion, 
potentially indicating a higher tumour burden, as this was strongly associated with a 
higher incidence of internal PNF in one retrospective study (OR 6.8)(112), although 
this has not been noted in other studies(105).  
 
The importance of comprehensive and timely evaluation of severe or persistent back 
and abdominal pain in childhood to identify and treat spinal tumours and cord 
compression has been emphasised previously(113-116), and certainly applies in the 
management of children with tumour predisposition syndromes such as NF1 as 
illustrated by Case 1. The origin or extent of abdominal masses must also be 
established, bearing in mind possible spinal involvement, which has been reported in 
a child with NF1, associated with development of MPNST(117).   
 
Cutaneous changes or increased tissue bulk associated with PNF overlying the spine 
or limb girdles should raise the clinician’s suspicion of tumour extension into the 
spinal canal or underlying bony involvement, as described in in Cases 3, 5 and 7.  In 
contrast, neuroimaging may exclude deep spinal involvement as in Case 4 despite 
superficial hyperpigmentation with PNF. This child experienced significant 
functionally impairing pain, requiring both pharmacologic and non-pharmacologic 
treatment.  Similarly, brisk reflexes may occur with or without the presence of 
significant cord pathology. Careful clinical surveillance remains essential to monitor 
for changes that may indicate repeat neuroimaging is necessary over time.  
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Scoliosis is recognized as a red flag in all children with back pain(113), and 
commonly occurs in association with spinal tumours in NF1(118). In a series of 53 
children with NF1 (mean age 9.6 years, range 11 months-18 years) and normal 
neurologic examination, routine screening spinal MRI was performed to assess the 
yield for tumour diagnosis. Seven (13%) children with spinal neurofibromas (aged 5 
to 18 years; four solitary neurofibromas, and three PNFs) were identified (109).  
Scoliosis was coincident with spinal tumours in 5 of these 7 patients (109), 
constituting an important clinical clue to underlying tumour. Two patients were 
treated with surgical resection due to intradural tumour with significant cord 
compression in one and due to the development of associated thigh pain in the other. 
Clinical management/outcome was altered in only 1.9% (1/53) indicating routine 
spinal imaging was not justified for all children with NF1, and should be directed by 
clinical suspicion of spinal pathology, including presence of scoliosis (109).  Other 
neuroimaging studies for individuals of all ages with NF1 and recognized scoliosis 
have demonstrated presence of associated tumour in 37% of cases(118).  
 
Orthopaedic management by specialists experienced in NF1 is essential to correctly 
characterise scoliosis as dystrophic, having a range of associated dysplastic 
features(118, 119), or non-dystrophic, due to differences in the natural history and 
recommended management approaches. Whilst non-dystrophic scoliosis in NF1 
behaves like idiopathic scoliosis, the dystrophic variant can occur in very young 
children, is more likely to result in relentless progressive spinal curvature and to occur 
in association with adjacent spinal tumours. Bracing is ineffective in dystrophic 
scoliosis(118, 119). Spinal MRI is important in monitoring scoliosis in NF1 to 
identify evolution of non-dystrophic to dystrophic curves over time (which was 
reported in 80% of cases in one study of all ages)(119, 120), and to assess for 
intraspinal and paraspinal tumours(121). Tumours adjacent to the spinal convexity are 
common in dystrophic scoliosis(121). Clinicians must also be monitoring for the 
presence of kyphosis which is more strongly correlated with risk of neurologic deficit 
from the spinal deformity(118).  
 
Early aggressive surgical management for dystrophic scoliosis is recommended to 
stabilize the spine using anterior and posterior fixation with abundant autologous bone 
graft to minimize risk of non-union(118).   Halo-traction prior to fixation should also 
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be considered for cervical kyphosis(120). The orthopaedic team should recognize the 
increased risks of spinal deformities associated with adjacent tumour in NF1 which 
have been well described over time (119), including destabilization of the spine, 
myelopathy, radiculopathy, cord compression, intraoperative bleeding due to 
hypervascularity of the tumour, and the need for multi-stage procedures to resect 
tumour and adequately stabilize the spine (118, 120).  Spinal deformity and instability 
is at least twice as common following laminectomy for removal of spinal tumours in 
children compared with adults(122), and is expected to be higher in the NF1 
population.  
 
Spinal deformity with adjacent neurofibroma may cause significant nerve or cord 
compression (120) (as in Cases 1-3, 5-6), or excessive traction on the spinal cord or 
exiting nerve roots (as in Cases 5 and 7). In one case series, sixteen percent of 102 
patients with NF1 and spinal deformity were found to have spinal cord or cauda 
equina compression(119). For those individuals having high cervical/paraspinal 
tumours with kyphoscoliosis, assessment of respiratory function is essential. 
 
Dedicated diagnostic spinal imaging in children with NF1 should be arranged to 
evaluate concerning symptoms and signs, to monitor for change in known tumours, 
and for surgical planning purposes. While routine spinal imaging has been advocated 
for NF1 in the past(123), most authors recommend imaging based on clinical 
suspicion only, because asymptomatic tumours may not require intervention (109, 
111).  Neuroimaging protocols for neurofibromas typically include STIR (short time 
inversion recovery) (124). Although WBMRI is increasingly used in management of 
NF1 in some centres, and may help to identify spinal tumours as part of an assessment 
of whole body tumour burden(66, 125), smaller tumours may be missed(126).  The 
benefits of routine WBMRI have not yet been established outside a research setting in 
large clinical populations.  
 
In cases where spinal tumour is identified with spinal cord compression or significant 
bony changes in children with NF1, establishing clinical and radiological change over 
time is essential. It is noteworthy that marked displacement of the spinal cord as seen 
in Cases 2 and 3, presented with limited symptoms and signs aside from 
hyperreflexia. This reflects the relatively slow growth rate of benign NF-1 associated 
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tumours. With initial identification of any tumour in the spinal canal, in the absence of 
neurologic symptoms and signs, conservative management may be appropriate, as the 
tumour may be in a static phase of growth. However, the potential for progressive 
growth and acute vascular compromise of the cord remains, along with risk of 
neurologic deficit secondary to bony dysplasia, which may prompt surgical 
intervention, as in our patients (Case 2 and 3) and others.  
 
Characterisation of spinal tumours during a natural history study in a cohort of 97 
symptomatic NF1 patients for whom spinal imaging was performed (median age 14.2 
years, SD 7.6) showed the frequency of spinal tumours increases with age, 70% less 
than 10 years, 80% 10-18 years and 89% older than 18 years (127).  The yield of 
spinal MRI for symptomatic patients has been reported as high as 96% in one NF 
clinic including all ages(111). In this study tumours were extradural in 33% of 
patients (18/54), 57% (31/54) had transforaminal tumours, while intramedullary 
tumours occurred infrequently (6%, 3/54 patients)(111) as in other case series(128).  
A predilection for the lumbosacral spine has been observed(129), though all spinal 
regions can be affected(111), as shown in our selected patients (Table 1).  The entity 
of spinal neurofibromatosis is recognized in a subset of individuals with bilateral 
neurofibromas at every spinal level, and is characteristically associated with fewer 
other manifestations of typical NF1(130).  
 
Children with neurofibromas in the spinal canal are likely to be among those who 
should be considered for active surgical and/or medical management. Surgical 
treatment is the primary mode of therapy for NFs in the spinal region.  This may 
include acute tumour resection.  Subacute intervention may be appropriate depending 
on the patient’s presentation with a view to resolution of existing symptoms and 
prevention of clinical deterioration.  Whilst extensive multi-level disease associated 
with spinal NF1 is not readily amenable to surgical intervention, selective resection of 
neurofibromas causing focal cord compression may yield significant clinical 
improvement(131), as seen in our patient (Case 6).  Unfortunately, not all patients 
experience improvement in symptoms such as pain or paresis following resection of 
plexiform neurofibromas.  Furthermore, new neurologic deficits occur as permanent 
sequelae in a proportion of cases(104).  
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For some children and adolescents with NF1, the clinical consequences of NF1-
associated tumours may reflect the impact of multiple lesions, which complicates 
surgical decision-making.  This occurred for our patient Case 6 for whom progressive 
clinical decline occurred over late adolescence presumed due to multilevel 
transforminal spinal neurofibromas, PNF in the pelvis, lumbosacral plexus, and 
multiple peripheral nerves. Despite extensive disease, focused surgery was needed to 
halt the accelerated decline attributable to growth of cervical spine neurofibromas, 
and was provided with good effect in this patient. 
 
In a retrospective assessment of children and young adults enrolled in early phase I 
treatment trials at the NIH from 1996 to 2007, spinal cord involvement was present in 
24 percent, and identified as a potential complication in 47 percent (n=59, median age 
8 years, range 2-21 years).  The cervical cord was most frequently involved (7/24) 
with remaining patients having multi-level involvement (17/24)(96).  Limited efficacy 
has been demonstrated with a range of agents with different mechanisms of action to 
date, including inhibition of RAS signaling(98), mTOR(69) and cKIT (68, 132), with 
MEK inhibitors showing the most promise recently with clinical trials ongoing. In 
certain circumstances, medical treatment should be considered for progressive lesions 
at risk of significant complications, with close follow up. Clinical and neuroimaging 
surveillance initiated based on clinical suspicion should commence from diagnosis to 
identify children with plexiform neurofibromas likely to cause significant symptoms 
during early childhood, to ensure optimal therapy, including selective use of novel 
medications where possible, ideally in the setting of a clinical trial. 
 
There is currently inadequate evidence to recommend routine treatment of children 
with NF1 associated spinal tumours with targeted medical therapy. However, when 
possible, those with significant focal or multilevel spinal neurofibromas should be 
considered for medical therapy either in clinical trials or on a compassionate basis, so 
long as clinical and neuroimaging surveillance is frequent enough to allow 
identification of progressive disease that should be treated by surgical means. 
 
The occurrence of chronic pain in the cases presented here represents another 
important management issue in this population.  The impact of chronic pain 
associated with PNF in children and young people with NF1 was recently described 
 55  
for a group of 59 individuals aged between 6-18 years(67).  Despite analgaesic use in 
33% of patients, impairment in daily living/quality of life was endorsed by 73% of 
parents, and 59% of youth (aged 10-18 years, N=41). Higher tumour burden was 
associated with increased pain, as were anxiety, depression and difficulties in social-
emotional functioning(67), as also seen in our selected patients.  Multidimensional 
treatment approaches are required including biological agents and psychosocial 
therapies.  
 
During assessment of NF1 associated pain, clinicians must be cognisant of the risk of 
malignant peripheral nerve sheath tumour (MPNST) which is 8-13% during any 
individual’s lifetime (41).  Increasing pain is one of the sentinel signs of sarcomatous 
change, representing a diagnostic challenge in NF1 due an overlap of this symptom in 
both benign and malignant tumours. As illustrated in Case 7, in the presence of 
significant spinal disease in NF1, pain may also occur due to mechanisms such as 
radiculopathy associated with dural ectasia.  Nevertheless, increasing frequency and 
severity of pain, focal neurologic signs and rapid tumour growth should prompt 
investigation for MPNST(88). This entity portends the main threat of early mortality 
in NF1(43), with high likelihood of metastasis, frequent recurrence following 
resection, and poor response to chemotherapy and radiotherapy(89). Patients with 
high tumour load and NF1 whole gene microdeletion are at highest risk of MPNST. In 
NF1, sarcomatous change most commonly occurs in pre-existing neurofibromas or 
spinal nerve root tumour (88, 129). Although MPNST arising in the spinal region is 
rare for both sporadic and NF1 associated tumours (133), this can occur. A child 
diagnosed with NF1 initially presenting with bladder and bowel dysfunction was 
subsequently identified with spinal PNF and progression to MPNST (117).  
 
Neuroimaging features suggestive of sarcomatous change include inhomogeneity of 
MRI signal intensity and patchy contrast enhancement in the tumor area (suggestive 
of necrosis and hemorrhage), with invasion of adjacent tissues(72, 129).  High 
SUVmax on fluro-deoxy-glucose (FDG)-PET should raise suspicion and prompt 
consideration of tissue biopsy or tumour resection (134). MPNST have traditionally 
responded poorly to radiotherapy or chemotherapy(75, 89), with associated high risk 
of mortality(88). Identification of novel medications for treatment of MPNST with 
improved efficacy remains an active area of research(89, 135). 
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The genotype underlying NF1 was not available for most of the patients presented 
here based on limited routine clinical testing to date, due to the 5% false negative rate 
which mandates management for presumed NF1 anyway.  Questions remain 
regarding the remarkable phenotypic diversity in different symptoms and signs 
affecting patients with NF1.  Although many mutations have been described in the 
large NF1 gene, there are limited genotypes associated with a recognisable phenotype.  
One exception includes the NF1 microdeletion for which a high PNF tumour load and 
elevated lifetime risk of transformation to malignant peripheral nerve sheath tumour 
have been described(108).  There may be a role for considering NF1 microdeletion 
testing in suspected cases.  Other than the NF1 microdeletion, the entity of familial 
spinal neurofibromatosis has been acknowledged, for which missense or missense and 
splice-site germline NF1 gene mutations are more common(110). In the presence of 
resource limitation preventing genetic testing in all cases, maintaining a high index of 
clinical suspicion is mandatory.  It is possible that over time, additional tumour 
suppressor or susceptibility loci will be identified, which may assist in understanding 
the phenotypic variability observed, and with risk stratification and directing follow 
up imaging intervals.    
 
 
Conclusion 
In conclusion, outcomes for children with tumours in the intra/paraspinal region are 
variable in NF1, but morbidity is frequently significant, despite surgical and medical 
therapy [19]. A high threshold of suspicion for complications of neurofibromas 
including extension into the spinal canal is essential in management of children with 
NF1. This case series illustrates the following features as risk factors for spinal 
neurofibromas: cutaneous changes of externally visible PNF overlying the spine, limb 
girdles or adjacent limbs, scoliosis, presence of progressive back or abdominal pain, 
focal neurologic findings such as hyperreflexia, muscle wasting or weakness, bladder 
or bowel dysfunction.  Recognition of the association between neurofibromas and 
spinal deformity, particularly dystrophic scoliosis and kyphosis of the cervical spine, 
is important to facilitate identification of potential complications early, to optimize 
surveillance over time, and to institute active management in a timely fashion with 
assistance of experienced orthopaedic colleagues, before permanent sequelae occur. 
With prompt surgical intervention and the promise of molecularly targeted medical 
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therapy, it is hoped that the severity and extent of complications associated with 
spinal tumours in NF1 can be avoided in future.
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CHAPTER 4. NOVEL MEDICATION FOR COMPLEX NEUROFIBROMAS IN NF1 
 
Introduction 
Plexiform neurofibromas (PNFs) are primarily benign tumours occurring frequently 
in patients with neurofibromatosis type 1 (NF1); they are usually congenital in origin. 
PNFs can cause significant disfigurement, and variable functional impairment 
depending on location and extent, including cranial nerve dysfunction, spinal cord 
compression, pain, and abnormal functioning of adjacent organ systems that may be 
encased by tumour (104, 105). According to population−based studies, approximately 
25% of patients with NF1 have visible plexiform neurofibromas (PNFs) on physical 
examination (106), and additional lesions in deeper tissues are evident on imaging 
studies in between 50-60% of individuals (3, 9, 65, 66, 106). Studies of the natural 
history of PNF growth in NF1 have demonstrated that highest rates of growth occur in 
early childhood, and individual tumours vary in their growth trajectories over time 
(28, 107, 136).  
 
Historically, surgical approaches have been the mainstay of treatment. However, 
surgery remains challenging due to the numerous lesions and extensive growth of 
many tumours, which can be diffusely infiltrating involving surrounding tissues. Risk 
of haemorhage requires careful management, and regrowth after resection is common 
(29, 65, 137). Systemic therapy offers the potential to treat multiple lesions 
concurrently without surgical risks. Candidate medications must have a tolerable side 
effect profile (138), along with demonstrated efficacy. Potential agents have been 
identified based on an understanding of tumour biology including the molecular 
pathways downstream of neurofibromin. Candidates have been summarised in recent 
years (21, 24, 26, 27, 30, 68, 70, 139), but none have so far been recommended for 
routine use.   
 
Methodologic approaches for the study of novel medications for PNFs have been 
refined over time.  Importantly, volumetric tumour analysis has been shown to be 
more sensitive for measuring change compared with traditional 2-dimensional 
measurement(28, 140). Occasionally tumour shrinkage has been observed without 
intervention, which may rarely occur as a biological phenomenon, but alternately 
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represents measurement error(29, 107). Previous studies have also indicated non-
progressive lesions are less likely to respond to pharmacologic therapies (eg. 
siromlimus) (31, 69), suggesting the need to establish therapy during the most active 
phase of growth in childhood.  
 
At our centre, three agents have been used on a compassionate basis for patients with 
complicated plexiform neurofibromas since 2009. Firstly, the mammalian target of 
rapamycin (mTOR) inhibitor sirolimus (Rapamune, Pfizer), secondly, the c-kit protein 
kinase inhibitor imatinib mesylate (Gleevec, Novartis) and thirdly, the MEK inhibitor 
trametinib (Mekinist, Novartis; inhibits the mitogen-activated protein kinase enzymes 
MEK1 and/or MEK2). 
 
The most compelling evidence of potential efficacy for treatment of plexiform 
neurofibromas in mice and humans was for imatinib, at the time of this study. 
Rationale for use was based on recognition that c−kit−ligand is an important mediator 
of neurofibroma formation. Increased kit−ligand mRNA transcripts had been found in 
neurofibromas, and elevated serum kit−ligand detected in patients with NF1. In a 
mouse model of NF1, Yang et al. showed that loss of one copy of the NF1 gene in 
c−kit positive bone marrow−derived cells was sufficient to allow neurofibroma 
progression in the context of schwann cell NF1 deficiency, likely through activation 
of the c−kit receptor (141).  They performed in vitro and in vivo experiments 
demonstrating reduction in tumour size and metabolic activity of neurofibromas in 
mice following pharmacologic attenuation of c−kit signaling using imatinib(132, 141, 
142).  Furthermore, remarkable clinical effectiveness was demonstrated in a single 
three-year-old child with life−threatening airway compression from an enlarging 
plexiform neurofibroma. Treatment with imatinib resulted in symptomatic 
improvement, and 70% decrease in tumour volume(141, 142).  
 
Interim results of a Phase 2 trial of imatinib in a group of NF1 patients at that time 
suggested symptomatic improvement and reduction in tumour size in a proportion of 
cases, with final results published subsequently (68). In addition, imatinib had also 
been reported to show a favourable response in patients with NF1 and other tumour 
types such as metastatic gastrointestinal stromal tumours(143). 
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This chapter presents detailed results of treatment with imatinib in two patients with 
severe disease, illustrates principles of patient selection, along with the complexities 
of establishing optimal neuroimaging surveillance and monitoring of outcomes for 
PNFs in patients with NF1.  A brief overview of other children selected for medical 
therapy using this and other agents, is also included. 
 
Methods 
Patient selection-Inclusion/Exclusion Criteria 
A prospective audit of imatinib treatment for complex growing plexiform 
neurofibromas causing significant morbidity was conducted in patients meeting NIH 
diagnostic criteria for NF1, attending the Neurogenetics Clinic at The Children’s 
Hospital at Westmead (CHW).  These were among the first patients treated for this 
indication in Australia. 
 
The growth and morbidity associated with plexiform neurofibromas is monitored in 
this clinical service as part of routine care.  PNFs that may be considered potential 
targets for medical therapy include the following: (i) head/neck lesions causing 
symptoms or the potential to cause symptoms with progressive growth (including 
airway compression, involvement of other vital structures, periorbital lesions with risk 
of obscuring the visual axis, and lesions with the potential to cause significant 
cosmetic disfigurement, typically involving the face) or (ii) peripheral nerve/spinal 
lesions (progressive neurological symptoms/signs, spinal cord compression, bone 
involvement with erosion or joint deformity, impingement on internal organs; ie. 
potential for progressive functional change). MRI tumour surveillance is established 
for patients with such lesions to record the pattern of growth, particularly for 
interpretation of changes on medication. 
 
As part of the baseline pre-treatment selection process, patients were required to have 
evidence of progressive and symptomatic plexiform neurofibromas with ≥20% annual 
increase in tumour volume, and to be deemed unsuitable for alternative surgical 
treatment. Serial MRIs were acquired over time according to a neuroimaging protocol 
established for this study (Appendix 1); STIR (short T1 inversion recovery) images 
without gaps, including coverage of the entire lesion or region of interest. The 
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NFtumormetrics Group, Medical Imaging Centre, Massachussetts General Hospital, 
Boston, performed volumetric analysis. Information regarding surveillance versus 
treatment status was not provided to reporting radiologists. 
 
Prior to treatment with imatinib, baseline haematologic, renal and hepatic function 
was performed. Malignant peripheral nerve sheath tumour (MPNST) was considered 
as a possible differential diagnosis, which would mandate investigation including PET 
scan, plus/minus tissue biopsy and alternative treatment, prior to inclusion (3, 74, 
134).  Additional details regarding inclusion and exclusion criteria are shown in 
Appendix 2. 
 
Primary Outcome: Tumour Volume 
The primary outcome for efficacy was radiologic tumour response according to (i) 
true response ≥50% reduction in tumour volume, or (ii) partial response ≥20% 
reduction in tumour volume. Stable disease <20% change in volume could be 
considered to represent limited efficacy on a background of progressive disease.  
Progressive disease ≥20% increase in tumour volume was considered definite lack of 
activity.  
 
Secondary Patient-Reported Outcomes: Symptoms and Quality of Life 
Secondary outcomes included clinical response assessed using a novel NF1 symptoms 
questionnaire, a simple linear overall wellbeing scale, quality of life (QOL) according 
to Medical Outcomes Study 36-Item Short Form (SF36) questionnaire, and adverse 
events/medication toxicity.  Overall clinical response was assessed as: (i) 
improvement / resolution of symptoms, (ii) stable symptoms, (iii) disease 
progression/worsening of symptoms. 
 
Improvement of symptoms and radiologically stable disease or reduced tumour 
volume, without significant medication related adverse events, was considered an 
overall effective treatment response.   
 
An NF1 symptoms questionnaire was used to monitor disease activity consisting of 19 
items focusing on symptoms and functional parameters routinely evaluated during a 
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comprehensive systems review (targeted to neurologic and oncologic symptoms) for 
complex NF1 patients. Items included headache, nausea, dizziness, pain, and gait 
impairment (Appendix 3). One additional open question was included.  Frequency of 
clinical symptoms was scored on a 6-point scale where 0=nil, 1=less than monthly, 
2=monthly, 3=weekly, 4=daily, 5=many times a day. A total score was calculated for 
each patient, with a higher score representing greater burden of symptoms, and 
potentially increased functional impact.  Functional status was more extensively 
assessed using the SF36 questionnaire.  
 
An estimate of overall wellbeing was derived using a linear scale ranked from low to 
high (Linear Overall Wellbeing Scale-LOWS, Appendix 3), where the overall 
wellbeing score was calculated as a proportion of the total length of the line (distance 
along the line/14.5). 
 
The multidimensional SF36 questionnaire (Appendix 4) (144, 145), has become one 
of the most widely used general health status questionnaires(146). The SF36 requires 
patients to choose one of several responses to 36 questions across eight health 
domains: physical functioning, social functioning, role of limitations due to physical 
and emotional problems, vitality, general and mental health, and bodily pain (145). 
Questionnaires were scored using the method of Ware et al(145). Norms for the 
healthy Australian population were available from the Australian Bureau of Statistics 
for comparison with baseline patient responses in this study (147).  In addition, the 
SF36 has been used in an adult population of individuals with NF1 (N=128, including 
2 individuals <18 years), which showed a good correlation between clinical severity 
of NF1 as measured by the Riccardi scale, and SF36 responses(148).   
 
Medication Administration and Monitoring 
Imatinib was administered orally, at a dose of 300-400mg bd for a 12-month period, 
under the supervision of CHW oncologists. Discounted drug was provided with 
support of pharmaceutical partner Novartis on compassionate grounds. Dose 
modification was considered if necessary in the event of medication toxicity, with 
particular reference to recognized adverse effects (Appendix 5).  
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Participants were initially reviewed monthly regarding symptoms, and blood 
monitoring (haematology, chemistry and liver function).  Clinical evaluation, 
neuroimaging and administration of questionnaires were subsequently planned for 
intervals of 3, 6, 9 and 12 months after commencement of treatment.  
 
Adverse Events 
Adverse events/medication toxicity was categorized according to the Cancer Therapy 
Evaluation Program Common Toxicity Criteria Version 4.0.    
 
Additional children treated for PNF (outside the current protocol) 
Finally, characteristics of these two patients are considered briefly in the context of all 
patients treated with medical therapy at our centre to date, to highlight changes in 
approach evolving in recent years. 
 
Approval for this study was obtained from the regional human research ethics 
committee (Protocol 09CHW154). 
 
Results 
Two patients were selected for imatinib treatment, both aged 17 years as shown in 
Table 4.1. Patient 1 had bilateral thoracolumbar spinal disease causing pain and mild 
weakness with a spinal neurofibromatosis phenotype (Figure 4.1a-b)(130, 149).  
Regular analgaesics were prescribed including gabapentin and opioids. This 
adolescent was previously treated with sirolimus for approximately 36 months. 
Tumour shrinkage was not observed. A change in therapy was planned due to 
increasing pain and radiologic progression.   
 
Patient 2 had a large right facial plexiform neurofibroma causing significant cosmetic 
deformity, involving the auricle, periorbital region, and lower face with deep 
extension to involve the tongue (Figure 4.1c; see also Chapter 3, Case 6). Extensive 
plexiform neurofibromas were seen throughout the body including bilateral spinal 
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Table 4.1 NF1 patients with complex progressive plexiform neurofibromas treated with imatinib at the Children’s Hospital at Westmead  
Patient Age 
(y) 
Genotype 
  
Indications PNF Location Volume 
(mL) 
Procedures  
(N) 
Agent Duration 
(months) 
Outcome Side effects 
1  13 
 
 
 
 
16 
c7258G>C 
heterozygous 
splice site 
mutation 
c7258G>C 
Back/leg pain 
Muscle wasting 
Leg>arm weakness 
(independently mobile) 
 
Urogenital dysfunction  
including pain 
Multilevel spinal 
neurofibromas 
Pelvic nerves 
 
 
1588.1 Nil Sirolimus 
 
 
 
 
Imatinib 
40m 
 
 
 
 
9m 
Progressive  
disease  
 
 
 
Progressive  
disease 
Nil 
 
 
 
 
Nil 
2 17 NA Back/leg/other pain 
Muscle wasting 
Weakness 
(independently mobile) 
Neuropathy 
Bladder/Bowel 
dysfunction 
(urinary catheterization; 
incontinence) 
Respiratory insufficiency 
(nocturnal ventilation) 
Cosmetic deformity 
Large head/neck 
peri-orbital; 
Extensive spinal, 
Pelvic nerves, 
Peripheral nerves  
 
9451.7 Facial PNF 
debulking (2) 
 
Tongue PNF 
debulking (1) 
 
Perineal PNF 
debulking (1) 
Imatinib 12m Progressive  
disease 
Hair loss;  
oedema 
 
 
 
NA-not available
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Figure 4.1 Coronal STIR MRI a. whole body, b. thoracolumbar spine (Patient 1);   
c. axial STIR face/neck, d. coronal STIR whole body (Patient 2). 
 
 
disease, involvement of pelvic nerves, and multiple peripheral nerves (Figure 4.1d). 
Cervical cord compression was present. Several debulking procedures had been 
performed for the facial lesion with good effect, followed by subsequent regrowth. 
Debulking of a symptomatic perineal plexiform neurofibroma had been completed 
prior to treatment. The patient experienced leg weakness, sensory change with foot 
drop, pain treated with daily analgaesics, and bladder and bowel dysfunction.  
Nocturnal ventilatory support (BiPAP) had recently been commenced.   
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Imatinib treatment was commenced in 2012 at a dose of 400mg bd for Patient 1 for 8 
months, and 300mg bd for Patient 2 for 6 months, increasing to 400mg bd for a 
further 7 months. Outcome measures were available at 8 months (both neuroimaging 
and patient reported outcomes, Patient 1), 10 months (patient reported outcomes, 
Patient 2) and 12 months (neuroimaging, Patient 2). Reason for cessation in both 
cases included inadequate response. 
 
Primary Outcome: Tumour Volume 
Volumetric data for Patient 1 was available from 18 months prior to imatinib, to 8 
months during treatment (Figure 4.2a). Tumour bulk increased by seventy eight 
percent in the eighteen months prior to imatinib treatment. At commencement of 
imatinib, spinal tumour volumes measured 1588.1mL. Four months after treatment, 
13% volume increase was recorded, followed by -2.3% (versus baseline) by eight 
months.  Overall, definite pre-treatment growth was observed, followed by stable 
disease.   
 
For patient 2, the right facial lesion measured 762mL 18 months prior to treatment, 
with an estimated annual growth rate of 40.2% (Figure 4.2b).   Unfortunately, follow 
up imaging to complement pre-treatment measurement was not available to monitor 
change in the facial lesion independently.  Instead, whole body measurements were 
initiated from the start of treatment, including measurement of the facial lesion. 
Baseline tumour burden measured 9451.7mL, with 1.1% volume increase evident at 4 
months, sustained at 12 months (Figure 4.2c), consistent with stable disease. Although 
not directly comparable, this stable volume contrasted with the background 
progressive disease evident on monitoring of the right facial lesion (representing 12% 
of whole body volume).  
 
Secondary Patient-Reported Outcomes: Symptoms and Quality of Life 
NF1 symptom questionnaire scores and LOWS scores at baseline and over time are 
shown in Figure 4.3 and Figure 4.4 respectively, suggesting disease progression in 
Patient 1 and stable disease in Patient 2.  One patient utilized the open question 
reporting pain during urination, defecation and sexual intercourse.  Overall, responses 
did not demonstrate clear improvement with treatment.  Although Patient 2 ranked  
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Figure 4.2 Plexiform neurofibroma volumes over time (months) pre- and post-
treatment with imatinib (0=start therapy). 
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Figure 4.3 NF1 Symptoms Questionnaire Scores over time  (months) 
on imatinib  (0=start therapy). 
 
 
 
 
 
Figure. 4.4 Linear Overall Wellbeing Scale (LOWS) scores over time (months)  
on imatinib (0=start therapy). 
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frequency of clinical symptoms higher than Patient 1, the former reported higher 
levels of overall wellbeing (LOWS scores), and both symptoms and wellbeing 
remained static over time.  In contrast, results for Patient 1 indicated increased 
symptoms and decline in wellbeing during treatment.   
 
Baseline SF36 results are shown on Table 4.2 along with Australian normative data 
for young adults, and results from a predominantly adult European hospital based 
NF1 population for comparison. Responses for Patients 1 and 2 were consistent with 
severe disease, reflecting the intended selection bias. Both reported limitations in 
physical functioning and pain along with significant impact on activities of daily 
living. Scores were also reduced for vitality and perceived general health, compared 
with the Australian young adult population.  Social functioning was affected to a 
lesser degree, with both individuals showing resilience in terms of mental health 
factors, reporting no impact on activities of daily living due to emotional difficulties.  
 
SF36 responses over time during treatment with imatinib are shown in Figure 4.5, 
with the eight domains clustered into physical and mental groups. At four months, 
improved scores were recorded for both physical functioning and activities of daily 
living (PhysFxn and LimPhysHlth, Figure 1a) for Patient 1, which may have related 
to other factors such as change in analgaesic treatment at that time. However pain 
responses remained the same.  This improvement was not sustained.  For the 
remaining six domains, responses were static over time or showed a decline in 
functioning. Similarly, for Patient 2, between baseline and ten months on treatment, 
responses across the eight domains showed static or declining functioning, in all 
except social functioning.  The explanation for change in social functioning is unclear 
and likely related to other environmental factors for this individual.  Pain was not 
improved in either patient. 
 
Adverse Events 
Treatment was well tolerated, without dose modification for adverse effects in either 
case.  Grade 1 hair loss (thinning of scalp hair) and oedema were recorded in Patient 2 
which were not treatment limiting.
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Table 4.2.  Baseline SF36 responses for Patient 1 and 2 compared with Australian norms and hospital cohort of French NF1 patients 
  Physical Health Domains    Mental Health Domains  
Population 
 
Physical Role Pain General Vitality Social Role Mental Health 
  
Functioning Phys Health** 
 
Health Energy/Fatigue 
 
Emotl Hlth*** Emtl Wellbeing 
          
         
Patient 1 85 25 35 15 65 75 100 96 
         
Patient 2 25 75 45 55 35 50 100 92 
NF1 adults‡ 
(SD) 
76.8 
(26.4) 
72.8 
(39.1) 
65.3 
(29.6) 
 
58.4 
(23.0) 
49.7 
(21.3) 
70.4 
(25.7) 
69.4 
(39.4) 
56.4 
(22.0) 75.2.5) 
         
Aust 
Norm* 
(SD) 
90.1 
(25.2) 
87.4 
(40.4) 
 
81.6 
(30.3) 
73.7 
(25.2) 
66.5 
(25.2) 
85.9 
(30.3) 
83.7 
(45.4) 
75.2 
(25.2) 
         
 
‡ Wolkenstein et al. (N=171, 2<18 years)(148); *Australian normative values of 18-24 year olds, combined genders(147); **Problems with work or other 
daily activities as a result of physical health; ***Problems with work or other daily activities as a result of emotional health;  Aust=Australian, 
Emtl=emotional, Hlth=health, Phys=physical.
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a. Patient 1 Physical Domains    b. Patient 1 Mental Domains 
 
 
 
 
c. Patient 2 Physical Domains    d. Patient 2 Mental Domains 
 
 
 
Figure 4.5 SF36 domain scores for physical and mental health over time (months) 
during treatment with imatinib. 
 
 
Long-term follow up 
Regarding long term follow up, both patients were treated prior to transition to adult 
services.  For Patient 1, issues regarding medication supply complicated treatment at 
transition to adult services. One further MRI was available for Patient 1, eight months 
after cessation of imatinib, showing a small increase in cervical tumours (volumetric 
data not available).  Phone follow up indicated no major functional change. Resection 
of selected cervical tumours was under consideration. At 12 months treatment Patient 
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2 experienced a rapid decline in motor strength associated with loss of independent 
ambulation (a wheelchair was required). Repeat spinal imaging demonstrated stable 
cervical cord compression with some cord oedema, little changed from previously.  
Imatinib was ceased due to the need for definitive surgical intervention. C1-C4 spinal 
laminectomy was performed plus debulking of cervical neurofibromas with good 
effect.  Independent ambulation was regained, and sustained at 24 months post-
surgery. 
 
Additional children treated for PNF (outside the current protocol) 
Table 4.3 presents an overview of children in the Neurogenetics Clinic at The 
Children’s Hospital at Westmead treated with novel medications between 2009 and 
2015.  
 
Discussion 
Tumour Volume 
In the two patients closely followed in this study, stable tumour volumes were 
demonstrated in response to imatinib treatment. The primary outcome for efficacy 
based on full or partial radiologic response (tumour shrinkage) was not attained in 
either case.  In one patient, stable disease contrasted with progressive pre-treatment 
disease, suggesting some efficacy.  Interpretation of the stable result was difficult in 
the second patient due to a change in tumour measurement pre- and post-treatment. 
Tumour shrinkage was not demonstrated in either case. Although medication was 
well tolerated, secondary outcomes of clinical response based on patient reported 
symptoms and quality of life failed to indicate significant benefit in any of the 
measured outcomes.  
 
These patients, both older adolescents, had severe disease. A high tumour load was 
present, with tumour volumes measured in Patient 2 being in excess of that measured 
in 171 individuals of all ages who participated in a study of patterns of PNF growth 
using whole body MRI (107).  In this cohort median volume was 86.4ml, ranging 
from 5.2 to 5878.5mL (107). Such large tumour burden is more likely in patients with 
NF1 deletions (>3,000ml) (150). Baseline tumour growth rates in our patients showed 
progressive disease, in contrast with the median growth rate of 3.7% per year (range 
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Table 4.3 Additional NF1 patients with complex symptomatic PNFs treated at the Children’s Hospital at Westmead since 2009 
Patient Age NF1 Genotype  Indication PNF Location Volume 
(mL) 
Procedures (N) Agent Study Type Duration Outcome Side effects 
3  15y NA Pain (hips) 
Limited mobility 
Cosmetic deformity 
Hip/Gluteus 
maximus 
Para-pharyngeal 
 
NA 
 
98.33 
No Imatinib Compassionate 
Use 
6m Unchanged imaging 
and clinical status 
Nil 
4  5m 
 
 
 
 
30m 
Hz truncating 
mutation c.147C>G 
(p.Tyr49*) 
Paternal  
Airway obstruction 
Tracheostomy 
Nocturnal ventilation 
Pericardial effusion 
Neck/ 
Mediastinal/ 
Thoracic PNF 
 
51.65‡ Biopsy neck 
lesions/debulking 
mediastinal lesions; 
Stent L main 
bronchus; 
Tracheostomy 
(4) 
Imatinib 
 
 
 
 
Trametinib 
Compassionate 
Use 
 
 
 
Compassionate 
Use 
 
7m 
 
 
 
 
36m 
ongoing 
Progressive disease 
 
 
 
 
Stable clinical 
disease 
 
Nil 
 
 
 
 
Itch 
5  18y NA Pain (buttocks/legs) 
 
T-L spine / Gluteus 
maximus 
Peripheral nerves   
 
690.09 Debulking sciatic 
nerves 
(2) 
Trametinib International 
Clinical Trial 
 
8m Pending 
Discontinued  
Patient choice (rash) 
Acneiform  
rash 
6  8y c.[4270-2A>G] 
Paternal 
Pain;Daily analgaesia 
Anxiety 
 
Paraspinal  (T-L)/ 
Gluteus maximus 
 
422.21 No Trametinib International 
Clinical Trial 
 
18m 
ongoing 
Clinical response Coarsening  
scalp hair 
7  5y Paternally 
inherited NF1 
Cosmetic disfigurement 
Threatening visual axis 
 
Periorbital  PNF 
 
26.19 No Trametinib International 
Clinical Trial 
 
12m 
ongoing 
Clinical response Folliculitis x2; 
Other skin  
Infection x1 
8 10y NA Unilateral leg paresis c-
spine* with cord 
compression 
Multilevel spinal 
disease; discrete  
c-spine tumours 
2010.7 No Trametinib Compassionate 
Use 
27m 
ongoing 
Radiologic response 
Clinically stable 
Eczematoid  
rash 
 
* c-spine=cervical spine; NA=not available; Hz=heterozygous, m=months, y=years; ‡ underestimate of baseline volume prior to treatment reflecting most recent NFtumormetrics data (2012/2013); NA-difficult to measure. 
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13.4% to 111.1%) during follow up of 2.2 years (range 1.1-4.9 years, N=171) (107). 
Both patients experienced significant daily pain treated with analgaesics, and narcotics 
in one case.  This contrasts with 59 children selected for 7 medical treatment trials at 
NIH between 1996-2007, where 53% experienced pain, and 5% required daily narcotic 
use.  In a broader patient group with spinal and paraspinal neurofibromas (71% younger 
than 18 years), half of patients experienced pain, with a quarter reporting daily 
symptoms(127). 
The CHW approach to treatment with imatinib shares a number of features, and some 
differences with the largest series of treated patients published to date by Robertson et 
al(68). In Robertson’s study, patients were not selected based on static or progressive 
growth, as pre-treatment growth rates were not measured. In addition, patient reported 
outcomes were not included, with limited subjective data regarding functional outcomes 
only. Thirty-six patients with clinically significant PNFs were treated with imatinib 
including 47% children and adolescents (median age 13 years, range 3-52 years).  Of 23 
evaluable patients treated for at least 6 months, six (26%) had a 20% or more decrease in 
volume of one or more PNFs. Interestingly, a trend toward larger tumours showing 
reduced response was reported. It may be that optimal response with any systemic 
therapy will be achieved in smaller actively growing lesions, a hypothesis to be tested in 
future studies. Subjective symptomatic improvement was reported in 30% of patients 
(7/23) including reduction in pain, improved motor functioning and improved bladder 
functioning such that catheterization was no longer required.  The authors recognized the 
need to quantify functional responses objectively, and to formally include patient-
reported outcomes, leading to development of recommendations to enhance future study 
design (151, 152).  
Patient-Reported Outcomes 
The inclusion of patient-reported outcomes in response evaluation for our patients 
provided evidence regarding clinical response in addition to radiologic response. 
However, determining the clinical meaningfulness of changes in scores is challenging. 
Whilst the NF1 questionnaire has not been validated in a large group of patients utilizing 
comparisons with comparable established tools, the trends observed over time paralleled 
results of SF36 responses in our patients.  This questionnaire may be helpful for 
monitoring clinical status over time in other complex NF1 patients, and could be further 
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assessed with a view to formal validation in future.  
The Linear Overall Wellbeing Scale generally mirrored results from other assessment 
tools, without providing additional detail. A simple overview measure such as this is 
most appropriate in populations with limited capacity to complete more detailed 
assessments. More comprehensive scales would be preferable for future use in the NF1 
population. For the purpose of generalizability and comparison with treatment results at 
other centres, future studies at our site will include tools for assessing pain and other 
functional outcomes such as the Pain Interference Index (for ages 6-24 years) and the 
Patient-Reported Outcome Measurement Information System (PROMIS) Physical 
Functioning Scale (for ages ≥5 years).  These scales have been recommended by the 
Response Evaluation in Neurofibromatosis and Schwannomatosis (REiNs) 
collaboration, subsequent to the conduct of this study (152). 
Regarding quality of life assessment, the SF36 is a validated tool for use in adults. It has 
however, been utilized in other populations with individuals younger than 18 years, due 
to the unavailability of other appropriate tools in the past(148).  It is likely that responses 
for younger patients would be conservatively represented here for physical functioning 
as these scores typically decline with increasing age in the normal population, although 
small increases occur in several domains of the mental health cluster with increasing 
age. 
 
SF36 domains deviating from population norms in a hospital-based French cohort of 
NF1 patients included physical functioning, bodily pain, general health perception and 
vitality. Similar domains were affected for our treated patients with severe disease. Their 
responses showed greater functional impact in several domains (including physical 
functioning, pain and general health perception) than the French cohort, which included 
patients of all ages.  Despite this, both patients scored highly in regard to perception of 
social functioning and emotional wellbeing/mental health factors.  For Patient 2 this was 
somewhat surprising considering others have identified a strong association between 
reduced emotional wellbeing and a high burden of skin disease and deformity(148). 
 
The protocol for this study identified both the PedsQL(153) and Impact of Pediatric 
Illness Scale(154) as possible tools for use in children.  Difficulties were experienced in 
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accessing the former. The Pediatric Illness Scale evaluates CNS symptoms, 
medical/physical status, adaptive behaviour, and psychological/emotional functioning 
given to both parents/caregivers and children older than six years. However the SF36 
was used in preference here due to the older age of the patients included, and our 
increased familiarity with this tool. Quality of life data derived using the Impact of 
Pediatric Illness Scale are now available from other populations of children with NF1 
treated for PNF, establishing important comparative data for future studies(97, 98). In 
addition, seven other quality of life studies for children with NF1, using different 
measurement tools, have recently been reviewed (155). Although these all showed 
reduction in quality of life, improved standardization of measurement is needed for 
future studies (155). 
 
Additional children treated for PNF (outside the current protocol) 
As shown in Table 4.3, subsequently treated children are younger, with smaller, actively 
growing lesions, representing examples from the high-risk groups now followed closely 
with clinical and radiologic surveillance from an early age. One younger adolescent 
(aged 15 years) received imatinib prior to the two patients described in detail here. 
Treatment was indicated for a large plexiform neurofibroma eroding the hip joint, 
causing significant pain and limiting mobililty. Symptoms failed to improve 
significantly, and the diffusely infiltrative nature of the tumor made accurate 
measurement difficult. Radiologic response in a second measurable para-pharyngeal 
plexiform neurofibroma failed to show tumour shrinkage(156).  
 
Based on reports of medication tolerability in younger children (157), imatinib was also 
offered to an infant with significant airway involvement followed by clinical and 
radiological progression after six months, leading to cessation of treatment.   Around 
this time, data from in vitro studies using MEK inhibitors showed promise. In mouse 
and human cells, and in vivo mouse models, shrinkage of plexiform tumours was 
observed in a majority of treated animals along with prolonged survival of animals with 
MPNST(158, 159). On this basis, we prescribed the MEK inhibitor Trametinib, which 
has a favourable side effect profile (160), and was available in Australia. This resulted in 
clinical improvement, including reduction in ventilatory support, with sustained 
improvement over 36 months.  Radiologic response has been difficult to demonstrate 
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based on accepted volumetric criteria. This is in part due to suboptimal imaging 
associated with risk management of a tenuous airway during anaesthesia.  Another 
patient subsequently treated with trametinib on a compassionate basis has had a 
reduction in the size of cervical neurofibromas.  Both have tolerated treatment well.   
 
Three additional children have now been enrolled in a multi-centre international clinical 
trial with encouraging clinical progress, including improvements in functional status due 
to reduction in pain.  One patient elected to cease treatment with trametinib due to 
acneiform skin rash, a recognized adverse effect. Phase 1 results recently published 
described exciting observations of MEK inhibition using selumetinib in children with 
plexiform neurofibromas. Tolerability during a median of 30 cycles (range 6-56) was 
established, with 71% of children (17/24) showing partial radiologic response to 
treatment (≥20% reduction in tumour volume) together with anecdotal evidence of 
improved pain, disfigurement and motor functioning (70). 
 
Limitations and Future Directions 
Limitations of this study include the small number of patients involved, and short 
duration of treatment and follow up. Data were not available for all time points planned. 
However, the detailed approach to assessment of outcomes provided helpful information 
regarding the limited potency of imatinib for both radiologic and clinical response.  
Other authors have highlighted the need to provide an adequate treatment trial in terms 
of duration of therapy, recommending 12 months as a minimum (68). It could be argued 
that additional benefits may have been seen in these individuals with a longer course of 
treatment. Given the limited data available in this study, interpretation has been made 
from simple graphical presentation rather than statistical analysis, which would be 
necessary to assess confidence in observed differences in a larger dataset. Despite these 
limitations, this study helped to establish effective surveillance of high risk PNFs in our 
paediatric population of NF1, along with principles of methodology in medical treatment 
trials for this indication, including recognition of radiologic and patient reported 
outcomes.  Overall, we gained invaluable experience in the selection and monitoring of 
patients for compassionate treatment of these complex tumours, and this has led to our 
inclusion as a site in international clinical trials.  
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Although not included in this study protocol, other functional outcomes such as 10 
metre-walking tests were monitored over time in these patients. This measure may be 
helpful in certain circumstances such as in motor decompensation due to spinal cord 
compression, as described in Patient 2. Objective measures of muscle strength using 
dynamometry may also have a role as an outcome measure.  
 
Moving forward, the potential utility of tissue biomarkers to assist in interpretation of 
variable responses to treatment, and in the longer term to direct individualized patient 
therapy, is also recognized. The CHW biobank includes tumour samples and serum 
samples for selected individuals, which may be helpful in this regard, and represents a 
resource to maintain and expand in future. 
 
Conclusion 
In conclusion, this chapter highlights many of the significant challenges inherent in 
managing individuals with NF1-associated PNFs. The extensive tumour burden and 
associated morbidity that can occur by late adolescence is sobering. It is hoped that early 
treatment of potentially complicated tumours will prevent progession and associated 
morbidity in the near future.  Assessing radiologic response in complex tumours is 
difficult, even in established NF centres. Because of the complexity of tumour 
measurement, selected centres of excellence calibrated for accuracy and reproducibility 
of volumetric analysis are essential to ensure integrity of data for radiologic response 
evaluation.  Furthermore, significant advances have been made in recent years through 
the work of the REiNS collaboration, to improve the methodology used in clinical trials, 
from radiologic to functional outcomes and quality of life in patients with PNFs (25). 
The approach utilized in this study represents part of the evolution of clinical research 
and clinical care for children with NF1 complicated by complex PNFs. 
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CHAPTER 5.  NEUROFIBROMATOSIS TYPE 2: PRESENTATION, MAJOR 
COMPLICATIONS AND MANAGEMENT, WITH A FOCUS ON THE PAEDIATRIC 
AGE GROUP. 
 
 
Introduction 
Neurofibromatosis type 2 (NF2) is an autosomal dominant disorder caused by mutations 
to the NF2 tumour suppressor gene, characterised by multiple non-malignant nervous 
system tumours, including schwannomas, meningiomas, ependymomas and gliomas, 
with bilateral vestibular schwannomas (VS) being a classical feature. Ocular and 
cutaneous manifestations also occur. Incidence is estimated at 1 in 33,000-40,000 and 
prevalence 1 in 100,000 (161). The condition is typically diagnosed at age 20-30 years, 
but features are often present for many years before the diagnosis is made in both 
sporadic cases and in those with a family history (162-164). About 10% of patients 
present before the age of 10 years, and 18% before the age of 15 years, with a greater 
diversity of clinical problems than seen in adults, and often with increased severity 
(165). In this review we explore the presentation and clinical course of NF2 with 
particular reference to children and adolescents, and a view to improving outcomes for 
all affected individuals.  
 
Diagnostic Criteria 
The diagnosis of NF2 based on clinical criteria has been refined over time, reflecting the 
typical presentation of adults with symptoms of vestibular schwannoma (Table 5.1) (11, 
166, 167). However, these criteria are less helpful in children who frequently present 
with other symptoms and signs of NF2, and for whom vestibular tumours may be too 
small to appreciate on initial neuroimaging. Examination of the skin and eyes often 
yields important diagnostic clues during childhood, and as such is of fundamental 
importance in suspected cases. Parents of children suspected of having NF2 should also 
be assessed carefully for symptoms and signs of NF2. 
 
Time to diagnosis is highly variable and is often prolonged despite symptoms presenting 
in childhood.  A recent report cited time to diagnosis in subgroups of adults and children  
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Table 5.1 Clinical diagnostic criteria for NF2 
 
Primary Finding  Additional features needed for diagnosis  
 
 
Bilateral vestibular schwannomas None needed 
  
First degree relative with NF2  Unilateral vestibular schwannoma  OR  
Any two other NF2-associated lesions: Meningioma, 
schwannoma, glioma, neurofibroma, cataract 
 
Unilateral vestibular schwannoma Any two other NF2-associated lesions: 
Meningioma, schwannoma, glioma, neurofibroma, cataract 
 
Multiple meningiomas Unilateral vestibular schwannoma  OR 
 Any two other NF2-associated lesions: 
 Schwannoma, glioma, neurofibroma, cataract 
 
Modified from (166, 167). 
 
 
at 5 years and 8 years respectively, with the delay ranging up to 21 years for adults and 
up to 36 years for children (168).  
 
Genetics 
The NF2 gene is located on chromosome band 22q12, and encodes a protein known as 
merlin (a moesin-ezrin-radixin-like protein) or schwannomin (14, 169). Merlin is 
important in anchorage of the cytoskeleton to the cell membrane, the organization of cell 
membrane proteins and interaction with cytosolic proteins. The pathways involved are 
required for cell growth, protein translation and cellular proliferation. The absence of 
normal merlin is associated with a predisposition to tumour formation (170). A detailed 
description of the complex cellular and molecular neurobiology of merlin is outside the 
scope of this article, but has been reviewed by others (167, 171). 
 
In most NF2 tumours, biallelic inactivating mutations are found. The gene may be 
inactivated by mutation, silencing or allelic loss (172, 173).   
 
 NF2 has almost complete penetrance by the age of 60 (161) . About fifty percent of 
patients are the first affected in their family, and are described as having de novo 
mutations. The other fifty percent are due to sporadic mutations (161), which may occur 
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in parental germline cells (prezygotic), or in postzygotic cells in which case mosaicism 
may result, such that only a proportion of cells carry the mutation. It is estimated that 
25% of sporadic mutations are mosaic (174). The transmission rate depends on the 
degree of mosaicism. For children of patients with a de novo mutation, the transmission 
rate is 50%, because all the child’s cells contain the mutation.  However, the 
transmission rate may be lower in de novo patients, as germ cells may not contain the 
mutation(175).  
 
Identification of a mutation in the NF2 gene is possible in over 90% of familial cases 
(167), and 80-85% of individuals with sporadic mutations (176), confirming the 
diagnosis when present in both tumour and blood (177). In mutation-negative 
individuals, confirmation of the clinical diagnosis is possible through careful follow up 
over time.  
 
In children presenting early with a more severe clinical course, mosaicism is less likely 
and consequently the mutation detection rate is higher. One study exploring the utility of 
mutation testing to screen for NF2 in patients presenting with unilateral VS showed that 
this is justified in those presenting <20 years of age. 83% of patients presenting under 
the age of 20 with a unilateral VS were found to have a detectable NF2 mutation 
compared to 7.7% when looking at all ages (178). 
 
In children of a parent with NF2, identification of a mutation has a major impact on the 
further screening of that individual (179). In sporadic cases, failure to identify a 
mutation does not obviate the need for ongoing surveillance, due to the phenomenon of 
mosaicism, or possibly presence of mutations in intronic regions, promotor mutations or 
large multiexonic deletions (164).  
 
Genotype-phenotype correlation 
Missense mutations usually cause mild symptoms and signs of NF2 (180). 
Nonsense/frameshift mutations produce a truncated protein, and tend to be associated 
with a more severe phenotype, earlier onset, more rapid disease progression and higher 
tumour burden with more spinal and intracranial tumours in addition to VS (166, 181).  
Mutations in the 3’ half of the NF2 gene are associated with lower risk of meningioma 
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than mutations in the 5’ half of the gene with a cumulative risk of cranial meningioma to 
age 50 years highest at 81% for exons 4-6, and lowest at 28% for exons 14-15(182).  
Clinical heterogeneity amongst established NF2 families is now recognised (i.e those in 
whom mosaicism is unlikely), suggesting that NF2 gene expression may be affected by 
other environmental or epigenetic factors (183). 
 
In some cases, NF2 can occur in children with additional features including 
dysmorphism, intellectual disability and congenital abnormalities, due to a large 
cytogenetically visible deletion including the NF2 and other genes, which may be 
identified on karyotype or chromosomal microarray(184).   
 
NF2 Associated Tumours 
Tumours occur in intracranial and spinal regions as well as on peripheral nerves, causing 
variable symptoms and signs depending on their location.  Within the intracranial 
compartment, tumours can cause deafness, blindness, headaches, seizures, gait 
abnormalities and a range of other focal deficits. Spinal cord tumours occur in between 
60 to 90% of patients (181, 185, 186), causing sensory and motor dysfunction including 
paralysis, and bladder and bowel dysfunction. Pain may be a feature of central or 
peripheral tumours, and is positively associated with tumour burden (187).  
 
Spinal tumours occur both within the cord (intramedullary) and within the canal on 
exiting nerve roots or originating from the meningeal covering of the cord 
(extramedullary). There appears to be no predilection for a particular location, multiple 
tumours being common in cervical, thoracic and lumbar regions. One study examining 
spinal tumours found that, of the 63% of NF2 patients affected (N=31/49), 53% had 
intramedullary, 55% extramedullary tumours and 45% had at least one of each tumour 
type (181).  Multiple tumours commonly occur in a single patient. 
 
The risk of malignant transformation of tumours in individuals with NF2 is higher than 
in the general population. Among 1348 patients across North American and European 
centres, 9 cases of malignant nervous system tumours were identified, equivalent to 725 
per 105 population compared with 1.13 per 105 in the general population. Radiation 
associated malignant transformation was estimated to occur in 4717 per 105 in the NF2 
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population (188). Some authors have estimated exposure to radiotherapy increases the 
risk 10-fold (188, 189). 
 
Schwannomas 
Bilateral vestibular schwannomas are the characteristic tumour of NF2, affecting 95% of 
all patients, causing tinnitus, vertigo, hearing loss, and brain stem compression (Figure 
5.1b-f). They tend to form on the inferior vestibular branch of the 8th cranial nerve.  In 
the general population with VS, 7% of individuals have NF2 (190). Increased morbidity 
is associated with these tumours among individuals with NF2 compared to patients with 
sporadic tumours (isolated vestibular schwannomas associated with mutation in the NF2 
gene in tumour tissue only), in part due to an increased growth rate of tumours in NF2 
(191). There is significant risk that an NF2 patient with a unilateral VS will develop 
bilateral VS, with a mean delay of 6.5 years reported in one study. In the paediatric age 
group, the time to development of the second VS is shorter; mean delay of 3.25 years for 
radiological evidence of VS and 7.3 years for hearing loss becoming bilateral (192). 
 
Schwannomas occur on other cranial nerves, the most common being unilateral or 
bilateral involvement of the trigeminal nerve (186), also around the spinal cord and 
exiting spinal nerve roots, along peripheral nerves, and in the skin. In one series, spinal 
and intracranial schwannomas occurred nearly as frequently as VSs (163).  
 
Meningiomas 
Meningiomas are the second most common tumour type in NF2 (Figure 5.1f), occurring 
throughout the central nervous system in 50-75% of individuals, often with multiple 
tumours (162, 166, 193, 194).  Whilst some meningiomas remain static and require no 
active treatment, NF2-associated meningiomas tend to be higher grade than sporadic 
tumours (195). Some meningiomas have been found to grow more rapidly than 
schwannomas, although growth rates are variable for both tumour types (177).  Female 
sex and younger age at NF2 diagnosis have been associated with increased growth rate 
in one recent report (196). 
 
While there is no specific site in which they form as commonly as VS, meningiomas 
usually occur around the spinal cord, supratentorially in the falx, and around the frontal, 
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Figure 5.1 NF2 associated tumours: cervical spinal ependymoma with associated syrinx 
in a 14 year old shown on sagittal T2 weighted MRI (a) and post-resection (b); bilateral 
vestibular schwannomas at age 14 years (b,e), and at 18 years (c,f) shown in T1 
weighted MRI with gadolinium contrast (b-c) and T2 weighted images (e-f), larger on 
left (white arrows). Parasagittal meningioma also shown (f, black arrow). 
 
 
temporal and parietal regions, including the optic nerve sheath.(177). Optic nerve sheath 
meningiomas may be bilateral, occur early in life and can be associated with complete 
vision loss (165, 197, 198).  
 
Schwannomas and meningiomas occur infrequently during childhood, having an 
estimated association with NF2 in at least 10-18% of cases.  Constitutional NF2 is now 
acknowledged as the most frequent cause of meningioma presenting in childhood (199). 
NF2 has been diagnosed in 28% of children with optic nerve sheath meningioma (197, 
198). 
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Gliomas 
Glial cell tumours (ependymomas and astrocytomas) are often detected radiographically, 
but cause symptoms less frequently than other tumour types. They tend to affect the 
lower brain stem and upper cervical cord more often than other locations(165). The 
prevalence of intracranial astrocytomas and ependymomas in NF2 varies between 1.6-
4.1% and 2.5-6% respectively (200); the frequency of both tumour types is much higher 
(24%) in the paediatric NF2 population (179).  
 
About 30% of NF2 associated spinal tumours are intramedullary(201), and are most 
likely to be ependymomas (Figure 5.1a,d).  These tumours occur in childhood but may 
be clinically silent for many years.  A series of 12 patients, aged between 10 to 56 years, 
with spinal ependymomas was reported recently (202). Ten of twelve patients presented 
with gait abnormality, eight with paresis/paralysis, four with pain, and two patients 
experienced sensory deficits and limb ataxia. Based on detailed pathology studies, the 
authors concluded that NF2 associated gliomas in the spinal region are almost 
exclusively ependymomas (202). These tumous can be surgically resected without 
significant residual deficits. They are of low malignant potential. 
 
 Manifestations of NF2 Affecting the Skin, Eyes, and Peripheral Nerves  
Cutaneous findings 
Café au lait macules (CALM) are more prevalent than in the general population and are 
often present in children with NF2 (Figure 5.2a), but rarely reach the size or numbers 
seen in NF1 patients (165, 203, 204). They tend to be paler and have more irregular 
margins compared to those of NF1 (179). Hypopigmented areas can also occur (204).  
CALM are often present early in childhood, followed by increase in number and size of 
skin tumours over time (205). 
 
Whilst about 68% of individuals have characteristic cutaneous features of NF2, these 
constitute the first recognisable symptoms or signs in up to 25% of cases (204).   
Three types of skin tumours occur in NF2; NF2 plaques, nodular schwannomas and 
neurofibromas (Figure 5.2 d,f). Flat dermal NF2 plaques are cutaneous schwannomas 
appearing as well defined, slightly raised hyperpigmented lesions, often with excess 
hair, typically less than 2cm in diameter (204). During childhood, these can occur on the 
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Figure 5.2 Cutaneous and ophthalmologic findings of NF1 (a-b) and NF2 (c-f): Café au 
lait macules (a), pigmented cutaneous neurofibroma in NF1 with numerous other 
subtle raised neurofibromas on the trunk of a 15 year old with NF1 (b). Posterior 
subcapsular cataract (c), optic atrophy in child with optic nerve sheath meningioma and 
epiretinal membrane (black arrow, e), NF2 plaque (d) and nodular schwannoma (f).   
 
 
trunk (206) as commonly seen in adults, or on the upper and lower limbs, including 
hands and feet (179). Nodular schwannomas are well defined and usually spherical, 
occurring subcutaneously around peripheral nerves.  There is no pigment change to the 
overlying skin which can be palpated as separate from the tumour (165). Neurofibromas, 
 88  
although classically associated with NF1, can occur in NF2, but do not comprise the 
main tumour burden (177, 200).  
 
A high burden of skin tumours is associated with increased severity of disease overall, 
with about 10% of individuals having greater than 10 tumours (165, 204). 
 
Ophthalmologic findings 
Ophthalmologic abnormalities are present in the majority of NF2 patients, including 
cataracts (70-80%), retinal changes (20-44%), strabismus (12-50%), amblyopia (12%), 
optic nerve sheath meningiomas and other optic pathway tumours (10-27%), and extra-
ocular movement abnormalities (10%) (168, 207-209). Optic nerve sheath meningiomas 
are the characteristic tumour of NF2, whereas optic pathway gliomas including the optic 
nerves and posterior optic pathway are more typical of NF1 (Figure 5.3) (103). 
Nystagmus may occur due to eye involvement, peripheral vestibular dysfunction, or 
posterior fossa tumours with brain stem compression.  Corneal injury affects about 10% 
of NF2 patients with other ocular abnormalities, and in association with facial nerve 
weakness.  
 
Most ocular changes are congenital in origin and specific to NF2, and as such have been 
highlighted as early diagnostic clues to NF2 in children (210). Cataracts are often 
bilateral, occurring as posterior subcapsular or peripheral cortical lens opacities (Figure 
5.2c). These may not require removal, but reduce visual acuity in 10-20% of cases (168, 
179, 207). Retinal abnormalities include combined pigment epithelial and retinal 
hamartomas. Epiretinal membranes (Figure 5.2e) are recognised in association with a 
severe phenotype of ocular involvement, which can lead to macular impairment and 
retinal detachment (162, 207, 211). The characteristic appearance of epiretinal 
membranes on ocular coherence tomography has been described recently (208, 211).  
Unfortunately, misdiagnosis of ophthalmologic complications of NF2 in early childhood 
(retinal hamartomas and optic nerve sheath meningiomas) as retinoblastoma has resulted 
in enucleation of the globe in a number of cases. 
 
A recent study of 30 patients (60% children with onset NF2 symptoms ≤18years, 40% 
adults, onset >18 years) in a university ophthalmology department, documented more  
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Figure 5.3 Optic nerve sheath meningioma in a 7-year-old with NF2 (left side a, c) and 
optic nerve glioma in a 10-year-old with NF1 (right side b, d) shown on axial T1 
weighted MRI (a non-contrast, b with contrast) and coronal T1 weighted images (c, d 
both with contrast). 
 
frequent ophthalmologic abnormalities in the paediatric population (94%) compared  
with the adult population (67%) (168). While impairment in visual acuity has previously 
been estimated to affect over 30% of NF2 patients overall (208), this study documented 
significantly poorer visual outcomes for children, with only 14% having normal visual 
acuity at the end of similar periods of follow up compared to 78% of adults, due to 
increased incidence of cataracts, epiretinal membranes, and optic nerve sheath 
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meningiomas among children (168).  The authors reported a significant correlation 
between younger age of onset and increased number of central nervous system tumours. 
   
Peripheral neuropathy 
Peripheral nerve dysfunction can occur in NF2 without obvious focal tumour.  Cranial 
nerve deficits are more frequent presenting signs in childhood than adulthood, occurring 
in forty percent of children in one study (eg. commonly facial palsy; strabismus due to 
third nerve palsy, swallowing impairment, tongue atrophy)(164). Children may also 
present with a mononeuropathy in the limbs, most commonly foot drop, in the absence 
of a focal brain stem, spinal cord or peripheral nerve tumour (10, 165). Marked wasting 
may be associated with the footdrop, and significant wasting can also be seen in the 
hands, most prominently in the thenar and hypothenar eminences(175). 
 
The peripheral neuropathy associated with NF2 tends to be a mixed motor and sensory 
axonal neuropathy occurring in a glove and stocking distribution, with distal weakness, 
fasciculations and hypaesthesia (165, 212, 213). Pathologic studies have identified loss 
of both myelinated and unmyelinated nerve fibres, sometimes with an onion bulb 
appearance (212). Schwann cell and epineurial cell proliferation with entanglement of 
axons has been described, without formation of a discrete tumour (212, 213).  
 
Investigations 
Audiology 
Hearing evaluation typically includes pure tone audiometry, speech intelligibility 
assessment and brainstem auditory evoked responses for clinical evaluation, with 
recommendations recently published regarding optimal outcomes for use in clinical 
trials (214).  
 
Neuroimaging 
The best radiologic investigation of intracranial and spinal tumours is MRI with 
gadolinium contrast, including detailed views of the internal auditory canal (a minimum 
of 3mm slices in both axial and coronal planes for clinical evaluation) (177, 179). 
Volumetric approaches to tumour measurement provide the most sensitive assessment of 
tumour size for vestibular schwannomas both for monitoring disease progression and 
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response to treatment (22, 124, 215).  Whole body MRI to assess total tumour burden 
may play an increasing role in management of patients with NF2 (126).  A whole body 
approach allows identification of symptomatic or potentially symptomatic lesions.  
Radiologic response to systemic therapy may ideally include multiple target tumours in 
future reflecting the complexity and multiplicity of tumours and clinical symptoms in 
NF2.  However, the role of whole body MRI is not clearly established as yet. 
 
Other Investigations 
Fluoro-deoxy-glucose positron emission tomography (FDG-PET) may have a role in 
selected cases where malignant transformation is suspected. Depending on the clinical 
context, a range of other investigations may be needed to evaluate new symptoms or 
deficits, including nerve conduction studies, electroencephalography, and other 
functional studies.   
 
Clinical Course 
While individuals with NF2 typically experience progressive symptoms and signs of 
disease, the clinical course varies between individuals, depending on age of onset, 
genotype, tumour burden, complications and management. Saltatory growth (alternating 
periods of growth and quiescence) is most common for NF2 associated tumours, 
although linear growth and exponential growth do occur (196). Age of onset and age of 
diagnosis are the two most important factors in predicting disease severity (180, 183). 
The presence of meningiomas and treatment in non-specialist centres have also been 
associated with risk of earlier mortality (180).  
 
Natural history studies of vestibular schwannomas, have demonstrated progressive 
disease over time, though rate of progression varies between tumours, and change in 
hearing is not necessarily directly correlated with tumour growth (216, 217).  Significant 
tumour progression (defined as ≥20% increase in tumour volume) of 31% at 1 year and 
79% at 3 years has been reported in 120 patients (200 tumours), associated with 
cumulative hearing decline of 16% over 3 years (defined as decrease in word recognition 
score exceeding the 95% critical difference compared with baseline) (218).  
 
The natural history of 287 cranial meningiomas in 74 patients with NF2 was reported 
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recently, with a mean follow up of 9 years.  About one quarter of the group were aged 
<18 years at the time of diagnosis. Sixty nine percent of patients had at least a single 
operation for VS, 23% for spinal tumours (194).  Significant growth of at least one 
meningioma during one year (≥20% increase in volume) was found in 28% of patients 
(7.3% of 267 tumours).  46% required surgical treatment for meningioma, for variable 
indications including epilepsy, intracranial hypertension and specific neurologic deficits 
(194).  
 
Limited data are available regarding longevity in NF2. However, 38% survival at 20 
years from diagnosis, has been estimated for the population as a whole (219). 
 
Clinical Presentation and Natural History of Paediatric Cases 
Presentation of NF2 in the paediatric age group is often unrecognised.   In a group of 
368 individuals reported previously, 153 (42%) had onset of symptoms between 1-19 
years of age (180). While adults typically present with hearing loss and tinnitus as a 
consequence of vestibular schwannomas, these symptoms often follow other presenting 
features in the paediatric population. In fact, VSs account for only15-30% of presenting 
symptoms in paediatric cases (10). Symptoms of VS have been delayed by over 40 years 
in some patients presenting in childhood (220). Children are more likely to present with 
visual symptoms, spinal cord compression or neurologic symptoms from other 
intracranial tumours (162, 164, 203, 221). Furthermore, where both VS and spinal 
tumours are present, children are more likely to be symptomatic from spinal tumours 
than from VS (163). Astute clinicians may suspect the diagnosis of NF2 based on 
cutaneous or ophthalmologic manifestations alone in a proportion of children. 
 
In five paediatric case series (total N=109), mean age at first presentation varied 
between 5.5-7.0 years, whilst mean age at diagnosis varied from 8.8 to 14.9 years (10, 
162, 164, 179, 221). The presenting features of these children are summarised in Table 
5.2.  
 
Tumour burden and associated morbidity and mortality among children are typically 
higher than in the adult NF2 population.  Among 12 children from a North American 
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Table 5.2 Presenting symptoms in NF2 populations including paediatric patients 
Age Group Hearing  
loss 
 
Tinnitus 
 
 
Vertigo/ 
loss of 
balance 
Muscle 
weakness 
wasting  
Facial  
nerve 
palsy 
Seizures Pain Headache Visual 
Involvement 
Sensory 
symptoms 
Footdrop Cutaneous 
 
Other Ref. 
All Ages 
(2-52 yrs) 
N=100 
 
All Ages 
(7-71 yrs) 
N=63 
44 
 
 
 
19 
(30%) 
10 
 
 
 
7 
(11%) 
8 
 
 
 
2 
(3.4%) 
12 
 
 
 
3 
(4%) 
- 
 
 
 
- 
8 
 
 
 
2 
(3.4%) 
4 
 
 
 
3 
(4%) 
- 
 
 
 
2 
(3.4%) 
1 
 
 
 
10 
(16.4%)a 
2 
 
 
 
- 
- 
 
 
 
- 
NI 
 
 
 
8 b 
(13%) 
11 
Pre-sympt. 
 
 
2 (3.4%) c  
5 (8%)  
Pre-sympt. 
 (165) 
 
 
 
(203) 
               
10 yrs 
N=11 
2 
(18%) 
- - - 3 
(27%) 
3 
(27%) 
 
- 1 
(9%) 
1 
(9%) 
 
- 1 
(9%) 
NI - (165) 
 
<16yrs 
N=18 
1 
(5%) 
- - 2 
(9%) 
- 1 
(5%) 
2 
(9%) 
- 8 d  
(44%) 
  5 e 
(28%) 
- (162, 206) 
               ≤10 yrs 
N=30 
4 
(13.5%) 
1 - 3 f 
(10%) 
5 g 
(17%) 
8 
(27%) 
- 2 
(6%) 
4 h 
(13.5%) 
1 
(3%) 
1 
(3%) 
1 
(3%) 
1 
(3%) 
Weight loss 
(glioma) 
(10) 
               ≤17yrs 
N=12 
3 
(25%) 
1 
(8.3%) 
- 2 
(16.5%) 
2 
(16.5%) 
- - - 1 
(8.3%) 
- - NI 3 i  
(25%) 
(164) 
               ≤ 15yrs 
N=24 
1 
(4%) 
2 
(8%) 
- 6 
(25%) 
1  
(4%) 
1 
(4%) 
1 
(4%) 
- 7 j 
(29%) 
 
- - 8 CALM 
(33%) 
3 tumours 
(12.5%) 
3 k 
(12.5%) 
(179) 
               
<17yrs 
N=25 
5 
(20%) 
- - - - See 
other 
See 
other 
- 3  
(12%) 
- See other 5 b (+1 CALM) 
(24%)  
5 l+ 6m 
(20% + 24%) 
(221) 
 
 
a Ocular cause of vision loss (N=7), CNS tumour (N=2), diplopia (N=1); b painful or growing skin tumours; c personality change and dysphagia; d cataracts (N=3), oculomotor nerve (N=2), diplopia, 
epiretinal hamartoma, epiretinal membrane (N=1); e oculomotor nerve and skin (N=1); f spinal schwannomas (N=2), neuropathy (N=1); g presumed secondary to vestibular schwannoma; h plus 
nystagmus due to retinal hamartoma (N=1); i swallowing difficulty, foot eversion, nystagmus; j strabismus (N=3), amblyopia and strabismus (N=2), cataract (N=1), amblyopia (N=1), pigmentary retinal 
hyperplasia (N=1); k ptosis (N=2); voice changes/hiccups (N=1); l gait disturbance, leg or neck pain, footdrop due to peripheral nerve sheath or intradural-extramedullary tumour; m seizure, abdominal 
pain, incidental finding on chest x-ray, hoarseness (N=2); NI=not included -skin lumps and cataracts excluded in [5] as usually asymptomatic; skin lumps and amblyopia (non-specific) not included [4]; 
CALM= café au lait macules, pre-sympt=pre-symptomatic, Ref=reference. 
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tertiary NF treatment centre (164), hearing loss associated with VS was present by age 
18y in 75% of patients.  Seven children underwent surgical treatment for VS at an 
average age of 10 years, with immediate postoperative hearing loss in 4 cases.  
Progressive hearing loss occurred in all patients over time.  
 
All children had other intracranial tumours, including 83% schwannomas, and 75% 
meningiomas; 75% also had spinal tumours. Only two patients were not treated 
surgically during childhood.  One child had undergone five procedures and one 
received radiation therapy for progressive orbital meningioma. Outcomes were 
assessed across four domains – hearing, vision, ambulation and school performance. 
By 18 years of age, 83% of patients had visual impairment, 75% had hearing loss 
(bilateral in 2 patients). One patient was paraparetic, 2 others had difficulties with 
ambulation. 25% were functioning below age expectation at school, attributable to 
physical impairments and frequent hospitalization rather than baseline intellectual 
disability. Two children had impairments in all four domains.  The authors 
highlighted significant morbidity despite active surveillance in familial cases and 
early surgical intervention (164). 
 
In 2005, Ruggieri et al (179) described 24 individuals aged between 4 to 22 years 
followed at a European centre. Nineteen were ≤10 years old at the time of diagnosis, 
22 were diagnosed aged ≤ 18 years. Bilateral vestibular schwannomas were present in 
75% patients, with unilateral vestibular tumours in 16%.  Other intracranial tumours 
included meningiomas (66% patients), astrocytomas (25%), ependymomas (25%), 
and other cranial nerve tumours (40%). Brainstem tumours were associated with a 
poor prognosis. Twenty one individuals had spinal tumours with successful resection 
achieved in 4 of 21 children with extradural lesions, and 3 with intradural tumours. 
Surgical treatment had been provided for 16 of 24 patients. 50% suffered significant 
morbidity during childhood, including 2 children who did not survive beyond 16 
years of age (179).  
 
Other case reports have documented early mortality associated with NF2, including a 
patient presenting at age 13 years with multiple craniospinal tumours, who died four 
years later despite multimodal treatment including surgery and chemotherapy (222).  
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Management 
Patients are best managed in tertiary centres by a well-resourced multidisciplinary 
specialist team experienced in dealing with the multiple complications associated with 
NF2 (180). Specialties involved may include neurology, genetics, ophthalmology, 
audiology, dermatology, radiology, neurosurgery, otolaryngology, medical and 
radiation oncology, clinical nurse consultants, allied health staff and psychologists. 
 
Follow up of Children with Suspected NF2 
Children with suspected NF2 require ongoing follow up to clarify the diagnosis over 
time; this may be based on the development of additional clinical features, and/or on 
genetic testing to identify NF2 mutations in blood and tumour (Table 5.3).  
 
Molecular genetic testing is recommended for children of affected parents, 
recognising that clinical features may be insufficient to meet diagnostic criteria for 
NF2 until later in life. Leukocyte DNA from blood is usually tested in children of 
parents with NF2 (Table 5.3). Alongside genetic testing, baseline skin, neurology and 
ophthalmology (including slit-lamp) assessments are required, with annual clinical 
reviews thereafter. Hearing assessment and craniospinal MRI should occur from 10 
years of age, unless clinical suspicion mandates earlier assessment (103).   
 
In suspected sporadic cases, genetic testing is first performed on tumour DNA, with a 
view to identifying NF2 mutations on both alleles. This is followed by testing of 
leukocyte DNA to establish which mutation is constitutional and which is somatic 
(present only in the tumour). Failure to detect a mutation in blood may occur due to 
mosaicism, mutations located in intronic or promotor regions, or due to large multi-
exonic deletions (164). This can occur in patients presenting with unilateral vestibular 
schwannoma.  Additional features of NF2 may be identifiable over time in a 
proportion of patients.  Therefore, careful multimodal follow up is indicated (outlined 
in Table 5.3) to identify and treat complications early.  Annual MRI scans are 
recommended from the age of 10 years (103, 166). Only when mutation in blood is 
negative, and two NF2 mutations are identified in tumour, is the diagnosis of 
constitutional NF2 unlikely (223).  
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Table 5.3 Recommended follow up for children at risk of having NF2 
 Child of affected parents 
(50% risk) 
Child with suspected NF2 
(schwannoma, meningioma, skin 
features*) 
Baseline  
Assessment 
 
Birth – ocular, skin, 
neurological + formal 
ophthalmology exam during 
early years 
Ocular, skin, neurological exam 
Audiology 
Full craniospinal MRI 
 
DNA analysis Pre-symptomatic diagnosis if 
familial mutation known 
 
Mutation found in blood:  
NF2 carrier à follow up  
 
Mutation not found in blood:  
NF2 excluded à no follow 
up 
Mutation analysis (blood and 
tumour) 
 
No mutation in blood: NF2 not 
excludedàfollow up 
 
No mutation in blood, 2 mutations 
in tumour:  
NF2 excluded **à infrequent follow 
up 
 
Follow up 
Clinicial 
 
 
 
 
 
 
 
Neuroimaging 
2-10 years of age: 
Annual ocular, skin, 
neurological  
Formal ophthalmology 
assessment if symptomatic 
 
10-30 years of age: 
As above + audiology 
 
 
 
> 10 years of age:  
Baseline craniospinal MRI  or 
At any stage based on clinical 
suspicion 
Tumour à follow up as 
suspected NF2 
No tumour à cranial MRI 
every 2 years to age 20 
years, then every 3 years. 
2-10 years: 
Annual ocular, skin, neurological 
Ophthalmology, audiology 
 
 
>10 years of age: 
As above + neuroimaging if not 
already indicated on clinical grounds 
 
<10 years of age: 
As clinically indicated 
 
>10 years: 
Repeat craniospinal MRI 
Then annual cranial MRI  
 
Spinal tumours present:  
à annual spinal MRI 
*Fewer than 6 café au lait macules ie. not fulfilling criteria for NF1, or skin lumps;  
** Other than small risk of mosaicism; modified from (179, 223).  
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Surveillance and Secondary Prevention in Confirmed NF2 
Most individuals diagnosed with NF2 should be followed with a minimum of annual 
clinical evaluation and investigations, with increased frequency in the presence of 
significant complications (Table 5.4). Some adults with mild disease presenting in 
later life, may be managed with less frequent assessments.   
 
 
Table 5.4 Recommended follow up for confirmed cases of NF2  
         Frequency 
 
Clinical examination        
    Neurologic examination   Annual    
Skin examination    Annual 
    Ophthalmologic examination   Annual 
Audiologic examination   6-12 monthly** 
     Pure tone audiometry 
     Speech recognition 
     BAER*  
 
Neuroimaging – contrast enhanced MRI      
    Brain with IAMs    6-12 monthly** 
    Spine     6-12 monthly** 
 
Psychosocial Support  Assess employment/school/family Annual 
     Functioning    
 
Genetic Counselling      At diagnosis then  
at any stage 
 
* BAER= brainstem auditory evoked response; ** frequency of follow up is dependent on 
age and disease burden.  Modified from references (103, 162, 166, 167, 223, 224). 
 
 
 
Medical management  
Significant effort has been invested in developing medical treatments for NF2 (100, 
135, 225, 226) and appropriate clinical trial protocols in recent years, with a major 
focus on symptomatic, progressive vestibular schwannomas (23, 219). The most 
effective agent to date inhibits vascular endothelial derived growth factor (VEGF), 
which has a central role in angiogenesis for NF2 schwannomas (225). Anti-VEGF 
monoclonal antibodies such as bevacizumab (administered as a fortnightly 
intravenous infusion) provide a beneficial effect in treatment of vestibular 
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schwannomas including tumour shrinkage and hearing improvement in a proportion 
of patients (37, 227). The largest series reported to date included 31 patients aged 
between 12-73 years (median 26 years) with progressive vestibular schwannomas 
showing a median of 64% volume increase during 12 months prior to treatment. 
Tumour shrinkage (≥20% volume) was documented for 55% (17/31) patients, 
constituting radiographic response, while 57% (13/17) patients experienced hearing 
improvement based on a statistically significant increase in word recognition score.  
Both radiographic and hearing improvements were sustained for up to 1 year in about 
90% of patients, with stable to improved status in 61% and 54% for hearing and 
tumour volumes respectively after 3 years (228).  Limited efficacy in slowing 
progression of meningiomas has also been documented (226, 229). Although 
progressive vestibular schwannomas remain the primary indication for treatment, 
bevacizumab should also be considered for other progressive symptomatic NF2 
associated tumours. Symptomatic benefit was recently reported in a series of 8 
patients with spinal ependymomas, with radiologic response demonstrated in 5 cases 
based on a >20% reduction in linear measurements(230).  
 
Lapatinib (available as an oral tablet) targets the epidermal growth factor receptor 
(EGFR/Erb2 inhibitor), and had some effect on vestibular schwannomas in a single 
institution phase II study (21 patients, 4 aged <18 years) (36).  Radiographic response 
(≥ 15% tumour volume reduction), occurred in 4 of 17 evaluable patients (23.5%), 
varying from 15.7 to 23.9% volume reduction over a median of 4.5 months.  Hearing 
response (defined as ≥10dB improvement in pure tone average or statistically 
significant improvement in word recognition score) was recorded in 4 of 13 eligible 
patients. Median time to progression was 14 months (based on either volume increase 
or hearing loss), and overall progression-free survival at twelve months was estimated 
at 64.7% (36).   
 
Other agents such as mTOR inhibitors may halt tumour progression (231). 
 
Medical therapies for this population must be tolerable, with care given to minimizing 
side effects. For young adults receiving bevacizumab or other agents which can affect 
future fertility, anticipatory care should include consultation with reproductive 
specialists.  
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Peripheral neuropathies that are unrelated to tumours can be treated symptomatically, 
with drugs such as gabapentin or pregabalin to control pain and other sensory 
symptoms (167). 
 
Surgical management 
Until recently, surgery has been the mainstay of treatment for NF2 associated 
tumours, and continues to play an important role for most patients (186, 219). 
Surgical management should be carefully planned by surgeons experienced in the care 
of NF2 patients. The aim is to remove tumours before they cause irreversible damage, 
minimizing potential adverse surgical consequences, bearing in mind that operative 
morbidity increases with size of the tumour (167, 186). Tumour should be reserved 
for genetic testing, with patient consent (200). 
 
Complete resection of schwannomas for NF2 patients is achievable at lower rates than 
for sporadic tumours (232), presumably because the schwannomas of NF2 tend to 
incorporate more nerve fascicles, with increased adherence to surrounding nerves 
(233). Risks associated with vestibular schwannoma resection include hearing loss 
and damage to the facial nerve.  Some surgeons advocate for early surgery when 
vestibular schwannomas are <2cm in greatest diameter, to achieve hearing 
preservation with minimal surgical risks (186, 234). Other approaches include 
decompression of the internal auditory canal without tumour removal or partial 
tumour debulking to relieve symptoms of brain stem compression (186).  A specific 
aim is to preserve the cochlear nerve, due to the potential future utility of a cochlear 
implant, which can provide stable serviceable hearing over at least 8 years in the 
majority of patients (235). Approaches to improving cosmesis, in the event of facial 
nerve damage, have been described, along with recommendations for assessing facial 
nerve outcomes during treatment (214).  
 
Postoperative hearing preservation has been reported at rates of up to 50% over three 
years (234). In a group of 35 children with NF2 (47 vestibular schwannoma resections 
performed between 1992-2004), 55% of surgeries achieved hearing preservation at 
≥70dB, with a similar hearing level to that reported in Friedman’s study (48%) (236). 
In another series of 29 paediatric patients (23/29 with NF2), hearing preservation was 
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possible in only 30% of cases, with greater risk of hearing loss and facial nerve 
damage (8%) following resection of larger tumours (232).  Surgery is required in up 
to 30-60% of patients with spinal tumours with likelihood of surgery varying by 
tumour location (extramedullary tumours more likely) (181, 186). 
 
Because surgery carries the risk of exacerbating neurologic deficits and other 
complications, evolving medical options are favoured where available. 
 
Radiotherapy/Radiosurgery 
Stereotactic radiosurgery for vestibular schwannomas has been estimated to achieve 
tumour control in between 60-80% of the general NF2 population at 5 years (237), 
significantly better than the natural history of the disease.  Hearing preservation in 
those with serviceable hearing was estimated at 73% after one year, 59% after 2 years 
and 48% after 5 years, with low risk of injury to the facial (5-12%) and trigeminal 
nerves (2-7%) (237, 238). Long-term results are less robust than for sporadic 
vestibular schwannomas (219).  In one paediatric case series, whilst hearing 
preservation after gamma knife surgery compared favourably with adult patients (67% 
at 1 year, 53% at 5 years, n=11 tumours), tumour control was poor (35% at 3 years, 
n=17 tumours) (221). It should be noted that these studies have utilised alternative 
defined endpoints versus those recently recommended for studies of NF2 patients 
(22).  Optimal comparability between natural history and treatment outcome datasets 
is dependent on measurement standardization. 
 
There is concern regarding the increased risk of malignant transformation after 
radiosurgery in NF2 (188, 189). While NF2 patients number about 7% in studies of 
vestibular schwannomas treated with gamma knife surgery, nearly half of the cases of 
malignant change occur in the NF2 population, indicating that this treatment modality 
should be utilised with caution(189). Nevertheless, radiosurgery and radiotherapy 
may have a role in management of selected vestibular and other tumours, such as 
optic nerve sheath meningiomas (198, 238, 239).  
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Assistive Devices and Psychosocial Management 
Optimising quality of life through enhanced community participation can be achieved 
using a range of approaches including assistive devices to improve vision and 
communication (auditory brainstem implants, cochlear implants (232) and lip-
reading). Allied health support to maximize ambulatory function and minimise risk of 
injury is important.  Psychosocial support for affected individuals and families is 
critical. 
 
Conclusion 
Neurofibromatosis type 2 is a rare autosomal dominant neurocutaneous disorder 
associated with multisystem effects, predominant in the central nervous system, 
related to loss of tumour suppressor function. Presentation in childhood is associated 
with more severe disease and risk of significant early morbidity and mortality. Whilst 
diagnosis in adults can be delayed due to a limited awareness of the condition among 
physicians, the challenge of timely diagnosis in children is further complicated by the 
variable presentation in this age group. Furthermore, the clinical diagnostic criteria 
used for adults may not be met during childhood. Careful skin and eye examination 
may uncover helpful clinical signs of NF2 in children. A high index of suspicion, 
genetic testing and attentive clinical follow up are needed to establish the diagnosis.  
When NF2 is confirmed, comprehensive multimodal surveillance is recommended at 
a minimum of annual intervals, and more frequently in cases where progressive 
disease and significant complications have been identified. The involvement of 
experienced specialist teams familiar with NF2 is recommended to optimise disease 
specific care and outcomes, and to facilitate inclusion of adults and children in natural 
history studies and treatment trials wherever possible.
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CHAPTER 6: NF2 IN CHILDHOOD: EXPERIENCE AT THE CHILDREN’S 
HOSPITAL AT WESTMEAD FROM 1994 TO 2015 
 
 
Introduction 
Neurofibromatosis type 2 (NF2) presents in childhood in about 18 percent of 
cases(10).  As a rare neurocutaneous syndrome (1:30,000), knowledge of the 
condition is limited in the community and among many medical practitioners.  NF2 
causes tumour formation within the nervous system causing dysfunction in motor and 
sensory systems, and the special senses involving hearing and vision. Cutaneous and 
ophthalmologic disease manifestations are important diagnostic features, and can 
cause symptoms in some cases(162, 164, 179). Progressive tumour growth may lead 
to complete loss of function including deafness, blindness, immobility and pain.  
Unfortunately, children with NF2 often experience more severe disease(10). 
 
The presenting symptoms of NF2 in childhood frequently differ from the typical 
presentation with hearing loss attributable to vestibular schwannomas occurring in 
adulthood (10, 162, 221), which can lead to delayed diagnosis (179). A high threshold 
of suspicion for the diagnosis will assist with early recognition, patient education and 
appropriate ongoing monitoring for complications.  
 
This chapter reports experience of NF2 in childhood at a single Australian centre, 
highlighting many of the challenges of diagnosis and management in the paediatric 
age group. The variable presentations and complications occurring in children are 
illustrated.  Trends in treatment are outlined, reflecting the changing landscape for 
therapy to optimise outcomes in this potentially devastating condition. 
 
Methods 
Records of children attending the Neurogenetics Clinic at The Children’s Hospital at 
Westmead meeting a clinical diagnosis of NF2 were reviewed over a 22-year period, 
from 1994 to 2015. Genotype was recorded where available, as well as whether the 
disease was inherited or sporadic. Clinical details were extracted including gender, 
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age at initial symptoms attributable to NF2, age at last follow up, evolving symptoms 
and signs, and criteria on which diagnosis was based.  Complications experienced 
during childhood were recorded including visual and hearing impairment, weakness 
and gait abnormality, pain, and seizures. The impact of morbidity on community 
participation in each case is also described. Treatments provided are summarised 
including medical, surgical, radiotherapy interventions, hearing augmentation and 
allied health/rehabilitation strategies.  
 
This project was reviewed and approved by the local Human Research Ethics 
Committee (LNR/13/SCHN/61). 
 
Results 
Patients 
Fifteen children met a clinical diagnosis of NF2. Six were girls, and 9 were boys 
ranging in age from 5 to 18 years at first clinic visit (median= 9.1 years). Clinical 
characteristics of children at presentation are shown in Table 6.1. Five children were 
evaluated during a single consultation only.  Otherwise, follow up ranged from 1.7 to 
13 years (median 7.0 years).  Three patients were first evaluated prior to the year 
2000.  
 
Patient 15 had inherited NF2, was seen only on one occasion aged 7 years, and was 
asymptomatic. Review of complications and treatment was therefore possible in 14 
children.  
 
Two children included in this series were followed into adulthood and treated with 
bevacizumab as described in Chapters 7 and 8 (Patients 3 and 6).  
 
Genetics 
Genetic test results were available for nine children (60%). A single child had familial 
disease (paternal inheritance) and was asymptomatic at the time of evaluation, aged 7 
years (Patient 15). Mosaic NF2 was diagnosed in one patient at 18 years of age, based 
on NF2 gene mutations present in 2 tumours, and absent from blood (Patient 6). Two 
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Table 6.1a Clinical characteristics of Australian children with NF2 at presentation 
Patient 
(Gender) 
Age (y) 1st 
symptoms 
Presenting symptoms/ 
signs 
Diagnostic criteria for NF2 
(age) 
Age (y) at 
diagnosis 
Genotype Inheritance 
1  (F) 5.5 Cutaneous/subcutaneous 
tumour 
Longstanding CALM 
Hearing lossà 
BVS, CN V, VII schwannomas 
Spinal lesions (MRI 9y normal) 
15 c.1564_1567 del  
p.Glu522 Lysfs27 
Sporadic 
2  (M) 4 Focal seizures 
 
MRI (14y)àBVS, CN V 
schwannoma, 
Spinal tumours (not seen at 
11y) 
14   Sporadic 
3  (F) 14 Hearing loss/tinnitus BVS ;  MRI spine surveillance 
(20y)àspinal lesions 
15   Sporadic 
4  (M) 2.5 
5 
Cutaneous tumour 
Poor vision  
Unilateral cataract, reduced 
VA 
ONSM (5y) 
BVS, CN VII schwnnoma and 
spinal lesions (6y) 
5 R198X exon 6 or Arg198 à 
stop (592 C->T) truncated 
protein 
 
Sporadic 
5  (M) 3 Head tilt  
CN IV palsy 
Dermal lump-schwannoma 
(6y) 
MRI->BVS, CNIV and V schw 
7    Sporadic 
6  (M) 16 Diplopia 
CNVI palsy 
BVS, CN VI scwh 16 c.1336_1337del 
p.Arg446GlufsX48 
frameshift mutation  
Sporadic  
(mosaic) 
7  (M) 8 Poor vision; CN IV palsy; 
epiretinal membranes 
BVS and CN IV schw; 
Spinal lesions (9y) 
8.5 c.559+1G>T 
 
Sporadic 
8  (M) 15 Double vision 
CN IV palsy 
BVS, CN IV schw, 
Spinal tumours 
15  Sporadic 
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Table 6.1b Clinical characteristics of Australian children with NF2 at presentation 
Patient 
(Gender) 
Age (y) first 
symptoms 
Presenting symptoms/ 
Signs 
Diagnostic criteria for NF2 (age) Age (y) at 
Diagnosis 
Genotype Inheritance 
9  (M) 5 Poor vision, proptosis, 
reduced VA 
CALM àsuspected NF1 
Bilateral ONSM (5y)  
BVS (6y)  
Spinal tumours (7y) 
6  Sporadic 
10  (M) Infancy Dysmorphism 
Developmental delay 
Squint* 
Non-specific WM changes (6y) 
BVS, spinal tumours (12y) 
12 4.7Mb deletion (NF2 
+34 other genes)  
Sporadic 
11  (F) 1.5 Poor vision 
amblyopia, unilateral 
retinal hamartoma 
SeizureàBVS, other CN schw (V)  
IC meningioma, spinal tumours 
14  Sporadic 
12  (M) 4 
 
5 
Unilateral hand 
weakness 
Poor vision 
Unilateral ONSM, BVS, CN V schw 
Spinal and brachial plexus tumours 
5 c.773G>A, p.Trp 258 X 
(alternate splicing at 
exon 8 ) 
Sporadic 
13  (F) 10 Headaches BVS  
Other IC schw (CN V) 
12 1.98Mb deletion  
(NF2 +3 other genes) 
Sporadic 
14  (F) 4.5 Poor vision 
Diplopia 
NF2 plaques  
Depigmented macules 
BVS 
Other IC schw (CN III, VII) 
IC meningioma 
Spinal tumours 
4.5 c.169C>T, p.Arg57Ter 
Hz truncating 
mutation exon 2 
Sporadic 
15  (F) Nil at 7y Asymptomatic Family History 
Genetic testing 
3 Familial variant  
c.1165C>T p.Gln 389 
Paternal 
BVS-bilateral vestibular schwannomas; CALM-café au lait macules; CN-cranial nerve, F-female, Hz-heterozygous, IC-intracranial, M-male, ONSM-optic nerve 
sheath meningioma, schw-schwannoma, VA-visual acuity, WM-white matter, y-years.  
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children had whole gene deletions as part of a larger chromosomal deletion. In Patient 
13, a 1.98Mb deletion in chromosome 22 was identified, encompassing the NF2 gene, 
and all aspects of the clinical presentation were consistent with NF2. Patient 10 
(4.7Mb deletion) was identified prior to becoming symptomatic with NF2, due to 
other medical problems presenting in infancy including dysmorphism, and 
developmental delay. Diagnosis of NF2 was based on CGH microarray result 
followed by MRI demonstrating bilateral vestibular schwannomas and spinal tumours 
at age 12 years. Frameshift mutations causing a truncated protein product were 
typically seen in the other five patients.  
 
 
Presentation and Diagnosis 
Presenting symptoms and signs are summarised in Table 6.2. 57% of children (N=8) 
experienced difficulties with vision early on.  Visual acuity was reduced in four 
children (28%), attributable to optic nerve sheath meningioma in three cases (21%) 
and retinal hamartoma in one case at age 1.5 years (Patient 11). Five children (36%) 
had eye movement disorders secondary to cranial nerve palsies. Head tilt with cranial 
nerve IV palsy was observed in early childhood in one case (Patient 5), and occurred 
in middle childhood in the developmentally delayed child (Patient 10).   Other 
presenting symptoms included hand weakness, headache, and seizure, each affecting 
one child. Two patients had cutaneous/subcutaneous lumps assessed at the first 
medical visit. Hearing impairment as first manifestation of NF2 occurred in only one 
patient, aged 16 years.  
 
Mean age of occurrence of first NF2-associated symptoms was 6.1 years (range 1.5-
16 years).  For sporadic patients, diagnosis occurred at a mean age of 10.6 years 
(range 4.5-16 years).  Diagnosis was delayed up to 12.5 years following first 
presentation (Patient 11), with a mean delay of 3.6 years.   
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Table 6.2. Presenting symptoms of NF2 among Australian children compared with other published populations* 
Age Group Hearing  
loss 
 
Tinnitus 
 
 
Vertigo/ 
loss of 
balance 
Muscle 
weakness 
wasting  
 
Facial  
nerve 
palsy 
Seizures Pain Headache Visual 
involvement 
Sensory 
symptoms 
Footdrop Cutaneous 
 
Other Ref 
               ≤ 18yrs 
N=14 
 
1 
(7%) 
1 
(7%) 
- 1 
(7%) 
- 1 
(7%) 
- 1 
(7%) 
8 
(57%) 
- - 2 a 
(14%) 
 2 This study    
(14%) 
(head tilt;  
dysmorphism/ 
DD) 
               
10 yrs 
N=11 
2 
(18%) 
- - - 3 
(27%) 
3 
(27%) 
 
 
- 1 
(9%) 
1 
(9%) 
 
- 1 
(9%) 
NI - (165) 
<16yrs 
N=18 
1 
(5%) 
- - 2 
(9%) 
- 1 
(5%) 
2 
(9%) 
- 8 b  
(44%) 
  5 c 
(28%) 
- (162, 206) 
               
               ≤10 yrs 
N=30 
4 
(13.5%) 
1 
(3%) 
- 3 d 
(10%) 
5 e 
(17%) 
8 
(27%) 
- 2 
(6%) 
4 f 
(13.5%) 
1 
(3%) 
1 
(3%) 
1 
(3%) 
1 
(3%) 
Weight loss 
(glioma) 
(10)  
               ≤17yrs 3 
(25%) 
1 
(8.3%) 
- 2 
(16.5%) 
2 
(16.5%) 
- - - 1 
(8.3%) 
- - NI 3 g  
(25%) 
(164) 
N=12               
               ≤ 15yrs 
N=24 
1 
(4%) 
2 
(8%) 
- 6 
(25%) 
1  
(4%) 
1 
(4%) 
1 
(4%) 
- 7 h 
(29%) 
 
- - 8 CALM 
(33%) 
3 tumours 
(12.5%) 
3 i 
(12.5%) 
(179) 
               
<17yrs 
N=25 
5 
(20%) 
- - - - See other See 
other 
- 3  
(12%) 
- See other 5 a (+1 CALM) 
(24%)  
5 j+ 6k 
(20% + 24%) 
(221) 
               
*Data reproduced from Chapter 5 with addition of Australian patients.  
a Painful or growing skin tumours; b cataracts (N=3), oculomotor nerve (N=2), diplopia, epiretinal hamartoma, epiretinal membrane (N=1); c oculomotor nerve and skin (N=1); d spinal 
schwannomas (N=2), neuropathy (N=1); e presumed secondary to vestibular schwannoma; f plus nystagmus due to retinal hamartoma (N=1); g swallowing difficulty, foot eversion, nystagmus; 
h strabismus (N=3), amblyopia and strabismus (N=2), cataract (N=1), amblyopia (N=1), pigmentary retinal hyperplasia (N=1); i ptosis (N=2); voice changes/hiccups (N=1); j gait disturbance, leg 
or neck pain, footdrop due to peripheral nerve sheath or intradural-extramedullary tumour; k seizure, abdominal pain, incidental finding on chest x-ray, hoarseness (N=2); DD-developmental 
delay; NI-not included -skin lumps and cataracts excluded in (165) as usually asymptomatic; skin lumps and amblyopia (non-specific) not included (164); CALM-café au lait macules. 
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A lack of diagnostic clarity was evident in three children for whom other 
neurocutaneous disorders were initially considered. Patient 1 had atypical café au lait 
macules (less than six lesions), and a subcutaneous tumour (pathology consistent with 
neurofibroma). This child was followed with surveillance for complications of NF1, 
but recognized as being atypical and not fulfilling clinical diagnostic criteria for NF1. 
Mosaic NF1 was considered.  Occurrence of hearing loss in adolescence with 
appearance of bilateral VS on neuroimaging clarified the diagnosis. At age 5 years, 
NF1 was also the initial working diagnosis for Patient 9 who had café au lait macules, 
hypopigmented macules and reduced visual acuity.  The diagnosis of NF2 became 
evident when an optic nerve sheath meningioma rather than optic nerve glioma was 
demonstrated on cranial MRI. Patient 2 first presented to another service with seizures 
and periventricular lesions, interpreted as subependymal nodules, leading to a clinical  
diagnosis of tuberous sclerosis (TSC).  The diagnosis was revised at age 14 years, 
when bilateral VS were seen on MRI along with a cervical intramedullary tumour 
with large syrinx. Seizures in this patient were likely secondary to cortical dysplasia. 
 
During follow up of this cohort, bilateral vestibular schwannomas were evident on 
cranial MRI in all patients, constituting important supportive diagnostic criteria in 
most cases. Multiple other intracranial and intraspinal tumours were also seen in the 
majority of children at diagnosis, and occasionally during follow up.   
 
Complications 
Major clinical problems occurring during childhood are shown in Table 6.3 along 
with characteristics of hearing and vision, and impact on community participation in 
symptomatic individuals. Table 6.4 summarises the incidence of specific disease 
complications during childhood in this cohort; information is available to late 
adolescence for 12 of 14 patients, with the remaining two patients aged 6 years.  
 
Eight of 14 children experienced some hearing loss, with unilateral deafness in 2 
cases.  Visual deficits continued to be the most common complication, affecting 10 
children (71%), with significant reduction in visual acuity in six cases (43%) and 
ocular motility problems in four cases (28%).  Severe visual impairment (reduced 
visual acuity) was attributable to optic nerve sheath meningiomas (N=3) and retinal  
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Table 6.3a Characteristics of children with NF2 at last follow up, including complications, hearing and vision, and impact on community participation* 
Patient Follow 
up (y) 
Age 
(y) 
Major clinical problems  
(age, y) 
Hearing** 
(age, y) 
Eye findings Visual Acuity Other features Community Participation 
1 8 17 Hearing loss with tinnitus 
(15) 
Discomfort from 
subcutaneous nodules 
Moderately 
severe loss /  
Normal 
contralateral  
Unilateral ERM 
and retinal 
hamartoma 
 
Normal  Minor limitation 
Communication 
 
2 5 16 Seizures (4) 
Unilateral visual impairment 
(13) 
Neck, back, shoulder pain 
(13) 
Normal Bilateral cataracts 
Retinal 
hamartoma 
Visual field defect 
6/120   6/12 Cervical 
ependymoma 
with syrinx 
Seizure precautions 
Minor limitation mobility 
Driving with glasses 
3 1 visit 16 Unilateral hearing loss Moderately 
severe loss /  
Mild 
contralateral  
Bilateral ERM 
Unilateral retinal 
hamartoma 
 
Normal  Minor limitation 
Communication 
4 13 18 Visual loss (6m) 
Gait abnormality (9) 
Scoliosis (13) 
Short stature 
Hoarse voice (15) 
Normal Unilateral 
blindness with 
proptosis (5y) 
 
 
NLP   3/60  
(with glasses) 
Bilateral ONSM 
 
Driving restriction 
Moderate limitation  
Vision 
Minor Mobility 
5 11 18 Head tilt/diplopia 
Seizures 
Hand weakness (8) 
Back pain, foot drop (12) 
Unilat hearing loss (13) 
Leg weakness and 
urinary dysfunction (14) 
Visual loss (15) 
Voice change (15) 
Unilateral 
moderate 
loss  
 
Normal 
contralater
al  
NA NA CN IV palsy 
 
 
 
Calcified 
meningioma 
cavernous 
sinus 
Limitation 
Communication  
Major mobility  
Fine motor 
 
Seizure precautions 
Home schooling 
 
DECEASED age 18 years 
6 1 visit 18 Tinnitus (16) Normal Unilateral 
cataract 
Normal  No limitation 
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Table 6.3b Characteristics of children with NF2 at last follow up, including complications, hearing and vision, and impact on community participation* 
Patient Follow 
up (y) 
Age 
(y) 
Major clinical problems  
(age, y) 
Hearing** 
(age, y) 
Eye findings Visual Acuity Other features Community 
Participation 
7 7 16 Mild visual loss Normal Bilat cataracts 
ERM 
Unilat retinal 
hamartoma 
6/9   6/20 Cholesteatoma 
 
Anxiety / school 
refusal 
Minor limitation 
Vision 
Major limitation 
School attendance 
8 1 visit 18 Diplopia (15) 
Visual loss (17) 
Vertigo (16) 
Hearing loss (17) 
Hand cramps (15) 
Leg weakness  
Gait abnormality (15) 
Back pain (15)  
Urinary dysfunction (16) 
Profound 
loss  
(18y) / 
Moderate 
contralat 
loss 
Papilloedema 
Visual field 
defect 
RAPD 
6/9   6/60 Additional tumours:  
CNV schw 
Hand schw 
 
Multiple IC 
meningiomas 
Multilevel spinal 
disease  
Significant limitation 
Communication  
Moderate  
limitation mobility 
 
Driving restriction 
9 13 18 Unilateral blindness (5) 
Reduced vision in other 
eye (13) 
Dizzyness (10) 
Hearing loss (10) 
Periorbital oedema (14) 
Unsteady gait (16) 
Profound 
loss  
(11y) 
Moderate 
contralat 
loss (14) 
Bilateral 
cataracts 
Bilateral ERM 
NLP   6/36 Bilateral ONSM 
Spinal tumours 
(cspine; asym-
ptomatic cord 
compression; 
multilevel other 
disease) 
Reduced dancing as 
young adult 
 
Other minor 
limitations 
10 5 16 Bilateral spasticity 
Developmental delay 
Scoliosis 
Head tilt (11) 
Hearing loss (11) 
Paresthesias hands (11) 
Back and hip pain (11) 
Leg weakness (11) 
Moderate 
unilat loss 
 (14) 
 
Mild  
Contralat 
loss   
 
 6/12   6/12 Spinal 
tumours-
thoracic schw 
Limitation due to non-
NF2 phenotype in early 
childhood, NF2 from 
11y 
(special school, 
reduced mobility and 
hearing, 
pain) 
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Table 6.3c Characteristics of children with NF2 at last follow up, including complications, hearing and vision, and impact on community participation* 
Patient Follow 
up (y) 
Age 
(y) 
Major clinical problems  
(age, y) 
Hearing** 
(age, y) 
Eye findings Visual Acuity Other features Community Participation 
10 ctd 5 16 Unsteady gait (12) 
Mild visual impairment 
(14) 
See above 
 
See above 
 
See above 
 
See above 
 
See above 
 
11 3.5 17 Visual impairment (1.5) 
Hearing loss (13)  
Seizures (14) 
Mild facial weakness 
CNVII palsy (post-op) 
Moderately 
severe loss  
Normal 
contralater
al  
Unilateral 
retinal 
hamartoma 
(macula) 
6/5   6/60+1 Narcolepsy 
 
Cervical schw 
causing cord 
compression 
Minor limitation 
Vision 
 
Seizure  
Precautions 
12 1 visit 6 Hand weakness (4) 
Visual impairment (5) 
Normal NA NA ONSM Minor limitation 
Vision 
Fine motor (Piano) 
13 3 16 Hearing loss Moderate 
loss  
Normal 
contralat 
Nil Normal  Minor limitation 
Communication 
14 1.7 6 Visual impairment 
 
Normal   CNIII: diplopia 
and ptosis 
àamblyopia 
Minor limitation 
Vision 
15 1 visit 7 Asymptomatic Normal Bilateral 
cataracts 
Normal  No limitation 
 
* Major complications included only. Incidence in Table 6.4 represents a comprehensive number of complications. 
** Hearing loss according to Goodman as follows: mild 25-40 decibels (dB), moderate 45-55dB, moderately severe 60-70dB, severe 75-90 dB and profound >90dB (240). 
CN-cranial nerve, contralat-contralateral, ctd-continued; ERM-epiretinal membranes, IC-intracranial, NA-not available, NLP-no light perception, ONSM-optic nerve sheath meningioma, 
RAPD-relative afferent pupillary defect, unilat-unilateral. 
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Table 6.4 Incidence of NF2 disease complications during childhood (≤ 18yrs, N=14) 
Complications/Disease Manifestations Number of patients Percentage 
Hearing loss 8 (12 ears) 57 (43)** 
     Unilateral deafness 2 14 
Visual difficulties 10 71 
     Reduced visual acuity 6 43 
     Blind in one eye 3 21 
     Eye movement disorder 4 28 
Facial nerve palsy (post-operative VS resection) 2 14 
Hoarse voice 2 14 
Pain 10 71 
     Back/neck pain 4 28 
     Headaches 9 64 
     Regular analgaesics 3 21 
Other sensory symptoms 6 43 
Weakness/Muscle wasting upper limbs 2 14 
Weakness/wasting lower limbs 3 21 
Gait abnormality* 7 50 
Urinary dysfunction 2 14 
Seizures 3 21 
Psychological distress (anxiety/depression) 4 28 
     Anxiolytic/antidepressant   2 14 
Cutaneous/subcutaneous tumours 3 21 
Other cutaneous features 13 92 
     CALM 7 50 
     Hypopigmented macules 7 50 
     NF2 plaques 7 50 
Ophthalmologic features 8 57 
     Cataracts 5 (9 eyes) 36 (32)** 
     Epiretinal membranes 3 (5 eyes) 21 (18)** 
     Retinal hamartomas 5 (5 eyes) 36 (18)** 
*Gait abnormality due to weakness, pain or unsteadiness; ** Percentage of ears or eyes 
affected in entire cohort (N=28). 
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hamartoma (with macular involvement, N=1).  Retinal hamartoma caused unilateral 
reduced visual acuity in one other child (6/120, Patient 2). Visual field defect was 
recorded along with reduced acuity in this case along with the last child (acuity 6/60, 
Patient 8) who had increased intracranial pressure associated with multiple 
intracranial tumours. Although ophthalmologic features of cataracts, epiretinal 
membranes and retinal hamartomas affected approximately one quarter to one third of 
children, most were not symptomatic. Similarly, cutaneous features occurred as an 
important diagnostic clue, but only occasionally caused clinical difficulties, usually 
due to discomfort/pain in tumours.   
 
Clinically significant weakness was less common. Two young children had 
functionally limiting arm/hand weakness at the ages of 4 and 8 years (Patient 5 and 
12; 14%). Weakness in the lower extremities affected 3 patients (21%).  By the time 
children with NF2 were ready to transition to adult services, 10 of 12 patients 
experienced pain, with three requiring regular analgaesia. Seven of these twelve older 
adolescents experienced gait difficulties.  All remained independently mobile, except 
for Patient 5 who had significant multilevel spinal disease causing pain, weakness and 
urinary dysfunction, and required a walker and wheelchair.  Depressed mood and/or 
anxiety occurred in four of 14 patients (28%), treated with medication in two cases.  
Approximately 20% of the population experienced seizures (3/14). 
 
In terms of the impact of disease manifestations on community participation (Table 
6.3), only one patient (with mosaic NF2) experienced no limitations approaching 
adulthood.  Two children were unable to attend school, in one case due to multiple 
disabilities, and in the other case due to mild visual impairment associated with 
significant psychological distress. Two adolescents were unable to drive due to visual 
impairment in one case, and coincident visual impairment and weakness in the other. 
 
Treatment 
Therapy provided for symptomatic patients is shown in Table 6.5. Only a single 
young patient (aged 6 years) received no active treatment. Medical therapy was 
provided for 9 patients, surgery for 11 patients, and radiotherapy for 2 patients. In 
those requiring medical management, steroids, analgesics, anticonvulsants, and  
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Table 6.5a Active management of disease complications for Australian children with NF2  
Patient Age 
(y) 
Medical Management* 
(indication/comment) 
Surgical Management* 
[total number of procedures] 
Complications of 
management 
Other 
1 17   Cutaneous schwannoma (1) Nil Hearing aid 
 
2  16 Anticonvulsant 
Analgesic 
Intramedullary spinal tumour (tanycytic ependymoma) / drainage 
of synrinx (1) 
Post-operative pain 
à improved over months 
Trace leg weakness 
 
  
3  16 Steroid 
(acute hearing loss) 
Unilateral VS (1) 
 
Nil Hearing aid 
4  18   R ONSM  
R orbital decompression 
Lumbosacral laminectomy L4/L5 schwannomas (3) 
Short stature  
post radiation 
Orbital radiation  
Glasses/telescop
e/braille 
5  18 Quinidine 
Hydroxyurea 
(IC tumours, prior 2005) 
CN IV 
L posterior interosseous nerve (elbow) for hand function 
Cutaneous schwannomas 
Tongue plexiform neurofibroma 
Tendon transfer (finger extensors) x2 
Cervical laminectomy C1/2, then C7/8  
Schwannoma resection 
(8) 
 
Nil significant Mobility aids 
(Walker/ 
wheelchair) 
Splints 
6  18   Intracranial meningioma adjacent  
CN VI (1) 
 
Complete CN VI palsy  
7  16 Anxiolytic/antidepressant Cholesteatoma (1) Nil significant Psychologist 
 
8  18 Antidepressant Cutaneous mass (forehead) 
Other cutaneous tumour (5) 
Thoracic laminectomy (meningioma) 
Unilateral VS 
(4) 
 
 
 
CN VII palsy 
Mobility aids 
 
Psychologist 
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Table 6.5b Active management of disease complications for Australian children with NF2  
Patient Age 
(y) 
Medical Management* 
(indication/comment) 
Surgical Management* 
[total number of procedures] 
Complications of 
management 
Other 
9  18 Steroid 
Somatostain analogue 
(meningiomas) 
VEGF inhibitor 
(VS growth/hearing loss; 
ONSM) 
Orbital decompression (ONSM) 
Unilateral VS 
(2) 
 Nil Hearing aid 
Radiotherapy 
10  16 Analgaesic 
VEGF inhibitor 
(VS growth/hearing loss; 
pain) 
Antihypertensive  
Cleft palate repair-not NF2 related 
(2) 
  
Proteinuria 
Hypertension 
Hearing aid 
 
Psychologist 
11  17 Steroid 
Anticonvulsant 
Analgaesic (headache) 
Retinal hamartoma 
C6 schw with complications 
Repair meningocoele 
(3) 
Nil 
Meningocoele with 
elevated ICP and 
mild CN VII palsy 
Psychologist 
12  6 Nil Nil NA Nil 
13 16 VEGF inhibitor  
(VS growth/hearing loss) 
Nil Proteinuria  
14  6 Nil Resection meningioma/schwannoma 
(one tumour adjacent CN III)  
(2) 
Unilateral ptosis Eye patching 
 
C-cervical CN=cranial nerve, IC=intracranial, ICP=intracranial pressure, L=left, NA=not applicable ONSM=optic nerve sheath meningioma, R=right, schw=schwannoma, VEGF=vascular 
endothelial derived growth factor, VS=vestibular schwannoma. 
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anxiolytic/antidepressant agents were prescribed.  Oncologic treatment to control 
tumour growth was provided in four cases.  Quinidine and hydroxyurea were trialled 
in one patient with severe disease prior to 2005, with limited success.  This patient 
died aged 18 years. One child received somatostatin analogue (for optic nerve sheath 
meningioma) for approximately 12 months, without definite benefit. Subsequent to 
2009, three patients were treated with bevacizumab (vascular endothelial growth 
factor inhibitor) during adolescence, over a total of approximately eight patient years 
follow up, with stabilization of symptoms and tumour growth (see Chapter 8).  Side 
effects of bevacizumab included proteinuria in two patients and hypertension in one 
patient, which were managed with dose adjustment and anti-hypertensives. 
 
Surgery for non-NF2 associated indications occurred in two patients-cleft palate 
repair in the child with large chromosomal deletion and cholesteatoma in the other 
case. Ten patients (71%) underwent 26 surgical procedures for NF2 associated 
indications, with a mean of 2.6 procedures per patient (range 1-8).  Three patients had 
unilateral vestibular schwannoma resection. Other procedures involved the eye (1), 
orbit (2), other intracranial tumour resection (4), spinal surgery (7), resection of 
peripheral schwannoma (1), and resection of cutaneous/subcutaneous lumps (3).  Five 
procedures (19%) were associated with surgical complications. None were severe or 
life threatening. Facial nerve weakness occurred following vestibular schwannoma 
resection in one case. Transient facial nerve palsy complicated resection of cervical 
schwannoma in another case, with raised intracranial pressure and meningocoele.  
Worsening of pre-existing cranial nerve palsies occurred post-surgery in two cases 
(14%; cranial nerves III and VI).  Post-operative pain and lower extremity weakness 
complicated laminectomy for cervical ependymoma resection and drainage of syrinx, 
which improved over time. 
 
Radiotherapy was provided for two patients (14%), both indicated for optic nerve 
sheath meningioma, with improvement. During three and 10 year follow up post-
treatment (Patients 9 and 4 respectively), the only side effect of radiotherapy observed 
was short stature for the child treated at a younger age of 8 years. Additional 
supportive therapy was provided for eight patients (57%), including hearing 
augmentation and psychology input in four cases each (28%). 
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Discussion 
Features of NF2 at Presentation and Diagnosis in Childhood 
This cohort of children illustrates many of the features of NF2 presenting to paediatric 
clinics.  The diversity of initial symptoms is most striking in this population along 
with other paediatric cohorts (Table 6.2). Although visual changes were most 
common, the prevalence at presentation in this study was higher at 57%, compared 
with other reports (8.3-44%)(162, 164, 206). Cutaneous features followed as the next 
most common abnormality seen in early life. However, neither ophthalmologic 
abnormalities nor cutaneous abnormalities alone constitute a clinical diagnosis of 
NF2. Rather, an astute clinician will ensure signs in the eyes and on the skin are 
carefully looked for in any child with features that may arise in NF2, including focal 
neurologic signs.  Clinical follow up, with surveillance for new symptoms and signs, 
should be established(241).  
 
The mean age at clinical diagnosis of NF2 for sporadic patients in this study was 10.6 
years, compared with 8.8-12.9 years in four other recent paediatric series(164, 179, 
221, 242).  Delay of 3.6 years between first symptoms and diagnosis in this group 
compares favourably with another study reporting 8.5 years(164). 
 
Hearing loss and tinnitus occurred at a low prevalence in only one child (7%) at 
presentation, within the range observed in the other six populations of children 
tabulated for comparison (4-25%). Considering numbers presenting in all seven 
populations, a prevalence of 12.7% was evident for hearing loss as a presenting 
symptom of NF2 in childhood (17/134; Table 6.2). The same patient with hearing loss 
in this study also experienced tinnitus. It is possible that other symptoms such as 
tinnitus and dizziness may have occurred in the absence of hearing loss in a few 
additional children in other studies, so that 12.7% may be an underestimate of 
symptoms of vestibular schwannoma at first presentation.  Even so, first presentation 
of NF2 with symptoms due to vestibular schwannomas in childhood likely falls within 
the lower range of the 15-30% reported previously(4).  
 
This series also demonstrates the potential diagnostic confusion among 
neurocutaneous syndromes (including NF1, NF2 and TSC) in early life, before 
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additional manifestations become obvious.  Overlaps occur in cutaneous and 
subcutaneous features including tumours, visual impairment and other focal 
neurologic deficits, along with seizures. Historically, there has been confusion in the 
diagnosis of NF2 and the more common disorder of NF1 (2, 162, 179). There are also 
overlaps in the clinical signs between NF2 and TSC(243) .  Nevertheless, a 
constellation of diagnostic signs exists for each condition, which are recognisable to 
the experienced clinician.  The establishment of clear clinical diagnostic criteria along 
with genetic testing has improved accurate diagnosis over the last couple of decades.  
All the same, surveillance over time may be required for diagnostic certainty in 
children, particularly if genetic testing is not available, or if testing is negative for the 
condition suspected.  Recommendations for monitoring are available to assist 
practitioners in cases of possible NF2, along with early identification of complications 
in children with established sporadic and inherited disease (241). 
  
Genetics 
It was surprising that only one patient (7%) in this study had familial NF2, in contrast 
with other reports of between 20-66% of affected children having inherited NF2 gene 
mutations (179).  Although advances in prenatal screening now allow for parents to 
reduce risk of transmission of genetic disorders to their offspring, a higher proportion 
of inherited cases were expected in this study dating back to 1994.  A majority of 
patients had nonsense or frameshift mutations in the NF2 gene causing a truncated 
protein product, as expected, in children with severe disease.  In contrast, two patients 
were found to have larger deletions involving the entire NF2 gene, along with a 
number of other genes.  The course of disease in such individuals is expected to vary 
with the extent and location of the deletion.  Certainly, other children with large 
chromosomal deletions have been reported having features shared with Patient 10, 
including NF2 as well as abnormal craniofacial development with cleft palate, 
reflecting contributions of the deleted NF2 gene along with adjacent genes(244).  
 
Complications 
A range of complications was evident among children included in this study. Visual 
problems remained important, affecting nearly three quarters of patients.  In cases of 
significant functional impairment in vision and hearing, patients often maintained 
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independence due to reliance on the contralateral eye or ear.  Severe disease 
manifestations were seen in patients with bilateral loss of function and spinal disease. 
Most experienced some limitations during childhood, with significant NF2-associated 
disability in four children, as well as the patient with the larger chromosomal deletion.  
One child with severe disease did not survive into adulthood (6.7% mortality).  This 
compares with three of 23 children (11.5%) in another study, who died at ages 2, 20 
and 24 years (162).  Given the complexity of disease manifestations in NF2, transition 
to adult services requires careful planning and information transfer between treating 
specialists.  Ideally members of the treating team will continue care from childhood 
into adulthood. 
 
Psychological distress requiring therapy occurred in more than a quarter of patients, 
underlining the importance of psychosocial support in this population as recognized in 
other NF centres(245, 246).  Wherever possible, the treating team should include 
members such as nurses, genetic counsellors and psychologists, experienced in the 
care of children and families with NF2. With the prospect of cumulative functional 
impairment over time, the usual transition to independence from parents is 
compromised in NF2, impacting on both the affected individual and close family 
members.  Financial and quality of life costs should be considered in cost-
effectiveness analyses of novel treatments in future. 
 
Assignment of level of disability in this study was based on the morbidity described 
and clinical knowledge of the patients. Eighty six percent of patients (13/15), 
experienced some limitations during childhood. The two unaffected children included 
one with inherited NF2 at a young age (7 years), and the patient with mosaic NF2 at 
18 years of age. This is similar to 83% of children (10/12) affected in at least one of 
four domains (vision, hearing, ambulation and grade level), in a US study (164).  This 
study could have been improved by utilization of a validated scale to allow 
comparison of level of disability and quality of life with other populations, and as a 
natural history baseline for interpretation of functional change in children managed 
with different treatment protocols in future.  Very little other comparative data is 
currently available for children with NF2, however tools such as the NFTI-QOL(247) 
or SF36 could be candidates. SF36 results for a group of eight children aged 10-17 
years, from USA, have recently been published, which interestingly, did not show 
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obvious deficits in quality of life compared with population norms for young adults 
aged 18-24 years (norms not available for children)(246).  
 
Treatment 
A diverse range of treatment was provided for these children, underlining the need for 
multidisciplinary communication and cooperation in the care of NF2 patients. 
Individual treatment decisions often proceeded only following consensus among the 
team of treating specialists.  Multimodal therapy was required in the majority of 
symptomatic patients (10/14; 71%). Surgical treatment was offered to more patients 
than medical management in this series (11/14 patients totalling 26 procedures, versus 
9/14 medical). This is similar to other reports including 12 children at a US centre 
prior to 2003, treated with 22 procedures in 10/12 patients (dermal, spinal or cranial, 
and all required at least one spinal or cranial procedure)(164).  Fewer procedures were 
performed in an Italian series of 24 children (22 procedures, predominantly 
cranial)(179).    
 
Three of our patients received VEGF inhibitor treatment for vestibular schwannomas. 
The response was modest in Patient 9 compared with Australian adults (see Chapter 
8), and associated with a clinical impression of stable disease in the other two 
patients. Proteinuria affected two patients and hypertension one patient, requiring only 
modest changes in treatment. Results have been published for only a small number of 
children treated with bevacizumab to date, with definite slowing of VS growth in 
seven patients from France(248). Detailed assessment of efficacy is important in 
larger groups of children, given observation of reduced response in children compared 
with adults in another study (249).   It remains to be seen, what is the optimal time for 
commencing therapy, and whether impact on renal function or other side effects will 
limit long-term treatment with VEGF inhibitors. 
Although hospital admissions were not overly prolonged (data not shown), 
admissions along with regular disease surveillance represent a significant burden of 
time, particularly for the patient requiring eight procedures during childhood. Surgical 
complications occurred in approximately 25% of patients, without a comparable 
number reported in the literature from other sites. These included recognised 
complications for the procedures performed, and no life threatening adverse effects. 
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 Radiotherapy was not commonly provided, and beneficial in both children with large 
optic nerve sheath meningiomas treated in this series.  This modality halted 
progression of optic nerve sheath meningioma for at least 8 years in another 
child(164). Auditory rehabilitation with hearing aids has been offered to selected 
children as accepted standard of care.  None of our patients have been considered for 
auditory brainstem implantation or cochlear implantation, approaches that warrant 
future consideration (250-252). Lastly, various additional allied health interventions 
provided supportive care, which played an important role in many cases.  
 
Conclusion 
In conclusions, children with NF2 present with a variety of symptoms and signs. The 
diagnosis may take time to establish with certainty, using clinically based criteria, 
neuroimaging and genetic testing. Cutaneous examination and ophthalmologic/visual 
assessment deserve special attention in childhood as a source of diagnostic clues and 
possible morbidity. The complications of disease are equally diverse, and typically 
require a multidisciplinary/multimodal approach.  There is cumulative multisystem 
functional decline in many children with NF2, without current options for cure. 
Timely diagnosis, identification of complications, and consultation with specialists in 
NF2 management, are more important than ever, as refinements in treatment evolve 
with a view to minimizing disability and risk of mortality in all affected individuals.  
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CHAPTER 7.  NF2 PATIENTS TREATED WITH BEVACIZUMAB: 
EPIDEMIOLOGY, FUNCTIONAL STATUS AND QUALITY OF LIFE 
 
Introduction 
As a tumour suppressor syndrome, NF2 manifests predominantly with formation of 
multiple benign tumours in the central and peripheral nervous systems and the skin.  
Since establishing the genetic basis of disease with identification of the NF2 gene in 
1993(14, 17), the clinical characteristics of NF2 have been well characterized in the 
literature (40, 167, 175, 241), although awareness of the condition among health 
professionals is generally limited due to rarity of the condition. Significant advances 
have been made regarding the molecular basis of disease and pathophysiology(253), 
paving the way for novel therapeutic approaches.   Accelerated translation of this 
knowledge into the clinical trials setting has been the focus of international research 
collaborations (23), with the vascular endothelial growth factor bevacizumab one of 
the first agents showing promise in initial case reports and small series of patients.  In 
considering response to therapy, appropriate objective disease specific end points 
have been proposed and assessed in early trials.  However, these end points do not 
necessarily represent overall functioning, disability secondary to the condition, or 
patient reported quality of life. 
  
In preparation for treatment of the first Australian patients with NF2 using 
bevacizumab, assessment of functional status and quality of life at baseline was 
considered an important complement to established outcomes of hearing function and 
radiologic response.   
 
This chapter outlines the rationale for selection of patients for bevacizumab therapy, 
and describes baseline characteristics in detail including presentation, complications 
of disease, and treatment to date.  Functional impact of disease and quality of life are 
reported, in comparison with published data from other populations.  These data form 
the baseline against which to measure changes associated with bevacizumab 
treatment.  
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Methods 
Patient population 
Referrals were received from specialists seeing NF2 patients around Australia and in 
New Zealand.  All patients met clinical criteria for diagnosis of NF2 (166), and had 
been seen by a clinical geneticist. Clinical review was undertaken by a neurologist 
and oncologist, either at Westmead Cancer Care Clinic (adult patients; SAH/MW), or 
The Children’s Hospital at Westmead (paediatric patients; SAH/GMcC). An 
assessment of disease and management recommendations were made for all patients.   
 
Suitability for trial of bevacizumab therapy was considered based on indications in 
published literature at that time, predominantly loss of hearing in the only hearing ear, 
according to the promising data of Plotkin et al (37). Detailed historical data, review 
of symptoms, examination findings, QOL assessments, and review of neuroimaging 
were undertaken to characterize baseline clinical status, disease burden and quality of 
life for the subset of patients enrolled on the prospective trial of bevacizumab therapy.  
 
Disease Characteristics 
Presenting symptoms, age at presentation and age at diagnosis were recorded for 
treated patients, along with inheritance pattern (sporadic versus familial disease), and 
genotype where available.  Active medical problems were summarized. An overview 
of tumour burden was based on number and location of tumours.  A detailed analysis 
of radiologic disease burden is beyond the scope of this chapter.  Greater detail is 
included in Chapter 8 which considers volumetric response of target and selected 
non-target tumours in treated patients, and in Chapter 9 which presents an assessment 
of tumour response across multiple tumours in a single patient.  
Hearing assessment included pure tone audiometry and speech discrimination score 
(SDS, also known as word recognition score, WRS). SDS was used as the primary 
hearing outcome consistent with proposed functional outcomes for treatment of VS in 
NF2(22).  Hearing loss was also described using the American Academy of 
Otolaryngologists-Head Neck Surgery grading system for comparison with other 
populations (254).  Presence of other clinical features such as ocular complications, 
(subcapsular cataracts, retinal hamartomas, epiretinal membranes) and visual 
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impairment, epilepsy and peripheral neuropathy were recorded.  Prior treatment 
received was documented including medical and surgical management.  
 
Functional Status and Quality of Life 
Psychosocial factors were recorded during clinical evaluation including impact on 
schooling or employment, and independence such as ability to drive.  
 
Functional status and quality of life were assessed using three self-administered 
patient reported measures: a novel NF2 symptoms questionnaire, developed for this 
study, with linear measure of overall wellbeing (NF2 linear overall wellbeing scale, 
LOWS, see below), the Speech, Spatial and Qualities of Hearing Scale (SSQ49)(255), 
and the Australian Short Form 36 (SF36) quality of life questionnaire.   
 
The NF2 symptoms questionnaire devised for this study, consisted of 20 items 
concerning symptoms and functional parameters routinely evaluated during a 
comprehensive systems review for complex NF2 patients (targeted to neurologic and 
oncologic symptoms; Appendix 6). Items in this questionnaire are listed in the NF1 
symptoms questionnaire, with the addition of tinnitus. Frequency of clinical 
symptoms was scored on a 6-point scale where 0=nil, 1=less than monthly, 
2=monthly, 3=weekly, 4=daily, 5=many times a day. A total score was calculated for 
each patient, with a higher score representing greater symptom frequency/functional 
impact. One additional open question was included.    
 
The estimate of overall wellbeing was derived using a linear scale ranked from low to 
high (Linear Overall Wellbeing Scale-LOWS, Appendix 6), where the overall 
wellbeing score was calculated as a proportion of the total length of the line (distance 
along the line/14.5). 
 
The SSQ is a freely available 49 item self-reported questionnaire of auditory disability 
(validated for individuals older than 18 years), which includes questions assessing 
complex listening skills in real-life situations (Appendix 7)(255, 256). It was designed 
as a self-reported assessment tool for use in interventional studies. The 49 items are 
clustered in 3 domains, assessing speech (14 items), spatial features (17 items) and 
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qualities of hearing (18 items).  A summary score was calculated for each domain, 
along with mean scores for the group of patients.  
The SSQ has not previously been used with NF2 patients to our knowledge.  
However, this tool has been used in evaluation of patients undergoing surgical 
removal of unilateral vestibular schwannoma (257), in treatment trials assessing 
utility of hearing aids(258) and cochlear implantation (257, 259). In these 
interventional studies, the SSQ has effectively established either no difference (260) 
or a statistically significant difference between interventions (cochlear implantation; 
post intervention SSQ results not shown here)(259).  An equivalent standardized tool 
was not available for evaluation of children at the time of this study. 
 
SSQ responses from three separate hearing impaired non-NF2 populations were 
sourced as a comparison with results for our NF2 patients. Population 1 represents the 
original cohort of Gatehouse and Noble involving 153 older adults, presenting to a 
general audiology service (males 73, females 80; average age 71y, SD 8.1)(255). 
Causes of hearing loss were not detailed, but likely include presbycusis in most cases. 
Hearing impairments were reported as 38.8dB (SD 15.5) (calculated as PTA using 
decibel levels at 0.5, 1, 2, and 4kHz) in the better ear and 52.7dB (SD 24.4), in the 
worse ear(255).   
 
Population 2 consists of a younger patient group (N=58) with unilateral deafness of 
various aetiologies assessed for effectiveness of bone-anchored hearing aids (BAHA) 
(average age 56 years, range 30-76y; 19 males, 39 females) (260).   Sporadic 
vestibular schwannomas affected 45% (27/58 patients; NF2 associated tumours not 
included; in the remainder childhood illness or congenital deafness N=7, sudden onset 
hearing loss in adulthood N=9, and acquired deafness following surgery or in 
association with systemic illness N=15).   40% of patients had hearing impairment in 
the contralateral ear (24/58; >20dB). Percentage change in speech discrimination 
scores were reported without baseline PTA.  
 
Population 3 summarises responses from twenty adults with unilateral sensorineural 
deafness of variable aetiologies (not including NF2), treated with cochlear 
implantation (259). Mean duration of deafness was 8.9 years (SD 11.6), with surgery 
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at mean age 51.6 years (SD 12.5).  Mean pure tone averages (0.5, 1, 2 and 4 kHz) 
were reported for individuals with some hearing loss in the contralateral ear 60.1 dB 
(SD: 14.4 dB) and 17.7 dB (SD: 9.1 dB) for those with contralateral normal hearing. 
Pre-treatment results are shown. 
 
Quality of life was measured using the Medical Outcomes Study 36-Item Short Form 
(SF36) questionnaire (Appendix 4) (144, 145), which has become one of the most 
widely used general health status questionnaires (146). This tool had been used in pre- 
and post-treatment studies of individuals with sporadic VS (261, 262), and since 
design of this protocol, also in NF2 patients (263). The SF36 requires patients to 
choose one of several responses to 36 questions across eight health domains: physical 
functioning, social functioning, role of limitations due to physical and emotional 
problems, vitality, general and mental health, and bodily pain(145). Questionnaires 
were scored using the method of Ware et al(145).  Baseline responses were compared 
with norms for the healthy Australian population available from the Australian 
Bureau of Statistics (147), and responses for other populations with sporadic 
vestibular schwannomas and NF2 (187, 261, 263).  
 
This project was completed with approval from the Children’s Hospital Westmead 
Human Research Ethics Committee (10CHW14). 
 
Results  
Patient population: Adults 
Nineteen adults were referred for evaluation between 2009-2011, ranging in age from 
17 to 57 years (mean 34.7 years, SD 12.8 years; 10 females, 9 males). Selected 
patients were followed through 2013.  ENT specialists and neurosurgeons referred 8 
and 9 patients respectively, with the remaining 2 referrals from neurologists. Thirteen 
patients were not considered suitable for bevacizumab therapy at that time for several 
reasons. Four had complete bilateral deafness, eight had unilateral hearing loss with 
intact hearing in the other ear; one patient was excluded for logistic reasons, being 
resident in New Zealand.    
 
Six adults were considered candidates for VEGF therapy, aged from 22 to 32 years 
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 (mean 27 years, SD 4.7 years, Table 7.1). Three were resident in NSW; one patient 
each came from Queensland, Western Australia, and South Australia. Indication for 
therapy was primarily hearing loss, with several patients having brain stem 
compression, and 1 patient with spinal cord compression and back pain (Table 7.3).  
 
Patient population: Children 
Fifteen children with a diagnosis of NF2 attended Neurogenetics Clinic from 2009-
2015. A detailed assessment of disease characteristics of these children is presented in 
Chapter 6). 2 children aged 12 and 13 years were included here (Table 7.1). The 
indication for bevacizumab treatment was hearing loss in both cases, although both 
children had additional disease related problems that were potential targets for 
therapy, to be monitored in follow up. 
 
Disease Characteristics 
All but one patient had sporadic disease. Genotypes are shown where available, along 
with inheritance pattern (Table 7.1).  One of the children had an atypical phenotype 
for NF2, with NF2 deletion identified on CGH microarray performed for investigation 
of developmental delay and spasticity (patient 8). 
 
Age at onset of symptoms referable to NF2 ranged between 5 and 22 years (mean 
13.6y, SD 5.8y). Diagnosis was made in late adolescence or early adulthood for most 
patients within 12 months of initial symptoms.  Two patients experienced NF2 
associated symptoms for 2-3 years prior to diagnosis.  
 
Most patients experienced clinical problems in multiple domains. Hearing impairment 
affected 8/8, ranging in severity.  Vision was affected in 4/8, with unilateral functional 
blindness in one child; a single adult had significant daily functional visual difficulties 
due to bilateral visual impairment.  Four adults and one child experienced pain 
(headache, backache or neck pain) on at least a daily basis.  All patients were 
independently mobile.  However, three adults experienced daily dizziness, and two 
reported falls on a daily basis.  Significant gait difficulties atypical for NF2 were 
experienced by patient 8, which was multifactorial in nature (spasticity, dizziness, 
pain), associated with chromosomal deletion extending beyond the NF2 gene.      
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Table 7.1 Clinical characteristics at presentation / diagnosis and genotype of NF2 patients treated with bevacizumab 
Patient 
(Gender) 
Age 
(y) 
Genotype  Inheritance Presenting symptoms Age (y) first 
symptoms 
Diagnostic 
criteria 
Age (y) 
Diagnosis 
1  (F) 22 NA Sporadic Tinnitus, unilateral hearing loss; 
unsteady, headache 
13 Bilateral VS  13 
2 (F) 23 [c.41_42delTC p.Leu14GInfsX34] 
 
Sporadic Multiple cutaneous schw; Foot 
dropà ankle reconstruction 
 15 Bilateral VS  17 
3 (F) 32 65688 G>A (IVS7-1 G>A)  
deln exon 8+inframe deln 45 aas (codons 226-
270); likely pathogenic 
Sporadic Focal sensorimotor seizures  19 Bilateral VS   19 
4 (M) 22 NA Familial Foot drop  10 Bilateral VS  10 
5 (M) 32 [c.1627_1628del  
p.Lys543 AspfsX21] (Hz) 
Frameshift->insertion prem stop codon 
Sporadic Headache 
Blurry vision 
Diplopia 
 22 Bilateral VS   22 
6 (M) 31 [c.1336_1337del p.Arg446 GlufsX48] (Hz)  
frameshift mutation exon 12àlikely 
pathogenic; likely mosaic: 2 tumours, not in 
blood. 
Sporadic Diplopia à Meckel’s cave tumour 
on MRI àresection 
 17 Bilateral VS  20 
7 (M) 12 NA Sporadic Unilateral visual and hearing loss 5y  VS 
OPSM 
5 
8 (M) 13 22q12.1q12.2 
(A_16_P03609081>A_16_P21309118) x1 ** 
Sporadic Developmental delay; Spasticity 
NF2 specific: tinnitus, hearing loss 
8y CGH  
Bilateral VS 
8 
 
*For sporadic cases only; familial cases identified pre-symptomatically with surveillance; ** Chromosome 22 deletion detected on CGH microarray including 
the NF2 gene.  This patient presented with clinical features likely secondary to the larger deletion; aas-amino acids, CGH-chromosomal microarray, deln-
deletion, IC-intracranial, ONSM-optic nerve sheath meningioma, NA-not available, prem-premature; schw-schwannoma, VS-vestibular schwannoma, y-
years.
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Impact on community participation was common in adults, including difficulty in 
vocational training or the workplace due to hearing impairment in 5/6; 1/6 adults had 
resigned from employment due to NF2 associated morbidity, and 1/6 young adults 
had not been able to pursue desired vocational training. One adult was no longer able 
to drive due to visual impairment.   
 
Hearing function is shown in Table 7.2.  All patients except one had audiology results 
demonstrating progressive decline in PTA and SDS consistent with the known natural 
history of NF2 (data not shown).   
 
An overview of radiologic disease burden indicates most patients had significant 
intracranial and intraspinal disease (Table 7.2).  Vestibular schwannomas were the 
primary target lesion for bevacizumab therapy in seven patients.  In contrast, patient 2 
had a large trigeminal schwannoma, along with smaller bilateral VS and multiple 
large cervical presumed schwannomas causing cord compression.  Patient 7 was 
treated for hearing loss associated with VS as the primary target tumour, along with 
monitoring of bilateral meningiomas, and enlarging schwannomas around the cervical 
cord, threatening cord compression.  
 
Prior treatment is summarized in Table 7.3.  All patients were receiving medical 
therapy despite their young age. Medications included anticonvulsants, analgaesics, 
antidepressant medication and intermittent steroids.  Steroid side effects (weight gain, 
striae) were prominent in one patient. Seven individuals had undergone surgical 
treatment, ranging from 1- 6 procedures (mean 2.9).   
 
Functional Status and Quality of Life 
Scores for the baseline NF2 symptoms questionnaire were available for all adults 
ranging from 20-48 (mean 34.5, SD 11.9; Table 7.4).  For many patients, items such 
as bladder and bowel incontinence and constipation were non-contributory throughout 
the course of the study.  For this reason, scores have also been reported with these 
items deleted.  
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Table 7.2a Major complications of NF2 in patients identified as candidates for bevacizumab therapy 
Patient Age 
(y) 
Major clinical 
problems 
Eye findings Visual Acuity Radiologic features Other features Community 
Participation 
 
1  
 
22 
 
 
Decreasing hearing in 
only hearing ear 
Symptoms of brain 
stem compression 
Leg weakness 
Depressed 
mood/anxiety   
 
 
ERM 
 
6/9  bilat 
 
Unilateral VS with brain 
stem compression 
Multiple small lesions 
along spinal cord 
 
CALM 
Cutaneous schw 
Multiple spinal tumours  
Peripheral nerve 
schwannoma 
Peripheral neuropathy 
 
Choice of 
vocational training 
2  23 Foot drop 
Generalised weakness 
due to neuropathy 
Mild hearing loss 
ERM  6/9  6/45 Bilateral VS without 
brain stem compression 
Large trigeminal 
schwannoma 
Multiple cervical 
schwannomas with cord 
compression 
Multiple other spinal 
schwannomas 
Large axillary mass 
Trigeminal schw,   
IC ependymomas/schw 
Peripheral neuropathy 
Nil known 
3 32 Hearing loss 
Altered voice 
Weakness 
Gait instability  
Intracranial 
hypertension 
Depressed mood 
Post subcaps 
cataracts 
R/L optic 
atrophy  
NLP   6/12 
Improved VA 
6/45 Apr 12 to 
6/12 Apr 13  
after 16 months 
therapy 
 
VS, ONSM 
Intracranial 
meningioma 
Multiple IC tumours 
(incl meningioma)  
CALM 
Cut schw 
 
Resigned from 
Employment 
Unable to drive 
due to visual loss 
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Table 7.2b Major Complications of NF2 in patients identified as candidates for bevacizumab therapy 
Patient Age 
(y) 
Major clinical 
problems 
Eye findings Visual Acuity Radiologic features Other 
features 
Community 
Participation 
 
4 22 Hearing loss 
Visual loss 
Gait instability 
Pain 
 Post subcaps 
cataracts 
(visual axis) 
ERM 
6/9   6/45  
(6/18 pinhole) 
Unilateral VS with 
brainstem 
compression 
SC 
 Choice of vocational 
training 
5 32 Hearing loss 
Peripheral 
neuropathy 
(upper and lower) 
Gait instability 
Pain 
Depressed 
mood/anxiety 
 2012 
Diplopia (R partial 
CNIII due to R CNIII 
schw) 
Post subcaps 
cataracts  
ERM 
 
6/9   6/45  
(6/18 pinhole) 
Unilateral VS with 
brain stem 
compression 
 Impact on 
employment 
6 31   Unilat anaesthetic 
cornea; 
Corneal ulcer 
scarring 
 6/12   6/15 Unilateral VS 
without brain stem 
compression  
Trigeminal 
schw 
Peripheral 
neuropathy 
 
Impact on 
employment 
7 12 Hearing loss 
Visual loss  
Pain 
 Bilateral optic nerve 
sheath meningiomas 
Cataract 
NLP   6/36 Bilateral VS 
Bilateral ONSM 
Cervical schw with 
cord displacement 
Other sp schw 
 Nil known 
8 13 Pain 
Hearing loss 
Gait instability 
Tinnitus 
     6/12   6/12 Bilateral small VS 
Multiple spinal 
schw 
 Nil known 
 
 
CN=cranial nerve, ERM-epiretinal membranes, IC-intracranial, L-left, ONSM- optic nerve sheath meningioma, prn-as needed, R-right, SC-spinal cord, schw-
schwannoma, subcaps-subcapsular, unilat-unilateral, VS-vestibular schwannoma, y-years. 
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Table 7.3 Previous management and indications for bevacizumab treatment  
Patient Age 
(y) 
Medical Management 
[total number] 
Surgical Management 
[total number procedures] 
Complications of 
management 
Indication for 
bevacizumab 
1 22 Steroid Resection unilateral VS aged 15y [1] Unilateral deafness 
Decreased lacrimation 
A*/ Brainstem 
compression 
 
2 23 Antidepressant 
Analgesics prn 
Resection cutaneous schwannomas-multiple 
Ankle reconstruction 
Laminectomy with resection spinal tumours (x3) [6] 
 B** /Brainstem 
compression/ 
Cervical cord 
compression 
 
3 32 Anticonvulsant  
 
Intracranial tumour resection (meningioma, unilat 
VS, CN 10 schw) by 28y age [3] 
 
Unilateral CN VII palsy A 
4 22 Anticonvulsant  
Steroid [2] 
Resection cutaneous schw 
Foot reconstruction 
Radiation for unilat VS aged 15 years with  
stabilisation hearing [3] 
 
Steroid side effects 
Partial CN VII palsy 
A 
5 32 Steroid Resection cutaneous schw 
Resection unilat trigeminal schw 
Resection unilat VS [3] 
 
Complete hearing loss; 
partial CN VII palsy 
A / Brainstem 
compression 
6 31 Anticonvulsant  Resection intracranial tumours (Meckels’ cave, unilat 
VS, unilat trigeminal schw) [3] 
 
  A 
7 12 Steroid 
 
Biopsy/resection optic nerve sheath meningioma [2] 
 
  A 
8 13 Analgesics (3) Nil  B / Back pain 
*A= Decreasing hearing in only hearing ear; **B= Mild bilateral hearing loss; CN=cranial nerve, prn-as needed, schw-schwannoma, unilat-unilateral, VS-vestibular 
schwannoma, y-years. 
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Table 7.4 Baseline NF2 Symptoms Questionnaire scores and Linear Overall Wellbeing 
Scores  
Patient NF2 Symptom 
Score 
NF2 Symptom Score 
(Items X-Y excluded) 
Linear Overall  
Wellbeing Score (LOWS) 
1 38 38 0.43 
2 47 44 0.57 
3 48 47 0.41 
4 23 23 0.34 
5 31 31 0.62 
6 20 19 0.77 
    
Mean (1-6) 34.5  0.52 
SD 11.9  0.16 
    
8 14 14 0.99 
 
 
A single response was recorded in the open question only, so this was overall non-
contributory. Scores for the LOWS among adults varied from 0.34 to 0.77 (mean 
0.52, SD 0.16; Table 7.4). 
 
A range of SSQ49 responses were observed for NF2 patients across the 3 domains 
(Table 7.5) for all individuals, along with mean scores for adults (as this tool is 
validated in the adult population only). NF2 scores were lower than in the Gatehouse 
and Noble cohort, consistent with expectation, as their patients had less severe 
hearing impairment compared with our patients who had unilateral complete deafness 
along with impairment in the remaining ear.  
 
Mean scores for each domain in our NF2 patients were also lower than in population 
2, suggesting greater disability in a population that included patients with sporadic VS 
or unilateral hearing loss of other aetiologies. Similarly, NF2 patients reported greater  
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auditory disability than in Population 3, which included some patients with preserved 
hearing on one side.  
 
Table 7.5 SSQ responses for NF2 patients (shaded) and other hearing impaired 
populations 
NF2 Patient/ SSQ Domain   
Population Speech Spatial Quality 
1  1.00 0.88 2.72 
2  4.29 3.12 5.06 
3  2.86 2.53 5.33 
4  1.21 1.18 0.89 
5  0.86 0.88 3.11 
6  3.86 3.86 4.78 
7  7.43 7.88 9.33 
Mean (Adults 1-6)  
(SD) 
2.35 
(1.52) 
2.07 
(1.27) 
3.65 
(1.72) 
    
Population 1* 
N=153 
4.39 
(1.35) 
5.65 
(0.97) 
6.34 
(1.32) 
    
 Population 2** 
Cases N=58 
5.0 
(1.8) 
3.2 
(2.0) 
6.5 
(1.7) 
Controls N=49 4.5 
(1.9) 
3.3 
(2.1) 
6.7 
(1.4) 
    
Population 3*** 
Contralateral HA N=9 
2.1  
(1.2) 
1.9 
(1.0) 
3.5 
(1.7) 
 
Contralateral NH 
N=11 
3.9 
(1.4) 
3.0 
(1.5) 
5.8 
(1.5) 
*Original cohort of older adults reported using the SSQ (255); **Patients treated with bone 
anchored hearing aids, including some patients with sporadic VS; no significant difference 
between groups (260); *** Patients with unilateral sensorineural deafness of various 
aetiologies, prior to treatment with cochlear implantation having either normal hearing (NH) 
or a hearing aid (HA) on the opposite side (259). 
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Individual SF36 responses and means are shown in Table 7.6a for comparison with 
other populations (Table 7.6b). Our NF2 mean scores were reduced compared with 
Australian normative data for age-matched patients, and versus post-operative 
vestibular schwannoma patients. Greater similarity was seen with the UK population 
of NF2 patients.  Confidence intervals were broad in the Australian cohort reflecting 
small sample size. 
 
Discussion 
The group of patients selected for therapy with bevacizumab included predominantly 
patients in the young adult age range.  The main reason for exclusion of older adults 
was significant pre-existing bilateral hearing loss. 
 
These patients do not represent a population-based sample of NF2 patients, and as 
such cannot be compared directly with other population-based studies of impact of 
disease on individuals with NF2.  However, this subset represents a group of 
individuals with progressive disease, requiring active treatment, likely with 
similarities to NF2 patients selected for bevacizumab therapy at other centres in 
recent years, using similar selection criteria.  
 
At the time of initiating this study, consideration of cervical tumours as an indication 
for treatment deviated from use of VEGF inhibitors at other sites.  While specific 
effects on hearing and tumour volume were clearly appropriate for 5/6 adults 
identified for systemic therapy for VS, we were cognisant of the possible benefits of 
systemic therapy for other schwannomas.  In Patient 2, risks associated with 
progression of cervical disease were considered to warrant treatment alongside 
bilateral VS. This patient demonstrates the complexity/high disease burden seen in 
many cases and highlights the challenges of monitoring outcomes in a complex 
systemic disease such as NF2. For this reason, a generalized symptom checklist was 
designed to monitor for change in multiple items, along with a simple overall measure 
of quality of life using the linear scale (LOWS), and SF36.    
 
The eight patients described in detail here were heterogeneous in terms of disease 
burden, and active medical problems. Disease-related morbidity was significant, with
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Table 7.6a SF36 responses for NF2 patients 
PATIENT  PhysFxn RolePhys Pain Gen Hlth Vitality    Social RoleEmtl        Mental Hlth 
   
LimPhysHlth 
  
En/Fatigue    LimEmtlHlth EmtlWellbeing 
          
1 65 0 22.5 20 20 50 33.3 56 
          
2 5 25 55 50 65 75 100 88 
          
3 5.6 0 67.5 0 10 0 33.3 56 
          
4 65 0 55 50 60 62.5 0 64 
          
5 70 0 32.5 37.5 50 50 0 48 
          
6 100 75 100 85 80 62.5 100 84 
          
7 
 
95 
 
100 
 
90 
 
95 
 
80 
 
100 
 
100 
 
96 
 
8 45 50 77.5 35 45 50 66.7 76 
          
Mean*  51.8 16.7 55.4 40.4 47.5 50.0 44.4 66.0 
(SD)  (38.3) (30.3) (27.4) (29.1) (27.2) (26.2) (45.5) (16.3) 
         
*Mean of adult patients 1-6. 
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Table 7.6b Mean (SD) SF36 responses for Australian NF2 patients, and comparative populations 
Population  PhysFxn RolePhys Pain Gen Hlth Vitality Social RoleEmtl Mental Hlth 
   
LimPhysHlth 
  
En/Fatigue 
 
LimEmtlHlth EmtlWellbeing 
          
          
Aust*  51.8 16.7 55.4 40.4 47.5 50.0 44.4 66.0 
  (38.3) (30.3) (27.4) (29.1) (27.2) (26.2) (45.5) (16.3) 
         
         
NF2UK** 
 
40.1 
(14.5) 
41.2 
(12.3) 
45.8 
(13.3) 
38 
(12.2) 
42.6 
(11.1) 
40.1 
(11.8) 
40 
(14.7) 
41.9 
(13.1) 
         
         
VS*** 
 
76.2 
(28.07) 
63.78 
(43.71) 
74.35 
(26.50) 
67.13 
(25.57) 
61.41 
(22.87) 
78.44 
(27.86) 
77.55 
(35.09) 
75.51 
(19.32) 
         
Aust 
Norm‡ 93.3 82.8 80.8 79.2 64.6 87.5 85.6 77.8 
         
 
*Australian NF2 adults 1-6; **Manchester NF2 adults, N=62 (263); ***Australian postoperative QOL in VS patients (N=98, mean age 55y, range 10-77y) (261); 
 ‡Australian normative values of 25-50 year olds, combined genders (147).  
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all adults experiencing daily functional limitations.  Most required regular or 
intermittent medical therapy, and several had adjusted life goals/community 
participation/employment due to their disease.  The negative impact of NF2 on daily 
activities including work, and social interaction has been identified as a key finding in 
other studies of adults with NF2 (245, 264). In a study of 62 adults (mean age 39y, 
mean age of NF2 diagnosis 28y), 28% of adults were unemployed due to NF2, and an 
additional 15% had taken early retirement on medical grounds(265). 
 
Multiple surgical procedures had been performed with some complications but overall 
benefit based on general clinical assessment in our patients. As effective systemic 
medical therapies become available, it is likely that the timing and nature of surgical 
intervention will change in the future.   
 
Overall, patient-reported outcomes (PROs) demonstrated a range of responses among 
individuals, with clustering of higher or lower scores consistently in any one patient 
across different assessment tools.  Scores in the two children included demonstrated 
fewer symptoms and functional limitations than in adults. One child has atypical NF2 
as part of a larger chromosomal deletion, and thus, his functional impairments do not 
reflect isolated NF2 related morbidity. The other child with severe disease resulting in 
unilateral deafness and blindness demonstrated remarkable resilience on patient 
reported measures, suggesting adequate functioning of the remaining sensory systems 
to prevent significant functional impairment.  It should be noted that this 
questionnaire was administered partway through VEGF therapy for this child only 
(following cessation and prior to restarting therapy), so represents partially treated 
status rather than naïve pre-treatment responses.  As such it may reflect positive 
response of prior therapy. 
 
The NF2 symptoms questionnaire yielded variable scores for different patients, 
depending on clinical presentation, such as frequency of pain.  In general, symptom 
scores appeared to correlate with other PROs, suggesting the NF2 symptoms 
questionnaire may be useful for stratifying functional status in NF2 patients 
(correlation based on statistical testing not possible). Use in a larger patient group 
would be needed to assess this further.  In addition, scoring responses in normal 
individuals versus NF2 patients would be helpful to further validate this tool as 
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specific for identifying relevant NF2 symptoms, with the expectation that scores 
would cluster across non-overlapping ranges for the patient and general population 
groups. The open question was not useful, possibly due to the comprehensive nature 
of other questions included. Of note, items in this questionnaire assessed physical 
functioning only, leaving psychosocial factors unaddressed.  The Linear Overall 
Wellbeing Scale (LOWS) is expected to reflect other such features.  
The range of scores observed for the LOWS was generally aligned with other PRO 
measures.  Although linear analogue scales for overall quality of life contain limited 
information, such scales have been used in assessing response to therapy for cancer 
patients, and have been found to correlate with other measures of treatment efficacy 
and quality of life (266, 267).  Simple linear analogue scales likely have greatest 
value for populations limited in ability to complete longer instruments or when use of 
a simpler scale is warranted (267).  Most patients in this study completed 
questionnaires without difficulty, suggesting young NF2 patients have the capacity to 
use detailed tools. However, follow up data was incomplete for some individuals (see 
Chapter 8), which may reflect that the multiple questionnaires utilized here proved 
onerous for others.  In principle, PRO tools should include items sensitive to change 
over time, with minimal overlap between items, and the fewest items possible to 
detect change ie, removal of redundant items, as has occurred with refinement of the 
SSQ over time (see below). Utility of the NF2 LOWS will be assessed further in the 
next chapter compared with other PRO after treatment with bevacizumab. 
Regarding disability associated with hearing impairment, SSQ responses in our 
patients revealed greater difficulties than in older adults with age-related hearing loss, 
and individuals with hearing loss due to other aetiologies, including sporadic VS.  
This is probably due to the nature of NF2 associated hearing loss, which becomes 
profound, and bilateral in most cases.  In addition, these NF2 patients were selected 
due to severe disease, with inclusion criteria of predominantly unilateral deafness 
with progressive hearing loss in the remaining ear.  
An alternative simplified tool, the SSQ12 (published since this study was conducted), 
may be useful to consider in future NF2 trials(268).  The SSQ12 has the potential 
advantage of use for interview style administration in children older than 10 years, 
and for parents and teachers of children 5 years and older (268, 269).  A comparative 
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study of the new SSQ12 versus SSQ49 for NF2 patients would be of interest to assess 
whether the shorter tool yields equivalent data and could be used in preference. 
SF36 responses for our small cohort demonstrated reduced quality of life compared 
with the normative Australian population, with broad confidence intervals due to 
small sample size. Responses more closely resembled the Manchester NF2 population 
(Table 7.6). Interestingly, role limitations due to physical health and social 
functioning showed the greatest differences compared with healthy norms, as was 
found previously in post-operative VS patients (261). In contrast, another study of 
quality of life in postoperative sporadic VS showed 7/8 domains affected (excluding 
vitality)(270).   
 
In considering clinical trial design, it is important that outcome measures are 
clinically relevant.  In NF2 as a tumour suppressor syndrome, assessment of tumour 
volumes has been an obvious focus.   A recent study assessed correlation of overall 
tumour burden measured using 3D volumetry on WBMRI in NF1, NF2 and 
schwannomatosis, demonstrating an association between overall tumour burden and 
bodily pain on SF36 in schwannomatosis and NF2, with other domains not 
significantly affected. We agree with the authors’ emphasis on monitoring 
psychosocial outcomes in addition to tumour volume, as tumour volume may not be 
directly associated with quality of life (187). Whether specific tumour volumes (eg. 
VS) may correlate with change in quality of life in response to treatment is a question 
which can be explored further in our study and others. 
 
Other recent data supporting the potential utility of the SF36 as a useful clinical trial 
PRO measure in NF2 comes from the work of Neary and colleagues, who established 
hearing, balance, visual problems and psychosocial issues as being the most important 
concerns for adults with NF2 (N=62, mean age 39, mean age diagnosis 28y)(265), 
and provided evidence that SF36 responses are associated with communication, 
balance, and hearing difficulties in these patients(263).  
 
A number of factors suggest our NF2 cohort represents a subset of severely affected 
individuals with NF2.  Referral bias is likely, and younger age at onset of symptoms 
is typically associated with more severe disease.   Severity of disease in NF2 is known 
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to vary depending on inheritance pattern and genotype, with familial cases and 
truncating mutations often manifesting with earlier onset, more severe disease (241, 
271). Genotypes were available for only a proportion of patients, reflecting local 
practice of expectant management of NF2 due to resource limitation for genetic 
testing.   In our setting, genetic testing is typically arranged to facilitate prenatal 
testing or to assist in the diagnosis of pre-symptomatic potentially-affected children. 
 
The economic implications of NF2 have not been considered in this study.  However, 
these descriptive data would inform a cost effectiveness assessment for bevacizumab 
in NF2.  It is anticipated that disease related costs would be significant, and extend to 
experiences of family members. The impact of NF2 on family members providing 
such support has been acknowledged by affected patients previously(245).  In this 
cohort, all but one patient attended appointments with a close family member for 
practical and social/psychological support.  
 
Conclusion 
NF2 is a heterogeneous condition with variable age of onset and severity.   
Individuals with the condition are at risk of significant morbidity, disability and early 
mortality, due to the “biologically malignant” nature of NF2 associated “benign” 
tumours.  Young adulthood is a key stage for many individuals when systemic 
therapy may be useful.  NF2 presenting in childhood is often associated with a severe 
phenotype and may require systemic therapy earlier.   
 
Patient reported outcomes should be considered where possible in NF2 treatment 
trials, assessing specific functional domains, along with measures of quality of life.  
The NF2 symptoms questionnaire and LOWS may be helpful during routine 
surveillance of complex NF2 patients, and possibly in systemic treatment trials.  SSQ 
responses indicated significant disability associated with hearing impairment in this 
pre-selected cohort of NF2 patients compared to other populations with hearing loss. 
The SF36 offers a good general assessment of QOL, and showed pronounced disease 
impacts in NF2. 
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Chapter 8.  Bevacizumab for Vestibular Schwannomas in 
Neurofibromatosis type 2 
 
 
Introduction 
Vestibular schwannomas are the hallmark lesion in individuals with NF2, typically 
occurring bilaterally, and affecting 95% of individuals. These tumours cause 
headaches, tinnitus, hearing loss, dizziness and gait instability, and risk of early 
mortality due to brainstem compression estimated at up to 60% by the age of 44 years 
in one report (191).  About 20% of patients with NF2 present with symptoms before 
the age of 15 years, and of these, up to 43% may have symptoms associated with 
vestibular schwannoma (10).  Unfortunately, increased morbidity is associated with 
these tumours among individuals with NF2 compared with patients with sporadic 
vestibular schwannoma (in the absence of NF2), which is, in part, due to an increased 
growth rate of tumours in NF2.   
 
Until recently, surgery and radiosurgery have been first line treatment approaches.  
Surgical treatment can be associated with risk of further hearing loss and damage to 
the trigeminal and facial nerves. These complications occur at a lower rate with 
gamma knife stereotactic radiosurgery (272, 273).  Malignant transformation can 
occur rarely, and has been reported after radiosurgery (274).  Patients with NF2 are at 
increased risk of radiation-induced malignancy compared to those with sporadic 
disease (189).  For this reason, they may be excluded from treatments such as gamma 
knife stereotactic radiosurgery.  While surgery and radiation treatment may decrease 
the size of tumours and associated symptoms of brainstem compression, these 
treatments do not typically yield improvements in hearing.  Effective alternative 
medical treatments are needed for vestibular schwannomas, to prevent the morbidity 
associated with hearing loss and symptoms of brainstem compression.  Furthermore, 
medical approaches for patients with complications of NF2-associated tumours are 
desirable because many patients experience morbidity from multiple tumours in the 
central and peripheral nervous system over time. As such, systemic therapy may 
deliver off-target tumour responses yielding significant clinical benefits (see Chapter 
9).   
 143  
Angiogenesis inhibitors such as bevacizumab (Avastin) have been recognised as 
important therapeutic agents for tumour management (23, 275), and have shown 
promise as therapy for vestibular schwannomas in NF2(37, 227, 228, 249).  
Bevacizumab is a monoclonal IgG1 antibody that binds to and inhibits the activity of 
vascular endothelial growth factor-A (VEGF-A). The goal of treatment with 
bevacizumab, via effects on tumour vasculature, is to reduce the size of vestibular 
schwannomas and to improve hearing loss and / or symptoms of brainstem 
compression in patients with NF2. Reduction of tumour growth rate and stabilisation 
of hearing function may constitute treatment response on a background of progressive 
growth and loss of function. As systemic therapy, this agent also has the potential to 
improve functional outcomes via effects on other tumours. 
 
In recent years, significant consideration has been given to identifying appropriate 
outcome measures for use in clinical trials for the NF2 population (22, 23, 124, 214), 
with a focus on hearing and radiologic response of vestibular schwannomas.  
 
In this chapter, I present in detail the response of the first Australian NF2 patients 
treated with bevacizumab, as well as a comparison with the growing international 
experience. Outcomes of interest included audiologic functioning and radiologic 
response of vestibular schwannomas, along with selected secondary tumours in some 
patients. Other patient-reported outcomes included physical symptoms measured with 
a novel NF2 symptoms questionnaire and simple overall wellbeing score, in addition 
to hearing disability measured using the SSQ49, and quality of life according to the 
SF36 questionnaire.  Medication tolerability was also assessed and reported here. 
 
Methods 
A prospective audit of bevacizumab treatment for vestibular schwannomas causing 
significant morbidity (hearing loss and symptoms of brainstem compression) was 
conducted in children and adults with NF2, followed at the Children’s Hospital at 
Westmead, and Westmead Public Hospital in Sydney between 2009-2013(200). The 
local Human Research Ethics Committee approved this study (10CHW14). 
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Patients 
Patients were evaluated in the Neurogenetics Clinic at CHW or Oncology Clinic 
Westmead, and met clinical criteria for NF2 (200). Recruitment from other centres 
around Australia was undertaken to increase medication availability for patients and 
to facilitate centralised review of efficacy and tolerability. Participating institutions 
included three sites in NSW (Prince of Wales Hospital, Randwick; Liverpool 
Hospital; Royal Prince Alfred Hospital, Camperdown), Perth (Hollywood Private 
Hospital, Nedlands, Western Australia), Adelaide (Flinders Medical Centre, South 
Australia), and Queensland (Haematology and Oncology Clinics of Australia, Gold 
Coast Cancer Centre and Day Hospital). This series includes Patients 1-7 from 
Chapter 7, and excludes Patient 8 due to incomplete outcome data.  
 
Patients selected for bevacizumab treatment had either hearing loss documented in 
both ears or in their only hearing ear, and/or symptoms of brainstem compression.  All 
treated patients had symptomatic vestibular schwannomas identified as the target 
lesion.  
 
All patients were screened prior to treatment for factors that would increase risk of 
side effects from bevacizumab including uncontrolled hypertension, history of stroke, 
cardiac or peripheral vascular disease, deep vein thrombosis, known personal or 
family history of coagulopathy, hepatic dysfunction (parameters 2-3 x upper limit of 
normal for age), renal dysfunction (serum creatinine greater than 1.5x upper limits of 
normal for age) or haematologic dysfunction (absolute neutrophil count of less than 
1,000, haemoglobin of less than 9 g/dl, or platelet count less than 100,000). No 
patients were pregnant or breast feeding during treatment.  Advice was provided to 
females of reproductive age to use contraception and avoid pregnancy during 
treatment. In addition, based on animal data, alerts from oncology trials (CABARET), 
and observed changes in menstruation among our treated patients, advice was 
provided regarding potential effects of bevacizumab on fertility.  Referral to fertility 
experts was recommended and arranged, to assess management options.  No patients 
had prior exposure to Avastin, or other anti-angiogenic agents. One patient received 
prior chemotherapy, and one patient received a combined chemotherapy regimen 
during treatment with bevacizumab.  
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Patients were assessed with clinical evaluation, audiology, neuroimaging, and 
functional assessment questionnaires at baseline then at 3, 6, 12, 18, 21, 24 and 30 
months on the Westmead campus where possible, alongside local treating oncologists 
who administered, and monitored therapy.  
 
Bevacizumab therapy – Funding and Medication Administration 
As bevacizumab was not licensed for use in NF2, and not funded for this patient 
group, individual applications were made to the Drug Committee of the eligible 
patient’s Area Health Service for assistance in the provision of medication. 
Information was also provided to individual patient medical insurance companies 
outlining the rationale for treatment, and requesting financial support. Application 
was made to Roche Pharma for discounted medication for use in this study based on a 
cost sharing arrangement (one free dose for every three purchased doses).  
 
Bevacizumab was administered as a fortnightly infusion (5mg/kg/dose), or 
7.5mg/kg/dose every three weeks (Patient 3 only).  Dose adjustment (pause in therapy 
or reduction in dose) was considered in the event of adverse effects of medication 
(Appendix 8).  Bevacizumab was ceased prior to elective surgery or other therapy. 
 
Evaluation of disease progression/efficacy of treatment 
Outcomes were divided into primary and secondary categories. Primary outcomes of 
hearing response and radiologic vestibular schwannoma response assessed at 3, 6, 12, 
18, 24 and 30 months after commencement of treatment, in line with published 
recommended outcomes for use in clinical trials for treatment of vestibular 
schwannomas available at that time (22).  Selected readily measurable non-vestibular 
intracranial tumours were also assessed. Symptoms, functional status and quality of 
life were assessed as secondary outcomes (described in detail in Chapter 7). 
 
Baseline pre-treatment evaluation consisted of comprehensive medical assessment, 
audiology assessment and 3D volumetric cranial MRI (including thin slices (3mm) 
through the internal auditory canal) and cranial MRA, as well as whole spine, within 6   
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weeks of commencement of treatment with bevacizumab, and administration of 
questionnaires. 
 
Primary Outcome: Hearing 
Audiology evaluations were performed in the audiology department CHW, Hearing 
Australia, (Chatswood and Hurstville) and at local audiology centres for out-of-state 
patients, based on a recommended protocol, with a view to standardisation across 
centres and time.   
 
Speech discrimination score (SDS) was used as the primary audiologic outcome 
measure.  SDS is a clinically relevant measure of speech discrimination proposed as a 
primary hearing endpoint in clinical trials for vestibular schwannoma in NF2 (22, 
214), disproportionately affected compared with pure tone thresholds in patients with 
vestibular schwannoma and NF2. This was measured using a 10-item monosyllable 
word list, yielding a result ranging from 0 to 100%.  
  
Hearing response was defined as improvement in SDS over baseline, meeting criteria 
for statistical significance at the P=0.05 level, according to published methods (22, 
276, 277).  This approach allows the number of pre- and post-treatment correct 
responses to be compared for each individual.    The significance of changes in SDS 
compared with baseline was evaluated using published binomial confidence intervals 
(Critical Difference Values based on Binomial Distribution of Arthur Boothroyd and 
Carol Mackersie; Appendix 9)(278).   This approach reflects the fact that the degree 
of change required for statistical significance depends on the initial deficit.   
 
Primary Outcome: Tumour Volume 
Recommendations for imaging were provided to outside radiology institutions to 
optimise/standardise image quality across centres and for longitudinal measurements 
(Appendix 1).  Vestibular schwannomas were chosen as primary target lesions, and 
followed for evaluation of change in tumour size over time. Secondary tumours were 
selected in some cases, to monitor response of non-vestibular tumours (intracranial 
schwannoma or meningioma).  
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Tumour size was assessed using three-dimensional volumetric analysis. Pre-treatment 
tumour growth rate was calculated where possible. Volumetric analysis was performed 
by the NFtumormetrics Group, Medical Imaging Centre, Massachusetts General 
Hospital, Boston.  In addition, selected scans were reviewed using an alternate 
approach, by two radiologists at Westmead Hospital, to assess variability between 
methods (detailed in Chapter 9). Radiologic response was determined by changes in 
three-dimensional tumour volume compared with baseline volume and defined as 
follows; radiologic response: ≥ 20% reduction in tumour volume; stable disease: <20% 
change in volume; progressive disease: ≥ 20% increase in tumour volume according to 
recommended parameters for NF2 tumours (124).   
 
Secondary Outcomes: Hearing  
Hearing was also described pre- and post-treatment using combined results of speech 
discrimination (SDS) and pure tone audiometry according to the classification system 
of the American Academy of Otolaryngologists-Head Neck Surgery (AAO-HNS) 
(279), with Class A and B representing functionally useful hearing. Pure tone 
thresholds were included in routine audiologic evaluation, and reported as minimum 
decibels heard over a range of individual frequencies, then averaged to represent the 
“pure tone average” (PTA; 500Hz, 1kHz, 2kHz, 4kHz).   An audiometer detecting 
increments of 1-2dB (instead of 5dB) was used where possible to increase the 
sensitivity of this test. Minor hearing response was defined as an improvement in the 
pure-tone average of ≥ 10dB in the setting of stable speech discrimination scores with 
reference to baseline pure tone averages.  Change in AAO-HNS hearing class over 
time was assessed. 
 
Secondary Patient Reported Outcomes: Symptoms, Hearing Disability and 
Quality of Life  
Functional assessment tools utilised as secondary outcome measures have been 
described in detail along with baseline functional status of treated patients (Chapter 
7). Secondary outcomes included functional measures based on questionnaire 
surveillance of symptoms (using the NF2 Symptoms Questionnaire, Appendix 6), 
hearing disability (SSQ49, Appendix 7), and quality of life (Linear Overall Wellbeing 
Scale-LOWS, Appendix 6; SF36 Appendix 4), scored at baseline (0), 3, 6, 12, 18, 21, 
 148  
24 and 30 months of treatment when possible.   Longitudinal change in the mean 
SF36 scores over time were analysed using repeated measures analysis of variance.  A 
probability level of <0.05 was considered statistically significant.   
 
Secondary Outcomes: Adverse Events 
Laboratory studies were monitored over time (≥ 3 monthly) including electrolytes, 
(Na, K, bicarbonate, urea, creatinine, calcium, phosphate, glucose), liver function tests 
(ALT, AST, bilirubin, albumin), coagulation profile (PT, APTT), and urinalysis.  
Adverse events/medication toxicity were categorized according to the Cancer Therapy 
Evaluation Program Common Toxicity Criteria Version 4.0 (280).  
 
Treatment for VS as the target tumour was considered effective in the presence of 
radiologic response (≥ 20% reduction in tumour volume), and stable or improved 
hearing, or stable/ improved symptoms of brainstem compression (in cases where no 
functional hearing was present at baseline).  
 
Results 
Patients, Target Tumours and Treatment Overview 
Three females and four males were treated, ranging in age from 13.8 years to 33.4 
years (mean age 25.9y, SD 7.2y, Table 8.1). The primary indication for treatment was 
hearing loss. Several patients also experienced symptoms of brainstem compression at 
baseline (Patient 1, Patient 2, Patient 5, Table 8.1).  In one patient (Patient 2) with 
moderate hearing loss, a large trigeminal schwannoma contributing to brainstem 
compression was assessed (Figure 8.1, 8.5).  This patient also had large bilateral 
cervical schwannomas with the potential to cause significant morbidity, which were 
measured in a separate sub-study, and showed radiologic response (see Chapter 9).  
Patient 4 had two intracranial meningiomas, and Patient 7 had 2 optic nerve sheath 
meningiomas followed in addition to bilateral VS. Patient 5 received chemotherapy 
(Imatinib) for 5 months prior to bevacizumab.  Imatinib was ineffective and caused 
gastrointestinal toxicity (nausea and vomiting).   
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Table 8.1 Characteristics of patients treated with bevacizumab 
 
Patient Age at 
treatment 
(years) 
Indication for treatment Hearing Ears 
measured (n=9) 
VS measured  
       (n=13) 
Other tumours (n=5) Avastin* 
(months) 
1 23.0 A †/Brain stem compression R 1  30 
2** 23.8 B ††/ Brain stem compression R / L 2 Trigem schw (1) 30+ 
3 33.0 A L 2 Intracranial Men (2) 18+ 
4 22.8 A R / L 2  18+ 
5 31.5 A/ Brain stem compression L 2  9+ 
6 33.4 A L 2  6+ 
7  13.8 A L 2 ONSM (2) 9+ 
Mean (SD) 25.9 (7.2)      
Total   9 13 5  
 
* Treatment interruptions common due to funding, variations in patient follow up, other medical indications (Patients 3,4,5,6,7; see Figure 8.2) 
** Additional tumours studied in a separate sub-study (Chapter 9); Men-meningioma, ONSM-optic nerve sheath meningioma, Trigem schw-
trigeminal schwannoma; † A-Decreasing hearing in only hearing ear; †† B-Mild bilateral hearing loss; CN-cranial nerve, prn-as needed. 
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Figure 8.1 T1 fat saturated gadolinium enhanced MRIs showing vestibular schwannomas (thin white arrows) and other tumours followed 
with 3D volumetric analysis; a. bilateral vestibular schwannomas and large left trigeminal schwannoma (thick white arrow; Patient 2, axial 
view); b. left vestibular schwannoma, right parasagittal (thick black arrow) and left posterior frontal meningiomas (thin black arrow; Patient 
3, coronal view); c. bilateral vestibular schwannomas and large optic nerve sheath meningiomas (thin black arrows; Patient 7, axial view). 
a b c 
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The child included in this series (Patient 7) experienced significant complications of 
NF2, including unilateral deafness and blindness by 5 years of age.  NF2 tumours of 
concern included large bilateral optic nerve sheath meningiomas, small but growing 
bilateral VS, and cervical schwannomas.  Selected tumours are illustrated in Figure 
8.1. 
 
Bevacizumab was provided with a view to reducing risk of disability due to these 
lesions, with VS selected as primary tumours to follow, and selected non-vestibular 
schwannomas or meningiomas   as secondary tumours for radiologic measurement. 
 
Clinical follow up occurred between 6-30 months (mean 22.86 months, SD 8.78).  
Radiologic and audiologic data were available for variable time points for different 
individuals.  
 
Bevacizumab Supply and Administration 
Details regarding supply of medication are summarised in Appendix 10. For this 
study, duration of treatment ranged between 6-30 months (median 15.8 months), 
although treatment was continued for a longer duration in a number of cases. Six 
patients received medication funded by the local area health drug committee, with a 
cost sharing arrangement negotiated with Novartis Pharma.  The duration of public 
funding varied from 4 months to 26 months.  Indefinite funding was not available in 
any case, despite evidence of clinical benefit. After 26 months, one patient elected to 
cease therapy, being unable to self-fund extended treatment (estimated cost of 
$20,000 per annum), and proceeded to vestibular schwannoma resection (Patient 1). 
One patient self-funded medication for at least a period of 9 months following 
withdrawal of public funding, in circumstances where subjective hearing 
improvement occurred and tumour volume remained static (Patient 6).  In one case, 
public funding was granted following a period of self-funded treatment showing 
positive response (Patient 3). One patient received financial support from the private 
health insurer from commencement of treatment (with cost sharing arrangement with 
Novartis Pharma), and received donated funds from community fundraising to cover 
costs of follow up visits to Sydney (P2). Bevacizumab was funded by the private 
health fund (in a cost sharing arrangement with Novartis Pharma) after demonstrated 
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response to therapy in another case (Patient 4, following re-treatment response).  
Overall three patients self-funded treatment for periods ranging between 6 to 12 
months, (either at commencement of treatment or following public funded therapy), 
representing a significant personal financial burden.  
 
Patients were generally treated with 5mg/kg/dose fortnightly infusion (5 of 7 
patients).  Patient 3 received 7.5mg/kg/dose three weekly infusion.  Patient 7 was the 
first treated in this cohort, commencing at 15mg/kg/dose, reducing after 10 months to 
5mg/kg/dose.  In Patient 7, the first nine months of bevacizumab treatment overlapped 
with treatment with a somatostatin analogue. The somatostatin analogue was 
prescribed as the patient had progressive optic nerve meningioma and visual loss in 
his one seeing eye, and there was evidence of potential benefit (281). The 
meningioma was subsequently treated successfully with radiation therapy and the 
somatostatin analogue ceased 
.  
Breaks in bevacizumab therapy occurred to monitor disease progression off treatment, 
to accommodate other modes of therapy, and in one case due to adverse events 
(Patient 4), as shown in Figure 8.2.  
 
Primary and Secondary Outcomes-Hearing   
Hearing was measurable in nine ears. Baseline hearing function is shown for each 
patient for SDS (Table 8.2), pure tone audiometry (PTA) and American Academy of 
Otolaryngology-Head and Neck Surgery (AAO-HNS) hearing class (Table 8.3, Figure 
8.3).  Speech discrimination scores at multiple time points were available for 5 
patients (follow up ranging between 6-30 months) showing increased scores over 
time. However, statistically significant change in this measure was not demonstrated 
in any case.  A trend toward sustained improvement was suggested in Patient 2 and 
Patient 3, at last follow up (30m and 18m respectively). One additional patient 
(Patient 1) showed improvement approaching a significant level.  Table 8.2 shows the 
speech recognition score required to accept the difference as statistically significant 
with 95% confidence using 10 items, and using 25 items.  Use of a larger number of 
items potentially facilitates demonstration of significant change over time, with 
modeling using extrapolation of this data.   
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Pre-baseline pure tone audiometry (PTA) data were available for 4 patients, showing 
clear increase in PTA in 3 patients prior to therapy consistent with progressive 
disease.  On bevacizumab, four patients showed definite decline in PTA, with a drop 
of >20dB observed in 3 patients. The tendency to maintenance of stable PTA is 
evident, in contrast with progressive increase typical in untreated NF2.  However, the 
response was not sustained in all cases, with considerable rise in PTA in Patient 2 (left 
ear) over time despite medication (Figure 8.3).  
 
 
 
 
 
 
Figure 8.2. Overview of patient treatment with bevacizumab, including breaks in 
therapy. 
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Table 8.2 Speech discrimination scores for Patients 1-6 over time during treatment (AB 10-word lists), including model of effect of increasing 
number of items (phoneme scoring, 25 items per list) 
 
*Speech discrimination score required for significant difference at 95% confidence level using 10-word list (10 items).   
**Ceiling effect (SDS ≥68 using 10-word list ie. even 100% is not significantly different). 
*** Speech discrimination score required for significant difference at 95% confidence level using phoneme scoring (2.5x10=25 items).  This models 
the effect of increasing number of items on which each score is based. Listed scores represent improved performance at 95% confidence level.  
†Extrapolation of this dataset, to model result using phonemes (increasing to 25 items); AB=Arthur Boothroyd; NS=not significant; S=significant. 
 
Patient Months 
 
0 3 6 12 15 18 24 30 
Word List 
(10 items) 
Word list 
p<0.05* 
Phoneme 
Model  
(25 items) †*  
Phoneme 
Scoring 
Model 
p<0.05*** 
             
1 78 63 65 70 94 80 84  NS ≥98 S ≥87 
 
 
2 94  97 94  100  100 
 
 
NS 
 
 
Ceiling** 
 
 
NS 
 
 
Ceiling  
             
3 86  90 100    97 NS Ceiling S 100 
             
4 84  100   100   NS Ceiling S 100 
            
5 40        - ≥83 ≥68                           - 
             
6 70  75      NS Ceiling NS ≥92 
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Table 8.3 AAO-HNS Hearing Class pre- and post-treatment with bevacizumab 
Patient Baseline   Post-
treatment* 
  ≥ 10 dB 
decrease PTA 
 PTA SDS Class PTA SDS Class  
1 65 78 C * 46 84 B * Yes 
2 46 94 B 43 100 B No 
 50 86 B * 83 97 C * No 
3 39 84 B 49 100 B No 
4 119 0 D 83 6 D Yes 
 85 40 D 63 30 D Yes** 
5 41 60 B       
6 74 70 C 85 70 C No 
7 31   21   Yes 
        
* Best result; ** not sustained beyond 3 months; AAO-HNS-American Academy of Otolaryngology-Head and Neck Surgery,  
dB-decibels, PTA-pure tone audiometry, SDS-speech discrimination score.
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Figure 8.3 Pure tone averages (PTA) over time, pre- and post- bevacizumab treatment.
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The AAO-HNS Hearing Class grades pre- and post-treatment showed change in 
hearing class following treatment for Patient 1 (improvement) and Patient 2 (decline 
in hearing function in one of two ears coincident with ear infection, without recovery 
over time), with other ears remaining in the original class (Table 8.3). 
 
Primary Outcome-Tumour Volume 
Pre-treatment vestibular schwannoma MRIs were available for 9 tumours in 5 
patients, with annual growth rate estimates ranging between 8.7-105% as shown in 
Figure 8.4 (Mean 56.2%, SD 41.1).  Radiologic follow up ranged from 6 to 36 months 
(mean 20.1 months, SD 12.2). 
 
Thirteen VS were followed with baseline tumour volumes ranging from 0.36 to 
25.34ml (mean 7.35, SD 7.50). Five readily measurable non-vestibular tumours were 
selected for follow up in this study, including a large trigeminal schwannoma 
contributing to brainstem compression (Patient 2), two optic nerve sheath 
meningiomas (clinically significant, associated with unilateral blindness and risk of 
visual loss on the opposite side, Patient 7), and two other readily measurable 
intracranial meningiomas (which may have contributed to risk of seizures in a patient 
with history of epilepsy; Patient 4, Figure 8.1).  The trigeminal schwannoma was the 
largest lesion (range 1.58-43.05ml; mean 21.77, SD 17.79).   
 
On a background of typical progressive disease pre-treatment, clinical benefit was 
observed in 84% tumours (N=11) based on radiologic response and stable disease. 
Seven of 13 (54%) VS showed ≥20% volume reduction (ranging between 29-55% 
(mean=43.0%, SD 10.8%). 
 
All adult patients had at least one VS showing volume reduction.  However, neither 
VS in Patient 7 showed a significant radiologic response. Four VS (30%) showed 
relatively static growth (<20% volume reduction).  Two VS (15%) showed 
progressive growth (increase of 83%, Patient 3; increase 56%, Patient 7).  
 
Limited data were available regarding pre-treatment vestibular schwannoma growth 
rates (Figure 8.4). Those patients with clear pre-treatment growth (Patient 1,3,4,5) 
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Figure 8.4 Vestibular schwannoma volumes over time for each patient treated with bevacizumab. 
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tended to show tumour shrinkage with treatment.   For Patient 7, pre-treatment growth 
was relatively static, with a less impressive response to treatment observed.    
 
In terms of non-vestibular tumours, only the trigeminal schwannoma showed response 
(39% tumour shrinkage by volume; Figure 8.5).  One of the two intracranial 
meningiomas in Patient 3 showed little volume change, while the other showed 
progressive growth exceeding 80% volume increase over 12 months. Both optic nerve 
sheath meningiomas (Patient 7, Figure 8.1, 8.5) increased by 11% volume 
during the first 9 months of treatment with bevacizumab and somatostatin analogue.  
 
 
 
 
 
 
Figure 8.5 Non-vestibular tumour volumes over time during treatment with 
Bevacizumab. 
 
 
 
 160  
Patient Reported Outcomes 
A.  NF2 Symptoms Review Checklist/Linear Overall Wellbeing Scale (LOWS) 
The most robust data were available for patients 1-3 due to regular administration of 
the questionnaire at scheduled time points. These 3 patients showed improvement in 
symptoms review scores ranging from 3 to 18 points reduction between baseline and 
final measure (Figure 8.6). Considering post-treatment symptoms scores as a 
percentage of baseline, improvements ranged between 15-52%. Scores were reduced 
by ≥15 points in four patients.  
 
For one of these (Patient 4), the score increased during the initial phase of therapy, 
then showed reduction (improvement) during a second uninterrupted phase of 
treatment. Significant psychosocial factors affected this individual during the early 
phase, and were more settled later. Two patients showed static responses (Patients 2 
and 6; change in scores of 2-7 points only).  
Figure 8.6 NF2 Symptoms Questionnaire Scores over time on bevacizumab treatment  
(≥15-point reduction in scores considered improvement). 
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Patients 2 and 3 showed improvement in symptoms of brainstem compression with 
treatment (headache, dizziness, nausea and vomiting; data not shown), paralleling the 
clinical impression during therapy.  Pain improved for several patients with treatment.  
Other patients reported reductions in falls/unsteadiness, paresthesias and visual 
blurring. Symptoms that did not change with treatment included tinnitus, and speech 
difficulties.  Bladder and bowel dysfunction were not prominent symptoms in this 
group.  
 
Responses for the Linear Overall Wellbeing Scale generally paralleled the inverse of 
NF2 symptoms score for each patient (Figures 8.6 and 8.7) as expected. 
Improvements reported by patients 1-3, ranged between 15-37% above baseline.  As 
such, the magnitude of change using this tool was lower than for the NF2 symptoms 
questionnaire. 
 
B. SSQ responses  
SSQ49 results are shown in Figure 8.8.  Subscales most affected were Speech and 
Quality. Two of five patients showed improved scores across all domains (Patient 2 
and 5). One additional patient showed improvements in Speech and Quality domains 
(Patient 3).  The magnitude of improvement tended to be highest for the Speech 
followed by Spatial domains. Patient 1 did not record consistent improved responses 
even though other tools indicated benefit from treatment (NF2 symptoms score, 
LOWS and SF36).  
 
C. SF36 Quality of Life Responses  
SF36 response domains grouped into 2 clusters (physical and mental health) over time 
are shown in Figure 8.9. Overall, improved scores were seen in all patients during 
treatment across multiple domains (Patient 4 during second phase of treatment).  
Limits to physical functioning varied between extreme scores of 0-100 in some 
patients without demonstrating clear trends over time (Figure 8.9b). Overall, however, 
this domain and others within the physical health cluster tended to show improvement 
on bevacizumab therapy (including physical functioning, pain and general health). 
Similarly, domains within the mental health cluster tended to improve over time on 
medication.   
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Figure 8.7 Linear Overall Wellbeing Scale (LOWS) scores over time during 
bevacizumab treatment. 
 
 
Interestingly, Patient 2 recorded high scores in mental health parameters (consistent 
with good quality of life), with minimal change over time, despite endorsing 
significant hearing disability on the SSQ questionnaire. This observation suggests 
social/emotional resilience in this individual. 
 
Overview of Responses 
Table 8.4 summarises patient responses assessed using different outcome measures.  
Three patients showed hearing response (PTA criteria only), six showed vestibular 
schwannoma volume response (7/13 ears), and five of six assessable patients 
experienced variable symptomatic/quality of life benefits depending on the 
measurement tool.  
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       Months   
 
Figure 8.8 SSQ scores for each domain over time during bevacizumab treatment. 
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Figure 8.9 SF36 domain scores over time during bevacizumab treatment (a-d physical 
health; e-h mental health).
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Table 8.4 Overview of Patient Responses during bevacizumab treatment 
Patient Major Hearing 
Response 
(SDS) 
Minor Hearing 
Response  
AAO-HNS 
Class 
 
≥ 10 dB 
decrease PTA 
VS Volume 
Response 
Other  
Volume 
Sx LOWS SSQ SF36 
1 No Yes Yes Yes NA Yes Yes No Yes 
          
2 No No No Yes Yes* No Yes Yes Yes 
 No No No No (stable)      
          
3 No No No Yes No** Yes Yes No Yes 
    No (prog) No**     
          
4 No No Yes  Yes NA Yes*** No No*** Yes*** 
 No No No Yes      
          
5 NA NA NA Yes NA Yes No Yes Yes 
    No (stable)      
          
6 No No No Yes NA No No  NA NA 
    No (stable)      
          
7 No NA Yes No (prog) No** NA NA NA NA 
    No 
(stable)* 
No**     
          
TOTALS 0/8 1/7 3/8 7/13 1/5 4/6 3/6 2/5 5/5 
*Trigeminal schwannoma; **Meningioma; ***Improved symptom score during second phase of therapy only, SSQ responses not  
available for second phase; NA-not available, prog-progression, Sx-symptoms.
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Adverse events  
Adverse events are shown in Table 8.5. No Grade 4 or 5 events were recorded. The 
most frequent events were fatigue and infection. Hypertension and proteinuria 
developed only in Patient 3 (aged 34y) during three weekly therapy, which was 
treated and infusions continued at a lower dose.   
 
 
Table 8.5 Incidence of Adverse Drug Reactions and Laboratory Abnormalities 
according to CTCAE (Common Terminology Criteria for Adverse Events v4.0) 
Event Grade 1   Grade 2   Grade 3 
  Patients      
Fatigue  4(ongoing) 4      
Infection        
Dermatitis 1 1      
Cellulitis 1  1      
Otitis media 1 1      
Otitis 
externa 
1 1      
Viral URTI 3 3      
Viral 
encephalitis 
1 1     1* 
Proteinuria 1       
Hypertension 1       
Seizure    1*    
Menstrual 
irregularities 
2 
(ongoing) 
2      
Diarrhoea 1 
(ongoing) 
1      
Dizzyness 1 1      
Shortness of 
breath 
1 1      
Depression 1       
Haematemesis    1*    
Thrombotic 
events** 
   1*    
Stroke*** 0       
Elevated LFTs 1 1      
*Single hospitalisation; ** Peripheral venous thrombosis associated with intravenous line; 
*** Intracranial thrombotic/thromboembolic and haemorrhagic events; LFTs- liver function 
tests. 
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Menstrual irregularities were observed in this young population, coincident with 
information from the Cabaret Study (carboplatin and bevacizumab in recurrent 
glioblastoma multiforme) highlighting the risk of ovarian failure in women treated 
with bevacizumab.  While this was of limited concern in patients recruited to the 
CABARET study, it is certainly of relevance in a young cohort of women with NF2. 
No women in this cohort elected to cease treatment with bevacizumab. However, 
advice was sought from fertility experts and pause in therapy occurred in one case to 
allow egg harvest and storage. 
 
Treatment interruption due to adverse effects occurred in only one case. This involved 
hospitalisation due to haematemesis, viral encephalitis complicated by seizure, and 
thrombosis at an intravenous line site.  Bevacizumab was ceased. Three months 
following recovery from this illness including thrombus resolution, progression of 
NF2-associated disease prompted reconsideration of bevacizumab. Medication was 
cautiously restarted with no significant recurrence of these events observed during 18 
months subsequent therapy with the drug.  
 
Informal long-term follow up 
At last known follow up according to correspondence from local treating specialists, 
six of seven patients remained on therapy (mean duration of treatment for adults with 
interruptions, 24.5 months (SD 6.69) and including the child, 29.6 months (SD 
14.74)).  
 
Treatment had been ceased and recommenced for six patients.  The seventh patient 
discontinued bevacizumab and proceeded with surgical management. Interruption in 
treatment was due to funding problems in three cases.  Hospitalization with 
encephalitis (as documented above), interrupted therapy in one case.  Planned 
temporary discontinuation of bevacizumab occurred to allow egg harvest in one case 
and during radiotherapy in the other instance. Orbital radiotherapy was provided with 
good effect for progressive periorbital oedema associated with optic nerve sheath 
meningioma in Patient 7. During breaks in VEGF inhibitor treatment, gradual 
progressive growth of NF2 associated tumours was observed without significant 
rebound growth (data not shown).  
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Discussion 
As a treatment for NF2-associated schwannomas, bevacizumab resulted in clinically 
meaningful improvements in hearing, tumour progression and symptoms of brainstem 
compression and pain, with additional benefits across multiple domains in patient 
reported quality of life.   
 
Hearing Response 
Overall, this cohort was similar to NF2 populations in USA(37, 228) and the 
UK(249), treated with equivalent doses of bevacizumab, and followed using 
standardised outcome measures for radiologic and hearing response.  Radiologic 
response in our group (54% of VS) was generally comparable with these sites.  
However, we were unable to demonstrate primary hearing responses (SDS) matching 
the other patient series.  
 
In the first report of NF2 patients (N=10) with symptomatic bilateral vestibular 
schwannomas treated with bevacizumab, decreased tumour volumes exceeding the 20 
percent threshold were observed in 6 of 10 vestibular schwannomas, with statistically 
significant change in word recognition score (WRS) in four of seven assessable 
patients (57%)(37).  Follow up data published 3 years later showed similar results in a 
larger group of 31 patients with radiographic response in 55% (17/31) of vestibular 
schwannomas and hearing improvement in 57% of evaluable patients (13/23, using 50 
word lists)(228). In the subsequent UK report of 61 patients with progressive 
vestibular schwannomas, radiologic response using the same outcome measure (≥ 
20% reduction in tumour volume) was similar to the results seen in our Australian 
cohort (39% of tumours demonstrated radiological response and 45% of patients had a 
hearing response (5/11)(249).  In contrast to our patients, in the UK population, 
maintenance therapy was continued at a reduced bevacizumab dose of 2.5mg/kg 
fortnightly (249). Others centres have also used reduced doses with sustained benefit 
over time in order to minimise side effects(282). 
 
A significant limitation of the study method utilised here involves the assessment of 
speech discrimination scores using Arthur Boothroyd word lists limited to 10 words, 
 169  
which made it difficult to demonstrate significant change over time. This is because 
the variance in speech discrimination scores is related to the number of words 
presented, such that the upper and lower limits for the 95% critical differences (at 
probability level of p=0.05) for percentage scores are much broader when fewer 
words are presented (276).  For the sake of modelling the impact of this effect, had 
multi-phoneme (polysyllabic) words been utilised (extrapolating from 10 to 25 items), 
the likelihood of a significant difference between scores with 95% confidence could 
be demonstrated in 3 of 5 patients, increasing the power of this measure.  Based on 
the initial score derived from 10 word lists and the ceiling effect, only 2 of 6 patients 
in this study were eligible for a measurable hearing response. Only one patient had 
follow up data, approaching but not reaching a statistically significant score. In future, 
larger word lists should be used for monitoring hearing response in this population.  
 
As alternative hearing outcomes, change in PTA (>10dB hearing level decrease in 
PTA) and change in AAO-HNS hearing class were also assessed here, since they have 
been used in other trials for NF2 patients, including bevacizumab (283), and the 
epidermal growth factor inhibitor, lapatinib(36). Change in PTA exceeding the 10dB 
hearing level threshold was seen in 57% (4/7) of our patients, and improved hearing 
class in 14% (1/7). This contrasts with a lower proportion response in a European 
study of 12 adults treated with bevacizumab, where  1 of 9 ears (11%) responded to 
medication according to the PTA threshold, and 1 of 13 ears (8%) improved in AAO-
HNS hearing class; word recognition score showed greater improvement (23% ears; 
3/13)(283). In the lapatinib study, no patients met the PTA improvement criterion, 
while 4 of 13 patients (31%) had significant increase in word recognition score (using 
50 word lists)(36).  
 
Radiologic Response 
The reason behind the variable radiologic responses in different vestibular 
schwannomas remains unclear. This limited dataset cannot shed light on this question, 
although among our patients, smaller, slower growing tumours (Patients 6 and 7) 
tended toward reduced responses compared with others. Morris and colleagues 
(United Kingdom) found that tumours with a higher baseline growth rate were more 
likely to show a radiologic response, and that younger patients tended to have less 
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radiologic response, although their tumours had higher growth rates(249). In contrast, 
Plotkin et al. (USA) assessed these features along with others including baseline 
tumour volume and hearing level, and did not identify any clinical feature consistently 
predictive of either radiologic or hearing response(228). However, increased 
intratumor oedema, blood flow and capillary endothelial permeability may be 
important. Association between these features as estimated by apparent diffusion 
coefficient on diffusion-weighted imaging, and contrast transfer coefficient on 
dynamic contrast enhanced MRI have correlated with tumour response and warrant 
further consideration (37, 248, 284). 
There was significant tumour shrinkage in a trigeminal schwannoma contributing to 
brainstem compression in one patient, with additional shrinkage of cervical 
schwannomas as detailed in the following chapter. The observation that non-
vestibular schwannomas respond to bevacizumab is not surprising given shared 
tumour biology. The potential benefit of treatment beyond vestibular schwannomas 
may be very important in some individuals. Other authors have reported clinical and 
radiologic effect on non-vestibular tumours including facial schwannoma(248), and 
spinal schwannomas associated with complete resolution of pain(285).  In our series, 
no radiologic response was observed for meningiomas, compared to modest response 
of meningiomas to bevacizumab in other series(286).  Alternative medications are 
needed for meningiomas in this patient group. 
Patient Reported Outcomes 
One of the strengths of this study includes consideration of patient reported outcomes 
assessing hearing disability and quality of life, which demonstrated improvements 
during treatment.  Addition of QOL assessment is expected to capture some of the 
added benefits to patients from systemic therapy beyond hearing and tumour size 
(such as pain). We are not aware of any other patient reported tool used to date to 
assess detailed functional changes in hearing. The only other published study to assess 
quality of life in response to medical therapy in NF2 is the work of Morris et al, who 
demonstrated significant improvements on the NFTI-QOL with bevacizumab (249).  
This disease-specific tool includes a single question (out of 8 in total) regarding the 
impact of hearing on daily functioning (graded 0-3), has shown correlation with the 
SF36, and offers the advantage of being much shorter.  The NFTI-QOL may be 
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appropriate for use in children (247) upon further evaluation in the younger age group 
for whom clinical features differ versus  adults.  A simplified version of hearing 
disability tool, the SSQ12 may also be relevant for use in children(268).  
 
Observation of lack of improvement in SSQ responses for hearing disability in Patient 
1 contrasted with improvement in other quality of life measures. This highlights the 
potential benefit of systemic therapy in domains other than hearing for complex NF2 
patients in whom multiple intra and extracranial tumours are the norm.  SF36 
responses indicated improvements in physical functioning and pain.  Use of a range of 
tools in this study provided complementary information, identifying secondary 
benefits of systemic treatment in this disease which impacts patient functioning in 
multiple domains.  
While the symptoms checklist used here detected changes over time, it may contain 
redundant items, and covers primarily physical factors with little representation of 
psychosocial factors (although this could be reflected in the simple LOWS). As such 
the disease-specific NFTI-QOL could be recommended in preference, as a simpler 
tool, validated for individuals older than 16 years, showing good correlation with 
other existing tools which measure physical and psychological factors including the 
SF36. This tool may also be helpful during routine clinical care to monitor change in 
patient wellbeing over time outside a clinical trial setting, and has prompted addition 
of supportive management over time in response to reduction in scores, with 
subsequent improvement in scores following the intervention (247). 
Over the last several years, members of the REiNS International collaboration have 
considered options and recently produced recommendations for additional patient 
reported outcomes for pain and physical functioning which should be incorporated 
into future studies (152). Other outcome measures may be needed in selected 
individuals over time, relevant to other specific issues, such as visual functioning 
(likely visual acuity), as evident in Patient 7 in this study.  Alignment of outcome 
measures across sites offers the opportunity for collaboration, and increased power in 
interpreting treatment responses in this rare condition. 
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Medication Tolerability 
Bevacizumab was generally well tolerated in our patients. Hypertension and 
proteinuria are well recognised complications, and of particular concern in this 
population of predominantly young patients who may require prolonged treatment. 
Hypertension and proteinuria occurred only in a single patient (14%; patient aged 34 
years), in contrast with higher incidence reported in larger cohorts. Interestingly, this 
individual was treated according to the three-weekly infusion schedule using a higher 
dose, which has been identified in one report as associated with increased rates of 
hypertension(287). One of two additional children treated at our centre subsequent to 
this report required dose adjustment and treatment holidays due to these 
complications.  The low frequency of hypertension and proteinuria in our cohort may 
reflect the shorter follow up duration, as cumulative medication dose has been found 
to impact on hypertension in particular(288). Rates as high as 58% for hypertension 
and 62% for proteinuria have been reported after a median of 12.8 months of 
medication and almost double for proteinuria among 33 patients (median 28 years; 
fortnightly dosing 5mg/kg/dose)(288).  In contrast, median time to onset of 
hypertension was shorter at 2.7 months in the UK cohort, with increased incidence of 
50% in adults older than 30 years(287). Most common side effects in this group were 
fatigue, hypertension and infection(287).  
 
Various infections were observed in Australian patients. One patient required 
hospitalisation during treatment, which may have been treatment related, for CNS 
infection (complicated by seizure) with gastrointestinal haemorrhage and peripheral 
thrombotic complications. Bevacizumab was recommenced later without significant 
adverse effects. Seizure in association with CNS infection has been reported in other 
patients. Menstrual irregularities occurred in this small group, and appear to be a 
common experience in other centres as well, with 19% affected in the UK NF2 cohort 
reported recently(287).  Particular care is needed in counselling regarding potential 
impact on fertility, with appropriate anticipatory care in young women with NF2. 
 
Regarding optimal dosing regimens versus efficacy and side effects, a European 
centre prescribed adults 10mg/kg on a fortnightly basis for 6 months, followed by 
15mg/kg every three weeks, and did not demonstrate further benefit in response. 
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(N=12). Radiologic response (>20% volume reduction) was reported in 39% tumours 
(7/18 VS), and hearing response in 23% (3/13 ears) using variable outcome measures 
(not including statistical significance according to published tables for SDS).  One 
fatality occurred secondary to intracerebral haemorrhage, which may have been 
treatment related. It may be that dose reduction to 2.5mg/kg fortnightly offers 
sustained benefit with reduced risks in at least a subset of patients, after response is 
demonstrated on initial higher doses(249, 282). 
 
Response in Children 
Differential response of children to bevacizumab therapy warrants comment. As the 
only child in this group, response to treatment was generally poorer in patient 7 
compared with other patients, despite commencement on a higher medication dose. In 
a small French cohort of seven children reported recently (7 patients, 11 VS), over 
half received 10mg/kg/dose (4/7) while the remainder were treated with 
5mg/kg/dose(248) fortnightly.  No comment was made regarding dose adjustment 
during ongoing treatment. Median tumour volumes were smaller and word 
recognition scores overall indicated better hearing at baseline (1.2 cm3, range 0.52–
13.5; word recognition score 90 %, range 0–100) compared with this dataset, and the 
predominantly adult UK and USA series.  While annual tumour growth rate slowed 
significantly on treatment (138% versus 36% p=0.043), only a single tumour (14%) 
showed radiologic response (>20% volume reduction), and a single patient showed 
statistically significant improvement in word recognition score (248).  Morris et al 
also observed a tendency for ongoing tumour growth in the six children followed in 
their study(249).   
Commencement of therapy in children with smaller tumours likely reflects 
anticipation of increased severity/morbidity in this group compared with adults.  
Optimal indications for commencement of therapy should be discussed-at onset of 
hearing loss or a pre-determined tumor volume or growth rate. Increased dose at 
initiation of treatment may enhance response. Consideration should be given to the 
pattern of tumour growth/progression in children versus adults, and whether response 
criteria in the paediatric age group should be different, ie. stabilization of tumour 
growth in progressive tumours may be an acceptable endpoint compared with volume 
reduction in adults.  Pooled results for children treated to date, along with inclusion of 
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paediatric patients in clinical trials will help inform this debate.  Despite the need to 
control aggressive disease in children, assessment of response must be carefully 
balanced against risk of adverse effects of treatment. 
Practical challenges  
Difficulties encountered during this study included securing a supply of medication, 
which varied across regional health districts, and between private health insurers, 
raising ethical issues about inequity of access among patients.  Interruption to 
treatment was due to medication supply issues in several cases.  Strong advocacy for 
all individuals meeting eligibility criteria for treatment assisted in acquisition of 
medication. In addition, coordination between multiple departments to ensure 
adequate response monitoring required significant clinician input and administrative 
support, and limited availability of follow up data in some cases.   
 
Conclusion 
In conclusion, bevacizumab was well tolerated and offered improvements across 
multiple domains in these Australian patients with NF2 associated tumours. 
Individual responses varied, with radiologic response of vestibular schwannomas 
comparable to that reported in studies from other sites.  Although methodologic issues 
limited interpretation of hearing response alongside other populations, improvement 
was demonstrated in a proportion of cases using secondary outcome measures.  
Patient reported outcomes including experience of hearing disability and quality of 
life provided other evidence of benefit from therapy in most cases. Therefore, further 
consideration must be given to the place of bevacizumab for treatment of NF2 patients 
beyond change in hearing and tumour volume. In future, incorporating baseline 
imaging assessments such as apparent diffusion coefficient and contrast transfer 
coefficient on dynamic contrast-enhanced MRI may assist with patient selection and 
predicting response to therapy for VS and other schwannomas.  Since this study, 
several additional children have been treated at our site. It is hoped that the place of 
bevacizumab therapy for paediatric patients will become clearer over time as 
additional data become available.   
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CHAPTER 9.  EFFECT OF BEVACIZUMAB ON TARGET AND NON-TARGET 
TUMOURS IN A SINGLE PATIENT WITH NEUROFIBROMATOSIS TYPE 2 
 
 
Introduction 
 
Neurofibromatosis Type 2 (NF2) is an autosomal dominant condition associated with 
formation of multiple tumours affecting the central and peripheral nervous system in 
affected individuals, due to mutations in the NF2 tumour suppressor gene on 
chromosome 22 (167). This includes schwannomas, meningiomas, ependymomas and 
other glial tumours occurring within both the intracranial and spinal compartments 
and on peripheral nerves. Whilst histologically benign, the behaviour of NF2 
associated tumours is often malignant, causing significant morbidity including 
seizures, deafness, blindness, pain, paralysis, and early mortality in many cases (167, 
200).  Symptoms are primarily caused by compression of associated nerves and 
adjacent structures.  As such, tumour mass is an important characteristic, with rapid 
symptomatic progression possible once a critical, location-dependent threshold is 
exceeded. Radiologic response to treatment is therefore an important endpoint to 
monitor in the assessment of novel medications to treat such tumours. Parameters 
such as change in symptoms, functional assessments and quality of life are other 
important elements to assess in response evaluations, as reduction in the bulk of 
asymptomatic tumours may be irrelevant to the patient.  Functional assessments are 
considered in greater detail elsewhere. 
 
Surgical intervention has been the mainstay of treatment until recently (186). 
Radiosurgery and radiotherapy have a role in selected cases, but a cautious approach 
to this treatment modality is taken in many centres due to concerns regarding 
increased risk of secondary tumour formation and malignant transformation in 
populations with an underlying tumour predisposition (189).  Improvements in our 
understanding of tumour biology and the molecular pathways underpinning this 
genetic condition have provided a rationale for the development and use of novel 
medications in clinical trials initially focussing on vestibular schwannomas, the 
hallmark tumour affecting 95% of patients (225, 231).  Guidelines for radiologic trial 
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end points have been proposed for assessing the primary tumour target, vestibular 
schwannoma (124, 219).  
 
Beneficial effect of bevacizumab (monoclonal antibody against vascular endothelial 
derived growth factor (VEGF); Avastin, Roche) has been described for vestibular 
schwannomas in a series of patients as evidenced by an improvement in hearing and 
decrease in tumour size (37, 227, 228), due to altered vascular supply to tumours. 
Limited benefit has been observed in treatment of intracranial meningiomas (226, 
229).  However, despite the co-existence of multiple other intracranial and spinal 
tumours in most patients, limited information is available regarding treatment effect 
on tumours other than the primary target lesion, vestibular schwannoma.  Shrinkage 
or stabilisation of growth rate of non-target tumours may also constitute treatment 
response associated with significant clinical benefit to the patient. In fact, spinal 
tumours may be the symptomatic, target tumour in some cases. More information is 
needed about potential response of these tumours to agents such as bevacizumab. 
 
This chapter presents a detailed assessment of radiologic response of vestibular 
schwannomas and other intracranial and extracranial tumours following 12 months 
treatment with bevacizumab in a single patient with NF2, to assess the potential utility 
of this agent for both target and non-target tumours.   
 
 
Methods 
 
A twenty-three-year-old woman diagnosed with Neurofibromatosis Type 2 was 
referred to our specialist centre for assessment of multiple NF2 associated tumours in 
August of 2010.  The patient initially presented aged 15 years, with a peripheral 
schwannoma and unilateral foot drop. The diagnosis of NF2 was made following 
identification of bilateral vestibular schwannomas at age 17 years, due to a pathogenic 
mutation in the NF2 gene [c.41_42delTC p.Leu14GInfsX34].  The patient had 
undergone resection of multiple spinal tumours in a series of three operations over the 
preceding 6 years.  
 
Referral was prompted by deterioration of hearing, and increasing headaches with 
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vomiting (risk of brain stem compression) due to bilateral vestibular schwannomas. 
Pure tone audiometry indicated a mild to moderate severe bilateral mixed hearing loss 
(20bB at 250 Hz dropping to 45dB bilaterally at 1000Hz, varying between 35-55dB 
up to 2000Hz, dropping from 45 to 80dB bilaterally at higher frequencies).  Speech 
audiometry (AB words) showed 94% correct at 70dB in the right ear, and 91% at 
75dB in the left ear. Sensation to light touch was reduced in the distribution of all 
branches of the trigeminal nerve (V1>V2/V3). The left corneal reflex was absent.  
Significant muscle wasting and weakness was evident in selected muscle groups. 
Independent ambulation with a high stepping gait was possible, with reduced balance 
and coordination (unable to perform tandem gait). 
 
Cranial MRI showed a large left trigeminal schwannoma adjacent to the left vestibular 
schwannoma exerting additional mass effect (Figure 9.1a). Growth in multiple 
tumours was evident over time on serial cranial and spinal MRI. Following 
multidisciplinary review and discussion, the patient was treated with bevacizumab 
(Avastin, Roche Pharma) at 5mg/kg intravenous infusion on a fortnightly basis. 
Treatment was well tolerated with no missed doses. 
 
Patient symptoms were assessed during clinical follow up every 3 months using 
standardised questionnaires, and functional assessments including hearing testing and 
gait examination. Patient reported outcomes were assessed using the Speech, Spatial 
and Qualities of Hearing Scale (SSQ) (255) previously used in the evaluation of 
patients undergoing surgical removal of unilateral vestibular schwannoma (257).  
Quality of life was assessed using the widely validated SF36 questionnaire which has 
been reported in evaluation of NF2 patients undergoing surgical removal of unilateral 
vestibular schwannoma (261).  Side effects of treatment were recorded (details 
presented in Chapter 8).   
 
Radiologic response to treatment was assessed in target tumours causing active 
disease with significant associated morbidity (bilateral vestibular schwannomas and 
left trigeminal schwannoma) and non-target tumours (other intracranial, intraspinal 
and peripheral tumours meeting size criteria) with the potential to cause symptoms 
and signs with increasing tumour growth.
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Figure 9.1 Axial T1 fat saturated gadolinium enhanced MRI showing intracranial target lesions pre-treatment (a) and post-treatment 
(b); Decreased brain stem mass effect and increased cystic change (presumed necrosis) in large left trigeminal schwannoma with stable 
findings for bilateral vestibular schwannomas (b). 
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MRIs were acquired on a 1.5T Phillips scanner at the Perth Radiological Clinic, 
Western Australia.  Volumes were measured for intracranial tumours measuring 
>0.5cm in longest diameter and spinal tumours measuring >1.0cm in longest diameter 
(T0), then at the time of commencement of treatment 9 months later (T1), in the 
absence of a 12 month interval pre-treatment scan, and after 12 months treatment 
(T2). Measurements were made in the axial and coronal planes, on gadolinium 
enhanced T1 weighted sequences.  If theT1W GAD series was unavailable, T2 TSE 
sequence images were used. Volume underestimates are reported for a single tumour 
due to incomplete coverage of the lesion at time points T1 and T2 (L3/L4 tumour). 
Three-dimensional tumour volumes were estimated using (3D) slicer software 
(http://www.slicer.org).  This semi-automated method has been validated against 
manual segmentation approaches (289), used in clinical brain tumour studies (290, 
291). Tumours were considered inevaluable if the entire tumour was not fully imaged, 
or a complete set of images in two planes without gaps was unavailable. Non-
evaluable tumours were not included in the final analysis. 
 
Two independent radiologists (JL, LG) reviewed the scans, calculating volumes for all 
tumours at T0 (baseline), T1 (9 months after T0, commencement of bevacizumab) and 
T2 (post-treatment, 12 months after initiation of bevacizumab). In any case where 
volumes differed in excess of 10% between radiologist 1 and 2, tumours were 
remeasured and a consensus reached regarding optimal measurement.  Combined 
average tumour volumes were then calculated. Baseline growth rates (%) were 
estimated during the 9-month pre-treatment period (T1-T0/T0), along with growth 
rates after 12 months treatment (T2-T1/T1), by each reviewer, and then averaged to 
obtain combined estimates, which are reported here.  
 
Evaluation of inter-rater variability 
Independent measurements were available for comparison with our measurements at 
time points (T1 and T2) for the primary target tumours (bilateral vestibular 
schwannomas and trigeminal schwannoma) from an established service dedicated to 
NF tumour volumetric measurement (http://www.nftumormetrics.org). Inter-rater 
volume differences as a proportion of the smaller estimated tumour volume (to 
overestimate percentage difference) were calculated for JL and LG at time points T0, 
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T1 and T2 for these three tumours. Equivalent comparisons were made between our 
combined measurements (averaged volumes from JL and LG) and NFTumormetrics 
volume measurements for these 3 tumours at T1 and T2. The range and average of 
variability are reported for comparisons between JL and LG, and our combined data 
versus NFTumormetrics. 
Radiographically significant change in tumour size was conservatively estimated to be 
greater than 20% change in tumour volume (≥ 20% increase volume=progressive 
disease; ≥ 20% decrease in volume = treatment effect or baseline tumour regression; 
0-20% change in volume = stable disease), as recommended by experts in the 
field(22, 124, 219). However, on clinical grounds, radiologic treatment response is 
considered here to include both tumour shrinkage, and stable disease on a background 
of previous progressive disease (22).  
 
Comment was made on presumed pathology for each lesion based on radiologic 
appearances and location.  Tumours located adjacent to the meninges (with or without 
enhancement), particularly with appearances of a dural base or tail were presumed 
meningiomas. Tumours within the spinal compartment were judged to be 
schwannomas (including transforaminal lesions) or meningiomas (durally based) or 
ependymomas if intramedullary.  Pathology was not available for correlation with 
radiologic appearances. Due to the potential uncertainty in pathology without tissue, 
tumours are reported according to location in several cases. 
 
Results 
 
Seven out of nine tumours meeting size criteria were evaluable in the intracranial 
compartment, as were seven out of eight tumours in the spinal/paraspinal regions.  
Intracranially, primary target lesions included bilateral VS and left trigeminal 
schwannoma (Figure 9.1), and non-target lesions - two presumed schwannomas the 
left and right carotid spaces, another in the right tip Sylvian region, one presumed 
meningiomas on the left (selected lesions shown in Figure 9.1). In the spinal region, 
five presumed schwannomas were identified within the spinal canal, two in the 
cervical region (Figure 9.2, 9.3), two in the upper thoracic region (not shown), and 
one in the lumbar region (Figure 9.4a).
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Figure 9.2 Cervical spinal tumours pre-treatment (coronal T1FS cervical spine MRI, a) and post-treatment (non-fat saturated, gadolinium 
enhanced, b) with bevacizumab. Right sided C1 tumour volume remained in the stable range versus pre-treatment progression (10% volume 
reduction). Left sided C2/3 tumour showed radiologic response (42% volume reduction).  
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Figure 9.3 Cervical spinal tumour (C2/3) T1 weighted gadolinium enhanced axial and sagittal MRI images pre- 
treatment (a-b) and showing tumour shrinkage post-treatment (c-d). Trigeminal schwannoma indicated by thin arrow (a). 
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Figure 9.4 Extracranial lesions (indicated by arrows) on MRI for patient treated with bevacizumab. MRI showing sagittal view L2 spinal tumour 
(thick black arrow, a); coronal view parapsinal tumours left longissimus (thin white arrow) and psoas (thick white arrow) (b); axial view left 
longissimus and psoas tumours (c). 
 
 
 
 
a b c 
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       Figure 9.5 Large right axillary schwannoma shown in coronal MRI.  Inevaluable due to inadequate coverage in the second plane.
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Two clearly visible and readily measurable presumed schwannomas were included in 
the lumbar paraspinal area (left longissimus muscle and left psoas; Figure 9.4b,c).  A 
large brachial plexus lesion could not be included as tumour coverage was incomplete 
(Figure 9.5). 
 
Intracranial baseline tumour volumes ranged between 0.43cc3 and 38.73cc3 (x=7.27, 
SD=13.90, Table 9.1).  5 of 7 tumours measured less than 4cc3.  Baseline growth rates 
varied from 6.63% to 31.75%, with 3 of 7 tumours showing progression over the 9 
months preceding treatment (Table 9.1, Figure 9.6).  
 
In the spinal/paraspinal region, volumes were underestimated for the presumed 
schwannoma at L3/L4 at time points T1 and T2 due to incomplete coverage of the 
lesion. However, views were adequate to include with this data. Baseline volumes 
varied between 3.60cc3 to 29.84cc3 (x=8.45, SD=10.03, Table 2).  4 of 7 tumours 
measured less than 4.5cc3.  The two largest lesions were located in the paraspinal 
region rather than within the spinal canal.  Tumour progression pre-treatment was 
more frequent than for intracranial tumours, observed for 5 of 7 tumours, with four of 
these growing in excess of 40 percent volume over 9 months, and one of the 
paraspinal tumours more than doubling in size (Table 9.2, Figure 9.7).   
 
Qualitative changes were clearly evident on neuroimaging post-treatment, including a 
decrease in the cystic component of the large trigeminal schwanomma with reduced 
mass effect, and reduction in size of the right vestibular schwannoma and multiple 
spinal/paraspinal tumours.  In the intracranial compartment, significant tumour 
shrinkage occurred only for the largest trigeminal schwannoma (41.7% volume 
decrease), although regression of greater than 18% volume was seen in 2 other 
lesions, approaching a treatment response (including one vestibular schwannoma). 
One tumour showed progression, another approached criteria for progression and 2 
remained stable (Table 2, Figure 6).  Treatment response was achieved in 5 of 7 
tumours in the spinal/paraspinal region, while the other 2 lesions remained stable 
compared with pre-treatment progression. Reduction in tumour volume up to 53% 
was achieved. No tumours showed progressive growth (Table 9.2, Figure 9.7).  
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Inter-rater variation for the 3 primary tumours (bilateral VS and trigeminal 
schwannoma) ranged between 2.7 to 12.9% (x =6.9%, SD=3.8) for JL-LG, and 0.8 to 
12.6% (x =10.2%, SD=9.7) for combined JL/LG-NF Tumormetrics, the greater 
variance reflecting 6 (JL/LG-NF Tumormetrics) versus 9 comparisons (JL-LG). 
 
 
 
 
Table 9.1 Volumes and growth rates for intracranial tumours at time points T0, T1 
and T2* 
Tumour 
Location 
Tumour 
T0 
Volume 
T1 
(mL) 
T2 
Baseline Growth 
Rate (% change  
= T1-T0/T0) 
Treatment Growth 
Rate (% change  
=T2-T1/T1) 
Overall 
Response 
** 
Right VS  2.84 3.02 2.44 6.63 -19.32  
    stable stable** No 
Left VS 1.83 2.05 2.48 11.87 21.20  
    stable  progression No 
Left 
trigeminal 
38.73 46.12 26.91 28.61 
progression 
-41.71 
regression 
 
Yes 
Right carotid 
space 
2.36 4.09 3.32 30.96 
progression 
-18.74 
stable*** 
 
Yes 
Left carotid  
space 
10.68 13.72 16.11 14.78 
stable 
17.40 
stable 
 
No 
Right tip 
Sylvian 
0.43 0.64 0.57 31.75 
progression 
-9.42 
stable 
 
Yes 
Left 
meningioma 
3.64 4.48 4.49 9.52 
stable 
0.23 
stable 
 
No 
* T0=baseline, T1=T0 + 9 months, commencement bevacizumab, T2=T1 + 12 months, on treatment. 
Interpretation: 0-20% change in volume = stable disease;  20% increase volume = progressive disease; 
≥ 20% decrease in volume = tumour regression; negative number indicates tumour shrinkage; ** 
Response constitutes either tumour regression or stable disease versus previous progression; 
***approaching treatment effect; VS= vestibular schwannoma. 
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Figure 9.6 Growth rates of intracranial tumours at baseline (top/green) and 
with bevacizumab treatment (bottom/blue).  
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Table 9.2 Volumes and growth rates for extracranial tumours at time points T0, T1 
and T2* 
Tumour 
Location 
Tumour 
T0  
Volume 
T1 
(mL) 
T2 
Baseline Growth 
Rate (% change  
= T1-T0/T0) 
Treatment Growth 
Rate (% change  
=T2-T1/T1) 
Overall 
Response 
** 
Right C1 3.60 5.45 4.89 52.6 
progression 
-10.15 
stable 
 
Yes 
Left C2/3 7.06 8.12 4.71 15.08 
stable 
-42.07 
regression 
 
Yes 
Right T1/2 1.49 2.21 1.92 48.29 
progression 
-13.34 
stable 
 
Yes 
Left T1/2  3.59 5.10 3.83 42.26 
progression 
-24.67 
regression 
 
Yes 
Left L3/4 29.84 38.91 30.93 31.40 
progression 
-20.68 
regression 
 
Yes 
Longissimus 12.73 14.25 6.58 11.84 
stable 
-53.57 
regression 
 
Yes 
Psoas 4.35 10.41 6.26 139.32 
progression 
-39.87 
regression 
 
Yes 
*T0=baseline, T1=T0 + 9 months, commencement bevacizumab, T2=T1 + 12 months, on treatment. 
Interpretation: 0-20% change in volume = stable disease;  20% increase volume = progressive disease; 
≥ 20% decrease in volume = tumour regression; negative number indicates tumour shrinkage; ** 
Response constitutes either tumour regression or stable disease versus previous progression; VS- 
vestibular schwannoma. 
 
 
 
 
 
Functional responses 
Following treatment, hearing stabilised on a background of progressive decline, and 
the patient reported improvement in symptoms of headache, neck pain, muscle 
weakness, and balance, with a subjective improvement in global wellbeing. 
Functional responses are discussed in greater detail elsewhere (Chapters 7/8). 
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Figure 9.7. Growth rates of spinal and paraspinal tumours at baseline 
(top/green) and with bevacizumab treatment (bottom/blue). 
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Discussion 
 
This detailed study of tumour responses in a single NF2 patient with high tumour 
burden adds significantly to existing evidence that NF2 associated tumours, 
schwannomas, in particular, respond to treatment with the VEGF monoclonal 
antibody, bevacizumab.  Whilst both symptomatic/functional and radiographic 
responses were observed, the focus of this study was on volumetric response. 
Shrinkage of tumours occurred in both the intracranial and extracranial regions.  In 
fact, radiographic response was most impressive for extracranial tumours, both in 
terms of number of tumours demonstrating response and magnitude of response. 
Radiologic together with symptomatic response of extracranial schwannomas to 
bevacizumab has been observed at a UK centre among patients with NF2, mosaic 
NF2 and NF2 mutations associated with schwannomatosis (and documented 
SMARCB1 mutation) (292), and likely noted in other major NF treatment centres, 
though not published to our knowledge. One study assessed response of spinal 
ependymomas to bevacizumab in NF2, demonstrating reduction in intratumoural cyst 
dimensions and spinal cord oedema. Although changes did not meet the pre-defined 
study criteria for radiologic response, it was anticipated that changes may be 
associated with clinical benefit in some patients (293). 
 
In this patient, individual tumour responses varied from greater than 50% volume 
reduction to 37% tumour growth despite treatment.  One vestibular schwannoma 
approached radiographic response (19.3% volume reduction), while the other 
progressed. So while the target lesion is likely to be vestibular schwannoma for many 
patients, not all tumours will benefit.  Nevertheless, if some VS shrinkage occurs, 
with improvement or stabilisation of hearing, this will provide a meaningful benefit to 
the patient.  We note a direct relationship between tumour size and hearing function 
does not always exist particularly for smaller tumours (294).  Furthermore, there may 
be hearing benefits despite minimal radiographic change (228, 231).  
 
Interpretation of the clinical significance of changes in tumour volumes warrants 
comment. The magnitude of volumetric response per se, is not the most important 
factor, as tumour reduction in some locations may have no clinical impact. 
Conversely, modest tumour shrinkage or volume stabilisation may be very important 
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at a critical location-dependent volume associated with clinical symptoms. In our 
patient, shrinkage of tumours in the upper cervical region is noteworthy, given these 
lesions carried a high risk of increased morbidity and early mortality, in the event of 
progressive disease.  
 
Whilst imaging and tumour measurement in the spinal region was less well 
standardised/optimised here compared with cranial imaging, the radiographic 
response seen was well in excess of the threshold value in 3 of 7 tumours, at 
approximately 40 to 53% volume reduction versus a response threshold of >20% 
tumour shrinkage.  For this patient with a background of 3 prior spinal operations for 
tumour resection, and persistent significant spinal disease, this result is clinically 
meaningful.   
 
Factors that may contribute to variable responses of different tumours to treatment 
other than location, include tumour pathology, size and growth rate, and differences in 
VEGF expression.  Due to the limited number of lesions in this single patient, 
variability between tumours, and lack of pathological data, it was not possible to draw 
any firm conclusions regarding response of different tumour types.  Whilst variable 
response was evident in presumed schwannomas, response to treatment did not 
exceed the assigned threshold for either of the 2 presumed intracranial meningiomas 
included, consistent with other observations of limited benefit for intracranial 
meningiomas (226).  
 
Tumour size was not clearly associated with radiographic response in this small study. 
This contrasts with other evidence now available for vestibular schwannomas (20 
tumours in 12 patients), which found larger tumours overall more likely to respond to 
anti-angiogenic therapy(284).    
 
Baseline tumour growth rate was higher in the spinal/paraspinal tumours compared 
with the intracranial compartment, and may be important.  In the largest series 
reported to date for vestibular schwannomas, patient age and growth rates were found 
to be inter-correlated predictors of response (59 VS in 52 patients)(249).  Greater 
responses were noted in actively growing tumours, but poorer responses were seen in 
the cohort <18 years of age, possibly representing more severe disease. The extent to 
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which baseline growth rate can predict tumour response should be considered further 
in future population-based studies.  
 
Other approaches that may be helpful in predicting treatment response to monoclonal 
VEGF antibodies include scintigraphy (295) and specific vascular imaging such as 
dynamic contrast enhanced MRI (37, 228, 296), for which predictive value has now 
been confirmed for VS (284). These were not performed here, but may have a role in 
future trials with bevacizumab and similar agents. 
 
Inconsistencies between scans (available sequences) at different time points (T1 and 
T2), particularly for spinal MRI is acknowledged as one of the limitations of this 
study. This demonstrates the benefits of scanning complex NF2 patients at central 
facilities where protocols are optimised and consistency is maintained over time to 
reduce tumour measurement error. Imaging recommendations for the primary target 
tumours (including vestibular schwannomas in NF2) are now available for use in NF 
clinical trials (124). Given the rarity of NF2, ideally most patients requiring medical 
treatment should be included in a clinical trial. For clinical surveillance alone, 
simplified protocols may be appropriate. Consensus recommendations for optimal 
spinal imaging and approaches to tumour measurement in NF2 would be helpful.   
 
The semi-automated 3D slicer method utilised here yielded volumetric results 
comparable with those reported by an experienced NF imaging centre.  Software is 
freely available (http://www.slicer.org) and may be useful at other centres performing 
detailed neuroimaging studies, particularly if unable to submit images to nominated 
radiology facilities as part of an international trial. 
 
Unfortunately, the effect of treatment on a large brachial plexus tumour could not be 
evaluated in our patient because it was out of the field of view. Our observations 
regarding extracranial tumours in this patient, and comparable observations of others, 
support the potential utility of whole body MRI to measure whole body tumour 
burden in disease surveillance, and in the evaluation of treatment response in complex 
NF2 patients (124, 126).  
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Conclusion 
 
This study highlights the fact that multiple intracranial and extracranial tumours show 
radiologic response to medical therapy for NF2 patients, with associated clinical 
benefits.  Evaluation of novel medications in future clinical trials should incorporate 
use of vascular biomarkers, and measurement of primary and secondary target 
tumours using robust radiologic criteria and clinically relevant functional outcomes, 
on a case by case basis.  Medication combinations are likely to be needed, along with 
multimodal treatment during an individual’s lifetime. As such, the treatment of 
patients with this rare condition constitutes personalised medicine.  The combined 
experience of individuals through international clinical trial participation, offers the 
best opportunity to establish optimal treatment regimens over time. 
 
Alongside existing evidence, this report presents an increasingly strong argument in 
support of the use of medical therapy, including VEGF monoclonal antibodies, for 
treatment of NF2 associated tumours. Clear radiographic response has been illustrated 
which, in association with functional improvement, can significantly limit the 
morbidity caused by this condition, and improve quality of life for individuals and 
families.  
 
 194  
CHAPTER 10.  OVERVIEW AND FUTURE DIRECTIONS 
 
 
Despite the clear differences between NF1 and NF2 as distinct tumour suppressor 
syndromes, a number of similarities exist for these two single gene disorders in the 
current era of evolving disease-specific approaches to treatment. The development of 
focal neurological deficits secondary to compression by the tumour impinging on one 
or multiple nerves is common in both, along with the need to monitor clinical and 
radiological change over time. Medical treatment options include agents targeting 
various shared aspects of tumour biology and molecular signalling pathways. In both 
conditions, translation of novel treatments from the laboratory and animal models to 
the bedside remains a priority.  
 
At the dawn of molecularly targeted medical therapy for NF1 and NF2, the rationale 
for treatment and results of initial treatment trials in Australia have been described 
here using imatinib for plexiform neurofibromas and bevacizumab for vestibular 
schwannomas. Emphasis has been placed on objective outcome measures and 
clinically relevant functional parameters, as well as a focus on the patient experience 
via inclusion of patient reported outcomes. 
 
Although the efficacy of imatinib and bevacizumab was variable, lessons have been 
learnt which will enhance the clinical care of patients, improve neuroimaging 
surveillance (providing essential natural history and pre-treatment baseline data for 
subsequent trials), and the methodology of response evaluation for novel treatments. 
 
It is anticipated that refinements in the application of optimal image acquisition and 
interpretation according to consensus recommendations (using volumetric tumour 
measurements of on MRI), will allow confident assessment of change over time for 
individual patients, and ensure standardisation between centres participating in 
collaborative studies, as well as comparisons between independent research results 
(124).   Whole-body MRI and MRI-PET may have a role, with recommendations for 
these techniques still in development (297). 
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Regarding current and future directions at our centre for plexiform neurofibromas in 
NF1 an emphasis has been placed on identifying children at risk of significant 
complications early, with a view to prevention of severe manifestations such as those 
seen in the older adolescents treated in this study. Progressive tumours occurring 
around the head and neck (including the airway and orbit), the major nerve plexuses 
and spine, should be included as targets in ongoing and future treatment trials. The 
goal will be to arrest tumour growth in small tumours early, and to prevent 
establishment of large fibrotic lesions which may impact adjacent systems (such as 
bony involvement with scoliosis adjacent to spinal neurofibromas) and be resistant to 
therapy. Identifying agents that are tolerable and safe in early childhood is essential.   
 
In NF1, recent results with MEK inhibitors for plexiform neurofibromas are 
encouraging (70). However, more information is needed including possible adverse 
effects in the short and long term, the optimal time to commence treatment, and 
duration of therapy. There may be a critical period that is optimal for treatment 
response. Will this vary with tumour location, rate of growth, or patient genotype?  
Should the spinal neurofibromatosis phenotype be considered separately? What 
tumour surveillance will be appropriate for treated lesions in future? Will treatment of 
plexiform neurofibromas alter the natural history of development of malignant 
peripheral nerve sheath tumours (MPNST), which arise in pre-existing plexiform 
neurofibromas in 8-13% of patients, and are a significant cause for early mortality on 
NF1(88)? 
 
And what of current and future directions in NF2?  Fortunately, results to date have 
established a clear role for angiogenesis inhibition in the treatment of vestibular 
schwannomas in adults(21).  However, the optimal indications for treatment, 
including when to commence therapy, remain unclear. For example, what is the place 
of surgical resection versus medical therapy for small tumours in light of results with 
bevacizumab? Should surgery be deferred in all cases where medication can be 
offered? Should angiogenesis inhibitors be commenced when tumours exceed set 
dimensions, or be reserved until functional decline occurs (in one or both ears?), to 
minimize cost and risk of side effects? Guidelines based on current and evolving data 
may be helpful, particularly for centres with less experience in the use of angiogenesis 
inhibitors. However, it is probable that treatment decisions will vary between sites 
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based on a number of variables including differing experience and expertise of the 
treating multidisciplinary team, and regulations surrounding prescription, cost and 
availability of medication.  
 
More information is needed regarding the role of angiogenesis inhibitors in treatment 
of NF2 in childhood. Although benefit has been observed in a small number of 
children(248), we and others have noted the response to be less impressive for 
vestibular schwannomas in paediatric patients compared with adults(249). Will this be 
borne out in extended studies? Does the increased prevalence of symptomatic 
schwannomas on cranial nerves other than the vestibular nerve, and on other 
peripheral nerves, impact on response and response evaluation? Alternative 
indications for treatment (possibly broader than growth and symptoms of vestibular 
schwannomas) may be more appropriate for children. In addition, it may be important 
to track radiologic response in a group of tumours over time, along with clinical 
effects.   
 
There are a number of ongoing clinical trials for NF1 and NF2-associated tumours, 
and results will determine future directions (21, 24, 298).  In the longer term, 
treatment protocols utilizing multiple medications in parallel or in series may be 
tolerable and return added benefits (299).  It is expected that individualised 
management will remain the norm, incorporating a multimodal approach including 
surgery for many patients, and in selected cases, radiosurgery/radiotherapy and other 
treatments may have a role. 
 
Since design of the treatment trials described here, significant progress has been made 
in advancing clinical trials in the neurofibromatoses through efforts of the 
international multidisciplinary Response Evaluation in Neurofibromatosis and 
Schwannomatosis (REiNS) International Collaboration (25), and the 
Neurofibromatosis Clinical Trials Consortium (NFCTC) (24), with a view to 
assessing promising candidate medications most effectively. Recommendations from 
the REiNS consortium have been helpful for optimizing trial methodology including 
tumour measurement (124) and functional outcomes pertaining to vision (300), 
hearing and facial nerve function (214), sleep and pulmonary functioning (151), along 
with patient reported outcomes for assessing pain and physical functioning (152)
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Further refinements are ongoing and will offer the tools needed to explore the 
questions yet to be answered.  
 
Another topic addressed by REiNS for development in future studies involves that of 
biomarkers to monitor disease, stratify risk of complications and for response 
stratification (301). Published data on potential biomarkers are available exclusively 
for NF1 to date, and in the research and development stages only.  Nevertheless, 
biobanking is underway, and recommendations have recently been made regarding 
protocols for standardised sample collection and storage, minimal clinical datasets 
and data management. Sites such as The Children’s Hospital at Westmead are well 
placed to participate in these efforts through contribution of tissue samples along with 
clinical data. The existing Children’s Hospital at Westmead tumour bank includes 70 
samples from individuals with NF1 and NF2, to which more can be readily added per 
protocol over time (301). To what extent biomarkers from selected tumours can be 
used to inform observations about whole body disease, ie. response to medication at 
distant sites, remains to be seen.  
 
In terms of ongoing expert service provision for patients with NF in Australia, the 
studies described in this thesis have facilitated consolidation of a network of skilled 
physicians including oncologists, neurologists, radiologists, clinical geneticists and 
surgical colleagues, in NSW along with out-of-state providers. In the course of this 
study, advocacy for NF1 and NF2 patients has brought this patient group to the 
attention of regional hospital drug committees, private health care providers, the 
national Pharmaceutical Benefits Advisory Committee and the pharmaceutical 
industry for consideration. The ethical issues around development of disease-specific 
therapy in rare diseases, including equitable access to expensive drugs without undue 
delay, have been aired in medical forums for consideration in the broader community. 
Cost effectiveness evaluations need to be considered, and should include due 
recognition of the reduced quality of life and loss of income for patients with NF1 and 
NF2 and their families, which may be relieved by a period of medical therapy. 
 
Regarding routine clinical care at our site, opportunities for enhancement lie in 
expanding expertise within the clinical team (nursing/psychological support), 
considering benefits of more comprehensive genetic testing, and issues around 
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medication supply at time of transition.  We are fortunate to have a team of 
experienced and cooperative medical and surgical clinicians dedicated to addressing 
the needs of the NF population in our region. Patients with complicated NF1 and NF2 
experience significant medical and psychosocial morbidity(155, 264); thus 
comprehensive coordinated specialist services should include dedicated nursing and 
social/psychological support throughout the lifespan. Such a disease-specific 
coordinated care approach has been identified as a priority, and demonstrated to 
improve survival (180, 302).  Future endeavours must monitor healthcare goals not 
only of improved duration, but quality of life.  
 
In the past, genetic testing has not been performed in all cases, as it was not required 
to confirm the diagnosis. However, over the years, increasing information 
recommends genotype as a biomarker to inform prognosis and anticipatory care (130, 
303) in both NF1 and NF2. It may also be important to assess correlations between 
genotype/other biomarkers and response to novel medical therapies (284).  As such, 
we plan to offer genetic testing to an increasing proportion of our patients.  
 
As clinical practice changes to encompass medical treatment in a larger number of 
patients, the issue of medication access at transition to adult services will increasingly 
arise, for which consultation and planning between paediatric and adult arms of the 
healthcare system will be necessary.  
 
In conclusion, collaborative efforts and involvement in multi-center clinical research 
studies where possible, offer the potential for improving the care of Australian 
patients, as well as facilitating research through enhancement of recruitment and 
participation. While the challenges presented by the neurofibromatoses remain 
daunting at times, we are in the strongest position ever to meet them head on with 
confidence and optimism.  The therapeutic landscape is expected to continue evolving 
in the coming years - a necessary and exciting prospect indeed. 
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Neurofibromatosis Type 1 and Type 2: Background and recommended 
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Introduction: The application of novel medical treatments in Neurofibromatosis 
Type 1 and Type 2   
 
Neurofibromatosis Type 1 (NF1) and Neurofibromatosis Type 2 (NF2) are distinct 
tumour-prone genetic disorders for which new treatment options are becoming 
available due to advances in the understanding of tumour biology and specifically 
the underlying molecular basis of these conditions [1-4].  Neuroimaging surveillance 
of tumours occurring in patients with NF1 and NF2 is central to following the 
progression of tumours, identifying which patients may benefit from novel 
treatments, and evaluating treatment response. 
 
Your assistance with optimising tumour imaging for NF1 and NF2 patients in your 
area is very much appreciated. 
 
 
Background Information 
 
NF1 and NF2 are both autosomal dominant disorders, NF1 affecting about 1:3500 
individuals and NF2 between 1:25,000 to 1:40,000 people.   The gene for NF1 has 
been identified on chromosome 17 and encodes the protein neurofibromin.  NF2 is 
caused by mutations in the gene on chromosome 22, which produces the protein 
variably named scwannomin or “merlin”.   These proteins function as tumour 
suppressor, and as such, when mutations occur in the genes for NF1 and NF2 this 
tumour suppressor function is lost and  patients are vulnerable to the formation of a 
range of tumours affecting primarily the nervous system, but also other parts of the 
body.   
 
 
 
 
 
 
 217  
 
 
Neurofibromatosis Type 1: Plexiform Neurofibromas 
Some of the major medical complications of NF1 are due to plexiform neurofibromas 
(PNFs) which are usually diagnosed in children.   Plexiform neurofibromas are 
externally obvious  in approximately 25% of patients, and with increased use of MRI, 
it is now recognised that at least 40% of patients also have internal tumours [5].  
These tumours can cause significant disfiguration and functional impairment 
depending on the location of the tumour and involvement of adjacent tissues, 
including pain, visual loss, limb weakness, and abdominal obstruction.  There is a 
lifelong risk of malignant transformation [6] which carries a poor prognosis  for  five 
year survival.  The imaging of plexiform neurofibromas is complex due to the 
potentially extensive, infiltrative nature of these tumours.  Some of these tumours 
can be surgically removed, but unfortunately, regrowth is common. 
 
Neurofibromatosis Type 2:  Vestibular Schwannomas and Meningiomas  
Vestibular schwannomas are the most frequent tumours affecting 95% of all patients 
with NF2, causing tinnitus, vertigo, hearing loss, and risk of brain stem compression.  
About 20% of patients with NF2 present with symptoms before the age of 15 years, 
and of these, 43% have symptoms associated with vestibular schwannoma.  
Unfortunately, increased morbidity is associated with these tumours among 
individuals with NF2 compared with patients with sporadic vestibular schwannoma 
(in the absence of NF2).  Furthermore, there is a significant risk of early mortality 
secondary to vestibular schwannoma in the NF2 population, estimated at up to 60% 
by the age of 44 years in one report. 
A range of other tumours including meningiomas, schwannomas, gliomas, and 
ependymomas are characteristic of NF2, and meningiomas are the next priority 
target for medical treatment in patients with NF2.  
 
To date, surgery and radiosurgery have been first line treatment approaches.  
However, these treatments do not typically yield improvements in hearing loss 
secondary to vestibular tumours or other functional deficits such as visual loss due to 
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optic nerve sheath meningiomas. Furthermore, surgery and radiosurgery have other 
associated risks and side effects.   
 
Effective alternative medical treatments for NF1 and NF2 associated tumours are 
becoming available and need to be carefully/critically assessed for safety and 
efficacy in this patient population [1, 7].     
 
Neuroimaging in Neurofibromatosis Type 1 and 2 
 
Following the symptomatic and radiographic progression of tumours in NF1 and NF2 
patients is the essential backdrop against which novel medical therapies can be 
considered.   In recent years, advances in neuroimaging have allowed better 
evaluation of tumour growth due to improvements in image acquisition and data 
analysis.  It is now evident that 3 dimensional approaches provide a more sensitive 
assessment of tumour progression than 2 dimensional assessments [5, 8-10].  
 
In the management of NF1/NF2 patients, it is our goal to ensure close surveillance of 
progressive tumours to provide critical baseline information regarding growth rates 
which can be used in the assessment of response to novel medical therapies.   We 
hope to facilitate treatment of patients across Australia, in cooperation with 
neuroimaging and treatment facilities around the country. 
 
In order to provide the best ongoing treatment options, the MR Imaging for each of 
these patients needs to be standardised so that volume measurements of the 
various lesions can be calculated. 
 
It would be very much appreciated if all sites performing examinations on NF1 and 
NF2 patients could follow the protocols shown on pages 6 and 7 as closely as 
possible, with particular emphasis on ensuring that the entire lesion/s is covered and 
that the slices are acquired contiguously (with no gap). Acquisition of the data in this 
fashion will ensure the accuracy of subsequent volume measurements. 
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Recommended MRI protocols for tumours associated with Neurofibromatosis Type 
1 and Type 2  
 
The following guidelines are recommended to optimise assessment of NF1 and NF2 
associated tumours: 
 
Brain lesions 
Use your site's clinical pre-contrast protocol but with contiguous slices (no gap), 
including axial T1-W sequence 
Ensure all axial sequences cover entire brain so that no lesions are missed 
Post contrast in 2 planes (usually axial and coronal). Please cover brain entirely 
5mm slice thickness should be sufficient unless lesions are very small 
No need for fat saturation if lesions are intracranial  
 
Plexiform neurofibromas in body (including face) in NF1:  
Pre contrast axial and coronal T1-W  
Pre contrast axial and coronal T2-W FS OR STIR sequences 
Post contrast axial and coronal T1-W with fat saturation 
Contiguous 5-10mm slices (no gap)  
     (depending on size of lesion: 5mm slices for smaller lesions, 10mm for larger 
lesions) 
Cover entire lesion in 2 planes to enable lesion volumes to be calculated. 
 
Optional Whole-body STIR protocol for NF1(coronal plane). This protocol need 
only be run on patients who have multiple plexiform lesions involving the whole 
body. 
 
The parameters are per station. Usually need 5 stations to cover head to ankles. 
 
Slices 20 
FOV: 500 mm 
Slice thickness: 10 mm (no gap) 
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TR: 4190 ms 
TE 113 ms 
TI: 150 ms 
Averages 2 
Concatenations 2 
Flip angle 150 ms 
Bandwidth 252 
Resolution 320 x 240 
Imaging time: 2:56 min 
 
 
Optic meningioma and vestibular schwannoma in NF2:  
 
Pre contrast axial T1-W sequence 
Pre contrast axial and coronal T2-W fat saturated sequences   
2-3mm slice thickness (no gap)  
Lesion entirely covered in both planes 
 
T1-W post contrast on both axial and coronal planes because: 
1. very frequently, if two schwannomas are in very close proximity, it will 
not be easy to differentiate them in a single plane.  
2. if images are suboptimal in one plane for any reason, the second plane 
becomes vital for volume calculation.  
 
 
We hope you will find this a helpful resource and very much appreciate your efforts 
in catering for the specific requirements of our patients with NF1 and NF2.  
  
 
 
We would appreciate receiving a copy of images acquired at your centre on a CD 
for detailed analysis.    
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Contact Us 
Given the complexity of volumetric analysis of tumours associated with NF1 and 
NF2, we are developing a team of dedicated radiographers, radiologists and image 
analysis specialists to assess these images.   
 
Key Team Members are listed below with contact details. 
 
Please don’t hesitate to contact us with any questions or queries. 
 
 
Sheryl Foster   Senior MRI Research Radiographer  9845 7206 
Dr Lavier Gomes Neuroradiologist, Westmead Hospital    98456522  
Dr Mayuresh Korgaonkar Senior Imaging Scientist, Brain Dynamics Centre  9845 817 
Dr Simone Ardern-Holmes Paediatric Neurologist,    9845 1164 
The Children’s Hospital at Westmead   
Natalie Gabrael,    Clinical Trials Coordinator,   9845 1904 
 The Children’s Hospital at Westmead   
Dr Mark Wong Oncologist, Cancer Care Centre,   02 9845 9957 
Westmead Hospital 
Professor Kathryn North Clinical Geneticist/Paediatric Neurologist,  9845 1903 
Head, Institute of Neuroscience and Muscle Research,  
The Children’s Hospital at Westmead    
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Appendix 2. Additional protocol patient selection, treatment and 
adverse monitoring details for imatinib treatment of plexiform 
neurofibromas in patients with NF1. 
 
Eligibility criteria (to minimize risk of adverse events): 
Hepatic function:   
Participants must have adequate liver function defined as bilirubin (sum of 
conjugated + unconjugated) ≤2x upper limit of normal for age, and AST and ALT ≤3 x 
upper limit of normal for age; 
Renal function:   
Participants must have adequate renal function defined as serum creatinine ≤1.5x 
upper limits of normal for age, or a creatinine clearance of greater than 70 
ml/m/1.73m2; 
Haematologic function:   
Participants must have an absolute neutrophil count of greater than 1,000, a 
haemoglobin of greater than 9 g/dl, and a platelet count of greater than 100,000. 
 
Discontinuation of medication: 
A participant may be taken off imatinib for the following reasons: 
• The development of significant drug toxicity, such as recurrent grade 3 or 4 
toxicity after dose reduction; and/or persistent grade >2 toxicity for >X days 
without administration of the drug 
 (see adverse event monitoring below);  
• Treatment failure: ≥20% increase in 3D tumour volume; 
• Serious non-compliance as determined by the research team;  
• The participant refuses further treatments and/or wishes to withdraw from the 
study;  
• The development of a concurrent serious medical condition that might preclude 
or contraindicate the administration of imatinib; 
• It is deemed in the best interest of the participant to stop the study by the 
research team. 
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Adverse Events and Relationship to Imatinib Administration: 
• Adverse Event – Any unfavourable and unintended sign (including an abnormal 
laboratory finding), symptom or disease regardless of whether it is considered 
related to the study medications (attribution of unrelated, unlikely, possible, 
probable, or definite). 
 
Participants who experience grade 2 toxicity related to imatinib will have the 
medication withheld until the toxicity resolves (grade <1), and then restarted at the 
same dose level. If grade 2 toxicity recurs, the dose will be withheld again until the 
toxicity resolves (grade <1) and then reduced to 50% of the dose. If grade 2 toxicity 
recurs, medication will be ceased.   
 
Participants who experience grade 3 or 4 toxicity related to imatinib will have the dose 
withheld. If the toxicity returns to grade <1 within 10 days, the participant may resume 
imatinib at a reduced dose. If the toxicity persists at grade >2 for >10 days without 
administration of imatinib or the grade 3 or 4 toxicity recurs at the lower dose, 
medication will be ceased. 
 
Treatment will be ceased in the event of any significant adverse event (Grade 4/5).  
In the event of milder adverse events, consideration will be given to temporary 
cessation and/or decreasing the treatment dose.    
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Appendix 3 
 
 
 
NF1 Symptoms Questionnaire 
 
 
Headache: 
 
 Never        Less often than monthly       Monthly          Weekly              Daily             Many times a day                     
 
    0         1                  2                 3             4   5 
 
 
Dizziness: 
 
Never        Less often than monthly       Monthly          Weekly              Daily             Many times a day                     
 
    0         1                  2                 3             4   5 
 
 
 
Falls: 
 
Never        Less often than monthly       Monthly          Weekly              Daily             Many times a day                     
 
    0         1                  2                 3             4   5 
 
 
 
Fatigue: 
 
Never        Less often than monthly       Monthly          Weekly              Daily             Many times a day                     
 
    0         1                  2                 3             4   5 
 
 
 
Weakness in Legs:       
 
Left Leg: 
 
N/A       Never        Less often than monthly          Monthly           Weekly           Daily         Many times a day                     
 
  X              0   1                     2                     3                4          5 
 
Right Leg: 
  
N/A       Never        Less often than monthly          Monthly           Weekly           Daily         Many times a day                     
 
  X              0   1                     2                     3                4          5 
 
 
 
         Name: ___________________________                      
 
         Date:   _____________________ 
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Paraesthesia:      
Pins/Needles: 
 
N/A       Never        Less often than monthly          Monthly           Weekly           Daily         Many times a day                     
 
  X              0   1                     2                     3                4          5 
 
Numbness: 
  
N/A       Never        Less often than monthly          Monthly           Weekly           Daily         Many times a day                     
  
  X              0   1                     2                     3                4          5 
 
   
 
Back Pain: 
 
N/A       Never        Less often than monthly        Monthly         Weekly          Daily         Many times a day                     
 
 X           0      1                     2               3        4                 5 
 
 
Neck Pain: 
 
N/A       Never        Less often than monthly        Monthly         Weekly          Daily         Many times a day                     
 
 X           0      1                     2               3        4                 5 
 
 
Speech: 
 
Never        Less often than monthly       Monthly          Weekly              Daily             Many times a day                     
 
    0         1                  2                 3             4   5 
 
 
Swallowing: 
 
 Never        Less often than monthly       Monthly          Weekly              Daily             Many times a day                     
 
    0         1                  2                 3             4   5 
 
 
Incontinence:      
Bladder: 
 Never        Less often than monthly       Monthly          Weekly              Daily             Many times a day                     
 
    0         1             2                     3                    4   5 
Bowel: 
 Never        Less often than monthly       Monthly          Weekly              Daily             Many times a day                     
 
    0         1             2                     3                    4   5 
 
 227  
 
Constipation: 
 
Never        Less often than monthly       Monthly          Weekly              Daily             Many times a day                     
 
    0         1                  2                 3             4   5 
  
 
 
Vision:       
Blurry: 
 
N/A       Never        Less often than monthly          Monthly           Weekly           Daily         Many times a day                     
 
  X              0   1                     2                     3                4          5 
 
Double vision: 
  
N/A       Never        Less often than monthly          Monthly           Weekly           Daily         Many times a day                     
 
  X              0   1                     2                     3                4          5 
 
 
 
Nausea: 
 
 Never        Less often than monthly       Monthly          Weekly              Daily             Many times a day                     
 
    0         1                  2                 3             4   5 
 
 
Vomiting: 
 
 Never        Less often than monthly       Monthly          Weekly              Daily             Many times a day                     
 
    0         1                  2                 3             4   5 
 
 
 
Other: (please describe) ___________________________________________ 
 
 Never        Less often than monthly       Monthly          Weekly              Daily             Many times a day                     
 
    0         1                  2                 3             4   5 
 
 
 
Linear overall well-being scale (please indicate by placing an “X” on the line):  
 
I                                                                                                                          I 
 
[Low]                                                                                                                                 [High] 
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Appendix 4. Medical Outcomes Study 36-Item Short Form (SF36) 
questionnaire. 
  
SF-36 QUESTIONNAIRE
( 1992 -- Medical Outcomes Trust)
Patient Name: ______________________________                Date: _____________________
1.  In general, would you say your health is: (circle one)
Excellent   Very good    Good          Fair       Poor
2.  Compared to one year ago, how would you rate your health in general now? (circle one)
Much better now than one year ago.
Somewhat better now than one year ago.
About the same as one year ago.
Somewhat worse than one year ago.
Much worse than one year ago.
3.  The following items are about activities you might do during a typical day.  Does your health
      now limit you in these activities?  If so, how much? (Mark each answer with an X)
           ACTIVITIES
Yes,
Limited
A Lot
Yes,
Limited
A Little
No, Not
Limited
At All
a. Vigorous activities, such as running, lifting heavy objects, participating in
     strenuous sports
b. Moderate activities, such as moving a table, pushing a vacuum cleaner,
    bowling, or playing golf
c. Lifting or carrying groceries
d. Climbing several flights of stairs
e. Climbing one flight of stairs
f. Bending, kneeling or stooping
g. Walking more than a mile
h. Walking several blocks
i. Walking one block
j. Bathing or dressing yourself
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4. During the past 4 weeks, have you had any of the following problems with your work or other
regular daily activities as a result of your physical health? (Mark each answer with an X)
YES NO
a. Cut down on the amount of time you spent on work or other activites
b. Accomplished less than you would like
c. Were limited in the kind of work or other activities
d. Had difficulty performing the work or other activities (for example, it took extra effort)
5. During the past 4 weeks, have you had any of the following problems with your work or other
    regular daily activities as a result of any emotional problems (such as feeling depressed or
    anxious)? (Mark each answer with an X)
YES NO
a. Cut down the amount of time you spent on work or other activities
b. Accomplished less than you would like
c. Didn’t do work or other activities as carefully as usual
6. During the past 4 weeks, to what extent has your physical health or emotional problems
    interfered with your normal social activities with family, friends, neighbors or groups?
    (circle one)
   Not at all             Slightly             Moderately              Quite a bit              Extremely
7. How much bodily pain have you had during the past 4 weeks? (circle one)
   None            Very mild            Mild            Moderate           Severe            Very severe
8. During the past 4 weeks, how much did pain interfere with your normal work (including both
    work outside the home and housework)?
   Not at all             A little bit            Moderately             Quite a bit              Extremely
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9. These questions are about how you feel and how things have been with you during the past 4
    weeks.  For each question, please give the one answer that comes closest to the way you have
    been feeling. How much of the time during the past 4 weeks – (Mark each answer with an X)
All of the
Time
Most of
the Time
A Good
Bit of the
Time
Some of
the Time
A Little
of the
Time
None of
the Time
a. Did you feel full of pep?
b. Have you been a very nervous
    person?
c. Have you felt so down in the
    dumps that nothing could cheer
    you up?
d. Have you felt calm and peaceful?
e. Did you have a lot of energy?
f. Have you felt downhearted and
   blue?
g. Did you feel worn out?
h. Have you been a happy person?
i. Did you feel tired?
10. During the past 4 weeks, how much of the time has your physical health or emotional
      problems interfered with your social activities (like visiting with friends, relatives, etc.)?
      (circle one)
All of the time    Most of the time      Some of the time      A little of the time      None of the time
11. How TRUE or FALSE is each of the following statements for you?
Definitely
True
Mostly
True
Don’t
Know
Mostly
False
Definitely
False
a. I seem to get sick a little easier than other
    people
b. I am as healthy as anybody I know
c. I expect my health to get worse
d. My health is excellent
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Appendix 5. Adverse effects/toxicity of imatinib. 
 
 Common  
Happens to 21-100 
children out of every 
100 
 
Occasional  
Happens to 5-20 
children out of 
every 100 
 
Rare 
Happens to <5 children 
out of every 100 
 
Immediate: 
Within 1-2 days of 
receiving drug 
Dyspepsia/heartburn, 
nausea/vomiting, 
headache, swelling in 
limbs, face, periorbital 
area, weight gain 
 
Fever, liver 
dysfunction, 
abdominal pain and 
cramping, muscle 
and joint aches and 
pains   
Brain swelling, 
inflammation of the bone, 
Inflammation of the lungs 
 
Prompt: 
Within 2-3 weeks, 
prior to the next 
course 
 
Low blood counts 
predisposing to 
anaemia, infection, or 
bleeding, 
fatigue 
 
Decreased bone 
marrow cellularity, 
skin rash, muscle 
pain and cramping, 
anorexia 
 
GI bleeding, diarrhoea, 
swallowing difficulties, 
esophagitis, pain while 
swallowing, severe skin 
rash, bleeding associated 
with low platelets 
 
Delayed: 
Any time later 
during therapy, 
excluding the 
above conditions 
 
Growth restriction may 
occur in children 
Pigmentation 
changes 
(hypo-, vitiligo) 
 
Liver dysfunction  
(associated with 
coincident 
acetaminophen use) 
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Appendix 6.   
 
 
NF2 Symptoms Questionnaire 
 
Headache: 
 
 Never        Less often than monthly       Monthly          Weekly              Daily             Many times a day                     
 
    0         1                  2                 3             4   5 
 
 
 
Dizziness: 
 
Never        Less often than monthly       Monthly          Weekly              Daily             Many times a day                     
 
    0         1                  2                 3             4   5 
 
 
Tinnitus: 
 
 Never        Less often than monthly       Monthly          Weekly              Daily             Many times a day                     
 
    0         1                  2                 3             4   5 
 
 
Falls: 
 
Never        Less often than monthly       Monthly          Weekly              Daily             Many times a day                     
 
    0         1                  2                 3             4   5 
 
 
Fatigue: 
 
Never        Less often than monthly       Monthly          Weekly              Daily             Many times a day                     
 
    0         1                  2                 3             4   5 
 
 
Weakness in Legs:       
 
Left Leg: 
 
N/A       Never        Less often than monthly          Monthly           Weekly           Daily         Many times a day                     
 
  X              0   1                     2                     3                4          5 
 
Right Leg: 
  
N/A       Never        Less often than monthly          Monthly           Weekly           Daily         Many times a day                     
 
  X              0   1                     2                     3                4          5 
 
         Name: ___________________________                      
 
         Date:   _____________________ 
 233  
 
Paraesthesia:      
Pins/Needles: 
 
N/A       Never        Less often than monthly          Monthly           Weekly           Daily         Many times a day                     
 
  X              0   1                     2                     3                4          5 
 
Numbness: 
  
N/A       Never        Less often than monthly          Monthly           Weekly           Daily         Many times a day                     
  
  X              0   1                     2                     3                4          5 
 
   
 
Back Pain: 
 
N/A       Never        Less often than monthly        Monthly         Weekly          Daily         Many times a day                     
 
 X           0      1                     2               3        4                 5 
 
 
Neck Pain: 
 
N/A       Never        Less often than monthly        Monthly         Weekly          Daily         Many times a day                     
 
 X           0      1                     2               3        4                 5 
 
 
Speech: 
 
Never        Less often than monthly       Monthly          Weekly              Daily             Many times a day                     
 
    0         1                  2                 3             4   5 
 
 
Swallowing: 
 
 Never        Less often than monthly       Monthly          Weekly              Daily             Many times a day                     
 
    0         1                  2                 3             4   5 
 
 
Incontinence:      
Bladder: 
 
 Never        Less often than monthly       Monthly          Weekly              Daily             Many times a day                     
 
    0         1             2                     3                    4   5 
 
Bowel: 
  
 Never        Less often than monthly       Monthly          Weekly              Daily             Many times a day                     
 
    0         1             2                     3                    4   5 
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Constipation: 
 
Never        Less often than monthly       Monthly          Weekly              Daily             Many times a day                     
 
    0         1                  2                 3             4   5 
  
 
 
Vision:       
Blurry: 
 
N/A       Never        Less often than monthly          Monthly           Weekly           Daily         Many times a day                     
 
  X              0   1                     2                     3                4          5 
 
Double vision: 
  
N/A       Never        Less often than monthly          Monthly           Weekly           Daily         Many times a day                     
 
  X              0   1                     2                     3                4          5 
 
 
 
Nausea: 
 
 Never        Less often than monthly       Monthly          Weekly              Daily             Many times a day                     
 
    0         1                  2                 3             4   5 
 
 
Vomiting: 
 
 Never        Less often than monthly       Monthly          Weekly              Daily             Many times a day                     
 
    0         1                  2                 3             4   5 
 
 
 
Other: (please describe) ___________________________________________ 
 
 Never        Less often than monthly       Monthly          Weekly              Daily             Many times a day                     
 
    0         1                  2                 3             4   5 
 
 
 
Linear overall well-being scale (please indicate by placing an “X” on the line):  
 
I                                                                                                                          I 
 
[Low]                                                                                                                                  
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Appendix 7. Speech, Spatial and Qualities of Hearing Scale. 
  
SSQ 5.6  page 1
The following questions inquire about aspects of your
ability and experience hearing and listening in
different situations.
For each question, put a mark, such as a cross (x),
anywhere on the scale shown against each question
that runs from 0 through to 10. Putting a mark at 10
means that you would be perfectly able to do or
experience what is described in the question. Putting
a mark at 0 means you would be quite unable to do or
experience what is described.
As an example, question 1 asks about having a
conversation with someone while the TV is on at the
same time. If you are well able to do this then put a
mark up toward the right-hand end of the scale. If
you could follow about half the conversation in this
situation put the mark around the mid-point, and so
on.
We expect that all the questions are relevant to
your everyday experience, but if a question
describes a situation that does not apply to you,
put a cross in the “not applicable” box. Please also
write a note next to that question explaining why it
does not apply in your case.
Your name : 
Today’s  date  :  
I use one hearing aid (left ear ) 
I use one hearing aid (right ear) 
I use two hearing aids (both ears)
If  you have been using hearing aid/s, for how long?
______ years
______ months
or
_____ weeks 
I have no hearing aid/s
Please answer the following questions, then go 
on to the questions  about  your  hearing
Please check one of these options:
Speech Spatial Qualities
Advice about answering the questions
Your age:
If you have two aids and have used them for 
different lengths of time, please write down both.
0 1 2 3 4 5 6 7 8 9 10 Not applicable
Not at all Perfectly1. You are talking with one other person and there is a TV on in the 
same room. Without turning the 
TV down, can you follow what the 
person  you’re  talking  to  says?
2. You are talking with one other 
person in a quiet, carpeted lounge-
room. Can you follow what the 
other person says?
3. You are in a group of about five 
people, sitting round a table. It is 
an otherwise quiet place. You can 
see everyone else in the group. 
Can you follow the conversation?
4. You are in a group of about five 
people in a busy restaurant. You 
can see everyone else in the 
group.  Can you follow the 
conversation?
5. You are talking with one other 
person. There is continuous 
background noise, such as a fan or 
running water. Can you follow 
what the person says?
0 1 2 3 4 5 6 7 8 9 10 Not applicable
Not at all Perfectly
0 1 2 3 4 5 6 7 8 9 10 Not applicable
Not at all Perfectly
0 1 2 3 4 5 6 7 8 9 10 Not applicable
Not at all Perfectly
0 1 2 3 4 5 6 7 8 9 10 Not applicable
Not at all Perfectly
SSQ 5.6  page 2
Speech Spatial Qualities (Part 1: Speech hearing)
0 1 2 3 4 5 6 7 8 9 10 Not applicable
Not at all Perfectly6. You are in a group of about five people in a busy restaurant. You 
CANNOT see everyone else in the 
group.  Can you follow the 
conversation?
7. You are talking to someone in a 
place where there are a lot of 
echoes, such as a church or 
railway terminus building. Can 
you follow what the other person 
says?
8. Can you have a conversation with 
someone when another person is 
speaking whose voice is the same 
pitch  as  the  person  you’re  talking  
to?
9. Can you have a conversation with 
someone when another person is 
speaking whose voice is different 
in  pitch  from  the  person  you’re  
talking to?
10. You are listening to someone 
talking to you, while at the same 
time trying to follow the news on 
TV. Can you follow what both 
people are saying?
0 1 2 3 4 5 6 7 8 9 10
Not applicable
Not at all Perfectly
0 1 2 3 4 5 6 7 8 9 10 Not applicable
Not at all Perfectly
0 1 2 3 4 5 6 7 8 9 10 Not applicable
Not at all Perfectly
0 1 2 3 4 5 6 7 8 9 10 Not applicable
Not at all Perfectly
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Speech Spatial Qualities (Part 1: Speech hearing, continued)
0 1 2 3 4 5 6 7 8 9 10 Not applicable
Not at all Perfectly11. You are in conversation with one person in a room where there are 
many other people talking.  Can 
you follow what the person you 
are talking to is saying?
12. You are with a group and the 
conversation switches from one 
person to another.  Can you easily 
follow the conversation without 
missing the start of what each new 
speaker is saying? 
13. Can you easily have a 
conversation on the telephone? 
14. You are listening to someone on 
the telephone and someone next to 
you starts talking.  Can you follow 
what’s  being  said  by  both  
speakers?
0 1 2 3 4 5 6 7 8 9 10
Not applicable
Not at all Perfectly
0 1 2 3 4 5 6 7 8 9 10 Not applicable
Not at all Perfectly
0 1 2 3 4 5 6 7 8 9 10 Not applicable
Not at all Perfectly
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Speech Spatial Qualities (Part 1: Speech hearing, continued)
0 1 2 3 4 5 6 7 8 9 10 Not applicable
Not at all Perfectly
2. You are sitting around a table or at 
a meeting with several people. 
You  can’t  see  everyone.    Can  you  
tell where any person is as soon as 
they start speaking?
3. You are sitting in between two 
people.  One of them starts to 
speak.  Can you tell right away 
whether it is the person on your 
left or your right, without having 
to look?
4. You are in an unfamiliar house.  It 
is quiet.  You hear a door slam.  
Can you tell right away where that 
sound came from?
5. You are in the stairwell of a 
building with floors above and 
below you.  You can hear sounds 
from another floor.  Can you 
readily tell where the sound is 
coming from?
0 1 2 3 4 5 6 7 8 9 10 Not applicable
Not at all Perfectly
0 1 2 3 4 5 6 7 8 9 10
Not applicable
Not at all Perfectly
0 1 2 3 4 5 6 7 8 9 10 Not applicable
Not at all Perfectly
0 1 2 3 4 5 6 7 8 9 10 Not applicable
Not at all Perfectly
1. You are outdoors in an unfamiliar 
place.  You hear someone using a 
lawnmower.    You  can’t  see  where  
they are.  Can you tell right away 
where the sound is coming from?
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Speech Spatial Qualities (Part 2: Spatial hearing)
0 1 2 3 4 5 6 7 8 9 10 Not applicable
Not at all Perfectly6. You are outside.  A dog barks loudly.  Can you tell immediately 
where it is, without having to 
look?
7. You are standing on the footpath 
of a busy street.  Can you hear 
right away which direction a bus 
or truck is coming from before 
you see it?
8. In the street, can you tell how far 
away someone is, from the sound 
of their voice or footsteps?
9. Can you tell how far away a bus 
or a truck is, from the sound?
10. Can you tell from the sound which 
direction a bus or truck is moving, 
for example, from your left to 
your right or right to left?
0 1 2 3 4 5 6 7 8 9 10 Not applicable
Not at all Perfectly
0 1 2 3 4 5 6 7 8 9 10 Not applicable
Not at all Perfectly
0 1 2 3 4 5 6 7 8 9 10 Not applicable
Not at all Perfectly
0 1 2 3 4 5 6 7 8 9 10 Not applicable
Not at all Perfectly
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Speech Spatial Qualities (Part 2: Spatial hearing, continued)
0 1 2 3 4 5 6 7 8 9 10 Not applicable
Not at all Perfectly11. Can you tell from the sound of their voice or footsteps which 
direction a person is moving, for 
example, from your left to your 
right or right to left?
12. Can you tell from their voice or 
footsteps whether the person is 
coming towards you or going 
away?
13. Can you tell from the sound 
whether a bus or truck is coming 
towards you or going away?
14. Do the sounds of things you are 
able to hear seem to be inside your 
head rather than out there in the 
world?
15. Do the sounds of people or things 
you hear, but cannot see at first, 
turn out to be closer than expected 
when you do see them?
0 1 2 3 4 5 6 7 8 9 10 Not applicable
Not at all Perfectly
0 1 2 3 4 5 6 7 8 9 10 Not applicable
Not at all Perfectly
0 1 2 3 4 5 6 7 8 9 10 Not applicable
Inside my head Out there
0 1 2 3 4 5 6 7 8 9 10 Not applicable
Much closer Not closer
SSQ 5.6  page 7
Speech Spatial Qualities (Part 2: Spatial hearing, continued)
0 1 2 3 4 5 6 7 8 9 10 Not applicable
Much further Not further16. Do the sounds of people or things you hear, but cannot see at first, 
turn out to be further away than 
expected when you do see them?
17. Do you have the impression of 
sounds being exactly where you 
would expect them to be?
0 1 2 3 4 5 6 7 8 9 10 Not applicable
Not at all Perfectly
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Speech Spatial Qualities (Part 2: Spatial hearing, continued)
0 1 2 3 4 5 6 7 8 9 10
Not applicable
Not at all Perfectly
2. When you hear more than one 
sound at a time, do you have the 
impression that it seems like a 
single jumbled sound? 
3. You are in a room and there is 
music on the radio.  Someone else 
in the room is talking.  Can you 
hear the voice as something 
separate from the music?
4. Do you find it easy to recognise 
different people you know by the 
sound  of  each  one’s  voice?
5. Do you find it easy to distinguish 
different pieces of music that you 
are familiar with?
0 1 2 3 4 5 6 7 8 9 10 Not applicable
Jumbled Not jumbled
0 1 2 3 4 5 6 7 8 9 10 Not applicable
Not at all Perfectly
0 1 2 3 4 5 6 7 8 9 10 Not applicable
Not at all Perfectly
0 1 2 3 4 5 6 7 8 9 10 Not applicable
Not at all Perfectly
1. Think of when you hear two 
things at once, for example, water 
running into a basin and, at the 
same time, a radio playing.  Do 
you have the impression of these 
as sounding separate from each 
other?
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0 1 2 3 4 5 6 7 8 9 10 Not applicable
Not at all Perfectly6. Can you tell the difference between different sounds, for 
example, a car versus a bus; water 
boiling in a pot versus food 
cooking in a frypan?
7. When you listen to music, can you 
make out which instruments are 
playing?
8. When you listen to music, does it 
sound clear and natural?
9. Do everyday sounds that you can 
hear easily seem clear to you (not 
blurred)?
10. Do  other  people’s  voices  sound  
clear and natural?
0 1 2 3 4 5 6 7 8 9 10 Not applicable
Not at all Perfectly
0 1 2 3 4 5 6 7 8 9 10 Not applicable
Not at all Perfectly
0 1 2 3 4 5 6 7 8 9 10 Not applicable
Not at all Perfectly
0 1 2 3 4 5 6 7 8 9 10 Not applicable
Not at all Perfectly
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0 1 2 3 4 5 6 7 8 9 10 Not applicable
Unnatural Natural11. Do everyday sounds that you hear seem to have an artificial or 
unnatural quality?
12. Does your own voice sound 
natural to you?
13. Can you easily judge another 
person’s  mood  from  the  sound  of  
their voice?
14. Do you have to concentrate very 
much when listening to someone 
or something?
15. Do you have to put in a lot of 
effort to hear what is being said in 
conversation with others?
0 1 2 3 4 5 6 7 8 9 10 Not applicable
Not at all Perfectly
0 1 2 3 4 5 6 7 8 9 10 Not applicable
Not at all Perfectly
0 1 2 3 4 5 6 7 8 9 10 Not applicable
Concentrate hard Not need to concentrate
0 1 2 3 4 5 6 7 8 9 10 Not applicable
Lots of effort No effort
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0 1 2 3 4 5 6 7 8 9 10 Not applicable
Not at all Perfectly16. When you are the driver in a car can you easily hear what someone 
is saying who is sitting alongside 
you?
17. When you are a passenger can you 
easily hear what the driver is 
saying sitting alongside you?
0 1 2 3 4 5 6 7 8 9 10 Not applicable
Not at all Perfectly
18. Can you easily ignore other 
sounds when trying to listen to 
something?
0 1 2 3 4 5 6 7 8 9 10 Not applicable
Not easily ignore Easily ignore
SSQ 5.6  page 12
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Appendix 8. Adverse effects/toxicity of bevacizumab. 
 
 Common  
21-100/100 
 
Occasional  
5-20/100 
 
Rare 
<5/100 
 
Immediate: 
Within 1-2 days 
of first dose 
Asthenia, 
hypertension, 
Nausea, vomiting, 
anorexia, diarrhoea, 
constipation, cough, 
pruritus, headache, 
dyspnoea 
Dyspepsia, fever, chest, 
back and abdominal 
pain, dizziness, rhinitis 
 
Infusion reactions, 
flatulence, dry mouth, 
altered taste, tearing, 
rash, drowsiness, acidosis 
Prompt: 
Within 2-3 weeks 
 
Epistaxis, 
proteinuria, 
infection, myalgia, 
arthralgia, 
neutropenia  
 
Stomatitis, URI, GI 
haemorrhage, GI ulcer, 
alopecia, weight loss, 
sinusitis, cytopenias, voice 
change, depression, UTI, 
fever 
 
Thrombotic/ 
thromboembolic events, 
exfoliative dermatitis, skin 
ulcer, ↑ AST/ALT, ↑ 
creatinine, Haemorrhage, 
colitis, GI perforation*,  
GI obstruction, 
Hypokalaemia, Hyper-
bilirubinaemia, 
Thrombocytopenia, 
Hyperaesthesia, 
paraesthesia, infection, 
leukoencephalopathy,  
Delayed: 
Any time later 
during therapy 
 
 Nasal-septal perforation Wound dehiscence, CHF, 
nephrotic syndrome, TOF 
with chemo and radiation 
of oesophagus/ trachea, 
renal failure  
Unknown 
Frequency and 
Timing 
 
Teratogenicity in rabbits (doses two-fold greater than recommended human 
dose on a mg/kg basis; decreases in maternal and foetal body weights, 
increased rate foetal resorption, increased specific gross and skeletal foetal 
alterations.   
 
*Toxicity may also occur later; CHF=congestive heart failure, TOF=trachea-esophageal fistula, 
UTI=urinary tract infection. 
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Appendix 9. Bevacizumab funding details 
 
Funding Source 
(Number of patients) 
Comment on funding 
Public Health Sector 
(6) 
Ongoing during paediatric care (1); Funding withdrawn 
due to static tumour volume, despite improved hearing 
(1); withdrawn due to variable compliance with follow up 
(1); withdrawn following treatment response, then 
restarted after disease progression off treatment (1); 
withdrawn after positive response to therapy at 
26months due to insufficient funds, followed by surgical 
treatment (1); commenced after self-funding 
demonstrated significant benefit (1) 
Self-funded 
(3) 
Duration 6-12 months; 2 following withdrawal of public 
funding; one at commencement of treatment, followed by 
public funding upon demonstrated benefit 
Private Health Insurer 
(2) 
One from commencement; one following demonstrated 
benefit  
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Opinion statement
Neurofibromatosis type 1 (NF1) and type 2 (NF2) are genetically and medically distinct
neurocutaneous disorders that are both associated with tumors affecting the central
and peripheral nervous systems. NF1 has a frequency of 1 in 3,000, compared with 1
in 30,000 for NF2. Careful surveillance is important for both conditions, to allow early
identification and treatment of complications. The most common and important problems
in NF1 are cognitive impairment, optic pathway gliomas, plexiform neurofibromas, and or-
thopaedic issues. Early intervention and tailored educational programs are indicated for
learning difficulties. Attention deficit hyperactivity disorder may be amenable to treat-
ment with stimulant medication. A clinical trial is under way to evaluate lovastatin in
the treatment of cognitive problems in children with NF1. Chemotherapy with vincristine
and carboplatin is the current standard of care for symptomatic optic pathway gliomas, but
new agents with improved efficacy are needed. Plexiform neurofibromas may be treated
with surgery, but often recur. To date, no medical therapy has proven effective in limiting
plexiform neurofibroma growth, but several candidate medications are under consideration
in clinical trials. Malignant peripheral nerve sheath tumors may arise in preexisting plexi-
form neurofibromas, so changes in tumor growth or an increase in pain or focal neurologic
deficit should prompt further investigation and early treatment withwide surgical resection,
with or without adjuvant chemotherapy or radiotherapy. Specialist surgical intervention
may be needed for scoliosis and tibial pseudoarthrosis. In NF2, surgical treatment remains
a cornerstoneofmanagement for symptomatic progressive vestibular schwannomas,menin-
giomas, and spinal tumors. Vascular endothelial growth factor inhibitors show promise for
the treatment of vestibular schwannomas, with the aim of delaying surgery, and other tar-
geted molecular therapies are becoming available as investigational options. Hearing aids
and brainstem and cochlear implants have a role in optimizing functional hearing
in some patients. Specialist ophthalmology input should be arranged to monitor
for ophthalmologic complications. A coordinated effort is needed to enroll NF1
and NF2 patients in international multicenter clinical trials of promising new pharmacologic
agents. Genetic testing is useful for prenatal diagnosis and may be important in
understanding individual responses to novel medical therapies in the future. Effec-
tive transition to adult services is important, considering the likelihood of further
complications in the adult years.
Introduction
Neurofibromatosis types 1 and 2 (NF1 andNF2) are dis-
tinct genetic disorders that are both characterized by cu-
taneousmanifestations and benign tumors of the central
and peripheral nervous system. NF1 has a frequency of 1
in 3,000, and most patients present during childhood
with multiple café au lait spots and skinfold freckling.
NF2 has a frequency of 1 in 30,000 and less obvious cu-
taneous features; the hallmark of NF2 is vestibular
schwannomas, and only 20% of patients present in
childhood. Patients with both disorders require regular
disease surveillance throughout life and a multidis-
ciplinary management approach. To date, effective
medical treatment has been limited, but recent
advances in our understanding of molecular patho-
genesis has led to a range of molecularly targeted
medications that are becoming available for investi-
gational use.
Neurofibromatosis type 1
Neurofibromatosis type 1 is caused by mutations in the large NF1 gene locat-
ed on chromosome 17q11.2, encoding the protein neurofibromin. Neuro-
fibromin is known to act as a tumor suppressor via Ras-GTPase
activation, which causes down-regulation of cellular signalling by the
Ras/mitogen-activated protein kinase (MAPK) pathway. In individuals with
NF1 and nonfunctional neurofibromin, Ras signalling is increased, promoting
cellular growth, proliferation, and differentiation leading to tumor formation
and other manifestations of disease, including deficits in hippocampal
learning [1, 2]. Neurofibromin is likely to have additional functions;
for example, loss of normal GABA-mediated inhibition has recently been
shown to contribute to corticostriatal dysfunction associated with working
memory deficits in NF1 [3].
Diagnosis
Clinical diagnostic criteria for NF1 were established in 1987 and are satisfied
when two of the following conditions are met [4•]:
& Café au lait macules (six or more larger than 5 mm before puberty or
15 mm after puberty)
& Skin-fold freckling (axillae, groin, neck)
& Two or more iris Lisch nodules
& Characteristic skeletal dysplasia (tibial dysplasia, sphenoidwingdysplasia)
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& Optic pathway glioma
& Two or more neurofibromas or one or more plexiform neurofibromas
& Presence of a positive family history of NF1 affecting a first-degree
relative.
Young children typically present with multiple café au lait macules in isolation,
with other signs of NF1 occurring over time [5, 6]. Macrocephaly affects about
45% of children and progressive head growth may occur over the first 1 or
2 years. A low threshold for neuroimaging is appropriate, given an in-
creased incidence of intracranial tumors. However, surveillance imaging
in the absence of focal neurologic deficit or signs of increased intracranial pres-
sure is not recommended.Optic pathway gliomas aremore common in children
less than 8 years of age and can occur during infancy. Plexiform neurofibromas
are mostly present from birth and becomemore obvious over the first few years
of life. Skin-fold freckling is typically seen from about 3 years of age, whereas
Lisch nodules may appear in middle childhood and cutaneous neurofibromas
more frequently occur in adolescence and adulthood.
Complications
A recommended surveillance and treatment approach for important compli-
cations is shown in Table 1. The most frequent neurologic complication in
childhood is cognitive dysfunction [7]. There is a “shift to the left” in intel-
lectual functioning: the mean IQ for patients with NF1 is in the low 90s, and
intellectual impairment (IQ G70) occurs in about 6% of patients. Academic
learning difficulties are common in NF1: about 50% of children with NF1
perform poorly on tasks of reading, spelling, and mathematics, and specific
learning disabilities (as defined by IQ–achievement discrepancies) are present
in 20% of patients. Between 38% and 49% of children with NF1 fulfil the diag-
nostic criteria for attention deficit-hyperactivity disorder (ADHD) [7, 8]. Careful
screening, supportive measures in pre-academic environments, and individ-
ually tailored educational programs are thus needed.
The neurobiologic basis of cognitive dysfunction and learning disabilities
in NF1 is not fully understood, although increased total brain volume and
corpus callosum volume, cerebral asymmetries, and differences in grey and
white matter have been described in affected individuals. Though T2 hyper-
intensities are commonly seen in childhood, these decrease with increasing
age and are of uncertain significance. However, the presence of discrete tha-
lamic T2 hyperintensities has been associated with severe and generalized cog-
nitive dysfunction [9]. Speech and language disorders have been estimated to
affect 18% to 58% of school-aged children and adolescents with NF1 [7, 10]
and 68% of preschoolers [11]. Children with NF1 often have mild generalized
hypotonia in association with less well-developed gross motor skills than their
unaffected peers, causing minimal functional impairment.
ADHD in the NF1 population is amenable to treatment with stimulant
medication (as in other children with ADHD), although data on efficacy
are limited [8]. Studies of cognitive functioning in the NF1 mouse model have
suggested that attention and visual spatial learning deficits (hippocampal-based
learning) are due to Ras activation. The cholesterol-lowering agent lovastatin,
which inhibits GTPases including Ras, reverses these deficits in the NF1 mouse
model [12], and trials of lovastatin in childrenwithNF1 are currently underway.
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Optic pathway glioma (OPG) affects 15% to 20%of childrenwithNF1 [13],
most before 8 years of age, with about half becoming symptomatic [14]. Symp-
toms and signs include strabismus, proptosis, visual impairment, optic disk pal-
lor, and precious puberty.
Current surveillance recommendations are for an annual general exami-
nation to monitor growth and pubertal status and an annual ophthalmologic
evaluation up to the age of 8 years, followed by an examination every 2 years
until 18 years of age [13]. All childrenwith a suspected diagnosis ofOPG should
undergo cranial MRI. From the time of diagnosis, monitoring to detect progres-
sive disease rests with regular skilled pediatric ophthalmology assessment to-
Table 1. Current surveillance and treatment of the major medical complications associated with neurofi-
bromatosis type 1
Complications Surveillance Treatment
Cognitive impairment Developmental screening during
preschool years
Early intervention
ADHD Screening at intervals during childhood
(e.g., at school entry)
Stimulant medication
Learning difficulties Psychologist assessment during early
school years (baseline) and when specific
learning difficulty identified
Individually tailored educational support;
candidate for medication in clinical trial
Speech/language disorder Speech evaluation Speech therapy
Optic pathway glioma (OPG) Annual ophthalmology evaluation until
8 years of age, every 2 years ages 8–18;
cranial MRI for suspected OPG.
–
For known OPG, quarterly ophthalmology
evaluation for 1 year, every 6 months for
1 year, then annually until 8 years of age;
if older than 8 years, for 3 further years
Chemotherapy using vincristine and
carboplatin if clinically indicated for
symptomatic or progressing tumor
Plexiform neurofibroma Annual clinical examination to identify
and monitor growth; MRI every
6–12 months for progressive lesions
Surgical debulking for progressive,
symptomatic tumors; candidate for
medication in clinical trial; analgesia
when indicated
Malignant peripheral nerve
sheath tumor
Urgent clinical examination for increasing
plexiform neurofibroma size, pain, or
neurologic dysfunction; MRI, PET, biopsy
of affected body region
Wide surgical excision; consider
chemotherapy and radiotherapy;
candidate for medication
in clinical trial
Tibial pseudoarthrosis Annual clinical evaluation (infants);
x-ray in the event of limb deformity
Referral to experienced orthopaedic
surgeon; bracing, surgical intervention,
and/or bisphosphonates
Scoliosis Annual clinical evaluation throughout
childhood; x-ray in the event of abnormal
spinal curvature
Referral to experienced orthopaedic
surgeon; surgical intervention if
clinically indicated
Hypertension Annual blood pressure monitoring; For
known hypertension, urinary catecholamines,
renal ultrasound with Doppler studies
Renal physician referral
Heart murmur Careful annual examination Echocardiogram; referral to cardiologist
Anxiety/mood disorder Annual clinical evaluation Referral to psychologist or psychiatrist
ADHD attention deficit hyperactivity disorder
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gether with repeat MRIs. Ophthalmology evaluations are recommended every
3 months for the first year, followed by assessments every 6 months for 2 years,
and then annual assessments. Optimal intervals for MRI surveillance have not
yet been established, and different centers screen at intervals between 3 and
6months in the first year. Ocular coherence tomographymeasures retinal nerve
fibre layer thickness, which may be helpful as an adjunctive measurement for
assessing progression in the future [15, Class IV].
Primary treatment for OPG is with chemotherapy, usually a combination
of vincristine and carboplatin. There are no definitive evidence-based criteria
to guide decisions about commencing chemotherapy. A retrospective multi-
center study of 10 major international NF1 centers recently reviewed indica-
tions for commencing chemotherapy, demonstrating practice variation
among institutions and visual deterioration in 29% of treated children [16,
Class IV]. Prospective studies using novel agents are needed.
Other intracranial tumors (typically low-grade gliomas) are less common
and tend to have a more favorable prognosis than in non-NF1 patients [17].
Cutaneous and subcutaneous neurofibromas can itch and cause localized
discomfort. The significant cosmetic deformity attendant on multiple lesions
typically occurs in adulthood; surgical removal is currently the only treat-
ment option.
Plexiform neurofibromas are more complex lesions, thought to be congen-
ital [18]. A recent MRI surveillance study identified plexiform neurofibromas
in 57% of 65 children aged between 1.7 and 17.6 years, similar to estimates
in adults. Of the children with plexiform neurofibromas, 46% experienced pain
or neurologic or motor difficulties, usually associated with larger tumors [19].
Symptoms associated with tracheal compression may be life-threatening.
The treatment of complicated plexiform neurofibromas remains a challenge.
Symptomatic lesions may be amenable to surgical debulking, but complete re-
section may not be possible because of the invasive nature of these tumors, and
regrowth is common. The goal of surveillance is to identify and treat actively
growing symptomatic lesions during early childhood to limit disease progres-
sion. Three-dimensional MRI has been shown to bemore sensitive than two-di-
mensional measurements for assessing growth, but it is not available in all
centers [20]. A range of novel molecularly targeted agents, including inhibitors
of the c-kit receptor such as imatinib [21], are currently being investigated.
PatientswithNF1, particularly those with a high plexiformneurofibroma tu-
mor burden, have a significantly increased risk of malignant peripheral
nerve sheath tumor (MPNST), with a lifetime risk of 8% to 13% [22];
this represents themajor threat of earlymortality. Whole-bodyMRI surveillance
during childhoodmay help to stratify patients into two groups: those requiring
infrequent ongoing scanning and those at risk of complications from existing
plexiform neurofibromas, including the risk of transformation to MPNST. How-
ever, there is currently a paucity of evidence regarding the utility of MR surveil-
lance in children with asymptomatic lesions. Prospective studies are needed to
evaluate the effectiveness of such surveillance. A rapid increase in plexiform neu-
rofibroma growth, increasing pain, and new focal neurologic deficits or other re-
gional symptoms and signs should prompt investigation with MRI [23] and
18F-2-fluoro-2-deoxy-D-glucose (FDG) positron emission tomography PET/
CT studies to detect increased glucose metabolism [24, Class IV]. MPNST con-
firmed on biopsy is treated with wide surgical excision and adjuvant therapy. Re-
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currence risk and metastatic potential are high, with median survival of
30.5 months across all ages and 20 months for children 1 to 17 years of
age [25]. Low response rates to chemotherapy and radiation therapy for
MPNST have focused efforts on the development of novel medical therapy
and carefully coordinated clinical trials to improve patient outcomes.
NF1 is associated with vasculopathy affecting multiple sites, including ab-
dominal, renal, spinal, and intracranial vessels, with various consequences. The
best-recognized manifestation of NF1 vasculopathy is hypertension secondary
to renal artery stenosis. Blood pressure should be monitored at least annually,
and hypertension should be investigated by renal artery ultrasound/Doppler,
with surgical or dilation therapy to treat stenotic lesions. Most cases of hyperten-
sion in NF1 are essential hypertension and respond to medical management.
Phaeochromocytoma is a very rare complication of NF1 but should be screened
for in patients with elevated blood pressure. Cerebral vasculopathy affects 2% to
5%of children; 30%of these cases presentwith symptoms associatedwith ischae-
mia, but the others are diagnosed incidentally. Aspirin is recommended for
patients with evidence of vasculopathy on neuroimaging [26, Class IV].
Epilepsy occurs at an increased frequency in patients with NF1, affecting
3.8% to 7% of children, often in association with cerebral tumors and cortical
malformations. In a series of 14 cases, 29%were drug-resistant [27]. A recent re-
port documented infantile spasms in 0.76% of NF1 patients, compared with
0.02% to 0.05% in the general population [28].
Headache is common in NF1, affecting about 20% of patients. Most
headaches are not associated with intracranial lesions, but MRI should be
performed in patients with severe or recurrent headaches or features sugges-
tive of increased intracranial pressure.
Orthopaedic complications of NF1 during childhood include scoliosis and
tibial pseudoarthrosis, which may require operative management. Scoliosis
occurs in about 20% of patients with NF1, but only about 5% require surgical
intervention; more severe scoliosis tends to present earlier (at 5–10 years of
age) and is often associated with vertebral dysplasia or bony lesions due to an
adjacent plexiform neurofibroma. Bony defects of the tibia or other long bones
are congenital and usually present with bowing or fracture on weight bearing.
Fracture can sometimes be prevented by protective bracing and bisphosphonate
therapy; bisphosphonate therapy has also been shown to promote healing after
surgery.
Genetic testing for NF1
NF1 is inherited in an autosomal dominant fashion with sporadic mutations
occurring in about 50% of patients and a 50% chance of transmission from af-
fected individuals during each pregnancy. A mutation is detected in about 95%
of individuals. If clinical criteria for NF1 are met, genetic testing is not indicated;
the 5% false negative rate necessitates annual clinical follow-up of all children
with suspected NF1 to detect potential complications. Furthermore, among the
many pathologic mutations identified in the NF1 gene, there are few specific ge-
notype-phenotype correlations. Deletion of the entire NF1 gene results in amore
severe phenotype [29], associated with facial dysmorphism, increased predispo-
sition for MPNST, cardiac abnormalities, and overgrowth. A 3-bp in-frame dele-
tion in exon 17 of the NF1 gene is associated with a milder phenotype, which is
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not associated with cutaneous or plexiform neurofibromas [30]. Genetic testing
has an important role in the context of prenatal testing and pre-implantation ge-
netic diagnosis, though its prognostic value is limitedby the variable expressivity
characteristic ofmost NF1mutations. Segmental neurofibromatosis and somat-
ic mosaicism in both NF1 and NF2 carries a lower recurrence risk [31].
The major known differential diagnosis of NF1 is Legius syndrome, an auto-
somal dominant disorder due tomutations in the SPRED1 gene, which is also in-
volved in the RasMAPK pathway [32]. Legius syndrome is characterized by café
au lait spots and skinfold freckling, as well as an increased frequency of learning
difficulties, but importantly, patients do not develop neurofibromas, OPGs,
Lisch nodules, or bone lesions. Of patients positive for a SPRED1 mutation,
48% fulfil NF1 diagnostic criteria based on café au lait spots, freckling, and/or
a positive family history of a parent with skinmanifestations. It is estimated that
2% of individuals with a clinical diagnosis of NF1 have Legius syndrome; the
estimated frequency is 1 in 120,000. At present, genetic screening for Legius syn-
drome is likely to be most useful in families with autosomal dominant café au
lait spots (with or without freckling) without a mutation in the NF1 gene.
Treatment: Neurofibromatosis type 1
& Treatment approaches for NF1 are diverse and depend on the specific
clinical problem. General approaches to therapy are summarized
under each subheading below.
Physical/occupational/speech therapy
& Early intervention including physical therapy, occupational therapy,
and speech therapy are recommended for children with NF1 and
developmental delay. No controlled studies have evaluated the
benefit of treatment.
Surgery
& Surgery usually is not necessary in NF1. It may be considered for
selected symptomatic cutaneous and subcutaneous neurofibromas
and complicated plexiform neurofibromas in NF1, as well as for
large OPGs causing mass effect and hydrocephalus with significant
visual impairment [33].
& Complications of surgery for plexiform neurofibromas include ex-
cessive hemorrhage and neurologic deficit due to nerve damage.
& Early diagnosis and surgical resection with wide margins is the
mainstay of treatment for MPNST [34, Class IV].
& Safety and efficacy of surgical correction of scoliosis in NF1 has been
demonstrated in a case series including 32 children between 11 and
19 years of age with follow-up for an average of 6.5 years [35, Class IV].
& Surgery including encephaloduroarteriomyosynangiosis (known as
EDAMS or pial synangiosis) may be indicated in the management of
moyamoya in NF1 [36, Class IV].
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& Standard inpatient costs are associated with diagnostic testing and
surgery, with significant benefits of early complete resection in the
treatment of suspected MPNST.
Radiotherapy/radiosurgery
& Cranial radiotherapy is usually avoided inNF1 because of the increased
risk of occlusive cerebral vasculopathy (moyamoya) and secondary
tumor formation [37, 38, Class IV].
& Radiotherapy occasionally may be used as a palliative treatment for
inoperable MPNSTs or as an adjunct to surgical resection when the
risks of progression or recurrence are thought to outweigh the risks of
secondary malignancy.
Pharmacologic treatment
& Data from the first randomized, double-blind, placebo-controlled
trial of statin therapy examined the effectiveness of simvastatin in 62
children with NF1. No significant benefit was demonstrated overall,
but a number of methodologic limitations were cited [39, Class II].
The potential benefit of statins is being further evaluated in an in-
ternational multicenter trial using lovastatin for the treatment of
cognitive dysfunction in children with NF1.
& Vincristine and carboplatin chemotherapy is the current standard
of care in children with symptomatic progressive OPG in NF1. The
efficacy of new agents (RAD001) is under investigation. Outcomes
of chemotherapy for children with NF1 treated with vincristine/
carboplatin regimens have included stabilization of vision in 40%
and improvement in 31%; vision deteriorated in 29% of children
studied [16, Class IV].
& Precocious puberty may require treatment with gonadotrophin
analogues.
& There are currently no proven medical therapies to treat plexiform
neurofibromas. Early clinical trials have employed differentiating
agents, antifibrotic agents, immune suppressants, and angiogenesis
and farnesyltransferase inhibitors without significant benefit [40–42,
Class III; 43]. Other agents are under investigation.
& Aspirin is recommended for patients with evidence of vasculopathy
on neuroimaging [26].
& Pain associated with nerve tumors may be treated with agents such
as gabapentin, but there are no specific data reporting optimal
dose or efficacy in NF1 patients.
& Seizures are treated with standard antiepileptic drugs.
Emerging therapies
& Multicenter phase II clinical trials are currently under way to assess
the utility of the mTOR inhibitor rapamycin, the VEGFR (vascular
endothelial growth factor receptor) and kinase inhibitor sorafenib,
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and the protein tyrosine kinase inhibitor imatinib in treating children
with plexiform neurofibromas. Multiagent regimens include the an-
giogenesis inhibitor bevacizumab with the mTOR inhibitor RAD001
for MPNST, and the epidermal growth factor receptor (EFGR) inhibitor
erlotinib with rapamycin, an mTOR inhibitor, for low-grade gliomas
[44••, 45••]. The observation of rapidly progressive moyamoya in a
child with glioblastoma treated with the angiogenesis inhibitor beva-
cizumab indicates that the NF1 population may be at increased risk of
adverse effects from this class of medications [46, Class IV].
Neurofibromatosis type 2
NF2 is caused by mutations in the tumor suppressor gene on chromosome
22q12, which encodes the protein merlin or schwannomin. This protein has
multiple functions, including a role in the organization of cell membrane
proteins, cell-to-cell adhesions, cytoskeletal architecture, and cytosolic pro-
tein interactions, with downstream modification of mitogenic signalling
pathways including the Ras/MAPK and phosphoinositide 3-kinase (PI3K)
pathways affecting cell growth and proliferation and protein translation [47].
Diagnosis
Clinical diagnosis is based on any one of the following four criteria [48•]:
1. Bilateral vestibular schwannomas or
2. First-degree relative with NF2 plus unilateral vestibular schwannoma or
any two of schwannoma, meningioma, glioma, neurofibroma, or
posterior subcapsular lens opacity, or
3. Unilateral vestibular schwannoma plus any two of meningioma,
schwannoma, glioma, neurofibroma, or posterior subcapsular lens
opacity, or
4. Multiple meningiomas (92) plus unilateral vestibular schwannoma
or two of schwannoma, glioma, neurofibroma, or posterior
subcapsular lens opacity.
Ependymomas and gliomas are also more frequent than in the general popu-
lation, as are peripheral neuropathy and ophthalmologic issues including ju-
venile cataracts, retinal hamartoma, and combined hamartoma of the retinal
pigmentary epithelium and retina. Café au lait spots and hypopigmented
macules are seen but are less common than in NF1.
Complications
The major medical complications in NF2 are due to vestibular schwannomas
occurring in 90% to 95% of patients, spinal tumors in 63% to 90%, and
meningiomas in 58% to 75% [47, 49]. Individuals with NF2 experience
greater morbidity associated with tumors than sporadic cases, in part due to
an increased growth rate of tumors in NF2. Morbidity and mortality is higher
with childhood onset: one report of 74 patients calculated a 20-year survival
rate of 28% for individuals symptomatic prior to 25 years of age comparedwith
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62% for those symptomatic after age 25 [50]. Patients with multiple meningi-
omas and truncating mutations in the NF2 gene also carry a poorer prognosis.
The presentation of NF2 varies across age groups, but symptoms secondary
to vestibular schwannomas aremore common in adults. About 18%of patients
with NF2 present before 15 years of age (some during infancy), with greater
symptomatic diversity than adults [51]. Symptoms are due to spinal cord
compression, cranial nerve or peripheral nerve schwannomas, or ocular mani-
festations of disease that cause visual problems; optic nerve sheath meningio-
mas may cause complete blindness [4•]. Mononeuropathy (facial nerve palsy
and foot drop) occurs less frequently, along with seizures, headaches, weight
loss, skin lumps, weakness, and paresthesias [51–53]. Careful neurologic,
ophthalmologic, and dermatologic examination, in addition to cranial and
spinal neuroimaging, are important for diagnosis, together with examination of
first-degree relatives and genetic testing. Children of affected parents may be
diagnosed in early childhood, while asymptomatic. Ongoing surveillance and
consideration of genetic testing is indicated for children with isolated vestibular
schwannomas or meningiomas, as 10% and 20% respectively may be affected
by NF2 [48•].
Optimal management of NF2 patients requires a multidisciplinary approach
in a specialist centerwith the involvement of experiencedneurologists, geneticists,
neurosurgeons, otolaryngologists, audiologists, ophthalmologists, radiologists,
and nurses. Current recommendations for surveillance and treatment, based on
consensus between treating specialists, are shown in Table 2 [54, Class IV].
The mainstay of surveillance in asymptomatic individuals is annual clinical
examination, hearing and ophthalmology evaluations, and neuroimaging,
which should include MRI of the brain and spine. Children of individuals with
NF2 should be screened for cataracts, which can be symptomatic in the first year
of life, and for intracranialmeningiomas, whichmay become symptomatic in the
first 10 years, whereas vestibular schwannomas rarely produce symptoms before
age 10 [47, 54]. At 10 years of age, presymptomatic genetic testing and genetic
counseling are recommended to identify individuals at increased risk of early and
severe complications, in addition to cranial and spinal MRI to identify tumors.
Earlier neuroimaging studies should be considered for children with any symp-
toms or signs of potential complications or those from families with known se-
vere genotypes. Thereafter, scans should be arranged at intervals of 2 to 3 years, or
earlier if new symptoms or signs occur. Once tumors are identified, surveillance
for progressive growth should be carried out every 6 to 12months, depending on
tumor size and growth rate. Three-dimensional volumetric analysis is now
established as themost sensitivemeans of documenting vestibular schwannoma
growth [55].
Surgical and medical treatment options available for tumors associated
with NF2 are summarized below, but disease progression is common de-
spite current approaches.
Genetic testing for NF2
Genetic testing is available for NF2, which, like NF1, is inherited in an autoso-
mal dominant fashion with sporadic mutations occurring in about 50% of
patients. There is a closer relationship between the genotype and phenotype in
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NF2 than in NF1. Nonsense and frame-shift mutations resulting in a truncated
protein product are associated with more severe disease than missense muta-
tions or large deletion [48•]. Genetic testing has an important role in the context
of prenatal testing and pre-implantation genetic diagnosis. Knowledge of the
patient’s genotype and broader genetic background may become more impor-
tant in understanding individual responses tonovelmolecularly targeted agents.
Treatment: Neurofibromatosis type 2
& Surgery and supportive therapy for hearing and vision loss are currently
the mainstays of therapy for NF2-associated tumors. Novel medical
therapies with demonstrated efficacy will be available in the future,
following controlled trials of molecularly targeted medication options.
Table 2. Current surveillance and treatment of the major medical complications associated with neurofi-
bromatosis type 2
Complications Surveillance Treatment
Vestibular schwannoma Annual general clinical evaluation from
time of diagnosis
–
Annual audiology evaluation from 10 years
of age or earlier if symptomatic
Cranial MRI study at 10 years, or earlier if
symptomatic, then every 2 years from 10
to 20 years of age and every 3 years after
age 20 for unaffected individuals
Known vestibular schwannoma: Audiology
examination and cranial MRI every
6–12 months
Surgery for progressive brain stem
compression; consider angiogenesis
inhibitors for progressive hearing loss,
other medication in clinical trial,
radiosurgery (controversial)
Meningioma Annual general clinical evaluation from
time of diagnosis
–
Cranial and spinal MRI at 10 years, or earlier
if symptomatic, with follow-up studies
every 2 years until age 20, then yearly
Known meningioma: Examination and cranial
MRI every 6–12 months
Surgery for accessible tumors.
Antiepileptic medication. Candidate
for medication in clinical trial
Spinal tumors Annual general clinical evaluation from time
of diagnosis; spinal MRI at 10 years or
earlier if symptomatic
–
Known spinal tumors: Examination and
spinal MRI every 6–12 months
Surgery for symptomatic tumors (if operable);
candidate for medication in clinical trial
Ophthalmologic effects Annual ophthalmology evaluation Specialist ophthalmologic intervention
(Adapted from Evans et al. [54].)
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Surgery
& Surgery for vestibular schwannomas is typically reserved for large
tumors associated with complete hearing loss and brainstem com-
pression because of the surgical risk of complete hearing loss and
facial nerve palsy. However, some surgeons advocate for early inter-
vention when tumors are less than 1.5 cm in diameter [56, Class IV].
& Surgery is the primary treatment for meningiomas, but they can re-
cur, and some tumors (such as skull base tumors) are not amenable
to resection.
Radiotherapy/radiosurgery
& Radiation may be considered for vestibular tumors less than 3 cm to
avoid the risks associated with surgery, but it is typically avoided
in NF2 because of the increased risks associated with treatment,
including secondary tumor formation and malignant transformation
in the NF2 population [48•, 57].
& Nevertheless a recent case series has described increased overall sur-
vival and progression-free survival, compared with non-NF2 patients,
following radiation treatment (mostly stereotactic radiosurgery) in
18 NF2 patients (median age 25 years) with progressive vestibular
schwannoma (16%), ependymoma (6%), low-grade glioma (11%),
meningioma (60%), and schwannoma/neurofibroma. This included
local control of 94% of vestibular tumors, with hearing preservation
for 50% [58, Class IV].
Pharmacologic treatment
& Agents that have shown some promise for treatment of vestibular
schwannomas include the EGFR (ErbB1) inhibitor erlotinib and a
monoclonal antibody against VEGF, bevacizumab,with improvement in
hearing and tumor shrinkage in a proportion of cases [59, 60, Class IV].
& No treatment trials dedicated to the assessment of responses of
NF2 patients with meningiomas have yet been undertaken, but a
limited number of NF2 patients have been included with sporadic
patients. Disease stabilization may be achieved with hydroxyurea,
interferon, or somatostatin analogues in some cases [61, Class IV]. A
recent phase II study of imatinib (targeting PDGFR, platelet-derived
growth factor receptor) in 22 adults with recurrent meningioma,
including one patient with NF2, showed minimal activity; ongoing
studies are evaluating imatinib in combinationwith erlotinib, an EGFR
inhibitor [62, Class III].
Assistive devices
& Hearing aids offer benefit for patients with some residual hearing,
and brainstem and cochlear implants have been used with success in
some patients [63]. These have a more important role for adult
patients than for children.
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Emerging therapies
& A consensus statement recently identified vestibular schwanno-
mas and meningiomas as the key focus for development of novel
medical therapy in NF2 and summarized potential candidates
[64••]. Response criteria for vestibular schwannoma trials have
been proposed in order to standardize monitoring and response
evaluations using different agents [65]. Phase 0 and phase II
trials with lapatinib (EGFR/ErbB2 inhibitor) are under way
[45••]. Questions remain regarding optimal agents and indica-
tions for treatment, duration of therapy, and alternative options
in the event of treatment failure.
& To date, data regarding the pediatric age group are limited, and a
coordinated multicenter approach is needed to assess the effective-
ness of novel agents targeting the molecular pathophysiologic basis
of disease in children affected by NF1 or NF2.
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Plexiform neurofi bromas are congenital lesions 
associated with neurofi bromatosis type 1 (NF1). 
They grow at variable rates, particularly in childhood, 
and can result in substantial morbidity and early 
mortality.1,2 Tumours can be multiple and extensive, 
and cause diﬀ ering symptoms depending on their 
location, including pain and disfi gurement, functional 
impairment of vision, mobility, bladder and bowel 
function, and respiratory compromise. 
In The Lancet Oncology, Kent Robertson and colleagues3 
present the results of a phase 2 pilot study, which has 
shown a reduction in size of symptomatic plexiform 
neurofi bromas in patients with NF1 treated with the oral 
kinase inhibitor imatinib mesylate. These fi ndings are 
important because surgery and radiotherapy are of limited 
applicability, and few established medical treatments 
are available to slow the growth or induce regression of 
these tumours. Preclinical studies in a NF1 mouse model 
showed reduced tumour volume in response to imatinib 
and established the rationale for the current clinical trial 
in plexiform neurofi bromas.4 The mouse studies were 
supported by a case report of a 3-year-old child with NF1 
and a plexiform neurofi broma that caused critical airway 
compression; treatment with imatinib resulted in a 
reduction in tumour volume of more than 50%.4 
Robertson and colleagues3 report that six (26%) of 
23 evaluable patients aged between 3 and 52 years 
(median 11 years) had a 20% or greater reduction in 
at least one tumour after 6 months or more of oral 
treatment with imatinib mesylate. A maximum of 38% 
volume reduction was noted in one tumour. Although 
eight (12%) of 69 individual tumours exceeded the 20% 
volume reduction threshold constituting treatment 
response, only one patient continued on long-term 
treatment. A further 36 (52%) tumours remained stable 
(<20% increase or decrease in volume) and 25 (36%) 
progressed (≥20% increase in volume). 
These fi ndings highlight the substantial variability in 
tumour response to treatment. The authors could not 
identify factors clearly aﬀ ecting treatment response, 
taking into account age, tumour location, or tumour 
size; however, larger tumours seemed to have a slightly 
reduced response. A previous study with the mTOR 
inhibitor sirolimus indicated that non-progressive 
plexiform neurofi bromas did not respond to treatment.5 
Consideration should be given to the selection of clearly 
progressive lesions for inclusion in follow-up studies, 
and in other prospective treatment trials to optimise 
treatment response. Demonstration of stable tumour 
volume in patients with progressive disease before 
treatment could also be consistent with treatment 
response, potentially with signifi cant clinical benefi t if 
sustained over time.
Robertson and colleagues are engaged in the search 
for potential biomarkers, and if such markers can be 
identifi ed, these could substantially alter the targeting 
and response rates in treatment of symptomatic 
patients. Few clinical trials for treatment of plexiform 
neurofi bromas in NF1 have been published,6–8 and 
this study makes an important contribution. Data are 
anticipated for studies with other candidate medications 
including mTOR inhibitors, pegylated interferon, MEK 
inhibitors, other kinase inhibitors, and VEGF inhibitors. 
Although change in tumour volume is an important 
endpoint, assessment of the clinical eﬀ ect of change 
in tumour size is crucial. The authors acknowledge 
limitations in this study with regard to assessments 
of the eﬀ ect of treatment on functional outcomes. 
Although 30% (seven of 23) of evaluable patients 
reported subjective symptomatic improvement, this 
change was not associated with reduced tumour bulk 
in all cases. The variable nature of individual morbidity 
and the wide age range of aﬀ ected patients pose a 
challenge for optimising the assessment of functional 
outcomes in future clinical trials. Nevertheless, the need 
for objective functional outcome measures together 
with the development of disease-specifi c mechanisms 
for assessment of quality of life in both adults and 
children has been recognised and is an active area of 
discussion among members of the NF Clinical Trials 
Consortium and international partners. 
The report by Robertson and colleagues identifi es the 
importance of medication tolerability to ensure sustained 
compliance, and suggests an adequate duration of 
treatment of 12 months during future clinical trials of 
these slow-growing tumours —an appropriate time 
frame. The fi nding of longer time to response in older 
patients is interesting and warrants further study. 
Adequate surveillance MRI and symptomatic 
monitoring should be undertaken for patients with NF1 
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and potentially complicated plexiform neurofi bromas. 
Large multicentre trials with refi nements in study 
design, which enrol patients with a well-documented 
history and neuroimaging surveillance from a young 
age, are needed to facilitate identifi cation of factors 
underlying variable treatment response to diﬀ erent 
candidate medications. Although imatinib mesylate 
seems to have a modest benefi t for some patients, 
eﬃ  cacy might be enhanced in combination with other 
agents. The continued cooperation between basic 
scientists and clinicians promises to improve outcomes 
over time for individuals with symptomatic plexiform 
neurofi bromas. 
Simone L Ardern-Holmes, Kathryn N North
TY Nelson Department of Neurology and Neurosurgery (SLA-H), 
and Institute for Neuroscience and Muscle Research, Children’s 
Hospital at Westmead (KNN), Sydney Medical School, University 
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Adjuvant bevacizumab in colon cancer: where did we go wrong?
The past decade has been an exciting time for research 
in colorectal oncology, with basic discoveries in cancer 
development and progression being translated into 
targeted therapeutics with tangible benefi ts for 
patients. However, it has also been a time of confusion, 
since compelling initial results have often been followed 
by disappointing or even adverse eﬀ ects in subsequent 
trials. This is especially true of the move to the adjuvant 
setting, where our therapeutic aim shifts from control 
of established metastases to the eradication of occult 
micrometastases. 
In the era of cytotoxic chemotherapy, the search 
for eﬀ ective adjuvant therapy followed a simple but 
generally reliable approach: the drugs and regimens 
most eﬀ ective against bulky, established metastases 
were then investigated in the adjuvant setting, where 
they were usually also more eﬀ ective in eradicating 
micrometastases and increasing the rate of cure. In 
bowel cancer therapy we progressed from observation 
to single-agent fl uorouracil, to leucovorin modulation, 
to oxaliplatin, and to capecitabine, and in each case the 
results in randomised adjuvant trials were consistent 
with predictions from preceding trials in patients with 
advanced disease. Only one cytotoxic drug, irinotecan, 
did not meet expectations in adjuvant trials;1 but even 
here the results, which fell just short of signifi cance, are 
not inconsistent with the general rule that activity in 
advanced disease correlates with adjuvant benefi t.
But if the eﬀ ect of non-specifi c cytotoxic agents 
might be broadly generalisable between the biologically 
very diﬀ erent targets of macrometastases and 
micrometastases, the same is not true for targeted 
therapies. The two leading targeted approaches in 
colorectal cancer—therapeutic antibodies against VEGF 
and EGFR—have both now failed unequivocally to 
translate to the adjuvant setting. Moreover, we are now 
faced with the startling fi nding that they have actually, 
in some trials, worsened patient outcomes. 
The AVANT trial 2 was launched in December, 2004, 
soon after publication of phase 3 data showing 
substantial survival benefi t with bevacizumab in 
metastatic colorectal cancer.3 In AVANT, a standard 
fl uorouracil–oxaliplatin regimen was compared with the 
same regimen plus bevacizumab during chemotherapy 
and continued for 1 year. This is an elegant comparison, 
involving 1915 patients, and therefore well-powered 
to show benefi t. The trial also had a third arm, 
capecitabine–oxaliplatin plus bevacizumab, which 
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Recommendations for imaging tumor
response in neurofibromatosis clinical trials
ABSTRACT
Objective: Neurofibromatosis (NF)-related benign tumors such as plexiform neurofibromas (PN) and
vestibular schwannomas (VS) can cause substantial morbidity. Clinical trials directed at these tumors
have become available. Due to differences in disease manifestations and the natural history of NF-
related tumors, response criteria used for solid cancers (1-dimensional/RECIST [Response Evaluation
Criteria in Solid Tumors] and bidimensional/World Health Organization) have limited applicability. No
standardized response criteria for benign NF tumors exist. The goal of the Tumor Measurement Work-
ing Group of the REiNS (Response Evaluation in Neurofibromatosis and Schwannomatosis) committee
is to propose consensus guidelines for the evaluation of imaging response in clinical trials for NF tumors.
Methods: Currently used imaging endpoints, designs of NF clinical trials, and knowledge of the
natural history of NF-related tumors, in particular PN and VS, were reviewed. Consensus recom-
mendations for response evaluation for future studies were developed based on this review and
the expertise of group members.
Results: MRI with volumetric analysis is recommended to sensitively and reproducibly evaluate
changes in tumor size in clinical trials. Volumetric analysis requires adherence to specific imaging
recommendations. A 20% volume change was chosen to indicate a decrease or increase in tumor
size. Use of these criteria in future trials will enablemeaningful comparison of results across studies.
Conclusions: The proposed imaging response evaluation guidelines, along with validated clinical
outcome measures, will maximize the ability to identify potentially active agents for patients with
NF and benign tumors. Neurology® 2013;81 (Suppl 1):S33–S40
GLOSSARY
CR 5 complete response; NF 5 neurofibromatosis; PD 5 progressive disease; PN 5 plexiform neurofibroma; PR 5 partial
response; RECIST 5 Response Evaluation Critera in Solid Tumors; REiNS 5 Response Evaluation in Neurofibromatosis and
Schwannomatosis; SD 5 stable disease; STIR 5 short TI inversion recovery; TTP 5 time to progression; VS 5 vestibular
schwannoma; WHO 5 World Health Organization.
Standard criteria for response evaluation in clinical trials for solid tumors are well established
(World Health Organization [WHO] criteria, Response Evaluation Criteria in Solid Tumors
[RECIST]).1,2 Linear measurements are performed for their ease of use and are suitable for
most malignant lesions that rapidly change in size. Disease-specific recommendations have been
developed for some diseases in which linear measurements are not practical or meaningful, such
as the Response Assessment in Neuro-Oncology (RANO) criteria for brain tumors.3,4 In addi-
tion, an international effort is under way to develop measurement guidelines for pediatric brain
tumors, which will be applicable to neurofibromatosis type 1 (NF1)-related gliomas.
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The neurofibromatoses (NF), consisting of
NF1, neurofibromatosis type 2 (NF2), and
schwannomatosis, are genetic tumor predispo-
sition syndromes characterized by the develop-
ment of predominantly benign nerve sheath
tumors. Plexiform neurofibromas (PN) in
NF1, vestibular schwannomas (VS) and
meningiomas in NF2, and schwannomas in
NF2 and schwannomatosis are the most fre-
quent histologically benign tumors for which
clinical trials with targeted agents have been ini-
tiated. Due to the limited applicability of
response criteria for solid tumors and the lack
of standardized response criteria for NF tu-
mors, previous trials have used a variety of pri-
mary and secondary endpoints, which limits
comparison of results between trials.
The Response Evaluation in Neurofibroma-
tosis and Schwannomatosis (REiNS) Tumor
Measurement Group was formed to develop
standardized consensus recommendations for
imaging response evaluation in clinical trials
for benign NF tumors. This includes guidelines
for image acquisition, target lesion selection,
image interpretation by volumetric analysis,
and trial design. We hope that the application
of these criteria in future clinical trials will
promote effective evaluation of the activity of
novel agents and facilitate the comparison of re-
sults across trials.
METHODS The Tumor Measurement Group is composed of
members from different disciplines, including neurology, oncology,
radiology, and genetics. The group reviewed currently used imaging
endpoints, designs of NF clinical trials, and the knowledge of the
natural history of NF-related tumors, in particular PN and VS.
Consensus guidelines for future studies were developed based on
this review and the expertise of group members. NF-related tumors
are rare and there was an emphasis on proposing criteria that could
be applied across multiple participating sites. When feasible, the
RECIST guidelines were used as a template.
RESULTS Current response evaluation of benign NF
tumors in clinical trials. PN involve multiple nerve fas-
cicles and branches5 and can cause substantial morbid-
ity, including pain, disfigurement, motor dysfunction,
airway compromise, and vision loss.6,7 In early clinical
trials PN size was measured by RECIST or WHO cri-
teria.8,9 Due to the complex shape, large size, and slow
growth of PN, linear measurements can be highly var-
iable and long time periods are required to detect mea-
surable change (figure 1). Therefore, more sensitive
methods, such as volume segmentation, were developed
for the analysis of PN and schwannomas.10–15 These
methods documented the feasibility of reproducibly
measuring tumor volumes in natural history studies
and treatment trials for PN and VS.13,14,16–19 Using
the MEDx-based lesion detection method developed
for PN, interobserver differences were less than 10%
and intraobserver variation was #5%.10 For VS mea-
sured using the Vitrea2 workstation, the coefficient of
variation ranged from 0.6% to 6.8%.11
The first PN clinical trial using volumetric MRI anal-
ysis with time to progression (TTP) as the primary trial
endpoint included the comparison of 1-dimensional
(RECIST), 2-dimensional (WHO), and volumetric
MRI analysis of PN.20 Volumetric analysis detected
tumor progression (PN volume increase $20%) much
earlier than linear measurements. The median TTP
with volumetric analysis was 14.3 months, compared
to 52.2 months using WHO criteria; the median TTP
could not be determined by RECIST criteria.20 Thus,
volumetric analysis significantly shortened both drug
exposure for study subjects and the duration of the trial.
In addition, this study provided valuable natural history
data on PN growth. Volume increase over time appeared
to be linear for all patients, with younger patients expe-
riencing more rapid growth. The inverse relationship
between age and PN growth rate has been confirmed
in other studies.21–23 Spontaneous PN shrinkage was not
observed in the placebo arm of the study and has only
infrequently been observed in other studies.22
NF2 is characterized by the development of bilateral
VS, other intracranial and spinal schwannomas,
Figure 1 Comparison ofmeasurement sensitivity to detect change in tumor size
Axial short TI inversion recovery MRI images show a large paraspinal, abdominal, and pelvic
plexiform neurofibroma at 3 time points (top to bottom: baseline, 12 months, 27 months)
measured by 3 methods (left to right: 1D/RECIST, 2D/WHO, 3D/volumetric criteria). Pro-
gressive disease was detected after 27 months by RECIST criteria, after 12 months by
WHO criteria, and after 6 months by the proposed volumetric criteria (20% volume increase,
not shown). At the time of 2D progression, the volume increase was 57%, and by the time of
1D progression, the volume had more than doubled. RECIST5 Response Evaluation Criteria
in Solid Tumors; WHO 5 World Health Organization.
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meningiomas, and ependymomas.24–26 In large NF2-
associated VS natural history studies, the average growth
in greatest diameter per year was reported to be between
1.3 and 1.8mm, corresponding to a 10%–14% increase
from the baseline averages of 12.4 and 13.0 mm.27,28
Another study evaluated the feasibility of volumetric
assessment of VS and demonstrated increased sensitivity
in detecting disease progression and reduced intrarater
measurement variability compared to linear measure-
ments.11 Finally, one study described the pattern of vol-
ume increase of VS and meningiomas as saltatory for
the majority of tumors and linear or exponential for
others.29 Volumetric analysis of MRIs has been recom-
mended to determine changes in tumor size30 and has
been incorporated into clinical trials targeting NF2-
related VS.17,18,31
Guidelines for response evaluation of benign NF tumors
in clinical trials. Image acquisition and analysis. The
working group recommends MRI and volumetric
analysis to measure benign NF-related tumors and
to assess response in clinical trials. Excellent tissue
definition can be achieved with appropriate MRI
techniques. Clinical trials require sequential imag-
ing with fairly short intervals. Subjects with benign
tumors remain in studies for much longer time pe-
riods than those with malignant solid tumors and
have a longer life expectancy.6 It is therefore pref-
erable to avoid CT imaging, as serial imaging results
in considerable radiation exposure and the tech-
nique has not been validated for volumetric analysis
of NF tumors.
Volumetric MRI analysis accounts for every part of
the tumor and thus reflects the actual size of the lesion
more closely than linear measurements. It is less sensitive
to differences in body position between scans and can
reproducibly detect small changes over time (figure 2).
Since every tumor-containing slice is included in the
analysis, volumetric analysis requires excellent image
quality. In order to achieve consistent high-quality
Figure 2 Examples of PN volume change over time
Small incremental changes are demonstrated in a complex large abdominal and flank plexiform neurofibroma (PN) with con-
sistent upward trend through several investigational treatments (A). Extended disease stabilization of a back PN in a patient
receiving peginterferon alfa-2b (B). PN growth accelerated upon discontinuation of treatment and slowed again when the
patient restarted peginterferon alfa-2b. While in most cases PN growth is linear over extended periods, some measurement
variation is not uncommon, as demonstrated by the example of a large neck and chest PN (C). The first observer performed
the volumetric analysis prospectively and a second observer repeated the analysis at the end of the observation period
while blinded to the chronological order of the scans.
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image acquisition and to minimize the variability of
volumetric readings, a detailed section on image acqui-
sition should be included in study protocols.
The MRI acquisition protocol should be opti-
mized for tumor type and tumor location. Images
intended for volumetric analysis need to be per-
formed without gaps between slices. The target tumor
should be positioned close to the center of the imag-
ing field and the outer edge of the tumor should be
within the field of view. Peripheral nerve sheath
tumors can be well visualized without the use of con-
trast agents on short TI inversion recovery (STIR)
sequences because they have high signal intensity
relative to normal tissues. Small lesions, such as some
orbital, facial, or paraspinal tumors, require imaging
with thin slices using small voxel sizes. Obtaining
complete coverage of extensive lesions can be chal-
lenging. MRI scanners capable of reconstructing
imaging series from several body segments into
whole-body images are now available and whole-body
scanning is increasingly affordable. Using multiple
phased-array coil technology, whole-body STIR
imaging can be accomplished in less than an hour.
Tumor volume can also be calculated from indepen-
dent series. For best alignment of separate series, 2 to
5 slices of complete overlap between the series is
advised. Image orientation should remain the same
throughout the study. Even slight changes in orienta-
tion can result in partial overlap between series. STIR
sequences can be performed on 1.5T or 3TMRI scan-
ners, although magnetic field inhomogeneity resulting
in signal intensity variation is more common using 3T
magnets when imaging with large fields of view.
The challenge in imaging VS is their relatively
small size. High-resolution postcontrast T1 com-
pletely covering the target area is the MRI sequence
best suited for volumetric measurement. The slice
thickness should be no more than 1 mm. Fat suppres-
sion is required in postsurgical VS cases to differenti-
ate tumor from fat packing.
Table e-1 on the Neurology® Web site at www.
neurology.org provides examples of recommended
imaging parameters for PN and VS. The parameters
may vary depending on the type of scanner, tumor
type, and location, but consistent use at each response
evaluation and across multiple sites is required for
optimal analysis. In multicenter studies, it is
important for quality assurance to document each
site’s ability to comply with the imaging protocol
prior to starting enrollment. One way to achieve
identical image acquisition across participating sites is
to distribute an optimized sample Digital Imaging and
Communications in Medicine dataset and duplicate the
imaging parameters from that dataset at each site. We
plan to provide access to sample images on the REiNS
Web site www.reinscollaboration.org.
Target lesions: Identification, considerations and chal-
lenges. Patients with NF often present with more than
one symptomatic tumor. Ideally the entire tumor bur-
den should be imaged at study entry. In most cases, the
most clinically significant lesion can be identified and
used as the target lesion to evaluate treatment response,
and other disease sites can be monitored as nontarget
lesions. The target lesion should meet minimum size
criteria, be seen on at least 3 imaging slices, and have
reasonably well-defined contours in all dimensions.
Recommended minimum tumor sizes for measurable
disease are 3 cm3 for PN and 1 cm3 for VS. Most
lesions$3.0 cm in longest diameter will have a volume
greater than 3 cm3, and lesions$1.5 cm a volume over
1 cm.3 Central review can help in assessing the mea-
surability of questionable lesions. The target lesion
should be distinguishable from the surrounding tissues.
Some tumors, while clinically very relevant, may not
have good tissue definition on MRI (figure 3, A and
B). In case of disease progression, adjacent tumors can
become confluent and no longer independently mea-
surable (for example, collision tumors in NF2 VS). In
addition, adjacent lymph nodes can be difficult to sep-
arate from PN and are prone to size fluctuations,
enough to give the impression of significant volume
change if the target lesion is small.
Lesions previously treated with locoregional therapy
such as radiation should not be selected as target lesions
unless growth has been documented since the interven-
tion. Similarly, following partial tumor resection, post-
surgical changes and edema may interfere with
meaningful response evaluation (figure 3, C and D).
Motion can blur the edge of lesions; regions espe-
cially prone to motion include the parapharyngeal
space, diaphragm, mesenteric structures, and extremi-
ties. Motion artifact is most relevant for small tumors
with high surface to volume ratios; at tumor sizes above
100 cm3 the effect of motion is usually negligible.
Metal instrumentation, such as spinal rods, dental
braces, or cochlear/brainstem implants, causes charac-
teristic distortion on MRI that is dependent on the
magnetic field strength and positioning within the
scanner, and can therefore vary between scans (figure
3, E and F). If part of the target tumor is obscured or
distorted by metallic artifact, the tumor may still be
measurable as long as that part of the lesion can con-
sistently be excluded from the analysis. The potential
need for future surgery or metal implants should be
considered prior to enrollment in a trial.
For very large tumors, partial volume measure-
ment between reproducibly visualized anatomical
landmarks can be considered, but should aim to
include the bulk of the lesion.
Some PN have nodular components that appear
encapsulated and separated from the surrounding
tumor in all directions (figure 4). These nodules can
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be independently measured and may serve as target
lesions. The growth rate of nodular lesions may
exceed the growth rate of the surrounding tumor.32
If the nodular component is selected as the target
lesion, changes in that nodule as opposed to the entire
PN should be used to determine response. Highly
disproportionate growth within parts of a tumor or
rapid growth exceeding that expected for PN should
raise concern for malignant transformation and
prompt further investigation.
Image interpretation by volumetric analysis. Several
methods are available for volumetric evaluation of
medical images. Simple systems use a graphic tool
to manually outline the target area. More sophisti-
cated segmentation methods use complex algorithms
to define a region of interest that displays specific
imaging characteristics; some of these methods were
specifically developed for NF-related tumors.10–13,15
Volumetric results can differ based on the method
of analysis; therefore, the same method should be
used throughout a study and across all participating
institutions, ideally with central review. The analysis
method should be validated to determine variation
within the same dataset as a reflection of precision,
and variation in trends over time as an indicator of
accuracy in segmenting the same structures at differ-
ent time points.
Response criteria. Response categories are established
to differentiate tumors that are shrinking, stable, or
growing. These categories are arbitrary and were de-
signed to minimize interrater variability. Significant
changes in tumor size, as defined by RECIST or
WHO criteria, can be easily recognized. Targeted agents
in NF may not result in substantial tumor shrinkage,
but rather lead to disease stabilization or minor shrink-
age. The goal of volumetric MRI analysis for response
evaluation in NF is to reproducibly detect small changes
that would not be otherwise discernible. Based on the
close intraobserver and interobserver agreement of
repeated volumetric MRI analyses,10,11 the group agreed
on a 20% volume change to indicate a decrease or
increase in tumor size. Therefore, the recommended
volumetric response categories for benign NF tumors
are defined as follows:
• Complete response (CR): Disappearance of the
target lesion.
• Partial response (PR): Decrease in the volume of
the target lesion by 20% or more compared to
the baseline. The PR is considered unconfirmed
at the first detection, confirmed when observed
again within 3–6 months, and sustained when
the response is maintained for 6 months or
longer.
• Progressive disease (PD): Increase in the volume
of the target lesion by 20% or more compared to
baseline or the time of best response after doc-
umenting a PR. The appearance of new lesions
or unequivocal progression of existing nontarget
lesions is also considered PD.
• Stable disease (SD): Insufficient volume change
to qualify for either PR or PD.
Table 1 illustrates equivalent size changes in spher-
ical lesions using different measurement methods.
Considerations for trial design and selection of endpoints
using volumetric response evaluation. Many of the molec-
ularly targeted agents evaluated for the treatment of
NF-related tumors are thought to be more likely to
extend the TTP than to result in tumor shrinkage.
Progression-free survival as a study endpoint requires
a control population. There is no established histori-
cal control for all NF populations. Data from one pla-
cebo-controlled pediatric trial for PN are available
and are currently used as a historical control for
Figure 3 Considerations for the selection of target lesions for volumetric
assessment
Volumetric analysis is only feasible on lesions with well-defined borders. The superficial flank
plexiform neurofibroma (PN) shown on axial (A) and coronal (B) short TI inversion recovery
MRI lacks tissue contrast (arrowheads) and it is not suitable for volume measurement.
Edema within a tumor or surrounding tissue affects the lesion volume (C, D). Image C shows
a facial PN 2 months after debulking surgery. The tumor volume gradually decreased over
the next 10 months until the complete resolution of postsurgical changes (D). Metal in the
imaging field results in image distortion on MRI (arrows), and the position of metal artifact
may vary between scans (E, F).
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several other studies.33,34 This control population is
only valid for trials with identical eligibility criteria
and study design, as TTP is influenced by age, tumor
growth rate, tumor size, and restaging intervals.20
Due to the slowly progressive nature of most
NF-related tumors, prolonged stable disease without
any intervention is common. Therefore, disease stability
can only be considered a response in subjects with docu-
mented imaging progression of a tumor for which linear
growth is expected. Ideally, progression at the time of
enrollment should be documented using the same
method of analysis that will be used in the clinical trial.
The need for an adequate control population and
the requirement of progressive disease at the time of
enrollment in a trial with TTP as the primary endpoint
may affect the rate of accrual, as progression may be
documented in only a subset of candidates and com-
peting trials without a control group may be selected
by investigators or potential research participants.
The objective response rate is defined as the pro-
portion of subjects experiencing a PR or CR in a
study. A correlation between response on imaging
and overall survival or clinical improvement has not
been established for most benign NF tumors. If feasi-
ble, in addition to imaging response, evaluation for
clinical benefit should be incorporated into clinical
trials as endpoints, including patient-reported and
functional outcomes. Since spontaneous regression
of NF tumors is rare, imaging response can be evalu-
ated without placebo control and in patients without
a prior history of progression.
Clinical studies for NF take longer than typical can-
cer trials. Even with the use of sensitive detection
methods, tumor progression and response may occur
slowly, over years rather than months. Compared with
cancer trials, longer restaging intervals are sufficient,
such as every 3–4 months for the first year on trial
and subsequently every 6 months. Allowing subjects
with minimal tumor shrinkage at 6 months (10–15%
decrease) to remain on treatment for up to 12 months
can maximize the identification of potentially active
agents while minimizing exposure to inactive agents.
The natural history of NF-related tumors should
also be considered in the design of trials. Several stud-
ies have described more rapid growth rates of PN in
younger children compared to older children or
adults.21–23 Therefore, stratification based on age or
progression status could be considered for clinical
trials evaluating TTP as the primary endpoint.
FUTURE PLANS The consensus guidelines provided
here are based on current knowledge and experience.
With new information, revisions may be implemented.
At this time, our understanding of the natural history of
NF1, NF2, and schwannomatosis is incomplete. Prior
studies describing the growth pattern of NF-related tu-
mors are limited to relatively short observation periods
of 1–4 years. Long-term prospective natural history
studies are needed in order to better characterize tumor
growth in all age groups and tumor types. Additional
efforts are under way to study the correlation of changes
in tumor size with changes in patient-reported and
functional outcomes. Where a correlation between
increasing tumor size and the development of morbid-
ity can be established, it can be assumed that agents
resulting in prolonged disease stabilization may result in
patient benefit by preventing the development of new
morbidity. Volumetric assessment methods currently in
use for NF may differ in their sensitivity to detect
change over time. As part of the REiNS Collaboration,
the Tumor Measurement Working Group is planning
pilot studies to evaluate the level of agreement between
methods. Finally, volumetric MRI analysis is time and
resource intensive and requires central review for the
most consistent results. The development of methods
that can be performed more easily and be incorporated
into routine clinical practice should be pursued.
Figure 4 Progression in target and nontarget lesions
The diffuse face and neck plexiform neurofibroma shown on axial short TI inversion recovery
MRI has a well-circumscribed nodular component on the left side. The complete volume of the
lesion increased from 1,870mL at the first time point (A) to 2,015mL (8% increase) at the sec-
ond time point (B) to 2,283 mL (22% increase) on the final evaluation (C). Concurrently, the vol-
ume of the nodular component increased from 28.2 mL to 34.3 mL (22% increase) and then to
63.0 mL (84% increase). Determination of disease progression depends on whether the entire
lesion or the nodular component is selected as the target lesion at trial entry.
Table 1 Equivalent changes in the size of
spherical lesions by 1-dimensional,
2-dimensional, or 3-dimensional
measurement
RECIST 1D (2r) WHO 2D (pr2) Volume 3D (4/3 pr3)
230% PRa 250% PRa 266%
27% 214% 220% PRa
6% 13% 20% PDa
12% 25% PDa 40%
20% PDa 44% 73%
Abbreviations: RECIST 5 Response Evaluation Criteria in
Solid Tumors; WHO 5 World Health Organization.
aChange required for partial response (PR) or progressive
disease (PD) as defined by RECIST, WHO, or volumetric
criteria.
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ABSTRACT
Objective: The goal of the Response Evaluation in Neurofibromatosis and Schwannomatosis
Visual Outcomes Committee is to define the best functional outcome measures for future neuro-
fibromatosis type 1 (NF1)-associated optic pathway glioma (OPG) clinical trials.
Methods: The committee considered the components of vision, other ophthalmologic parameters
affected by OPG, potential biomarkers of visual function, and quality of life measures to arrive at
consensus-based, evidence-driven recommendations for objective and measurable functional
endpoints for OPG trials.
Results: Visual acuity (VA) assessments using consistent quantitative testing methods are recom-
mended as the main functional outcome measure for NF1-OPG clinical trials. Teller acuity cards
are recommended for use as the primary VA endpoint, and HOTV as a secondary endpoint once
subjects are old enough to complete it. The optic disc should be assessed for pallor, as this
appears to be a contributory variable that may affect the interpretation of VA change over time.
Given the importance of capturing patient-reported outcomes in clinical trials, evaluating visual
quality of life using the Children’s Visual Function Questionnaire as a secondary endpoint is also
proposed.
Conclusions: The use of these key functional endpoints will be essential for evaluating the efficacy
of future OPG clinical trials. Neurology® 2013;81 (Suppl 1):S15–S24
GLOSSARY
CVFQ 5 Children’s Visual Function Questionnaire; logMAR 5 logarithm of the minimum angle of resolution; MS 5 multiple
sclerosis; NF1 5 neurofibromatosis type 1; OCT 5 optical coherence tomography; OPG 5 optic pathway glioma; PFS 5
progression-free survival; QOL 5 quality of life; REiNS 5 Response Evaluation in Neurofibromatosis and Schwannomatosis;
RNFL5 retinal nerve fiber layer; TAC5 Teller acuity cards; VA 5 visual acuity; VEP 5 visual evoked potential; VF5 visual field.
Optic pathway gliomas (OPG) arise in 15%–20% of children with neurofibromatosis type
1 (NF1), occur preferentially in young children compared with adolescents or adults, and cause
vision loss in as many as half of those affected.1 In this regard, the main objective in clinical
management of these tumors is preservation of visual function. Although prognostic factors have
been identified, there are currently no reliable indicators of future visual loss. This absence of
prognostic signs has led clinicians to avoid initiating treatment until visual function has declined.
When treatment is indicated, NF1-OPG are typically managed with a combination of carbo-
platin and vincristine—an approach that has not changed in 15 years.2
To date, OPG clinical trials have focused on imaging outcomes, with tumor response and/or
progression-free survival used as measures of treatment success.2–4 However, increasing evidence
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from case reports, case series, and larger studies
indicates that imaging outcomes do not corre-
late with visual outcomes following treat-
ment.5–7 In fact, in a large multi-institutional
retrospective review, only one-third of subjects
had concordant visual and imaging outcomes.8
Since the primary goal of treatment is preser-
vation of visual function, therapeutic success
should be based on visual rather than imaging
endpoints. In order to better understand treat-
ment outcomes for this tumor, future OPG
clinical trials will need to mandate functional
endpoints as primary outcome measures.
Response Evaluation in Neurofibromatosis
and Schwannomatosis (REiNS) is an interna-
tional collaborative initiative designed to
develop standardized criteria for determining
treatment response in patients with NF1,
NF2, and schwannomatosis. The overall
objective is to identify robust endpoints that
can be incorporated into future clinical trials
and used to most effectively define and compare
treatment efficacy. The goal of the REiNS
Visual Outcomes Committee is to define the
best functional outcome measures for future
clinical trials of NF1-OPG. The committee
considered the major psychophysical compo-
nents of vision (acuity, fields, and color vision),
other ophthalmologic elements affected by
OPG (optic disc appearance, strabismus,
nystagmus, and proptosis), potential biomarkers
of visual function (visual evoked potential and
optical coherence tomography), and quality
of life measures to arrive at consensus-based,
evidence-driven recommendations for func-
tional endpoints for OPG trials (table 1).
THE BEST FUNCTIONAL ENDPOINT Visual acuity.
Visual acuity (VA) reflects visual pathway integrity,
making it an ideal candidate to objectively measure
the visual impact of an OPG. It is likely the most
important functional ophthalmologic feature, as modest
amounts of VA loss can affect activities of daily living.9,10
There is good test-retest reliability, assessments can be
standardized, and the intervals of change (lines on an
eye chart) are universally understood and quantifiable.
Furthermore, ophthalmologists and ophthalmology
technicians universally understand how to perform
acuity testing.
VA testing has been used reliably and is sensitive
to change in clinical trials for other visual diseases
(e.g., amblyopia, diabetic retinopathy).11,12 To date,
VA is the only visual outcome measure that has been
assessed to any major extent in OPG, as well as the
only measure that has been shown to be sensitive to
change with treatment. In a large retrospective study,
32% of subjects with NF1-OPG experienced an
improvement in VA following treatment with chemo-
therapy.8 In addition, a decline in VA is the most
common reason to initiate therapy for OPG, and
Table 1 Consensus recommendations for functional outcome measures in NF1 optic pathway glioma clinical trials
Measure Primary endpoint Secondary endpoint Comments
Recommended
Visual acuity Recommended Report in logMAR; account for age-specific acuity norms
Teller acuity Recommended — All ages
HOTV — Recommended Older children (who are able to complete testing)
Visual QOL (CVFQ) — Recommended Validated only for children #8 years
Optic disc pallor — — Capture as a contributing variable
Not recommended
Visual fields — Not recommended More information needed
Color vision — Not recommended
Strabismus — Not recommended
Nystagmus — Not recommended
Optic disc swelling — Not recommended
Proptosis — Not recommended
Visual evoked potentials — Not recommended
Optical coherence tomography — Not recommended More information needed
Abbreviations: CVFQ5 Children’s Visual Function Questionnaire; logMAR5 logarithm of the minimum angle of resolution; NF1 5 neurofibromatosis type 1;
QOL 5 quality of life.
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other potential markers of functional decline, such as
visual field (VF) or color vision loss, typically occur
concurrently with acuity decline.8 As such, VA is the
best studied and most reliable functional measure of
vision for OPG and other visual diseases.
How should VA be tested? For the purpose of clinical
trials, it is crucial that the selection of testing method
is quantifiable so that the magnitude of change can be
accurately measured over time. Qualitative measures,
such as “fix and follow” will not always detect VA
changes.13 For example, a 2-year-old whose VA
changes from 20/40 to 20/100 will still fix and follow.
There are multiple testing methods available to assess
VA quantitatively. The choice of method depends on
a child’s age, developmental/cognitive level, and abil-
ity to cooperate. A detailed discussion of VA testing
methods and challenges is beyond the scope of this
report, but the topic has been previously reviewed.13
Quantitative testing methods (Teller acuity cards
[TAC]) exist for children as young as 6 months of
age and are reliable measures of VA. TAC (figure) is
a preferential looking test that relies on an infant’s
propensity to redirect his or her gaze toward a visually
interesting stimulus (alternating high-contrast black
and white lines). VA is quantified by knowing the
distance to the stimulus and the width of the smallest
lines the child is able to appreciate. Other methods
for testing the youngest age group include Cardiff
acuity cards, which use pictures of varying contrast;
however, these have not been studied as widely as
an outcome measure for clinical trials. In older chil-
dren, testing methods measure the ability to recognize
(“recognition acuity”) a figure (e.g., Lea symbols) or
letters (e.g., HOTV or Snellen) (figure). The complexity
of the test increases with age, such that a higher level
of cognition and cooperation is required to complete
HOTV compared with Lea, and Snellen testing com-
pared with HOTV. This makes testing in children with
NF1 particularly challenging, as a large proportion have
baseline deficits in attention and/or learning.
One of the challenges in monitoring VA over time
in children enrolled in a clinical trial is that the pre-
ferred clinical VA testing method may change as the
child gets older. Although there is reasonable correla-
tion of VA results between testing formats, they are
not identical.13 For example, when VA is near normal,
TAC may underestimate VA relative to recognition
acuity.14 In contrast, TAC may overestimate VA com-
pared with recognition acuity when VA is moderately
abnormal or worse.15 Hence, transitioning between
testing formats may confound the interpretation of
acuity changes over time. Therefore, we recommend
not switching testing formats for subjects during the
treatment and follow-up phases of the study. In addi-
tion, we would limit testing methods to TAC and
HOTV, as these are relatively easy to perform, stan-
dardized testing methods exist, and both methods have
been validated in clinical trials for other pediatric oph-
thalmologic diseases (e.g., retinopathy of prematurity,
amblyopia, cataracts).11,12,16 Of note, it is important to
use a standardized TAC and HOTV testing method at
all study sites.
To provide consistency from study enrollment
through study completion, we suggest the use of TAC
as the primary VA endpoint for all subjects regardless
of age, as this is the only visual testing method that all
subjects who are old enough for quantitative VA testing
can perform. Of note, in the retrospective study of
visual outcomes following chemotherapy, 37.5% of
subjects were unable to complete HOTV testing at
the start of treatment.8 In addition, in a study of
127 subjects 10 years and younger with OPG (NF1
and non-NF1), 30.7% could not complete HOTV test-
ing, and the number rose to 67.3% in children younger
than 5 years of age.17 Although the committee consid-
ered allowing HOTV as a primary outcome measure for
those capable of performing it at study entry, we re-
jected this for several reasons. First, in a retrospective
study8 a small percentage (3%) of children who were
able to perform HOTV at the start of therapy were
unable to perform it successfully at study end and
required Lea or TAC testing (data not published).
Second, although TAC and HOTV acuities are similar,
they are not identical, thus making comparisons
between subjects challenging.17 Last, the interval
between “lines” on the chart for TAC and HOTV
is not equivalent.
However, once a subject is old enough to perform
testing, we recommend adding HOTV testing as a
secondary endpoint. Although Teller acuity can be
Figure Visual acuity testing methods
(A) Teller acuity cards, (B) Lea, (C) HOTV, (D) Snellen.
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converted to a recognition acuity equivalent, the latter
is a more accurate reflection of how we understand
VA. Therefore, it is important to capture a recogni-
tion acuity measure that can place the Teller acuity
in context. In addition, these data will facilitate a bet-
ter evaluation of long-term changes in VA as a subject
enters adulthood. HOTV testing is preferred because
it can be started at a younger age and is more feasible
in children with NF1-related cognitive or behavioral
problems than other recognition acuity testing meth-
ods. Importantly, this recommendation does not pre-
clude testing using an alternate method (e.g., Snellen)
for clinical purposes.
How should VA be reported?Clinically, VA is typically
reported as a fraction (e.g., 20/20 in feet, 6/6 in meters),
and change in acuity is usually described by the differ-
ence in the number of lines on the eye chart between
testing sessions. Unfortunately, the difference between
lines can vary not only between testing methods but
also within the same method.13 Therefore, in order to
standardize the quantification of magnitude of change,
we recommend that VA be reported using the loga-
rithm of the minimum angle of resolution (logMAR).
For recognition acuity measures, this linear scale is cre-
ated by calculating the base 10 logarithm of 1/(VA
decimal notation [e.g., the decimal equivalent for
20/40 5 0.5]), a practice widely used in clinical oph-
thalmologic research. Intervals of change between lines
on logMAR charts are therefore of equal magnitude
(table 2). TAC can also be directly converted to log-
MAR (logMAR5213 log[spatial frequency/30]). It
is worth recognizing that classifying VA into categories
(e.g., good, fair, poor) is problematic as small nonfunc-
tional changes in VA can result in a change in VA
category. Reporting VA as a continuous measure will
allow for a more detailed evaluation of visual change
over time.
It is equally important to account for the normal
development of VA during early childhood. Normal
VA improves with age in young children, thereby
necessitating different age-based norms (e.g., 20/40
is normal at age 3 years, 20/20 is normal at age
6 years).13 Thus, we recommend calculating an age-
based VA by comparing all values to normal for age
VA (normal VA for age2 current VA) and reporting
the difference in logMAR from normal.
When reporting study results, we suggest report-
ing both per-subject and per-eye outcomes. The latter
is standard in the ophthalmology literature and is
important as vision may be affected in only one eye.
However, in a subject with a unilateral optic nerve gli-
oma, the unaffected eye should be excluded, as it will
bias the results. Per-subject reporting is also informa-
tive as illustrated by the following potential scenario:
the VA improves in one eye but worsens in the other
during therapy; this subject should be coded as a
treatment failure and come off study. In addition,
although reporting vision by the better or worse eye
may be useful when reporting long-term outcomes,
its relevance for assessing the effectiveness of a chemo-
therapeutic agent is unclear. Reporting intervals
should match those of radiologic reporting. For con-
sistency, we recommend reporting results at one or
more of the following times: end of therapy and 1-,
2-, 3-, and/or 5-year follow-up.
What constitutes visual progressive disease or response? At
present, there is no validated definition of clinically
significant VA change. Several previous OPG studies
have used a 2-line change (approximately 0.2 log-
MAR) from baseline, but this has not been validated.
However, given that the ophthalmologic literature
reveals a roughly 1-line variation between observers
and testing sessions,18,19 using a 2-line change is rea-
sonable. We recognize the potential risk of decreased
specificity by using such a narrow definition; how-
ever, we feel this is offset by increased sensitivity to
early decline in VA. We therefore recommend defin-
ing a significant VA change as a 0.2 or greater change
in logMAR. When visual response is detected, it
should be confirmed at a subsequent study visit to
be considered “durable.”
Table 2 Visual acuity equivalents in feet,
meters, and logMARa
logMAR
Lines on visual acuity chart
Feet Meters
20.1 20/16 6/5
0.0 20/20 6/6
0.1 20/25 6/7.5
0.2 20/32 6/10
0.3 20/40 6/12
0.4 20/50 6/15
0.5 20/63 6/20
0.6 20/80 6/24
0.7 20/100 6/30
0.8 20/125 6/38
0.9 20/160 6/48
1.0 20/200 6/60
1.1 20/250 6/75
1.2 20/320 6/96
1.3 20/400 6/120
1.4 20/500 6/150
1.5 20/640 6/192
1.6 20/800 6/240
Abbreviation: logMAR 5 logarithm of the minimum angle of
resolution.
a logMAR conversions from Snellen acuities.
S18 Neurology 81 (Suppl 1) November 19, 2013
How should ceiling and floor effects be handled? It is crit-
ical to consider ceiling and floor effects for VA when
establishing clinical trial enrollment criteria and ana-
lyzing study data. For example, eyes with normal VA
(20/20 5 0.0 logMAR or better) at baseline cannot
improve and should be eliminated from a study tar-
geting visual response. In contrast, blind eyes cannot
worsen and should be excluded from studies of visual
progression-free survival (PFS). Based on our defini-
tion of visual progression or response (60.2 logMAR
or greater change), we recommend a ceiling of 0.2
logMAR below normal for age or 0.2 logMAR below
a previous reliably documented VA. We set the floor
at 1.36 logMAR (20/470), which is the VA equiva-
lent of the lowest Teller acuity card from which a
0.2 logMAR decline can be measured with good reli-
ability (using a standard testing distance of 55 cm).
Based on these considerations, we recommend that
one eye must be evaluable (0.2 logMAR below nor-
mal for age or below a previous reliably documented
VA 2 1.36 logMAR) in order to enroll in a thera-
peutic OPG trial. When analyzing results, if the study
endpoint is best visual response, then eyes with VA at
the ceiling should be excluded. If the study endpoint
is visual PFS, then eyes with VA at the floor should be
excluded in the analysis.
How often should VA be monitored while on study? At
present, no evidence exists to recommend an ideal
monitoring interval to determine visual progression
or response in a clinical trial. Thus, we recommend
monitoring on the same schedule as imaging out-
comes, which is typically every 3 months while on
treatment. Following completion of treatment, we
recommend monitoring at 3, 6, 12, 18, 24, 30, 36,
48, and 60 months.
What if the examination is unreliable due to poor
cooperation or a change in VA is detected or suspected? If
the results of a VA evaluation are in doubt because
of poor effort or cooperation, testing should be
repeated in 1 to 2 weeks. If the result is still unre-
liable, then no data should be entered for that visit.
If the clinician is absolutely certain the VA change
is not related to effort/cooperation, then a repeat
examination is not required. In most instances, how-
ever, the exam will need to be repeated. If VA loss is
observed, it is crucial to exclude refractive error, ambly-
opia, or other non-OPG-related causes.
OTHER POSSIBLE FUNCTIONAL ENDPOINTS Visual
fields. VF deficits may occur in association with OPG;
therefore, recommendations for testing visual function
in children with NF1 have included VF testing during
selected ophthalmology evaluations.1,20 There is a range
of methods for VF testing, including simple confron-
tation (testing the ability to see fingers in all 4 quad-
rants) and computerized techniques (Goldmann or
Humphrey perimetry). Confrontation testing is not
as sensitive as perimetry but can be useful for detecting
large deficits (e.g., quadrantanopia or hemianopia).21
In contrast, the clinical significance of the smaller
changes noted with perimetry for patients with OPG
is unclear. Although all VF testing methods require the
patient to be alert and cooperative and to maintain
fixation reliably, the testing time for perimetry (5–7
minutes per eye) is longer than for other measures of
visual function (e.g., acuity). Given the high incidence
of learning difficulties and attention deficit disorder in
children with NF1, there are concerns about the reli-
ability of testing as well as the elevated false-positive
and false-negative rates in children younger than
10 years of age. In an audit of children with NF1
up to 7 years of age, none of the children was mature
enough to reliably complete VF testing.22
In the OPG literature, most studies do not report
VF, do so only in a small subset of subjects, or do not
provide within-subjects comparisons. In addition, de-
tails regarding VF testing method or consistency with
quantification are often lacking. Several studies reveal
that VF deficits are usually (89%–100%) associated
with concurrent VA deficits,8,23 VF change in the
absence of VA change is rarely a treatment indica-
tion,8 and VF outcome mostly mirrors VA outcome
following treatment.8
In summary, given the concerns about the reliabil-
ity of VF testing in this patient population, the lack of
adequate data from prior studies (especially compared
with VA), and the fact that VF deficits are usually
associated with concurrent VA deficits, the committee
does not endorse VF as a primary outcome measure for
OPG clinical trials. A more thorough evaluation of VF
in NF1-OPG is required before routine inclusion as a
secondary outcome measure can be recommended.
Color vision. Standard color vision testing (e.g., Ishihara)
requires cooperation and the ability to read numbers or
identify shapes; thus, most very young children with
NF1-OPG are unable to complete testing.22 Color
vision data are rarely collected,24 and changes in color
vision over time are rarely reported in OPG studies.
Testing color vision may be helpful in differentiating
the cause of VA loss. In this respect, color vision is
usually spared in amblyopia or refractive error, whereas
color vision loss typically accompanies the VA loss due
to OPG.1 Therefore, color vision loss is unlikely to
provide additional information about disease progres-
sion relative to VA. In summary, while color vision
testing may be a good adjunct measure in clinical trials,
further study is needed before it can be recommended
for routine inclusion.
Strabismus. Strabismus (ocular misalignment) is mea-
sured in prism diopters, but the variability in meas-
urements may be as much as 6 diopters, and it may
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be difficult to quantify reliably in uncooperative chil-
dren.25 Although eye deviation in OPG may be due
to optic nerve enlargement with downward displace-
ment of the globe, it is usually secondary to VA loss in
the affected eye (i.e., sensory strabismus).1 No correla-
tion has been reported between the amount of VA loss
and the occurrence or severity of strabismus. In addi-
tion, strabismus is rarely commented on or followed
longitudinally in large OPG series, and its incidence is
much lower than that of VA loss.8,26–28 Therefore, at
present strabismus is not recommended as an outcome
measure to follow OPGs.
Nystagmus. Nystagmus (rhythmic oscillation of the
eyes) can be a presenting sign of an OPG, typically
one located in the optic chiasm/hypothalamus. As
with strabismus, nystagmus in OPG is usually second-
ary to VA loss in the affected eye(s).1 Few studies report
on nystagmus, but in those that do the incidence is low
(2%–19%).8,27,28 It is difficult to quantify nystagmus
without sophisticated eye movement recordings, and
there does not appear to be a correlation between con-
tinued VA decline and the severity of the nystagmus.
Given these factors, the committee does not recom-
mend following nystagmus as an outcome measure
for OPG.
Optic disc swelling. Optic disc swelling is the visible
elevation of the optic disc with blurring of the disc
margin seen on fundus exam. Its incidence in OPG
varies widely (up to 21%) in the few studies that
report on optic disc swelling.8,26,28 It appears to be
more commonly associated with tumor involvement
of the optic nerve.28 Disc swelling from chiasmal
lesions more frequently reflects elevated intracranial
pressure from obstruction of CSF flow. Although disc
swelling may be associated with a change in the size of
the OPG on MRI scan, it is not always associated
with demonstrable VA loss. In addition, optic disc
swelling is not predictive of VA outcome, as it improves
in almost all subjects (91%) following chemotherapy.8
For these reasons, it is not recommended as an outcome
measure to follow OPGs.
Optic disc pallor.Optic disc pallor corresponds to atro-
phy of the optic nerve fibers and can reflect damage
anywhere along the optic pathway from the retina to
the lateral geniculate nucleus. It is easy to visualize
on fundus exam, is usually commented on in OPG
studies, and is present in almost half of OPG cases
(combined data of 18 studies). Unfortunately, it is
not clear whether disc pallor is associated with vision
loss, given that few studies have attempted to evaluate
this relationship, often with small sample sizes and
mixtures of NF1/sporadic OPG and treated/untreated
OPG. Optic disc pallor often occurs in patients with
OPG without a VA or VF deficit and may be absent
in those with vision loss. In addition, the development
of disc pallor can lag behind the appearance of a VA
deficit and vice versa. One study suggests that optic
disc pallor at the start of chemotherapy may be associ-
ated with worse VA outcomes; however, change in disc
pallor over time is not a useful marker, as it almost
never improves.8
In external compressive tumors of the optic chiasm
(e.g., pituitary adenoma or craniopharyngioma), disc
pallor correlates with the presence of decreased VA
but not the degree of vision loss.29–31 However, the
predictive value of pallor for VA recovery following
tumor decompression is variable, although it appears
that those with “mild” pallor may be more likely to
have some recovery of vision.32,33 This observation is
also supported by optical coherence tomography stud-
ies of the retinal nerve fiber layer in this population.34
The degree of disc pallor has also been suggested to be
an important factor in VA outcome for patients with
OPG5 and those with atrophy from any cause35; how-
ever, in these studies, the degree of pallor was deter-
mined subjectively (which is affected by the degree of
pigmentation of the fundus) or by using photographic
slides (in which the color of the optic disc depends on
the length of exposure).
In summary, monitoring changes in disc pallor over
time during a clinical trial does not appear useful, as it
rarely improves. Disc pallor is likely associated with VA
loss, but not universally. Although the degree of disc
pallor may be the more relevant feature, at present
there is no accepted scale to grade pallor or data indicat-
ing that it can be measured reliably, even using photo-
graphs. However, because of the correlation between
baseline disc pallor and VA outcomes in treated sub-
jects as well as the possible implication that pallor
may be an indicator of preexisting damage that heralds
subsequent vision loss,5,8 we recommend capturing disc
pallor (present or not) to define its role as a contributing
variable or correlative marker in future OPG trials.
Proptosis. There are scant objective data on measuring
proptosis in orbital tumors. Measurements can be
performed by exophthalmometry,36 and normative
measurements based on age have been reported in
children.37,38 Although there is interobserver reliability
of exophthalmometry in healthy adults with and with-
out Graves disease,39 there is no known large study
examining exophthalmometry in children with orbital
tumors. In contrast, proptosis has been measured suc-
cessfully and serially using MRI in children with optic
nerve gliomas40 and may be a more accurate method of
measuring the degree of proptosis; however, a recent
study demonstrated that improvement in proptosis did
not correlate with tumor shrinkage.41 Most impor-
tantly, it is unclear how to quantify the functional
impact of a change in proptosis. In addition, patients
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with proptosis comprise a minority of subjects enrolled
in OPG trials. Further study will be required before
considering the inclusion of routine proptosis measure-
ments in future therapeutic studies.
Visual evoked potentials. Visual evoked potentials
(VEPs) are an electrophysiologic test believed to pro-
vide a functional measure of visual pathway integrity.
Although VEP testing may detect OPG with some
sensitivity,42–46 some patients with NF1 have abnormal
VEP testing despite no evidence of glioma.47 Of greater
concern is the poor diagnostic sensitivity of VEP for
VA loss48 and the poor correlation of VEP changes over
time with VA changes and response to treatment.49,50
Several other issues limit the utility of VEP for OPG
clinical trials, including the challenge of testing young
children because of the level of cooperation required,
the lack of standardization of testing methods, the
absence of a validated definition of the amount of
change that defines “worsening” in longitudinal studies,
the lack of universal availability of the equipment, and
the variability in measures using different equipment.
Therefore, the committee does not recommend the
routine inclusion of VEP testing for OPG clinical trials.
Optical coherence tomography. The axons of the retinal
ganglion cells, termed the retinal nerve fiber layer
(RNFL), combine to form the pregeniculate portion
of the afferent visual pathway (i.e., optic nerve, chi-
asm, and tracts). RNFL thickness, a structural marker
of visual pathway integrity, can be measured using
optical coherence tomography (OCT). Thinning of
the RNFL correlates with VA and/or VF deficits in
patients with optic neuritis and multiple sclerosis
(MS).51,52 Studies also suggest that significant RNFL
thinning predicts persistence of visual deficits over
time for both MS and compressive tumors of the
optic chiasm.34,53 In addition, decreased RNFL thick-
ness correlated with visual loss (VA and/or VF) in a
cross-sectional study of children (6–21 years of age)
with OPG.54 This study is currently being replicated
in children with OPG younger than 6 years using
portable OCT equipment (necessary for evaluating
young children).55 Ultimately, longitudinal studies
will be required to determine whether a decrease in
RNFL thickness is predictive of future vision loss and
whether changes in RNFL thickness over time correlate
with changes in visual function. In addition, portable
OCT equipment is not yet widely available, RNFL
measurements vary between different OCT machines,
and the reliability of RNFL measures between centers
using the same equipment is unknown. Hence, routine
inclusion in clinical trials for OPG cannot be recom-
mended at this time.
Visual quality of life. Patient-reported outcomes, spe-
cifically those assessing quality of life (QOL), have
emerged as important measures for use in clinical
treatment trials. VA loss has been reported to affect
markedly an individual’s employment and overall
QOL.9,10 To evaluate the direct impact of vision loss
on particular QOL domains, vision-specific QOL
instruments have been developed for adults and were
found to correlate with the degree of visual impair-
ment.56–58 Visual ability and QOL measures that
assess the impact of vision loss in children have been
examined in a variety of pediatric eye diseases, with
most designed to evaluate children between 8 and
18 years of age.59–63 Using the review process developed
by the REiNS Patient-Reported Outcomes Subcom-
mittee (see Wolters et al., this supplement), we
reviewed the available pediatric questionnaires. Of
these, 2 examined visual ability rather than vision-
specific QOL.62,63 Two vision-specific QOL meas-
ures have been developed for children,59,60 although
the Children’s Visual FunctionQuestionnaire (CVFQ)59
is the only instrument designed to evaluate children
8 years of age and younger, the time during which
most patients with NF1-OPG become symptomatic.
To date, no studies have been published that evaluate
the impact of OPG-related vision loss on vision-
specific QOL in children. The inclusion of a vision-
specific QOL measure in NF1-OPG clinical trials is
complicated by a number of factors, including the
potential differential impact of VA vs VF loss, the
use of parent proxy reporting, the wide age range of
subjects enrolled, and the relevance of the vision loss
based on age. For example, moderate vision loss may
have only a modest impact on QOL for a 3-year-old,
whereas in an adolescent the same degree of vision loss
may result in the inability to drive a motor vehicle,
which might result in a more profound effect on
QOL. Additionally, it is unclear whether and how
the known developmental and behavioral complica-
tions of NF1 might influence the accuracy and rele-
vance of QOL measures. Therefore, the committee
does not recommend a vision-specific QOL measure
as a primary outcome at this time, although the CVFQ
could be considered as a secondary outcome measure
in children 8 years of age and younger. Ultimately,
development of a NF1-OPG-specific QOL measure
or adapting the CVFQ to include domains relevant
to all age groups may be helpful and is currently being
considered.
REiNS RECOMMENDATIONS VA should be the
main functional outcome measure in clinical trials
of children with NF1-OPG. The use of quantitative
testing methods is essential, and the testing format
should not be changed during the study. To that
end, we recommend the use of TAC as the primary
VA endpoint and HOTV as a secondary endpoint
once subjects are old enough. Results should be
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reported in logMAR, while taking into account the
acuity age-specific norms. The optic disc should be
assessed for pallor, as this appears to be a contributory
variable that may affect the interpretation of VA
change over time. Given the importance of capturing
patient-reported outcomes in clinical trials, the com-
mittee endorses collecting visual QOL using the
CVFQ as a secondary endpoint, as this is currently
the best available measure. Collectively, the imple-
mentation of these endpoints in future clinical trials
will facilitate the evaluation of potential promising
agents for the treatment of NF1-OPG.
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Neurofibromatosis Type 2: Presentation,
Major Complications, and Management,
With a Focus on the Pediatric Age Group
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Abstract
Neurofibromatosis type 2 (NF2) is a rare autosomal dominant disorder (incidence 1:33 000-40 000) characterized by formation of
central nervous system tumors, due to mutation in the NF2 gene on chromosome 22q12. Vestibular schwannomas are the
hallmark lesion, affecting 95% of individuals and typically occur bilaterally. Schwannomas commonly occur on other nerves
intracranially and in the spinal compartment, along with meningiomas, ependymomas, and gliomas. Although histologically benign,
tumors are associated with significant morbidity due to multiple problems including hearing and vision loss, gait abnormalities,
paralysis, pain, and seizures. Risk of early mortality from brainstem compression and other complications is significant. Severity of
disease is higher when NF2 presents during childhood. Children have a more variable presentation, which can be associated with
significant delays in recognition of the condition. Careful examination of the skin and eyes can identify important clinical signs of
NF2 during childhood, allowing timely initiation of disease-specific surveillance and treatment. Monitoring for complications
comprises clinical evaluation, along with functional testing including audiology and serial neuroimaging, which together inform
decisions regarding treatment. Evidence for disease-specific medical treatment options is increasing, nevertheless most patients
will benefit from multimodal treatment including surgery during their lifetime. Patient enrolment in international natural history
and treatment trials offers the best opportunity to accelerate our understanding of the complications and optimal treatment of
NF2, with a view to improving outcomes for all affected individuals.
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Neurofibromatosis type 2 (NF2) is an autosomal dominant
disorder caused by mutations to the NF2 tumor suppressor
gene, characterized by multiple nonmalignant nervous sys-
tem tumors, including schwannomas, meningiomas, ependy-
momas and gliomas, with bilateral vestibular schwannomas
being a classical feature. Ocular and cutaneous manifesta-
tions also occur. Incidence is estimated at 1 in 33 000-40 000
and prevalence 1 in 100 000.1 The condition is typically
diagnosed at age 20-30 years, but features are often present
for many years before the diagnosis is made in both sporadic
cases and in those with a family history.2-4 About 10% of
patients present before the age of 10 years, and 18% before
the age of 15 years, with a greater diversity of clinical
problems than seen in adults, and often with increased
severity.5 In this review we explore the presentation and
clinical course of NF2 with particular reference to children
and adolescents, and a view to improving outcomes for all
affected individuals.
Diagnostic Criteria
The diagnosis of NF2 based on clinical criteria has been refined
over time, reflecting the typical presentation of adults with
symptoms of vestibular schwannoma (Table 1).6-8 However,
these criteria are less helpful in children who frequently present
with other symptoms and signs of NF2, and for whom
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vestibular tumors may be too small to appreciate on initial
neuroimaging. Examination of the skin and eyes often yields
important diagnostic clues during childhood, and as such is of
fundamental importance in suspected cases. Parents of children
suspected of having NF2 should also be assessed carefully for
symptoms and signs of NF2.
Time to diagnosis is highly variable and is often prolonged
despite symptoms presenting in childhood. A recent report
cited time to diagnosis in subgroups of adults and children at
5 years and 8 years, respectively, with the delay ranging up to
21 years for adults and up to 36 years for children.9
Genetics
The NF2 gene is located on chromosome band 22q12, and
encodes a protein known as merlin (a moesin-ezrin-radixin-
like protein) or schwannomin.10,11 Merlin is important in
anchorage of the cytoskeleton to the cell membrane, the orga-
nization of cell membrane proteins and interaction with cyto-
solic proteins. The pathways involved are required for cell
growth, protein translation and cellular proliferation. The
absence of normal merlin is associated with a predisposition
to tumor formation.12 A detailed description of the complex
cellular and molecular neurobiology of merlin is outside the
scope of this article, but has been reviewed by others.8,13
In most NF2 tumors, biallelic inactivating mutations are
found. The gene may be inactivated by mutation, silencing or
allelic loss.14,15
NF2 has almost complete penetrance by the age of 60.1 About
50% of patients are the first affected in their family, and are
described as having de novo mutations. The other 50% are due
to sporadic mutations,1 which may occur in parental germline
cells (prezygotic), or in postzygotic cells in which case
mosaicism may result, such that only a proportion of cells carry
the mutation. It is estimated that 25% of sporadic mutations are
mosaic.16 The transmission rate depends on the degree of mosai-
cism. For children of patients with a de novo mutation, the
transmission rate is 50%, because all the child’s cells contain
the mutation. However, the transmission rate may be lower in de
novo patients, as germ cells may not contain the mutation.17
Identification of a mutation in the NF2 gene is possible in
over 90% of familial cases,8 and 80-85% of individuals with
sporadic mutations,18 confirming the diagnosis when present in
both tumor and blood.19 In mutation-negative individuals, con-
firmation of the clinical diagnosis is possible through careful
follow-up over time.
In children presenting early with a more severe clinical
course, mosaicism is less likely and consequently the mutation
detection rate is higher. One study exploring the utility of
mutation testing to screen for NF2 in patients presenting with
unilateral vestibular schwannomas showed that this is justified
in those presenting <20 years of age 83% of patients presenting
under the age of 20 with a unilateral vestibular schwannomas
were found to have a detectable NF2 mutation compared to
7.7% when looking at all ages.20
In children of a parent with NF2, identification of a mutation
has a major impact on the further screening of that individual.21
In sporadic cases, failure to identify a mutation does not obvi-
ate the need for ongoing surveillance, due to the phenomenon
of mosaicism, or possibly presence of mutations in intronic
regions, promotor mutations, or large multiexonic deletions.4
Genotype-Phenotype Correlation
Missense mutations usually cause mild symptoms and signs of
NF2.22 Nonsense/frameshift mutations produce a truncated
protein, and tend to be associated with a more severe pheno-
type, earlier onset, more rapid disease progression and higher
tumor burden with more spinal and intracranial tumors in addi-
tion to vestibular schwannomas.7,23 Mutations in the 3’ half of
the NF2 gene are associated with lower risk of meningioma
than mutations in the 5’ half of the gene with a cumulative risk
of cranial meningioma to age 50 years highest at 81% for exons
4-6, and lowest at 28% for exons 14-15.24 Clinical heteroge-
neity amongst established NF2 families is now recognized (ie,
those in whom mosaicism is unlikely), suggesting that NF2
gene expression may be affected by other environmental or
epigenetic factors.25
In some cases, NF2 can occur in children with additional
features including dysmorphism, intellectual disability and
congenital abnormalities, as a result of a large cytogenetically
visible deletion including the NF2 and other genes, which may
be identified on karyotype or chromosomal microarray.26
NF2-Associated Tumors
Tumors occur in intracranial and spinal regions as well as on
peripheral nerves, causing variable symptoms and signs depend-
ingon their location.Within the intracranial compartment, tumors
Table 1. Clinical Diagnostic Criteria for Neurofibromatosis Type 2.
Primary finding
Additional features needed
for diagnosis
Bilateral vestibular schwannomas None needed
First degree relative with NF2 Unilateral vestibular schwannoma
OR
Any 2 other NF2-associated
lesions:
Meningioma, schwannoma, glioma,
neurofibroma, cataract
Unilateral vestibular
schwannoma
Any 2 other NF2-associated
lesions:
Meningioma, schwannoma, glioma,
neurofibroma, cataract
Multiple meningiomas Unilateral vestibular schwannoma
OR
Any 2 other NF2-associated
lesions:
Schwannoma, glioma,
neurofibroma, cataract
Source: Modified from Evans7 and Asthagiri et al.8
Abbreviation: NF2, neurofibromatosis type 2.
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can cause deafness, blindness, headaches, seizures, gait abnorm-
alities, and a range of other focal deficits. Spinal cord tumors
occur in between 60 to 90% of patients,23,27,28 causing sensory
andmotor dysfunction including paralysis and bladder and bowel
dysfunction. Painmaybe a feature of central or peripheral tumors,
and is positively associated with tumor burden.29
Spinal tumors occur both within the cord (intramedullary) and
within the canal on exiting nerve roots or originating from the
meningeal covering of the cord (extramedullary). There appears
to be no predilection for a particular location, multiple tumors
being common in cervical, thoracic and lumbar regions. One
study examining spinal tumors found that of the 63% of NF2
patients affected (N¼ 31/49), 53% had intramedullary, 55% had
extramedullary tumors, and 45% had at least 1 of each tumor
type.23 Multiple tumors commonly occur in a single patient.
The risk of malignant transformation of tumors in individ-
uals with NF2 is higher than in the general population. Among
1348 patients across North American and European centers, 9
cases of malignant nervous system tumors were identified,
equivalent to 725 per 105 population compared with 1.13 per
105 in the general population. Radiation associated malignant
transformation was estimated to occur in 4717 per 105 in the
NF2 population.30 Some authors have estimated exposure to
radiotherapy increases the risk 10-fold.30,31
Schwannomas
Bilateral vestibular schwannomas are the characteristic tumor
of NF2, affecting 95% of all patients, causing tinnitus, vertigo,
hearing loss, and brain stem compression (Figures 1b, 1c,
1e,1f). They tend to form on the superior vestibular branch of
the eighth cranial nerve. In the general population with vestib-
ular schwannomas, 7% of individuals have NF2.32 Increased
morbidity is associated with these tumors among individuals
with NF2 compared to patients with sporadic tumors (isolated
vestibular schwannomas associated with mutation in the NF2
gene in tumor tissue only), in part due to an increased growth
rate of tumors in NF2.33 There is significant risk that an NF2
Figure 1. NF2-associated tumors: cervical spinal ependymoma with associated syrinx in a 14-year-old shown on sagittal T2-weighted MRI (a)
and postresection (d); bilateral vestibular schwannomas at age 14 years (b, e), and at 18 years (c, f) shown in T1-weighted MRI with gadolinium
contrast (b, c) and T2-weighted images (e, f), larger on left (white arrows). Parasagittal meningioma also shown (f, black arrow). Abbreviations:
MRI, magnetic resonance imaging; NF2, neurofibromatosis type 2.
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patient with a unilateral vestibular schwannomas will develop
bilateral vestibular schwannomas, with a mean delay of 6.5
years reported in one study. In the pediatric age group, the
time to development of the second vestibular schwannoma is
shorter; mean delay of 3.25 years for radiological evidence of
vestibular schwannomas and 7.3 years for hearing loss
becoming bilateral.34
Schwannomas occur on other cranial nerves, the most com-
mon being unilateral or bilateral involvement of the trigeminal
nerve,28 also around the spinal cord and exiting spinal nerve
roots, along peripheral nerves, and in the skin. In one series,
spinal and intracranial schwannomas occurred nearly as fre-
quently as vestibular schwannomas.3
Meningiomas
Meningiomas are the second most common tumor type in NF2
(Figure 1f), occurring throughout the central nervous system in
50-75% of individuals, often with multiple tumors.2,7,35,36
While some meningiomas remain static and require no active
treatment, NF2-associated meningiomas tend to be higher
grade than sporadic tumors.37 Some meningiomas have been
found to grow more rapidly than schwannomas, although
growth rates are variable for both tumor types.19 Female sex
and younger age at NF2 diagnosis have been associated with
increased growth rate in one recent report.38
While there is no specific site in which they form as com-
monly as vestibular schwannomas, meningiomas usually occur
around the spinal cord, supratentorially in the falx, and around
the frontal, temporal and parietal regions, including the optic
nerve sheath.19 Optic nerve sheath meningiomas may be bilat-
eral, occur early in life and can be associated with complete
vision loss.5,39,40
Schwannomas and meningiomas occur infrequently during
childhood, having an estimated association with NF2 in at least
10-18% of cases. Constitutional NF2 is now acknowledged as
the most frequent cause of meningioma presenting in child-
hood.41 NF2 has been diagnosed in 28% of children with optic
nerve sheath meningioma.39,40
Gliomas
Glial cell tumors (ependymomas and astrocytomas) are often
detected radiographically, but cause symptoms less frequently
than other tumor types. They tend to affect the lower brain stem
and upper cervical cord more often than other locations.5 The
prevalence of intracranial astrocytomas and ependymomas in
NF2 varies between 1.6-4.1% and 2.5-6% respectively;42 the
frequency of both tumor types is much higher (24%) in the
pediatric NF2 population.21 About 30% of NF2-associated
spinal tumors are intramedullary,43 and are most likely to be
ependymomas (Figures 1a, 1d). These tumors occur in child-
hood but may be clinically silent for many years. A series of
12 patients, aged between 10 to 56 years, with spinal ependy-
momas was reported recently.44 Ten of 12 patients presented
with gait abnormality, 8 with paresis/paralysis, 4 with pain, and
2 patients experienced sensory deficits and limb ataxia. Based
on detailed pathology studies, the authors concluded that
NF2-associated gliomas in the spinal region are almost exclu-
sively ependymomas.44 These tumors can be surgically
resected without significant residual deficits. They are of low
malignant potential.
Manifestations of NF2 Affecting the Skin,
Eyes, and Peripheral Nerves
Cutaneous Findings
Cafe´ au lait macules are more prevalent than in the general
population and are often present in children with NF2
(Figure 2a), but rarely reach the size or numbers seen in
neurofibromatosis type 1 (NF1) patients.5,45,46 They tend to
be paler and have more irregular margins compared to
those of NF1.21 Hypopigmented areas can also occur.46
Cafe´ au lait macules are often present early in childhood,
followed by increase in number and size of skin tumors
over time.47
While about 68% of individuals have characteristic cuta-
neous features of NF2, these constitute the first recognizable
symptoms or signs in up to 25% of cases.46
Three types of skin tumors occur in NF2: NF2 plaques,
nodular schwannomas, and neurofibromas (Figures 2d, 2f).
Flat dermal NF2 plaques are cutaneous schwannomas appear-
ing as well defined, slightly raised hyperpigmented lesions,
often with excess hair, typically less than 2 cm in diameter.46
During childhood, these can occur on the trunk48 as commonly
seen in adults, or on the upper and lower limbs, including hands
and feet.21 Nodular schwannomas are well defined and usually
spherical, occurring subcutaneously around peripheral nerves.
There is no pigment change to the overlying skin which can be
palpated as separate from the tumor.5 Neurofibromas, although
classically associated with NF1, can occur in NF2, but do not
comprise the main tumor burden.19,42
A high burden of skin tumors is associated with increased
severity of disease overall, with about 10% of individuals hav-
ing greater than 10 tumors.5,46
Ophthalmologic Findings
Ophthalmologic abnormalities are present in the majority of
NF2 patients, including cataracts (70-80%), retinal changes
(20-44%), strabismus (12-50%), amblyopia (12%), optic nerve
sheath meningiomas and other optic pathway tumors (10-27%),
and extra-ocular movement abnormalities (10%).9,49-51 Optic
nerve sheath meningiomas are the characteristic tumor of NF2,
whereas optic pathway gliomas including the optic nerves and
posterior optic pathway are more typical of NF1 (Figure 3).52
Nystagmus may occur due to peripheral vestibular dysfunction
or eye involvement. Corneal injury affects about 10% of NF2
patients with other ocular abnormalities, and in association
with facial nerve weakness.
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Most ocular changes are congenital in origin and specific to
NF2, and as such have been highlighted as early diagnostic
clues to NF2 in children.53 Cataracts are often bilateral, occur-
ring as posterior subcapsular or peripheral cortical lens opaci-
ties (Figure 2c). These may not require removal, but reduce
visual acuity in 10-20% of cases.9,21,49 Retinal abnormalities
include combined pigment epithelial and retinal hamartomas.
Epiretinal membranes (Figure 2e) are recognized in association
with a severe phenotype of ocular involvement, which can lead
to macular impairment and retinal detachment.2,49,54 The char-
acteristic appearance of epiretinal membranes on ocular coher-
ence tomography has been described recently.50,54
Unfortunately, misdiagnosis of ophthalmologic complications
of NF2 in early childhood (retinal hamartomas and optic nerve
sheath meningiomas) as retinoblastoma has resulted in enu-
cleation of the globe in a number of cases.
A recent study of 30 patients (60% children with onset NF2
symptoms "18 years, 40% adults onset >18 years) in a univer-
sity ophthalmology department, documented more frequent
ophthalmologic abnormalities in the pediatric population
(94%) compared with the adult population (67%).9 While
impairment in visual acuity has previously been estimated to
affect over 30% of NF2 patients overall,50 this study documen-
ted significantly poorer visual outcomes for children, with only
14% having normal visual acuity at the end of similar periods
of follow-up compared to 78% of adults, due to increased inci-
dence of cataracts, epiretinal membranes, and optic nerve
sheath meningiomas among children.9 The authors reported a
Figure 2. Cutaneous and ophthalmologic findings of NF1 (a, b) and NF2 (c-f): Cafe´ au lait macules (a), pigmented cutaneous neurofibroma in
NF1 with numerous other subtle raised neurofibromas on the trunk of a 15-year-old with NF1 (b). Posterior subcapsular cataract (c), optic
atrophy in child with optic nerve sheath meningioma and epiretinal membrane (black arrow, e), NF2 plaque (d), and nodular schwannoma (f).
Abbreviations: NF1, neurofibromatosis type 1; NF2, neurofibromatosis type 2.
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significant correlation between younger age of onset and
increased number of central nervous system tumors.
Peripheral Neuropathy
Peripheral nerve dysfunction can occur in NF2 without obvious
focal tumor. Cranial nerve deficits are more frequent present-
ing signs in childhood than adulthood, occurring in 40% of
children in one study (eg, commonly facial palsy, strabismus
due to third nerve palsy, swallowing impairment, tongue atro-
phy).4 Children may also present with a mononeuropathy in the
limbs, most commonly foot drop, in the absence of a focal brain
stem, spinal cord or peripheral nerve tumor.5,55 Marked wast-
ing may be associated with the foot drop, and significant wast-
ing can also be seen in the hands, most prominently in the
thenar and hypothenar eminences.17
The peripheral neuropathy associated with NF2 tends to be a
mixed motor and sensory axonal neuropathy occurring in a
glove and stocking distribution, with distal weakness, fascicu-
lations and hypaesthesia.5,56,57 Pathologic studies have identi-
fied loss of both myelinated and unmyelinated nerve fibers,
sometimes with an onion bulb appearance.56 Schwann cell and
epineurial cell proliferation with entanglement of axons has
been described, without formation of a discrete tumor.56,57
Investigations
Audiology
Hearing evaluation typically includes pure tone audiometry,
speech intelligibility assessment and brainstem auditory
evoked responses for clinical evaluation, with recommenda-
tions recently published regarding optimal outcomes for use
in clinical trials.58
Neuroimaging
The best radiologic investigation of intracranial and spinal
tumors is magnetic resonance imaging (MRI) with gadolinium
contrast, including detailed views of the internal auditory canal
(a minimum of 3 mm slices in both axial and coronal planes for
clinical evaluation).19,21 Volumetric approaches to tumor mea-
surement provide the most sensitive assessment of tumor size
for vestibular schwannomas both for monitoring disease pro-
gression and response to treatment.59-61 Whole body MRI to
assess total tumor burden may play an increasing role in man-
agement of patients with NF2.62 A whole body approach
allows identification of symptomatic or potentially sympto-
matic lesions. Radiologic response to systemic therapy may
ideally include multiple target tumors in future reflecting the
complexity and multiplicity of tumors and clinical symptoms
in NF2. However, the role of whole body MRI is not clearly
established as yet.
Other Investigations
Fluoro-deoxy glucose positron emission tomography may have
a role in selected cases where malignant transformation is sus-
pected. Depending on the clinical context, a range of other
investigations may be needed to evaluate new symptoms or
deficits, including nerve conduction studies, electroencephalo-
graphy, and other functional studies.
Clinical Course
While individuals with NF2 typically experience progressive
symptoms and signs of disease, the clinical course varies
between individuals, depending on age of onset, genotype,
tumor burden, complications and management. Saltatory
growth (alternating periods of growth and quiescence) is most
common for NF2-associated tumors, although linear growth
and exponential growth do occur.38 Age of onset and age of
diagnosis are the 2 most important factors in predicting disease
severity.22,25 The presence of meningiomas and treatment in
nonspecialist centers have also been associated with risk of
earlier mortality.22
Natural history studies of vestibular schwannomas, have
demonstrated progressive disease over time, though rate of
progression varies between tumors, and change in hearing is
not necessarily directly correlated with tumor growth.63,64 Sig-
nificant tumor progression (defined as#20% increase in tumor
volume) of 31% at 1 year and 79% at 3 years has been reported
Figure 3. Optic nerve sheath meningioma in a 7-year-old with NF2
(left side a, c) and optic nerve glioma in a 10-year-old with NF1 (right
side b, d) shown on axial T1-weighted MRI (a noncontrast, b with
contrast) and coronal T1-weighted images (c, d both with contrast).
Abbreviations: MRI, magnetic resonance imaging; NF1, neurofibro-
matosis type 1; NF2, neurofibromatosis type 2.
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in 120 patients (200 tumors), associated with cumulative hear-
ing decline of 16% over 3 years (defined as decrease in word
recognition score exceeding the 95% critical difference com-
pared with baseline).65
The natural history of 287 cranial meningiomas in 74
patients with NF2 was reported recently, with a mean follow-
up of 9 years. About one-quarter of the group were aged
<18 years at the time of diagnosis. In this group of patients,
69% had at least a single operation for vestibular schwanno-
mas, 23% for spinal tumors.36 Significant growth of at least 1
meningioma during 1 year (#20% increase in volume) was
found in 28% of patients (7.3% of 267 tumors). 46% required
surgical treatment for meningioma, for variable indications
including epilepsy, intracranial hypertension and specific neu-
rologic deficits.36
Limited data are available regarding longevity in NF2.
However, 38% survival at 20 years from diagnosis, has been
estimated for the population as a whole.66
Clinical Presentation and Natural History
of Pediatric Cases
Presentation of NF2 in the pediatric age group is often unrec-
ognized. In a group of 368 individuals reported previously, 153
(42%) had onset of symptoms between 1-19 years of age.22
While adults typically present with hearing loss and tinnitus
as a consequence of vestibular schwannomas, these symptoms
often follow other presenting features in the pediatric popula-
tion. In fact, vestibular schwannomas account for only15-30%
of presenting symptoms in pediatric cases.55 Symptoms of ves-
tibular schwannoma have been delayed by over 40 years in
some patients presenting in childhood.67 Children are more
likely to present with visual symptoms, spinal cord compres-
sion or neurologic symptoms from other intracranial
tumors.2,4,45,68 Furthermore, where both vestibular schwanno-
mas and spinal tumors are present, children are more likely to
be symptomatic from spinal tumors than from vestibular
schwannomas.3 Astute clinicians may suspect the diagnosis
of NF2 based on cutaneous or ophthalmologic manifestations
alone in a proportion of children.
In five pediatric case series (total N¼ 109), mean age at first
presentation varied between 5.5-7.0 years, while mean age at
diagnosis varied from 8.8 to 14.9 years.2,4,21,55,68 The present-
ing features of these children are summarized in Table 2.
Tumor burden and associated morbidity and mortality
among children are typically higher than in the adult NF2
population. Among 12 children from a North American tertiary
NF treatment center,4 hearing loss associated with vestibular
schwannomas was present by age 18 years in 75% of patients.
Seven children underwent surgical treatment for vestibular
schwannomas at an average age of 10 years, with immediate
postoperative hearing loss in 4 cases. Progressive hearing loss
occurred in all patients over time. All children had other intra-
cranial tumors, including 83% schwannomas, and 75% menin-
giomas; 75% also had spinal tumors. Only 2 patients were not
treated surgically during childhood. One child had undergone 5
procedures and one received radiation therapy for progressive
orbital meningioma. Outcomes were assessed across 4
domains—hearing, vision, ambulation, and school perfor-
mance. By 18 years of age, 83% of patients had visual impair-
ment, 75% had hearing loss (bilateral in 2 patients). One patient
was paraparetic, 2 others had difficulties with ambulation. In
all, 25% were functioning below age expectation at school,
attributable to physical impairments and frequent hospitaliza-
tion rather than baseline intellectual disability. Two children
had impairments in all 4 domains. The authors highlighted
significant morbidity despite active surveillance in familial
cases and early surgical intervention.4
In 2005, Ruggieri et al21 described 24 individuals aged
between 4 to 22 years followed at a European center. Nineteen
were"10 years old at the time of diagnosis, 22 were diagnosed
aged "18 years. Bilateral vestibular schwannomas were pres-
ent in 75% patients, with unilateral vestibular tumors in 16%.
Other intracranial tumors included meningiomas (66%
patients), astrocytomas (25%), ependymomas (25%), and other
cranial nerve tumors (40%). Brainstem tumors were associated
with a poor prognosis. Twenty-one individuals had spinal
tumors with successful resection achieved in 4 of 21 children
with extradural lesions, and 3 with intradural tumors. Surgical
treatment had been provided for 16 of 24 patients. 50% suffered
significant morbidity during childhood, including 2 children
who did not survive beyond 16 years of age.21
Other case reports have documented early mortality asso-
ciated with NF2, including a patient presenting at age
13 years with multiple craniospinal tumors, who died 4 years
later despite multimodal treatment including surgery and
chemotherapy.69
Management
Patients are best managed in tertiary centers by a well-
resourced multidisciplinary specialist team experienced in
dealing with the multiple complications associated with
NF2.22 Specialties involved may include neurology, genetics,
ophthalmology, audiology, dermatology, radiology, neurosur-
gery, otolaryngology, medical and radiation oncology, clinical
nurse consultants, allied health staff, and psychologists.
Follow-Up of Children With Suspected NF2
Children with suspected NF2 require ongoing follow-up to
clarify the diagnosis over time; this may be based on the devel-
opment of additional clinical features, and/or on genetic testing
to identify NF2 mutations in blood and tumor (Table 3).
Molecular genetic testing is recommended for children of
affected parents, recognizing that clinical features may be
insufficient to meet diagnostic criteria for NF2 until later in
life. Leukocyte DNA from blood is usually tested in children
of parents with NF2 (Table 3). Alongside genetic testing,
baseline skin, neurology and ophthalmology (including slit-
lamp) assessments are required, with annual clinical reviews
thereafter. Hearing assessment and craniospinal MRI should
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occur from 10 years of age, unless clinical suspicion mandates
earlier assessment.52
In suspected sporadic cases, genetic testing is first per-
formed on tumor DNA, with a view to identifying NF2 muta-
tions on both alleles. This is followed by testing of leukocyte
DNA to establish which mutation is constitutional and which is
somatic (present only in the tumor). Failure to detect a mutation
in blood may occur due to mosaicism, mutations located in
intronic or promotor regions, or due to large multiexonic dele-
tions.4 This can occur in patients presenting with unilateral
vestibular schwannoma. Additional features of NF2 may be
identifiable over time in a proportion of patients. Therefore,
careful multimodal follow-up is indicated (outlined in Table 3)
to identify and treat complications early. Annual MRI scans are
recommended from the age of 10 years.7,52 Only when muta-
tion in blood is negative, and 2 NF2 mutations are identified in
tumor, is the diagnosis of constitutional NF2 unlikely.70
Surveillance and Secondary Prevention in Confirmed NF2
Most individuals diagnosed with NF2 should be followed with
a minimum of annual clinical evaluation and investigations,
with increased frequency in the presence of significant compli-
cations (Table 4). Some adults with mild disease presenting in
later life, may be managed with less frequent assessments.
Medical Management
Significant effort has been invested in developing medical
treatments for NF271-74 and appropriate clinical trial protocols
in recent years, with a major focus on symptomatic, progressive
vestibular schwannomas.66,75 The most effective agent to date
inhibits vascular endothelial derived growth factor, which has a
central role in angiogenesis for NF2 schwannomas.71 Anti–
vascular endothelial derived growth factor monoclonal antibo-
dies such as bevacizumab (administered as a fortnightly intra-
venous infusion) provide a beneficial effect in treatment of
vestibular schwannomas including tumor shrinkage and
Table 3. Recommended Follow-Up for Children at Risk of Having NF2.
Child of affected parents (50% risk)
Child with suspected NF2 (schwannoma, meningioma,
skin featuresa)
Baseline
assessment
Birth—ocular, skin, neurological þ formal ophthalmology exam
during early years
Ocular, skin, neurological exam
Audiology
Full craniospinal MRI
DNA analysis Presymptomatic diagnosis if familial mutation known
Mutation found in blood:
NF2 carrier ! follow-up
Mutation not found in blood:
NF2 excluded ! no follow-up
Mutation analysis (blood and tumor)
No mutation in blood: NF2 not excluded! follow-up
No mutation in blood, 2 mutations in tumor:
NF2 excludedb ! infrequent follow-up
Follow-up
clinical
neuroimaging
2-10 years of age:
Annual ocular, skin, neurological
Formal ophthalmology assessment if symptomatic
10-30 years of age:
As above þ audiology
>10 years of age:
Baseline craniospinal MRI or
At any stage based on clinical suspicion
Tumor ! follow-up as suspected NF2
No tumor ! cranial MRI every 2 years to age 20 years, then
every 3 years
2-10 years:
Annual ocular, skin, neurological
Ophthalmology, audiology
>10 years of age:
As above þ neuroimaging if not already indicated on
clinical grounds
<10 years of age:
As clinically indicated
>10 years:
Repeat craniospinal MRI
Then annual cranial MRI
Spinal tumors present! annual spinal MRI
Source: Modified from Ruggieri et al21 and Janse et al.70
Abbreviations: MRI, magnetic resonance imaging; NF2, neurofibromatosis type 2.
aFewer than 6 CAL (cafe-au-lait macules) macules, ie, not fulfilling criteria for neurofibromatosis type 1 or skin lumps. bOther than small risk of mosaicism.
Table 4. Recommended Follow-Up for Confirmed Cases of NF2.
Frequency
Clinical examination
Neurologic examination Annual
Skin examination Annual
Ophthalmologic examination Annual
Audiologic examination 6-12 monthsa
Pure tone audiometry
Speech recognition
BAER
Neuroimaging—contrast enhanced MRI
Brain with IACs 6-12 monthsa
Spine 6-12 monthsa
Psychosocial support
Assess employment/school/family
functioning
Annual
Genetic counseling At diagnosis then at any stage
Source: Modified from MacCollin and Mautner,2 Evans,7 Asthagiri et al,8
Ardern-Holmes and North,52 and Janse et al.70
Abbreviations: BAER, brainstem auditory evoked response; IAC, internal
auditory canal; MRI, magnetic resonance imaging; NF2, neurofibromatosis type 2.
aFrequency of follow-up is dependent on age and disease burden.
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hearing improvement in a proportion of patients.76,77 The larg-
est series reported to date included 31 patients aged between
12-73 years (median 26 years) with progressive vestibular
schwannomas showing a median of 64% volume increase dur-
ing 12 months prior to treatment. Tumor shrinkage (#20%
volume) was documented for 55% (17/31) patients, constitut-
ing radiographic response, while 57% (13/17) patients experi-
enced hearing improvement based on a statistically significant
increase in word recognition score. Both radiographic and hear-
ing improvements were sustained for up to 1 year in about 90%
of patients, with stable to improved status in 61% and 54% for
hearing and tumor volumes respectively after 3 years.78 Lim-
ited efficacy in slowing progression of meningiomas has also
been documented.73,79 Although progressive vestibular
schwannomas remain the primary indication for treatment,
bevaizumab should also be considered for other progressive
symptomatic NF2-associated tumors. Symptomatic benefit was
recently reported in a series of 8 patients with spinal ependy-
momas, with radiologic response demonstrated in 5 cases based
on a >20% reduction in linear measurements.80
Lapatinib (available as an oral tablet) targets the epidermal
growth factor receptor (EGFR/Erb2 inhibitor), and had some
effect on vestibular schwannomas in a single institution phase
II study (21 patients, 4 aged <18 years).81 Radiographic
response (# 15% tumor volume reduction), occurred in 4 of
17 evaluable patients (23.5%), varying from 15.7 to 23.9%
volume reduction over a median of 4.5 months. Hearing
response (defined as#10 dB improvement in pure tone average
or statistically significant improvement in word recognition
score) was recorded in 4 of 13 eligible patients. Median time
to progression was 14 months (based on either volume increase
or hearing loss), and overall progression-free survival at
12 months was estimated at 64.7%.81
Other agents such as mammalian target of rapamycin
(mTOR) inhibitors may halt tumor progression.82
Medical therapies for this population must be tolerable, with
care given to minimizing side effects. For young adults receiv-
ing bevacizumab or other agents which can affect future ferti-
lity, anticipatory care should include consultation with
reproductive specialists.
Peripheral neuropathies that are unrelated to tumors can be
treated symptomatically, with drugs such as gabapentin or
pregabalin to control pain and other sensory symptoms.8
Surgical Management
Until recently, surgery has been the mainstay of treatment for
NF2-associated tumors, and continues to play an important role
for most patients.28,66 Surgical management should be care-
fully planned by surgeons experienced in the care of NF2
patients. The aim is to remove tumors before they cause irre-
versible damage, minimizing potential adverse surgical conse-
quences, bearing in mind that operative morbidity increases
with size of the tumor.8,28 Tumor should be reserved for genetic
testing, with patient consent.42
Complete resection of schwannomas for NF2 patients is
achievable at lower rates than for sporadic tumors,83 presum-
ably because the schwannomas of NF2 tend to incorporate
more nerve fascicles, with increased adherence to surrounding
nerves.84 Risks associated with vestibular schwannoma resec-
tion include hearing loss and damage to the facial nerve. Some
surgeons advocate for early surgery when vestibular schwan-
nomas are <2 cm in greatest diameter, to achieve hearing pre-
servation with minimal surgical risks.28,85 Other approaches
include decompression of the internal auditory canal without
tumor removal or partial tumor debulking to relieve symptoms
of brain stem compression.28 A specific aim is to preserve the
cochlear nerve, due to the potential future utility of a cochlear
implant, which can provide stable serviceable hearing over at
least 8 years in the majority of patients.86 Approaches to
improving cosmesis, in the event of facial nerve damage, have
been described, along with recommendations for assessing
facial nerve outcomes in the course of treatment.58
Rates of hearing preservation up to 50% over 3 years post-
operatively have been reported by Friedman and colleagues.85
In a group of 35 children with NF2 (47 vestibular schwannoma
resections performed between 1992 and 2004), 55% of sur-
geries achieved hearing preservation at #70 dB, with a similar
hearing level to that reported in Friedman’s study (48%).87 In
another series of 29 pediatric patients (23/29 with NF2), hear-
ing preservation was possible in only 30% of cases, with
greater risk of hearing loss and facial nerve damage (8%) fol-
lowing resection of larger tumors.83
Surgery is required in up to 30-60% of patients with spinal
tumors with likelihood of surgery varying by tumor location
(extramedullary tumors more likely).23,28
Because surgery carries the risk of exacerbating neurologic
deficits and other complications, evolving medical options are
favored where available.
Radiotherapy/Radiosurgery
Stereotactic radiosurgery for vestibular schwannomas has
been estimated to achieve tumor control in between 60-80%
of the general NF2 population at 5 years,88 significantly better
than the natural history of the disease. Hearing preservation in
those with serviceable hearing was estimated at 73% after one
year, 59% after 2 years and 48% after 5 years, with low risk of
injury to the facial (5-12%) and trigeminal nerves (2-7%).88,89
Long-term results are less robust than for sporadic vestibular
schwannomas.66 In one pediatric case series, while hearing
preservation after gamma knife surgery compared favorably
with adult patients (67% at 1 year, 53% at 5 years, n ¼ 11
tumors), tumor control was poor (35% at 3 years, n ¼ 17
tumors).68 It should be noted that these studies have utilized
alternative defined endpoints versus those recently recom-
mended for studies of NF2 patients.59 Optimal comparability
between natural history and treatment outcome datasets is
dependent on measurement standardization.
There is concern regarding the increased risk of malignant
transformation after radiosurgery in NF2.30,31 While NF2
18 Journal of Child Neurology 32(1)
patients number about 7% in studies of vestibular schwanno-
mas treated with gamma knife surgery, nearly half of the cases
of malignant change occur in the NF2 population, indicating
that this treatment modality should be utilized with caution.31
Nevertheless, radiosurgery and radiotherapy may have a role in
management of selected vestibular and other tumors, such as
optic nerve sheath meningiomas.40,89,90
Assistive Devices and Psychosocial Management
Optimizing quality of life through enhanced community par-
ticipation can be achieved using a range of approaches includ-
ing assistive devices to improve vision and communication
(auditory brainstem implants, cochlear implants,83 and lip read-
ing). Allied health support to maximize ambulatory function
and minimize risk of injury is important. Psychosocial support
for affected individuals and families is critical.
Clinical Trials for NF2
Information regarding clinical trials for NF2 patients can be
found at www.uab.edu/nfconsortium/clinical-trials (Neurofi-
bromatosis Clinical Trials Consortium) and www.clinicaltrials.
gov (US National Institutes of Health).
Conclusion
NF2 is a rare autosomal dominant neurocutaneous disorder
associated with multisystem effects, predominant in the cen-
tral nervous system, related to loss of tumor suppressor func-
tion. Presentation in childhood is associated with more severe
disease and risk of significant early morbidity and mortality.
While diagnosis in adults can be delayed due to a limited
awareness of the condition among physicians, the challenge
of timely diagnosis in children is further complicated by the
variable presentation in this age group. Furthermore, the clin-
ical diagnostic criteria used for adults may not be met during
childhood. Careful skin and eye examination may uncover
helpful clinical signs of NF2 in children. A high index of
suspicion, genetic testing and attentive clinical follow-up are
needed to establish the diagnosis. When NF2 is confirmed,
comprehensive multimodal surveillance is recommended at a
minimum of annual intervals, and more frequently in cases
where progressive disease and significant complications have
been identified. The involvement of experienced specialist
teams familiar with NF2 is recommended to optimize disease
specific care and outcomes, and to facilitate inclusion of
adults and children in natural history studies and treatment
trials wherever possible.
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The systemic treatment of patients with neurofibromatosis type 2 associated tumours is challenging, as
these patients often have prolonged survival but with the inevitable propensity for their disease to cause
symptoms, and no effective therapies other than local treatments such as surgery. Understanding the
molecular mechanisms driving NF-2 pathogenesis holds promise for the potential use of targeted ther-
apy. Initial studies of agents such as bevacizumab (angiogenesis inhibitor) and lapatinib (epidermal
growth factor and ErbB2 inhibitor) have indicated benefit for selected patients. As the biology of NF-2
is dependent on multiple interlinked downstream signalling pathways, targeting multiple pathways
may be more effective than single agents. Phase zero trials, adaptive phase II or small multi-arm trials,
are likely the way forward in this rare disease. Ideally, well-tolerated targeted therapy would appear
to be the most promising approach for patients with NF-2, given the natural history of this disease.
! 2014 Elsevier Ltd. All rights reserved.
Introduction
Neurofibromatosis type 2 (NF-2) is an autosomal-dominant,
multiple neoplasia syndrome resulting from a mutation in the
NF-2 tumour suppressor gene on chromosome 22q12 [1]. It occurs
at an estimated incidence of 1:25,000 [2] to 1:33 000 [3] and has a
penetrance of nearly 100% by age 60. The course of the disease is
usually progressive, though variable, causing significant morbidity
associated with deafness, blindness, brain stem compression, gait
instability and paralysis. Onset typically occurs while a patient is
in their 20s, but more than 40% die by the age of 50. Mean actuarial
survival in a series from 1995 was 62 years of age [4]. Other reports
state survival ranges between 30 and 50 years of age, however this
has likely improved over time given the advances in diagnosis and
treatment [5,6]. The distinctive clinical feature is the presence of
bilateral vestibular schwannomas. Schwannomas also commonly
occur on other cranial nerves, and along with intracranial meningi-
omas, often multiple, affect about 50% of patients. Spinal tumours
occur in 63–90% of NF-2 patients and are heterogenous, consisting
of meningiomas, schwannomas and ependymomas. Posterior
subcapsular lens opacities are the most common ocular findings
[2,5,7,6]. The clinical diagnostic criteria consist of bilateral
vestibular schwannomas, or unilateral vestibular schwannoma
and two of the other distinct tumours, or either of these latter
two criteria in addition to family history or multiple meningiomas
[6]. The development of novel medical therapy is targeted at
vestibular schwannomas in the first instance, with recommenda-
tions for standardised response criteria in treatment trials
developed by an international team of experts in the Response
Evaluation in Neurofibromatosis and Schwannomatosis (REiNS)
collaboration [8].
Differential diagnosis of NF-2
The neurofibomatosis family of syndromes includes Neurofibro-
matosis Type 1 (NF-1), NF-2 and schwannomatosis [5]. NF-1 was
clearly established as distinct from NF-2 in 1987 when it was
recognised as a different autosomal dominant disorder character-
ised by subcutaneous and plexiform neurofibromas, café au lait
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spots, intertriginous freckling, lisch nodules and optic pathway gli-
oma [9]. The main differential for NF-2 is schwannomatosis [10],
which is characterised by spinal, peripheral and cranial nerve sch-
wannomas in the absence of vestibular schwannomas. It is a
genetic disorder due to a mutation in tumour suppressor gene
INI1/SMARCB1, which is on the same chromosome as the causative
mutation in NF-2 [11].
Molecular biology of NF-2
NF-2 mutations are found in 93% of patients in the second gen-
eration [10]. Around 50% inherit the mutation, the remainder being
de novomutations. Tumorigenesis in NF-2 is thought to be second-
ary to mutational inactivation and allelic loss of the NF-2 gene, as
well as hypermethylation [12,13]. The specific type of mutation
may correlate with disease severity [14]. The NF-2 gene encodes
Merlin, also called schwannomin, a tumour suppressor protein
[15]. It resembles moesin, ezrin and radixin-like proteins, is
associated with the hyaluronic acid receptor CD44 and mediates
contact-dependent inhibition of proliferation. It also stabilises
cadherin-containing junctions. Effects mediated by membrane
organisation of proteins include cell-to-cell adhesion, cytoskeletal
architecture, interaction with cytosolic proteins and regulation of
downstream pathways. Two isoforms of Merlin exist, namely I
and II [5]. Only isoform I is capable of tumour suppressor function.
Merlin appears to regulate multiple signal transduction pathways,
and recent evidence suggests that it also has a role in suppressing
the E3 ubiquitin ligase CRL4 (DCAF1) in the nucleus to inhibit cell
proliferation [16]. However, its specific role is yet to be elucidated
[17]. The molecular biology of NF-2 is complex and beyond the
scope of our review. The role of inhibitors of selected pathways
is discussed below.
Clinical management
The mainstay of treatment of NF-2 currently is surgery for
symptomatic tumours. The indication and timing of surgery is
unclear (reviewed by Blakeley et al. [18]). For vestibular schwan-
noma, surgery is complicated by the proximity of the vestibular
nerve to the facial and acoustic nerves, with risk of facial nerve
palsy and complete hearing loss. Surgery may be considered as first
line therapy for vestibular schwannoma greater than 3 cm in diam-
eter without brainstem compromise or hydrocephalus [6,18].
However, many cases are managed expectantly and debulking
performed on symptom progression. Tumours less than 3 cm
may be excised, or managed expectantly. Radiotherapy treatment
is controversial in the treatment of schwannomas. A recent
meta-analysis has shown greater tumour control rates for stereo-
tactic radiation as compared to conservative management [19],
however there is insufficient evidence to make such a treatment
recommendation for hearing preservation. Moreover, there is a
definite increased risk of development of de novo malignant
gliomas and malignant progression of acoustic neuromas after
focused radiotherapy using stereotactic radiosurgery [20]. Hence
micro-neurosurgical removal should be considered, even if the
procedure is subtotal to minimize risks to the seventh cranial
nerve, especially in young patients who have become functionally
deaf on that side [20].
Systemic therapies
To date, cytotoxic chemotherapy has no established role in the
treatment of NF-2. Historical case reports of malignant schwanno-
mas have documented responses to chemotherapy in patients who
develop pulmonary metastases [21]. These tumours are likely
neurofibrosarcomas and may respond to cyclophosphamide, vin-
cristine and doxorubicin. These reports predate the reclassification
of neurofibromatosis and elucidation of the underlying genetic
mutation in NF-2. The slowly proliferating nature of NF2-associated
tumours would predict a low response to cytotoxic chemotherapy,
which is typically expected to be more active on rapidly dividing
cells. However, the increasing understanding of the molecular
mechanisms driving pathogenesis holds promise for the use and
efficacy of targeted therapy. The initial focus is on treatment of
vestibular schwannomas.
Given the slowly proliferating nature of schwannomas, and
their inevitable propensity to cause symptoms, there is a strong
need to find effective drug targets for this disease. Treating these
patients is challenging however, as they may have prolonged
survival during which unanticipated delayed toxic effects of any
therapy can manifest; further, patients are likely to require treat-
ment for prolonged periods of time, so low toxicity of therapy is
a priority for patients.
Novel therapeutics
Given the complexity of signalling pathways downstream of
Merlin loss (Fig. 1), a number of potential therapeutic targets have
been proposed [22]. The ErbB family of receptor tyrosine kinases
comprise Her-1, Her-2, Her-3 and Her-4. Theymediate downstream
signalling pathways including the Ras-Raf-MAPK/ERK kinase (MEK)
pathway and the phosphatidylinositol 3-kinase (PI3 K) Akt-mam-
malian target of rapamycin (mTOR) pathway [15]. Neuregulin-1
(NRG1) and NRG2 are agonists of Her-3. In vivo studies demon-
strated that NRG1, Her-2 and Her-3 are crucial for schwann cell
development. Hence Her- family receptors may be relevant targets
for schwannoma drug therapy. Trastuzumab, a Her-2 inhibitor, has
been found to inhibit cell growth in vestibular schwannoma xeno-
grafts [23]. However, in human primary schwannoma cells, the
Her-1/2 inhibitor lapatinib did not reduce basal activity of ERK1/2
and Akt or basal proliferation [15]. This suggests that autocrine
release of growth factors other than NRG1, such as platelet derived
growth factor (PDGF) or insulin-like growth factor (IGF), could be
more relevant in the pathophysiology.
Epidermal growth factor receptor (EGFR) antagonism has also
been proposed as a potential therapy for schwannomas [24]. A case
series of 11 patients who received erlotinib via compassionate
access, reported that a subset of patients experienced tumour
stabilisation [25]. All patients were poor surgical candidates, and
5 of these patients had experienced a growth rate of greater than
60% in the last 12 months. The median time to progression
was 9.2 months and none of the patients achieved a radiological
response. However, 27% of patients experienced stable disease,
indicating that erlotinib may have a cytostatic rather than a cyto-
toxic effect. Another study of inhibition of the Her-2/EGFR pathway
was more successful, suggesting that lapatinib could be a useful
treatment [26]. In this trial of 21 enrolled patients, a 23.5% volu-
metric response was achieved, as well as a 30.8% rate of hearing
improvement in 17 evaluable patients.
A recent phase II open-label study investigated the mTOR-
inhibitor everolimus in 10 patients with NF-2 related vestibular
schwannomas [27], with the primary outcome being objective
response rate. None of the 9 patients who could be evaluated
had a volumetric or hearing response. This is in line with in vitro
data supporting the cytostatic but not cytotoxic effect of inhibition
of mTORC1 [28].
These studies raise the question of whether time to progression,
as opposed to response rate, would be a more appropriate end-
point in this chronic disease [8,29]. The REiNS collaboration has
proposed the incorporation of functional and patient-related
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outcomes in clinical trials in NF-2 [30]. Whole body MRI has also
been investigated as a means of measuring tumour burden [31].
IGF-I receptor signalling regulates growth and metabolism of
variousorgans and tissues during embryonal andpostnatal develop-
ment [15]. In adult rodents, IGF-I and IGF-II are crucial for schwann
cell development and survival. An IGF-IR inhibitor, picropodophyl-
lin, markedly inhibited IGF-I-mediated proliferation and adhesion
of human primary schwannoma cells. None of these have been
tested in the clinic as yet. Inhibition of PDGFR and IGFIR might be
the most appropriate strategy for schwannoma treatment [15].
One candidate target is PI3 K, which is involved in PDGFR-mediated
ERK1/2 and Akt activation and could provide a common link. Over-
activation of the Akt pathway has been hypothesised to result in
Merlin phosphorylation and enhancement of its degradation via
the proteosome pathway [32]. The PI3 K-mTOR inhibitor BEZ235
significantly decreased basal proliferation and completely abro-
gated IGF-I-mediated proliferation in human primary schwannoma
cells. OSU-03012 is a derivative of cyclooxygenase-2 inhibitor cele-
coxib and inhibits PDK-1, which is an upstream kinase that phos-
phorylates Akt. It has been shown to be effective in inducing
apoptosis and inhibiting cellular proliferation in human schwan-
noma cells [33]. Interestingly, OSU-03012 is able to facilitate anti-
proliferative effects in imatinib-resistant cells by suppressing Akt
phosphorylation [34]. p-21 activated kinase (PAK) inhibitors could
act via direct blockage of growth factor dependent tumour cell
survival and reactivation of Merlin. Bio 30 with propolis from bee
venommay act as a PAK inhibitor [22].
As the biology of NF-2 is dependent on multiple interlinked
downstream signalling pathways (Fig. 1), and as many of the drugs
investigated thus far are multi-targeted, it is difficult to ascertain
whether there is one pathway which is more important in its path-
ogenesis. Thus, targeting multiple pathways may be more effective
than single agents. 17AAG is a compound that inhibits Heat Shock
Protein 90 (HSP90) and therefore reduces the stability of ErbB, Raf
and Akt [22] Curcumin, a polyphenol extracted from turmeric, has
also been investigated as a potential drug in NF-2, given its ability
to inhibit HSP90 [35]. It upregulates HSP90 in cell lines, including
HEI-193 schwannoma cell lines. Hence, combination of curcumin
and Hsp inhibitor KNK437 is synergistic [35]. However, curcumin
has limited bioavailability via the oral route, thereby limiting the
clinical utility of this approach.
Schwannoma proliferation is dependent on ERK1/2 activation,
basal and PDGF-DD-mediated activation of PDGFR-beta(b) and
Akt [15]. Utilising multi-targeted therapy like sorafenib and niloti-
nib may be expected to be effective [36]. Sorafenib has been shown
to be more effective than selumetinib (AZD6244, a MEK inhibitor)
and nilotinib in reducing schwannoma cell proliferation [37]. As
sorafenib differentially inhibits Raf over the other two drugs, it is
surmised that Raf may be more important in NF-2 pathophysiol-
ogy. However, use of sorafenib is limited by its toxicity profile.
Given the benign character of these tumours, long-term therapy
is often necessary. A drug that may fit the criteria for tolerability
is imatinib.
Imatinib targets c-KIT and PDGF-b, which appear to be overex-
pressed in NF-2, albeit perhaps not as significantly as in gastroin-
testinal stromal tumour (GIST). HEI-193 NF-2 null schwannoma
cells had decreased in vitro viability with imatinib in a dose-depen-
dent manner [38], possibly through increased apoptosis. The
authors concluded that this data would support the use of imatinib
in clinical trials of human schwannomas; this has been demon-
strated in a case report [39], albeit the response criteria should ide-
ally be based on volumetric response [40].
Nilotinib has also been evaluated in comparison with imatinib
[37]. Both drugs effectively inhibit PDGF-DD–mediated PDGFR-b,
ERK1/2, and Akt activation. Basal activity of those targets was also
inhibited by both drugs, except for ERK1/2, which was inhibited
only by Nilotinib. Nilotinib is more effective than imatinib
in vitro, with a maximal inhibitory effect at a concentration 10-fold
Fig. 1. Downstream signalling pathways involved in the pathogenesis of NF-2, with the drug targets shown in red. Abbreviations: EGFR = epidermal growth factor receptor;
ERK1/2 = extracellular signal-regulated kinase 1/2; HSP = heat shock protein; IGF1R = insulin-like growth factor 1 receptor; MEK1/2 = MAPK (mitogen activated protein
kinase)/ERK kinase 1/2; mTOR = mammalian target of rapamycin; PAK = p21-activated kinase; PDGF = platelet-derived growth factor; P13 K = phosphatidylinositol 3-kinase;
PKC = protein kinase C; VEGF = vascular endothelial derived growth factor. Adapted from references [15,35,42]. (For interpretation of the references to color in this figure
legend, the reader is referred to the web version of this article.)
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lower than that of imatinib. This difference in potency is likely due
to the higher cell-membrane permeability of nilotinib, which is
more lipophilic and hence relies less on active transport mecha-
nisms to enter cells. A low concentration of selumetinib in addition
to nilotinib resulted in a significant increase in the efficiency of nil-
otinib. This would suggest that inhibition of the MEK1/2/ERK1/2
pathway is synergistic with inhibition of PDGFR in reducing
schwannoma proliferation.
Other novel approaches include inhibition of histone deacetyl-
ase by AR42 [41], which induced apoptosis, inhibited phosphory-
lated Akt, and inhibited growth of xenografts.
Angiogenesis inhibitors
Targeting angiogenesis with the vascular endothelial growth
factor (VEGF) monoclonal antibody bevacizumab or small mole-
cule VEGF inhibitors appears promising. Merlin loss may lead to
downregulation of semaphorin 3F, which then promotes angiogen-
esis [42]; restoration of pro-angiogenic and anti-angiogenic func-
tions may therefore represent a rational approach to therapy. In
addition, VEGFR-2 expression has been demonstrated in 32% of
vessels in vestibular schwannomas [43]. The initial reports of hear-
ing improvement and tumour shrinkage with bevacizumab in a
small number of patients with vestibular schwannoma [43,44]
was followed by review of 31 patients demonstrating sustained
response for up to 3 years [45]. Patients aged 12–73 years were
included with 57% of evaluable patients (13/23) showing improve-
ment in word recognition score, and 55% (17/31) showing at least
20% tumour shrinkage, on a background of progressive growth.
Sustained hearing improvement was seen in 90% of patients after
1 year and 61% at 3 years; sustained radiologic response occurred
in 88% of patients at 1 year of treatment and 54% at 3 years.
Conclusions
In NF-2, as in other rare diseases, identifying the most effective
systemic therapy remains a challenging problem. Better understand-
ing of the molecular pathways and utilisation of well-tolerated
targeted agents would appear to be the most promising approach.
However, the complexity of inter-related signalling pathways in
NF-2 pathogenesis suggests that multiple agents administered in
concert, rather than a single drug, may result in the most effective
therapy. On the other hand, an aggressive approach has to be
weighed up against potential toxicity, given the slow growth of
schwannomas and prolonged survival of patients with NF-2. In
the absence of cure, a reasonable goal may be early symptomatic
treatment or pre-symptomatic treatment in familial cases, to
achievemaintenance of stable disease. Translational clinical studies
in small numbers of patients to explore the pharmacokinetics and
pharmacodynamics of targeted therapies based on molecular char-
acterisation, or Phase zero trials could be helpful. Alternatively, an
international multi-centre cooperative approach to the conduct of
adaptive phase II trials or small multi-arm trials [18] rather than
traditional phase III placebo-controlled trials, could be used to seek
regulatory approvals for new therapies in this rare tumour suppres-
sor syndrome.
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Hearing and facial function outcomes for
neurofibromatosis 2 clinical trials
ABSTRACT
Objectives: Vestibular schwannomas are the hallmark of neurofibromatosis 2 (NF2), occurring in
.95% of patients. These tumors develop on the vestibulocochlear nerve and are associated with
significant morbidity due to hearing loss, tinnitus, imbalance, facial weakness, and risk of early
mortality from brainstem compression. Although hearing loss and facial weakness have been
identified as important functional outcomes for patients with NF2, there is a lack of consensus
regarding appropriate endpoints in clinical trials.
Methods: The functional outcomes group reviewed existing endpoints for hearing and facial func-
tion and developed consensus recommendations for response evaluation in NF2 clinical trials.
Results: For hearing endpoints, the functional group endorsed the use of maximum word recogni-
tion score as a primary endpoint, with the 95% critical difference as primary hearing outcomes.
The group recommended use of the scaled measurement of improvement in lip excursion (SMILE)
system for studies of facial function.
Conclusions: These recommendations are intended to provide researchers with a common set of
endpoints for use in clinical trials of patients with NF2. The use of common endpoints should
improve the quality of clinical trials and foster comparison among studies for hearing loss and
facial weakness. Neurology® 2013;81 (Suppl 1):S25–S32
GLOSSARY
AAO-HNS 5 American Academy of Otolaryngology-Head and Neck Surgery; HB 5 House-Brackmann; HR 5 hearing
response; NF2 5 neurofibromatosis 2; PTA 5 pure-tone average; REiNS 5 Response Evaluation in Neurofibromatosis and
Schwannomatosis; SH 5 stable hearing; SMILE 5 scaled measurement of improvement in lip excursion; VS 5 vestibular
schwannoma; WRS 5 word recognition score.
Vestibular schwannomas (VS) are the hallmark of neurofibromatosis 2 (NF2), occurring in
.95% of patients. VS develop on the vestibulocochlear nerve and cause significant morbidity
due to hearing loss, tinnitus, imbalance, and risk of early mortality from brainstem compression.
Hearing loss develops over time in patients with NF2, and these declines are associated with
gradual VS growth.1 Facial weakness is a common sequela of surgery to remove VS and may also
occur as a late manifestation of large VS, secondary to facial nerve schwannomas, or as an
isolated mononeuropathy.1 Facial weakness causes articulation difficulties, oral incompetence,
lack of ability to smile and express emotions, and inability to blink and protect the cornea, which
can lead to vision loss. Facial weakness and hearing loss adversely affect quality of life2–4 and as
such represent important functional outcomes in clinical trials.
NATURAL HISTORY OF HEARING LOSS AND FACIAL WEAKNESS IN NF2 The natural history of hearing
loss in NF2 has been studied in the prospective multicenter NF2 Natural History Study sponsored by the
Department of Defense Consortium.5 In a cohort of 63 patients (108 VS) within 2 years of the diagnosis
of NF2, 27% of the ears experienced a significant loss in pure-tone average, defined as a change of 5 dB
compared with baseline.5 The natural history of facial weakness in NF2 has not been well studied. The best data
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come from large retrospective studies of facial function
after resection of NF2-related VS. These studies suggest
that preoperative tumor size does not correlate with
facial function after middle fossa approach or transla-
byrinthine approach.6,7
Consensus endpoints to study hearing loss and facial
weakness in the setting of NF2 are necessary. Currently,
there is no standard definition of hearing loss or facial
weakness that is used uniformly across clinical trials.
The lack of consensus makes it difficult to compare re-
sults between trials or between clinical reports of surgical
outcomes. The NF community would benefit from the
use of consensus definitions in future trials, particularly
those that will be presented to national regulatory bodies
as evidence for drug approval.
MEASUREMENT OF HEARING LOSS AND FACIAL
WEAKNESS Hearing is monitored in clinical prac-
tice by measuring pure-tone thresholds and word
recognition scores (WRS), also known as speech rec-
ognition scores or speech discrimination scores. Pure-
tone thresholds measure the minimum sound level
that an ear can perceive. Thresholds are typically mea-
sured at octaves and half-octaves from 250 Hz to
8,000 Hz. An average of thresholds at 500, 1,000,
2,000, and 4,000 Hz (pure-tone average [PTA]) is a
recommended standard outcome measure for report-
ing in cases of VS.8 WRS measure the ability of pa-
tients to meaningfully interpret sounds. WRS are
measured as the percentage of monosyllables patients
can correctly identify when they are presented at a
fully audible level. Paradoxically, WRS sometimes
decrease in individuals with VS when the words are
presented at high volume (rollover effect).9 Standard
audiologic techniques have been developed to avoid
potential pitfalls in testing patients with retrocochlear
lesions that exhibit rollover. Patients can be classified
into categories of hearing based on American Academy
of Otolaryngology-Head and Neck Surgery (AAO-
HNS) schemes: class A (PTA # 30, WRS .70%),
class B (PTA .30 to # 50, WRS $ 50%), class C
(PTA .50, WRS $ 50%), and class D (PTA any
level, WRS,50%). Class A and B hearing are termed
“serviceable”; class C and D hearing are termed “non-
serviceable.”
In clinical practice, facial function is monitored
using the House-Brackmann (HB) scale,10 which
grades facial function in 6 steps from normal (HB
I) to total paralysis (HB VI) (table 1). In 1985, the
AAO-HNS adopted the HB as a universal standard.
Over the years, the HB grading scale has been up-
dated.11 Other scales, such as Burres-Fisch, Notting-
ham, Sunnybrook, and Yanagihara, have also been
used to grade facial function.12
METHODS The Response Evaluation in Neurofibromatosis
and Schwannomatosis (REiNS) functional outcomes group was
formed to address the lack of consensus about appropriate func-
tional endpoints to use in NF clinical trials. The functional out-
comes group has 10–15 active participants that meet monthly for
teleconferences and present recommendations biannually to the
full REiNS International Collaboration group. The group con-
sists of professionals from various disciplines involved in NF care,
including neurologists, geneticists, otolaryngologists, audiolo-
gists, oncologists, therapists, radiologists, and statisticians. The
group has representation from the US, Europe, and Australia.
Selection of functional endpoints. During the first meeting,
the functional endpoint group agreed to discuss 4 functional end-
points that were relevant for patients with NF1, NF2, and
schwannomatosis as part of a clinical trial: 1) hearing function,
2) facial function, 3) walking function, and 4) pulmonary func-
tion. We report the first 2 endpoints assessed by the functional
endpoints working group.
Rating of functional endpoints. The functional outcomes
group modified the standardized form used for patient-reported
outcomes (see Wolters et al., this supplement). Using this form,
the group reviewed outcome measures for hearing function and
Table 1 Grading of facial strength using the House-Brackmann scale10
Grade Description Characteristics
I Normal Normal facial function in all areas
II Mild dysfunction Gross: slight weakness noticeable on close inspection; may have
very slight synkinesis
At rest: normal symmetry and tone
Motion
Forehead: moderate to good function
Eye: complete closure with minimum effort
Mouth: slight asymmetry
III Moderate
dysfunction
Gross: obvious but not disfiguring difference between 2 sides;
noticeable but not severe synkinesis, contracture, and/or hemifacial
spasm
At rest: normal symmetry and tone
Motion
Forehead: slight to moderate movement
Eye: complete closure with effort
Mouth: slightly weak with maximum effort
IV Moderately severe
dysfunction
Gross: obvious weakness and/or disfiguring asymmetry
At rest: normal symmetry and tone
Motion
Forehead: none
Eye: incomplete closure
Mouth: asymmetric with maximum effort
V Severe dysfunction Gross: only barely perceptible motion
At rest: asymmetry
Motion
Forehead: none
Eye: incomplete closure
Mouth: slight movement
VI Total paralysis No movement
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facial function. For hearing function, the review included use of
PTA, AAO-HNS hearing classification,13 the Gardner-Robertson
hearing classification,14 and the 95% critical difference for word
recognition.15 For facial function, the group reviewed use of the
HB scale11,16 and the scaled measurement of improvement in lip
excursion (SMILE) analysis.17
RESULTS For hearing endpoints, the functional
group chose to endorse the use of maximum WRS
as a primary endpoint, with the 95% critical differ-
ence for primary hearing outcomes15 and the SMILE
system for facial outcomes.18 These outcomes are dis-
cussed below.
Recommended primary outcome for hearing: Maximum
WRS.Hearing in patients with NF2 is measured using
an audiogram that includes measurement of pure-
tone thresholds and WRS. Word recognition is the
measure most closely associated with daily hearing
function since it measures the ability to comprehend
speech (rather than “detect” it). If word recognition
quality improves, the patient can converse success-
fully, even if a hearing aid is needed to make sounds
sufficiently loud.
Different statistical models have been used in clin-
ical trials to compare 2 word recognition tests (as in a
within-subject change with treatment). The use of a
fixed criterion for significance (e.g., a difference of
15 percentage points from baseline) is attractive given
the simplicity of implementing this rule. However, a
fixed criterion could allow certain errors, in that
changes that exceed the criterion might not be signif-
icant at p5 0.05 (false-positive) and changes that are
less than the criterion might be significant at p 5
0.05. If instead the significance level is fixed at
0.05, the criterion for difference varies depending
on the baseline WRS. This results in 2 scores, 1 above
and 1 below the starting value, which are known as
the critical differences at the selected probability level
(i.e., p 5 0.05, table 2).15
Feasibility. Audiology is widely available and it
takes about 20 minutes to perform testing that
includes a 50-word recognition list. Standardization
of testing is critical for use in clinical trials. For this
reason, the group recommends use of a recorded list
of standardized monosyllables.
Patient characteristics. Standard audiometry can be
administered reliably to individuals aged 5 years and
older.19 Audiometry is valid for important subgroups
such as the elderly and people with intellectual disa-
bility.20 Since the results are analyzed as repeated
measures, a participant may be evaluated using
English materials if the audiologist decides that the
results reasonably reflect comparative (test-to-test)
performance. A recommended approach may be to
require that participants be “testable in English” as
opposed to the narrower criterion of English as a first
language.8 There are also valid tests that can be re-
ported using the same mathematical criteria available
in several languages.21
Use in published studies. The 95% critical difference
has been used as a primary endpoint or as a secondary
endpoint in studies of sudden sensorineural hearing
loss15 and in studies of bevacizumab and lapatinib
for NF2-related VS.22–24
Baseline documentation of “target” and “nontarget”
lesions.When 2 functional ears are present at baseline,
the target ear and nontarget ear should be identified
and recorded at baseline. The goal is to target an
ear that lends itself to reproducible repeated measures.
Target ears should be selected on the basis of the qual-
ity of the hearing and the presence of an ipsilateral
VS. Hearing loss in the target ear should be attributed
to VS (rather than other causes of hearing loss).
The maximum WRS should be recorded for all
ears. To address rollover, an empirical search using
at least 2 levels (“high” and “low”) should be used
to identify maximum WRS at each evaluation.
Speech intelligibility should be evaluated for each
ear using standard word recognition of monosyl-
lables.25 All tests should use recorded lists (e.g.,
CID-W22, Ira Hirsh recording, Q/MASS v 2) from
a compact disc26 rather than spoken word lists since
this results in less variability of results. The initial
level should be set where maximum performance is
expected for each ear. The “high” level will be the
level calculated for maximum audibility, as in the
standard method for level setting in nontumor cases.
The “low” level will be the maximum level minus 10–
15 dB as chosen by the audiologist to reflect a level
with less chance of rollover. The maximum WRS is
defined as the greater WRS determined at the “high”
and “low” levels.
Response criteria. Hearing response criteria are
defined in reference to the baseline WRS at study ini-
tiation (table 2). Hearing response (HR) is defined as
an improvement in WRS above the 95% critical dif-
ference. Stable hearing (SH) is defined as persistence
of WRS within the 95% critical difference. Hearing
decline is defined as a decrease in WRS below the
95% critical difference.
Special notes on assessment of hearing. WRS is not a
continuous variable: it is a sum of binary responses
(correct/incorrect) that ranges from 0% to 100%. The
existence of upper and lower boundaries introduces a
“ceiling” and “floor” effect for patients with hearing
near the top and bottom of the range, respectively. As
table 2 shows, patients withWRS# 6% are not eligible
for hearing decline since the 95% critical difference
includes 0%; similarly, patients with WRS $94% are
not eligible for hearing improvement since the 95%
critical difference includes 100%. In the NF2 Natural
History study, the rate of spontaneous increase in WRS
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was 16% in patients with baseline WRS$ 90%.27 For
trials using hearing response as the primary outcome,
the functional group recommends excluding patients
with WRS$ 90% to allow for appreciation of hearing
improvement and to ensure that test-to-test variation
does not obscure true changes in hearing function.
Frequency of reevaluation. No evidence-based guide-
lines are available to help determine the interval
between evaluations. The functional group recom-
mends reevaluation of maximum WRS every 3
months during initial treatment and every 3–6
months during prolonged treatment.
Confirmatory measurement/duration of response. In
nonrandomized trials where response is the primary
endpoint, confirmation of response is desirable. The
time between audiograms should be at least 1 month.
Responses that are not confirmed by subsequent
audiology should be termed “unconfirmed response.”
For randomized trials or for trials where time to hear-
ing decline is the primary endpoint, confirmation of
response is not required. To declare stable disease,
audiograms must show stable disease at least once
after study initiation for a period of time that is
defined by the study protocol (usually 6 months).
Duration of hearing response. The duration of HR is
measured from the time when study measurement
first shows a HR until the first date that maximum
WRS is recorded within the 95% critical difference
of the baseline WRS.
Duration of stable hearing. SH is measured from the
start of treatment until the criteria for hearing decline
are met, taking as reference the 95% critical differ-
ence of the baseline maximum WRS. For protocols
designed to study the proportion of patients with
SH for a minimum period of time, the protocol
should specify the interval between audiograms.
It is important to note that the duration of HR/
SH and the determination of time to hearing decline
is influenced by the frequency of follow-up after base-
line evaluation. These intervals should be defined in
the study protocol.
Proportion free from hearing loss. Historically, most
patients with NF2 experience profound bilateral hear-
ing loss during the course of life. For young patients
and those with good hearing, a therapy that could
prevent hearing loss would be desirable, even if this
therapy did not improve hearing. In this scenario,
the proportion of patients free from hearing loss at
landmark time points might be considered appropri-
ate to provide an initial sign of biologic activity. How-
ever, in uncontrolled phase II trials this endpoint is
subject to bias from known and unknown factors that
influence hearing loss. Ideally, this endpoint is best
evaluated in the setting of a randomized trial. In the
case of NF2, spontaneous hearing improvement is
sufficiently uncommon (about 16% for patients with
Table 2 Hearing response guidelines
Baseline word
recognition score (%)
95% critical
difference (%)
Hearing
response (%)
Progressive
hearing loss (%)
0 0–4 $6 n/a
2 0–10 $12 n/a
4 0–14 $16 n/a
6 2–18 $20 0
8 2–22 $24 0
10 2–24 $26 0
12 4–26 $28 #2
14 4–30 $32 #2
16 6–32 $34 #4
18 6–34 $36 #4
20 8–36 $38 #6
22 8–40 $42 #6
24 10–42 $44 #8
26 12–44 $46 #10
28 14–46 $48 #12
30 14–48 $50 #12
32 16–50 $52 #14
34 18–52 $54 #16
36 20–54 $56 #18
38 22–56 $58 #20
40 22–58 $60 #20
42 24–60 $62 #22
44 26–62 $64 #24
46 28–64 $66 #26
48 30–66 $68 #28
50 32–68 $70 #30
52 34–70 $72 #32
54 36–72 $74 #34
56 38–74 $76 #36
58 40–76 $78 #38
60 42–78 $80 #40
62 44–78 $80 #42
64 46–80 $82 #44
66 48–82 $84 #46
68 50–84 $86 #48
70 52–86 $88 #50
72 54–86 $88 #52
74 56–88 $90 #54
76 58–90 $92 #56
78 60–92 $94 #58
80 64–92 $94 #62
82 66–94 $96 #64
84 68–94 $96 #66
86 70–96 $98 #68
Continued
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baseline WRS , 90%) that a nonrandomized trial
may be justifiable.27
Reporting best response results. For phase II trials, all
patients in the study must be included in the report
of the results, even those who are not evaluable or
experience major protocol deviations. Patients should
be designated as either HR, SH, hearing decline, or
not evaluable (e.g., early death, toxicity, assessment
not performed). In general, the denominator for cal-
culation of the response rate should include all eligible
patients. Conclusions should not be based on selected
“evaluable” patients. For phase III trials, hearing
response evaluation may be a primary or secondary
endpoint. If hearing response evaluation is a primary
endpoint (i.e., the study includes only patients who
are capable of hearing improvement), the discussion
above should apply. If response evaluation is a sec-
ondary endpoint (i.e., the study includes all patients
regardless of hearing), the hearing response rate may
be reported using an “intention-to-treat” analysis
(with all randomized patients in the denominator)
or using a predefined subset analysis (including the
subset of patients with hearing loss at baseline). The
study protocol should specify how response results
will be reported, including any planned subset
analyses.
Other outcomes for hearing: Pure-tone average. An alter-
native measure of hearing includes simple detection
of sound (i.e., the threshold of audibility). Pure-tone
thresholds are most often measured at the frequencies
of 250, 500, 1,000, 2,000, 3,000, 4,000, 6,000, and
8,000 Hz. The PTA is calculated as the average of
thresholds at 500, 1,000, 2,000, and 4,000 Hz,8
although other thresholds may be used.28 Changes
in pure-tone audiometry have been used in oncology
studies to monitor ototoxicity from chemotherapy.
However, in patients with VS, word recognition is
affected to a greater extent than detection of pure
tones29 due to cochlear and neural alterations.30 Fur-
thermore, patients’ quality of life is directly limited by
reduced word recognition rather than audibility,
which can be addressed by amplification. For this
reason, the committee does not endorse changes in
PTA as a primary outcome for hearing trials but does
recommend that PTA be recorded as a secondary
outcome.
Recommended primary outcome for facial function:
SMILE analysis. SMILE analysis is a technique to mea-
sure facial function that relies on computerized mea-
surement of facial excursion based on photographs
taken in standard positions (figure). The system uses
the iris diameter (corneal white-to-white diameter) as a
scale reference for all facial dimensions on the same
photograph. This built-in scale—in the same plane
as the oral commissure—allows measurements of hor-
izontal to vertical commissure excursion to be extrap-
olated from frontal photographs using readily available
photo-editing software.
Feasibility. SMILE analysis is performed using frontal
photographs of the patient at rest and with a full smile.
Photos are imported into the software program (Face-
gram), which then calculates an objective analysis of
smile symmetry and change in commissure excursion.
The Java-based SMILE analysis program is free for use
and can be downloaded at www.sircharlesbell.org/
facial_nerve_programs.html. Complete facial analysis
takes less than 5 minutes and may be stored
electronically for future use.
Patient characteristics and validity. SMILE analysis can
be reliably performed in individuals capable of standard
facial poses.17 The lower age limit for reliability of mea-
surement has not been determined. In a previous study
of 10 normal individuals (20 hemi-smiles), there was a
strong correlation between measured distances and the
true excursion (class correlation coefficients R 5 0.96–
0.99). There was strong correlation between the meas-
urements of excursion distances for multiple raters
(intraclass correlation coefficients: R 5 0.88–0.98).
The intratest reliability after 1 week (for a given rater)
was 0.99, indicating a strong correlation between meas-
urements over time.
Use in published studies. SMILE analysis has been
used as an endpoint in studies of facial reanimation
due to many causes, including NF2.31,32 To date,
the technique has not been used in multicenter
studies.
Baseline documentation of “target” and “nontarget”
hemi-smiles. When unilateral facial weakness is present
at baseline, the target hemi-smile should be identified
and recorded at baseline. In this instance, the contra-
lateral (nontarget) hemi-smile acts as a normal control
for the affected side. A history of previous surgery that
might affect facial strength (e.g., resection of VS)
Table 2 Continued
Baseline word
recognition score (%)
95% critical
difference (%)
Hearing
response (%)
Progressive
hearing loss (%)
88 74–96 $98 #72
90 76–98 100 #74
92 78–98 100 #76
94 82–98 100 #80
96 86–100 n/a #84
98 90–100 n/a #88
100 96–100 n/a #94
Abbreviation: n/a 5 not applicable.
Clinical criteria for definition of hearing response based on a 50-item monosyllable word
recognition test. Upper and lower limits for the 95% critical differences for percentage
scores are adapted from Thornton.35
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should be recorded. When bifacial weakness is pre-
sent at baseline, a target hemi-smile should be identi-
fied and recorded at baseline, based on normative
smile parameters.33
Patients should be photographed using at least 2
facial poses, including “at rest” and with a broad
smile. Using the software, the true smile excursion
from midline and the smile angle from horizontal
midline should be recorded for target and nontarget
hemi-smiles (figure). Comparison between smile an-
gles and smile excursion on the normal side and the
affected side at baseline provides an objective analysis
of smile symmetry. Comparison between smile angles
and smile excursion of the target hemi-smile before
and after intervention provides an objective analysis
of change in commissure excursion with treatment.
Response criteria. Consensus criteria using SMILE
analysis (or other facial rating scales) have not been
defined to date. Until more data are acquired, the
functional committee proposes to define a response
as an increase in true smile excursion of 25% com-
pared with the true smile excursion at baseline. Pro-
gression is defined as a decrease in true smile
excursion of 25% compared with the baseline true
smile excursion. Stable function is defined as all other
changes in true smile excursion compared with base-
line. These response criteria apply to patients with
both unilateral facial weakness and bifacial weakness.
Special notes on assessment of facial function. Patients
with facial weakness also experience paralytic lagoph-
thalmos, which can increase risk of complications
such as keratopathy. SMILE analysis of facial photos
is capable of measuring corneal exposure before and
after intervention. Measuring changes in lagophthal-
mos should be studied with a goal of defining
response criteria in the future. Presently, the group
recommends a 2-mm increase in lid position as a
functional response and a 2-mm decrease in lid posi-
tion as functional decline.
Frequency of reevaluation. No evidence-based guide-
lines are available to determine an appropriate interval
between evaluations. The functional group recom-
mends reevaluation of true smile excursion every 3
months during the first year after surgical interven-
tion and yearly afterwards.
Confirmatory measurement/duration of response. In
nonrandomized trials where response is the primary
endpoint, confirmation of response is desirable. The
minimum time between facial analyses should be at
least 1 month. Responses not confirmed by subse-
quent facial photos are termed “unconfirmed
response.” For randomized trials or for trials where
time to facial weakness is the primary endpoint, con-
firmation of response is not required. To declare sta-
ble facial strength, facial photos must show stable
strength at least once after intervention at a time that
is defined by the study protocol.
Duration of facial response. The duration of facial
response is measured from the time when study mea-
surement first shows a facial response until the first
date that facial photos demonstrate progressive facial
weakness compared to the best change in true smile
excursion.
Duration of stable facial function. Stable facial func-
tion is measured from the start of treatment or inter-
vention until the criteria for progressive facial
weakness are met, taking as reference the true smile
excursion at baseline. For protocols designed to study
the proportion of patients with stable facial function
for a minimum period of time, the protocol should
specify the interval between facial photos.
The duration of smiling response/stable facial
function and the determination of time to progressive
facial weakness are influenced by the frequency of
follow-up after baseline evaluation. These intervals
should be defined in the study protocol.
Proportion free from progressive facial weakness.Histor-
ically, patients with NF2 experience some facial weak-
ness over their lifetime. For patients with normal
facial function, a novel procedure or technique
(e.g., surgery or radiation) that minimizes, delays, or
otherwise prevents facial weakness would be desir-
able. In this scenario, the proportion of patients free
from progressive facial weakness at landmark time
points could be an appropriate measure of successful
intervention. However, in uncontrolled phase II trials
this endpoint is subject to bias from known and
Figure Example of SMILE analysis
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unknown factors that influence facial function. Ide-
ally, this endpoint is best evaluated in the setting of
a randomized trial.
Reporting best response results. For phase II trials, all
patients in the study must be included in results re-
porting, even those who are not evaluable or experi-
ence major protocol deviations. Patients should be
designated as either facial response, stable facial func-
tion, progressive facial weakness, or not evaluable
(e.g., early death, toxicity, assessment not performed).
In general, the denominator for calculation of the
response rate should include all eligible patients. Con-
clusions should not be based on selected “evaluable”
patients. For phase III trials, response evaluation may
be a primary or secondary endpoint. If response eval-
uation is a primary endpoint (i.e., the study includes
only patients who have baseline facial weakness), the
discussion above should apply. If response evaluation
is a secondary endpoint (i.e., the study includes all
patients regardless of facial function), the response
rate may be reported using an “intention-to-treat”
analysis (with all randomized patients in the denom-
inator) or using a predefined subset analysis (includ-
ing the subset of patients with facial weakness at
baseline). The study protocol should specify how
response results will be reported, including any
planned subset analyses.
Other outcomes for facial function: House-Brackmann
scale. As noted above, facial function in patients
with VS is commonly monitored using the HB
scale.10 Given the widespread use of this scale and
its correlation with other scales of facial function,34
the committee recommends that the HB score be
recorded as a secondary outcome for trials of NF2
patients with VS.
CONCLUSION These recommendations by the REiNS
Collaboration are intended to provide researchers with a
common set of endpoints for clinical trials for patients
with NF. The use of shared endpoints will improve
the quality of clinical trials and encourage pharmaceuti-
cal companies to invest in drug development in this
patient population. The REiNS International Collabora-
tion recognizes that no criteria are perfect and that alter-
native endpoints can be justified for these studies. In the
future, the group intends to update these recommenda-
tions as more information is published about clinically
relevant endpoints.
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